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ABSTRACT	  	  
Introduction	  Coronary	  revascularisation	  is	  a	  key	  component	  of	  the	  management	  of	  patients	  with	  coronary	  artery	  disease	  (CAD).	  The	  importance	  of	  combining	  functional	  with	  anatomic	  information	  to	  select	  appropriate	  patients	  is	  increasingly	  recognised.	  Established	  Cardiovascular	  Magnetic	  Resonance	  (CMR)	  techniques	  already	  provide	  much	  of	  the	  relevant	  functional	  information	  and	  the	  absence	  of	  ionising	  radiation	  makes	  CMR	  ideal	  for	  serial	  examinations.	  However,	  new	  CMR	  techniques	  continue	  to	  emerge,	  and	  require	  appropriate	  clinical	  evaluation.	  	  	  
Methods	  This	  thesis	  comprises	  a	  series	  of	  clinical	  studies	  developing	  and	  evaluating	  techniques	  for	  guiding	  revascularisation:	  	  i. Comparison	  of	  a	  high-­‐resolution	  k-­‐t	  accelerated	  perfusion	  sequence	  with	  a	  standard	  sequence.	  ii. Validation	  of	  CMR	  quantification	  of	  absolute	  myocardial	  perfusion	  using	  the	  high-­‐resolution	  sequence	  against	  PET.	  	  iii. Investigation	  of	  the	  relationship	  between	  an	  angiographic	  score	  (BCIS-­‐1	  Jeopardy	  score)	  and	  CMR	  estimations	  of	  CAD	  burden.	  	  iv. Determination	  of	  the	  inter-­‐study	  reproducibility	  of	  perfusion	  imaging	  and	  strain	  analysis	  with	  CMR	  feature	  tracking	  (CMR-­‐FT).	  	  v. Evaluation	  of	  a	  novel	  scar	  imaging	  technique	  using	  a	  dual-­‐inversion	  recovery	  (dual-­‐IR)	  pre-­‐pulse	  for	  the	  first	  time	  in	  patients.	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vi. The	  feasibility	  of	  combined	  CMR	  and	  coronary	  intervention	  in	  a	  hybrid	  laboratory.	  	  	  
Results	  The	  main	  findings	  for	  each	  component	  were:	  i. Perfusion	  imaging	  with	  the	  k-­‐t	  accelerated	  sequence	  resulted	  in	  significantly	  improved	  image	  quality,	  signal	  and	  contrast	  to	  noise	  ratios	  and	  a	  reduction	  in	  dark	  rim	  artefacts	  compared	  to	  the	  standard	  sequence.	  	  ii. There	  was	  good	  correlation	  between	  quantitative	  myocardial	  perfusion	  reserve	  (MPR)	  derived	  from	  CMR	  and	  PET.	  CMR	  and	  PET-­‐derived	  MPR	  were	  both	  comparable	  and	  accurate	  for	  the	  detection	  of	  CAD.	  However,	  absolute	  perfusion	  values	  from	  both	  modalities	  were	  only	  weakly	  correlated.	  	  iii. The	  correlation	  between	  the	  BCIS-­‐1	  Jeopardy	  score	  and	  CMR	  ischaemic	  burden	  was	  good	  and	  the	  score	  predicted	  a	  prognostically	  important	  ischaemic	  threshold	  of	  12%	  with	  high	  specificity.	  	  iv. The	  inter-­‐study	  reproducibility	  of	  quantitative	  myocardial	  perfusion	  and	  CMR-­‐FT	  was	  reasonable	  and	  better	  for	  global	  rather	  than	  regional	  measures.	  There	  was	  no	  detectable	  variation	  in	  perfusion	  or	  strain	  during	  the	  day.	  	  v. The	  dual-­‐IR	  sequence	  improved	  scar	  imaging	  compared	  to	  the	  IR	  technique.	  	  vi. Combined	  CMR	  and	  interventional	  coronary	  procedures	  were	  successful	  and	  well	  tolerated.	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Conclusions	  Quantitative	  analysis	  of	  perfusion	  is	  an	  exciting	  prospect	  with	  considerable	  potential	  and	  has	  demonstrated	  clinically	  utility,	  however,	  it	  application	  remains	  challenging.	  Novel	  scar	  and	  strain	  imaging	  techniques	  have	  also	  shown	  promising	  results.	  Further	  method	  refinement	  and	  appropriate	  clinical	  studies	  should	  allow	  the	  full	  potential	  of	  these	  tools	  for	  guiding	  revascularisation	  to	  be	  realised.	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1	   GENERAL	  INTRODUCTION	  
Despite	  many	  advances	  in	  prevention,	  detection	  and	  treatment	  coronary	  artery	  disease	  (CAD)	  remains	  a	  major	  public	  health	  problem.	  CAD	  is	  the	  leading	  cause	  of	  death	  worldwide	  and	  the	  World	  Health	  Organization	  estimates	  it	  caused	  7.25	  million	  or	  12.8%	  of	  all	  deaths	  in	  20081.	  In	  the	  United	  Kingdom	  alone	  more	  than	  2	  million	  people	  have	  CAD	  and	  in	  2009	  there	  were	  82,000	  deaths	  from	  CAD2.	  	  Coronary	  revascularisation	  has	  a	  central	  role	  in	  the	  management	  of	  patients	  with	  stable	  CAD,	  however,	  despite	  extensive	  published	  literature,	  appropriate	  selection	  of	  patients	  and	  lesions	  for	  revascularisation	  in	  stable	  CAD	  continues	  to	  be	  an	  area	  of	  controversy.	  Patients	  with	  complex	  CAD	  including	  multivessel	  disease,	  complex	  anatomy	  and	  with	  associated	  left	  ventricular	  (LV)	  impairment	  are	  at	  higher	  risk	  of	  procedural	  complications	  but	  also	  potentially	  benefit	  the	  most	  from	  revascularisation.	  Information	  regarding	  risks	  and	  benefits	  is	  therefore	  of	  critical	  importance	  for	  appropriate	  patient	  selection.	  	  	  The	  literature	  on	  coronary	  revascularisation	  is	  dominated	  by	  anatomical	  classification	  of	  CAD	  with	  decisions	  regarding	  revascularisation	  made	  solely	  on	  the	  basis	  of	  coronary	  angiographic	  appearances.	  Such	  an	  anatomy-­‐driven	  approach	  fails	  to	  assess	  coronary	  blood	  flow,	  myocardial	  perfusion	  and	  viability,	  which	  are	  central	  to	  the	  pathophysiology	  of	  CAD.	  Coronary	  artery	  blood	  flow	  is	  reduced	  when	  the	  luminal	  diameter	  of	  a	  coronary	  artery	  narrows	  below	  a	  threshold	  and	  as	  a	  result	  a	  reduction	  in	  coronary	  artery	  diameter	  of	  ≥50%	  -­‐	  70%	  is	  considered	  to	  be	  flow	  limiting.	  However	  this	  relationship	  between	  flow	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and	  luminal	  narrowing	  was	  determined	  in	  animal	  models	  using	  discrete,	  non-­‐atherosclerotic	  narrowings	  of	  the	  coronary	  arteries3	  and	  does	  not	  translate	  well	  into	  human	  clinical	  practice.	  Anatomic	  assessment	  of	  the	  severity	  of	  a	  coronary	  artery	  stenosis	  has	  been	  repeatedly	  shown	  to	  correlate	  poorly	  with	  the	  haemodynamic	  effects4,	  5.	  A	  number	  of	  factors	  contribute	  to	  the	  discrepancy	  between	  anatomic	  and	  physiologic	  assessment	  such	  as	  the	  diffuse	  nature	  of	  CAD,	  the	  presence	  of	  collateral	  vessels	  and	  calcification,	  dynamic	  changes	  in	  vasomotor	  tone,	  and	  difficulties	  identifying	  a	  truly	  normal	  vessel	  segment	  as	  a	  reference	  diameter.	  In	  addition,	  the	  anatomy-­‐only	  approach	  fails	  to	  take	  into	  account	  the	  viability	  of	  the	  myocardium	  subtended	  by	  the	  diseased	  artery.	  	  These	  considerations	  are	  widely	  accepted	  and	  the	  importance	  of	  functional	  assessment	  prior	  to	  revascularisation	  is	  reflected	  in	  guidelines	  for	  percutaneous	  coronary	  intervention	  (PCI)	  in	  stable	  CAD6.	  Despite	  this,	  many	  major	  contemporary	  trials	  continue	  to	  treat	  CAD	  as	  a	  purely	  anatomical	  disease.	  An	  example	  is	  the	  relatively	  recent	  SYNTAX	  trial7,	  which	  compared	  PCI	  and	  coronary	  artery	  bypass	  grafting	  (CABG)	  for	  the	  treatment	  of	  left	  main	  stem	  and/or	  three	  vessel	  CAD.	  Patients	  randomised	  to	  both	  PCI	  and	  CABG	  underwent	  protocol-­‐mandated	  complete	  anatomic	  revascularisation,	  i.e.	  all	  lesions	  of	  ≥50%	  in	  vessels	  of	  ≥1.5mm	  were	  treated	  without	  prior	  physiologic	  assessment.	  	  	  There	  may,	  of	  course,	  be	  some	  value	  in	  classifying	  patients	  according	  to	  their	  anatomy.	  For	  example	  CABG	  has	  been	  shown	  to	  confer	  a	  prognostic	  benefit	  in	  patients	  with	  left	  main	  stem	  disease	  or	  reduced	  LV	  function	  and	  two	  or	  three	  vessel	  disease	  involving	  the	  proximal	  left	  anterior	  descending	  (LAD)	  artery8.	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However,	  consideration	  of	  anatomy	  alone,	  and	  ignoring	  the	  physiology	  when	  selecting	  patients	  and	  lesions	  for	  revascularisation	  over	  simplifies	  a	  complex	  disease	  and	  trials	  adopting	  this	  approach	  risk	  underestimating	  the	  benefits	  of	  revascularisation.	  (This	  particular	  evidence	  also	  pre-­‐dates	  modern	  medical	  and	  surgical	  therapy	  and	  is	  therefore	  of	  questionable	  current	  relevance).	  	  
	  
Ischaemia	  The	  presence	  of	  myocardial	  ischaemia	  in	  stable	  CAD	  is	  associated	  with	  an	  adverse	  prognosis	  whether	  detected	  by	  exercise	  testing9,	  single	  photon	  emission	  computed	  tomography	  (SPECT)10,	  stress	  echocardiography11,	  or	  cardiovascular	  magnetic	  resonance	  (CMR)12.	  However	  the	  evidence	  that	  myocardial	  revascularisation	  improves	  prognosis	  in	  these	  patients	  is	  limited.	  	  Hachamovitch	  et	  al13	  assessed	  survival	  in	  10,627	  patients	  who	  had	  undergone	  clinical	  SPECT	  studies	  in	  a	  single	  US	  centre.	  Patients	  with	  no	  or	  mild	  baseline	  ischaemia	  had	  an	  improved	  prognosis	  with	  medical	  therapy	  compared	  to	  revascularisation	  whilst	  conversely	  those	  with	  moderate	  to	  severe	  ischaemia	  had	  an	  improved	  prognosis	  with	  revascularisation.	  An	  ischaemic	  threshold	  of	  10-­‐12.5%	  of	  myocardium	  differentiated	  patients	  who	  benefited	  from	  revascularisation	  from	  those	  who	  did	  not	  (figure	  1.1).	  Even	  though	  these	  data	  are	  from	  a	  very	  large	  cohort	  and	  the	  conclusions	  are	  interesting	  there	  are	  inherent	  limitations	  to	  the	  study	  as	  it	  was	  a	  non-­‐randomised,	  retrospective	  observational	  study,	  which	  used	  a	  propensity	  score	  to	  adjust	  for	  non-­‐randomisation.	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Figure	  1.1:	  Relationship	  between	  myocardial	  ischaemic	  burden	  and	  risk	  of	  
cardiac	  death.	  
Hazard	  ratio	  for	  cardiac	  death	  in	  patients	  treated	  with	  revascularisation	  (Revasc)	  versus	  medical	  therapy	  (Medical	  Rx).	  A	  threshold	  of	  10-­‐12%	  ischaemia	  burden	  defines	  those	  who	  appear	  to	  derive	  a	  prognostic	  benefit	  from	  revascularisation;	  from	  13.	  	  In	  the	  Asymptomatic	  Cardiac	  Ischemia	  Pilot	  (ACIP)	  study	  patients	  with	  asymptomatic	  ischaemia	  randomised	  to	  revascularisation	  (PCI	  or	  CABG)	  had	  significantly	  lower	  rates	  of	  death	  or	  myocardial	  infarction	  than	  those	  randomised	  to	  medical	  therapy14.	  There	  were,	  however,	  relatively	  few	  events	  (31	  in	  total)	  and	  the	  medical	  therapy	  used	  reflected	  practice	  at	  the	  time	  rather	  than	  current	  routine	  aggressive	  therapy.	  In	  the	  SWISSI	  II	  trial	  patients	  post	  myocardial	  infarction	  with	  demonstrable	  silent	  ischaemia	  had	  a	  significantly	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reduced	  rate	  of	  major	  adverse	  cardiac	  events	  with	  PCI	  than	  with	  medical	  therapy15.	  	  The	  landmark	  randomised	  controlled	  COURAGE	  trial16	  on	  the	  other	  hand	  concluded	  that	  there	  is	  no	  prognostic	  benefit	  from	  PCI	  in	  addition	  to	  optimal	  medical	  therapy	  as	  an	  initial	  treatment	  for	  stable	  CAD.	  This	  was	  despite	  the	  fact	  that	  the	  majority	  of	  participants	  had	  objective	  evidence	  of	  ischaemia	  at	  baseline-­‐including	  54%	  of	  patients	  with	  reversible	  defects	  on	  nuclear	  imaging.	  These	  data	  generated	  considerable	  controversy	  and	  led	  many	  to	  re-­‐evaluate	  entirely	  the	  role	  of	  PCI	  in	  stable	  CAD.	  It	  seems	  paradoxical	  that	  there	  was	  no	  incremental	  benefit	  from	  PCI	  given	  that	  the	  presence	  of	  demonstrable	  ischaemia	  confers	  a	  worse	  prognosis.	  There	  are	  a	  number	  of	  possible	  explanations	  for	  this.	  It	  could	  be	  that	  the	  procedural	  risks	  of	  PCI	  outweigh	  the	  benefits	  from	  ischaemia	  reduction.	  This	  however	  seems	  unlikely	  given	  that	  exclusion	  of	  peri-­‐procedural	  myocardial	  infarction	  from	  the	  COURAGE	  data	  does	  not	  alter	  the	  findings.	  It	  may	  be	  that	  the	  techniques	  for	  revascularization	  were	  not	  optimal	  for	  reducing	  ischaemia.	  Some	  have	  certainly	  criticized	  the	  relatively	  low	  overall	  rate	  (94%),	  and	  number	  of	  stents	  used,	  the	  low	  rate	  of	  drug	  eluting	  stent	  use	  (3%)	  and	  the	  relatively	  low	  procedural	  success	  rate	  (89%).	  However,	  the	  most	  important	  contributory	  factor	  is	  likely	  to	  be	  that	  the	  study	  design	  favored	  inclusion	  of	  lower	  risk	  patients	  with	  a	  lower	  burden	  of	  pre	  treatment	  myocardial	  ischaemia.	  As	  an	  example,	  patients	  with	  an	  exercise	  test	  positive	  in	  the	  first	  stage	  were	  excluded.	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In	  apparent	  contradiction	  to	  the	  main	  study	  the	  nuclear	  sub	  study	  of	  the	  same	  trial	  suggested	  that	  PCI	  might	  confer	  a	  prognostic	  benefit	  especially	  in	  patients	  with	  moderate	  to	  severe	  baseline	  ischaemia17.	  However,	  the	  sub	  study	  was	  underpowered	  and	  this	  finding	  did	  not	  reach	  statistical	  significance.	  Since	  the	  study	  design	  included	  lower	  risk	  patients	  40%	  had	  <5%	  ischaemia	  on	  baseline	  nuclear	  perfusion	  testing	  and	  only	  a	  third	  of	  patients	  in	  the	  PCI	  arm	  had	  a	  significant	  reduction	  of	  ischaemia	  following	  PCI.	  This	  suggests	  that	  revascularization	  may	  confer	  a	  prognostic	  benefit	  in	  patients	  with	  a	  significant	  ischaemic	  burden	  and	  improved	  patient	  selection	  may	  allow	  this	  benefit	  to	  be	  realised.	  	  	  Recognition	  of	  the	  importance	  of	  ischaemia	  is	  reflected	  in	  patients	  undergoing	  PCI	  with	  a	  change	  of	  emphasis	  away	  from	  complete	  anatomic	  revascularisation	  towards	  targeted	  revascularisation	  i.e.	  treating	  only	  the	  lesions	  causing	  ischaemia.	  Complete	  revascularisation	  and	  incomplete	  revascularisation	  are	  purely	  anatomic	  terms.	  By	  also	  assessing	  the	  physiology	  it	  is	  possible	  to	  achieve	  complete	  resolution	  of	  ischaemia	  without	  performing	  complete	  anatomic	  revascularisation.	  In	  patients	  undergoing	  PCI	  there	  is	  evidence	  from	  subgroup	  analyses18	  and	  registry	  data19	  that	  complete	  anatomic	  revascularisation	  is	  superior	  to	  incomplete	  anatomic	  revascularisation.	  The	  most	  compelling	  data	  however	  supports	  intervention	  targeted	  only	  at	  flow	  limiting	  lesions	  even	  when	  this	  results	  in	  incomplete	  anatomic	  revascularisation.	  The	  DEFER	  study20	  demonstrated	  that	  in	  single	  vessel	  disease	  it	  is	  safe	  to	  defer	  treatment	  of	  angiographically	  moderate	  stenoses	  that	  do	  not	  cause	  ischaemia	  as	  determined	  by	  fractional	  flow	  reserve	  (FFR).	  The	  more	  recent	  FAME	  study	  demonstrated	  
 26 
the	  utility	  of	  extending	  this	  approach	  to	  a	  multivessel	  setting21.	  This	  large	  multicentre,	  randomised,	  controlled	  trial	  demonstrated	  that	  ischaemia-­‐guided	  PCI	  confers	  a	  prognostic	  benefit	  (reduced	  rate	  of	  death,	  nonfatal	  MI	  and	  repeat	  revascularization)	  over	  PCI	  guided	  by	  angiographic	  appearances	  alone.	  	  	  	  The	  follow-­‐up	  FAME	  II	  study22	  is	  likely	  to	  add	  further	  support	  to	  ischaemia-­‐driven	  revascularisation	  with	  PCI.	  This	  study	  randomised	  1219	  patients	  with	  stable	  CAD	  to	  FFR-­‐guided	  PCI	  plus	  optimal	  medical	  therapy	  or	  optimal	  medical	  therapy	  alone.	  The	  results	  have	  yet	  to	  be	  formally	  published	  however	  the	  data	  safety	  monitoring	  board	  recently	  recommended	  cessation	  of	  recruitment	  after	  an	  interim	  analysis	  demonstrated	  a	  significant	  reduction	  in	  the	  need	  for	  hospital	  readmission	  and	  urgent	  revascularization	  in	  the	  FFR-­‐guided	  arm.	  	  	  Conversely,	  in	  the	  case	  of	  CABG,	  there	  is	  a	  large	  volume	  of	  evidence	  demonstrating	  a	  symptomatic	  and	  prognostic	  benefit	  with	  complete	  over	  incomplete	  revascularisation	  and	  thus	  complete	  revascularisation	  is	  widely	  considered	  the	  gold	  standard23.	  Unlike	  with	  PCI	  these	  data	  are	  largely	  non-­‐randomised	  and	  retrospective.	  However	  improved	  prognosis	  with	  complete	  revascularisation	  has	  been	  consistently	  reported	  and	  it	  is	  plausible	  that	  technical	  differences	  between	  the	  two	  techniques	  may	  explain	  why	  complete	  revascularisation	  is	  the	  method	  of	  choice	  in	  CABG	  and	  targeted	  revascularisation	  in	  PCI.	  In	  the	  case	  of	  PCI	  the	  risk	  of	  complications	  is	  proportional	  to	  the	  number	  of	  lesions	  treated	  whereas	  the	  number	  of	  grafts	  seems	  to	  add	  little	  to	  the	  overall	  risk	  of	  CABG.	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Viability	  LV	  dysfunction	  is	  an	  important	  determinant	  of	  prognosis24.	  When	  considering	  revascularisation	  in	  stable	  patients	  with	  LV	  impairment	  it	  is	  important	  to	  also	  consider	  viability	  as	  there	  is	  evidence	  that	  revascularisation	  of	  patients	  with	  significant	  viable	  myocardium	  is	  associated	  with	  improved	  LV	  function	  and	  survival.	  	  	  Demonstration	  that	  the	  function	  of	  viable	  myocardium	  improves	  after	  restoration	  of	  coronary	  blood	  flow	  comes	  from	  pooled	  data	  from	  105	  trials	  using	  nuclear	  techniques	  or	  stress	  echocardiography25.	  This	  meta-­‐analysis	  demonstrated	  a	  combined	  mean	  sensitivity	  of	  84%	  and	  specificity	  of	  69%	  for	  the	  prediction	  of	  regional	  functional	  recovery.	  An	  improvement	  in	  global	  left	  ventricular	  ejection	  fraction	  (LVEF)	  was	  detected	  in	  28	  studies.	  In	  patients	  with	  viable	  myocardium	  LVEF	  improved	  on	  average	  from	  37%	  to	  45%	  whilst	  patients	  without	  viability	  showed	  no	  improvement	  in	  LVEF	  (36%	  before	  and	  after	  revascularization).	  	  	  A	  2002	  meta-­‐analysis	  that	  pooled	  the	  data	  of	  3088	  patients	  from	  24	  viability	  studies26	  demonstrated	  improved	  survival	  with	  revascularisation	  in	  patients	  with	  viable	  myocardium.	  Viability	  was	  determined	  using	  nuclear	  perfusion	  techniques,	  positron	  emission	  tomography	  (PET)	  or	  dobutamine	  stress	  echocardiography	  (DSE)	  and	  patients	  followed-­‐up	  for	  approximately	  2	  years.	  Analysis	  of	  the	  combined	  results	  demonstrated	  a	  strong	  association	  between	  myocardial	  viability	  identified	  by	  non-­‐invasive	  testing	  and	  improved	  survival	  after	  revascularisation.	  Revascularisation	  in	  patients	  with	  viable	  myocardium	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was	  associated	  with	  a	  79.6%	  reduction	  in	  mortality	  from	  16%	  with	  medical	  therapy	  to	  3.2%.	  Conversely,	  in	  the	  absence	  of	  viability,	  there	  was	  no	  significant	  difference	  between	  the	  risk	  of	  death	  with	  revascularisation	  (7.7%)	  or	  medical	  therapy	  (6.2%)	  (figure	  1.2).	  	  	  
	  
Figure	  1.2:	  Mortality	  for	  patients	  with	  and	  without	  myocardial	  viability	  
treated	  by	  revascularisation	  or	  medical	  therapy.	  	  
There	  is	  79.6%	  reduction	  in	  mortality	  for	  patients	  with	  viability	  treated	  by	  revascularisation.	  In	  patients	  without	  myocardial	  viability,	  there	  is	  no	  significant	  difference	  in	  mortality	  between	  patients	  treated	  with	  revascularisation	  and	  those	  treated	  with	  medical	  therapy;	  from26.	  	  In	  contrast,	  a	  sub	  study	  of	  the	  recent	  STICH	  trial27,	  has	  questioned	  the	  role	  of	  viability	  testing	  prior	  to	  revascularisation.	  This	  prospective	  study	  of	  601	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patients	  used	  SPECT	  or	  DSE	  to	  identify	  viability.	  Patients	  were	  randomly	  assigned	  to	  intensive	  medical	  therapy	  and	  CABG	  or	  intensive	  medical	  therapy	  alone.	  37%	  of	  patients	  with	  viable	  myocardium	  and	  51%	  of	  patients	  without	  died	  during	  follow-­‐up.	  After	  adjustment	  for	  differences	  in	  baseline	  variables	  and	  risk	  factors,	  there	  was	  no	  significant	  association	  between	  viability	  and	  mortality.	  Furthermore	  patients	  with	  viable	  myocardium	  who	  were	  assigned	  to	  CABG	  plus	  medical	  therapy	  did	  not	  have	  improved	  survival	  compared	  to	  those	  assigned	  to	  medical	  therapy	  alone.	  However,	  it	  is	  important	  to	  understand	  the	  limitations	  of	  this	  study,	  which	  may	  well	  have	  affected	  the	  findings.	  Firstly,	  patients	  were	  not	  assigned	  to	  a	  treatment	  group	  based	  on	  the	  result	  of	  the	  imaging	  test.	  Secondly,	  viability	  imaging	  was	  not	  mandated	  as	  part	  of	  the	  main	  study	  protocol	  and	  was	  only	  performed	  at	  the	  discretion	  of	  the	  investigators.	  It	  is	  not	  clear	  which	  factors	  influenced	  the	  decision	  to	  perform	  viability	  imaging.	  Thirdly,	  the	  combination	  of	  two	  different	  modalities	  to	  determine	  viability	  resulted	  in	  different,	  and	  somewhat	  arbitrary,	  criteria	  being	  used	  to	  define	  viability.	  Viability	  was	  defined	  as	  the	  presence	  of	  11	  or	  more	  viable	  segments	  based	  on	  relative	  tracer	  activity	  with	  SPECT,	  or	  five	  or	  more	  segments	  with	  abnormal	  resting	  systolic	  function	  but	  manifesting	  contractile	  reserve	  during	  dobutamine	  administration	  with	  DSE.	  Fourthly,	  81%	  of	  patients	  were	  defined	  as	  having	  viability	  and	  only	  19%	  were	  defined	  as	  non-­‐viable.	  Fifthly,	  the	  imaging	  findings	  were	  not	  related	  to	  the	  coronary	  anatomy.	  Finally,	  there	  were	  important	  differences	  between	  the	  two	  treatment	  groups	  as	  patients	  in	  the	  medical	  therapy	  arm	  of	  the	  trial	  had	  a	  significantly	  higher	  rate	  of	  aspirin	  and	  statin	  use	  at	  baseline	  compared	  to	  patients	  who	  underwent	  CABG.	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There	  is	  therefore	  conflicting	  evidence	  about	  the	  role	  of	  viability	  imaging	  to	  guide	  revascularisation.	  To	  date	  there	  are	  still	  no	  prospective	  randomised	  trials	  on	  the	  prognostic	  value	  of	  viability	  imaging.	  
	  
Non-­‐invasive	  functional	  assessment	  On	  the	  basis	  of	  all	  of	  the	  above	  evidence	  most	  clinicians	  accept	  that	  combining	  anatomical	  information	  with	  a	  functional	  assessment	  pre	  revascularisation	  in	  patients	  with	  complex	  CAD	  is	  important.	  A	  number	  of	  non-­‐invasive	  imaging	  modalities	  are	  available	  each	  with	  its	  own	  inherent	  advantages	  and	  disadvantages.	  Clinicians	  frequently	  decide	  which	  method	  is	  most	  appropriate	  according	  to	  the	  clinical	  situation	  and	  to	  local	  expertise	  and	  the	  availability	  of	  different	  modalities.	  	  	  
Non	  invasive	  ischaemia	  detection	  When	  myocardial	  oxygen	  demand	  exceeds	  supply	  a	  sequence	  of	  haemodynamic	  and	  cardiac	  electrophysiologic	  changes	  occur	  that	  culminate	  in	  angina.	  This	  sequence	  of	  events	  is	  termed	  the	  ischaemic	  cascade28	  (figure	  1.3).	  Detection	  of	  one	  of	  the	  steps	  of	  this	  cascade	  forms	  the	  basis	  of	  all	  non-­‐invasive	  ischaemia	  detection.	  Investigations	  targeting	  earlier	  steps	  in	  the	  cascade	  in	  theory	  should	  be	  more	  sensitive	  than	  techniques	  targeting	  later	  steps	  in	  the	  cascade.	  This	  notion	  is	  supported	  by	  a	  study	  using	  echocardiography	  in	  dogs29.	  In	  this	  study	  myocardial	  contrast	  echocardiography	  (MCE)	  detected	  both	  lower	  grade	  stenoses	  and	  abnormalities	  of	  perfusion	  at	  lower	  doses	  of	  dobutamine	  than	  wall	  motion	  assessment.	  Furthermore,	  MCE	  identified	  a	  larger	  volume	  of	  abnormal	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myocardium	  than	  wall	  motion	  assessment.	  These	  findings	  particularly	  applied	  in	  cases	  of	  single	  vessel	  stenosis	  compared	  to	  multivessel	  stenosis	  	  
	  
	  
Figure	  1.3:	  The	  ischaemic	  cascade.	  	  
Diagnostic	  investigations	  target	  different	  steps	  on	  the	  pathway	  as	  marked.	  Targeting	  earlier	  steps	  may	  result	  in	  increased	  test	  sensitivity.	  	  Exercise-­‐ECG	  testing	  detects	  ECG	  changes	  and	  angina.	  Stress	  echocardiography	  and	  CMR	  detect	  wall	  motion	  abnormalities.	  Perfusion	  imaging	  is	  considered	  in	  more	  detail	  below.	  	  
CMR	  ischaemia	  testing	  by	  wall	  motion	  assessment	  Ischaemia	  detection	  by	  wall	  motion	  assessment	  requires	  the	  use	  of	  pharmacologic	  or	  exercise	  stress.	  Pharmacologic	  stress	  involves	  administration	  of	  a	  standard	  dobutamine/atropine	  protocol	  to	  achieve	  a	  target	  heart	  rate.	  The	  occurrence	  of	  new	  wall	  motion	  abnormalities	  during	  increasing	  doses	  of	  dobutamine	  is	  considered	  diagnostic	  of	  ischaemia.	  Nagel	  et	  al30	  were	  the	  first	  to	  validate	  dobutamine	  CMR	  for	  the	  detection	  of	  CAD.	  Dobutamine	  CMR	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performed	  better	  than	  stress	  echocardiography	  in	  the	  identification	  of	  CAD	  using	  at	  least	  50%	  stenosis	  on	  coronary	  angiography	  as	  the	  gold	  standard.	  CMR	  sensitivity	  and	  specificity	  in	  this	  study	  of	  208	  patients	  were	  88.7%	  and	  85.7%	  respectively.	  Many	  validation	  studies	  have	  been	  performed	  and	  reported	  similar	  results	  since.	  However	  as	  the	  studies	  are	  relatively	  small	  the	  confidence	  intervals	  are	  often	  wide.	  Nandalur	  et	  al31	  pooled	  the	  data	  from	  14	  studies	  and	  724	  patients	  and	  confirmed	  good	  sensitivity	  (83%;	  95%	  CI	  79-­‐88%)	  and	  specificity	  (86%;	  95%	  CI	  81-­‐91%)	  of	  stress	  induced	  wall	  motion	  abnormalities	  against	  X-­‐ray	  coronary	  angiography	  for	  the	  detection	  of	  CAD.	  It	  is	  noteworthy	  that	  there	  was	  a	  high	  prevalence	  of	  CAD	  (70.5%)	  in	  the	  735	  participants	  included	  in	  the	  13	  studies	  combined.	  	  High	  dose	  dobutamine-­‐atropine	  stress	  CMR	  is	  safe	  in	  addition	  to	  being	  effective.	  In	  a	  series	  of	  1000	  patients32	  adverse	  events	  included	  one	  case	  (0.1%)	  of	  sustained	  and	  four	  cases	  (0.4%)	  of	  non-­‐sustained	  ventricular	  tachycardia,	  16	  cases	  (1.6%)	  of	  atrial	  ﬁbrillation,	  and	  two	  cases	  (0.2%)	  of	  transient	  second	  degree	  AV	  block.	  	  	  Exercise	  stress	  CMR	  is	  also	  technically	  possible	  using	  a	  specific	  MRI-­‐compatible	  cycle	  ergometer.	  Recent	  work	  suggests	  that	  it	  may	  be	  possible	  to	  overcome	  some	  of	  the	  technical	  limitations,	  such	  as	  motion	  and	  difficulties	  in	  breath	  holding	  by	  using	  real	  time	  exercise	  stress	  CMR	  images33.	  However	  at	  present	  exercise	  stress	  is	  not	  in	  routine	  clinical	  use	  despite	  good	  preliminary	  clinical	  results34.	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Non-­‐invasive	  assessment	  of	  myocardial	  perfusion	  A	  number	  of	  different	  modalities	  have	  been	  developed	  for	  imaging	  myocardial	  perfusion.	  In	  order	  to	  understand	  these	  imaging	  techniques	  some	  knowledge	  of	  the	  myocardial	  blood	  supply	  is	  required.	  	  
Coronary	  physiology	  Under	  resting	  conditions	  myocardial	  oxygen	  extraction	  from	  the	  blood	  is	  very	  high-­‐around	  two	  thirds	  of	  the	  available	  oxygen.	  Myocardial	  perfusion	  is	  therefore	  tightly	  controlled	  by	  autoregulation	  and	  in	  normal	  hearts	  perfusion	  can	  increase	  up	  to	  3	  or	  4	  fold	  within	  seconds	  in	  response	  to	  an	  increase	  in	  demand.	  	  	  The	  coronary	  circulation	  is	  divided	  into	  three	  functional	  compartments	  (figure	  1.4).	  The	  proximal	  compartment,	  represented	  by	  the	  epicardial	  arteries,	  has	  a	  capacitance	  function.	  The	  mid	  compartment	  consists	  of	  pre-­‐arterioles	  and	  the	  distal	  compartment	  is	  made	  up	  of	  arterioles.	  The	  function	  of	  the	  pre-­‐arterioles	  is	  to	  maintain	  a	  constant	  pressure	  at	  the	  origin	  of	  the	  arterioles.	  Proximal	  pre-­‐arterioles	  respond	  to	  shear	  stress	  and	  higher	  flows	  result	  in	  flow-­‐mediated	  dilatation.	  Distal	  pre-­‐arterioles	  are	  more	  pressure-­‐responsive	  and	  dilate	  in	  response	  to	  increased	  intravascular	  pressure	  under	  myogenic	  control.	  The	  arterioles	  and	  endothelium	  have	  an	  important	  role	  in	  the	  regulation	  of	  myocardial	  perfusion.	  They	  have	  a	  high	  resting	  tone	  and	  dilate	  in	  response	  to	  the	  release	  of	  metabolites	  by	  the	  myocardium	  as	  a	  result	  of	  an	  increase	  in	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oxygen	  consumption35.	  Blood	  flow	  through	  the	  coronary	  system	  is	  regulated	  almost	  entirely	  by	  this	  vascular	  response	  to	  local	  demand.	  	  
	  
Figure	  1.4:	  The	  coronary	  circulation.	  
The	  three	  functional	  compartments	  of	  the	  coronary	  circulation	  are	  shown	  together	  with	  an	  illustration	  of	  the	  associated	  pressure	  changes	  and	  their	  responsiveness	  to	  shear	  stress,	  pressure	  and	  metabolites.	  From	  36.	  
	  At	  rest,	  myocardial	  perfusion	  is	  in	  the	  region	  of	  0.5-­‐1.0	  millilitres/minute/gram	  (ml/min/g),	  which	  is	  equivalent	  to	  approximately	  5%	  of	  the	  total	  cardiac	  output.	  In	  the	  presence	  of	  obstructive	  CAD	  rest	  perfusion	  is	  maintained	  by	  autoregulation	  until	  the	  mean	  diameter	  stenosis	  reaches	  approximately	  85%3.	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Hyperaemic	  perfusion	  however	  begins	  to	  reduce	  in	  the	  presence	  of	  stenoses	  of	  approximately	  40%3.	  Myocardial	  perfusion	  imaging	  must	  therefore	  be	  performed	  during	  hyperaemia	  to	  detect	  flow-­‐limiting	  CAD.	  Coronary	  vessel	  wall	  structure37	  and	  their	  epi	  to	  endocardial	  direction	  coupled	  with	  high	  left	  ventricular	  systolic	  pressures38	  result	  in	  the	  endocardium	  being	  more	  vulnerable	  to	  ischaemia	  than	  the	  epicardium.	  High-­‐resolution	  imaging	  techniques,	  which	  can	  differentiate	  the	  endo	  and	  epicardial	  layers,	  may	  therefore	  be	  more	  sensitive	  than	  lower	  resolution	  techniques.	  
	  
Stress	  perfusion	  imaging	  The	  most	  physiological	  and	  therefore	  best	  stressor	  to	  achieve	  coronary	  hyperaemia	  is	  exercise.	  However	  this	  is	  frequently	  impossible	  or	  difficult	  due	  to	  limitations	  related	  to	  the	  imaging	  technique	  or	  the	  patient.	  Imaging	  frequently	  requires	  the	  patient	  to	  be	  still	  or	  within	  a	  scanner	  limiting	  their	  ability	  to	  exercise.	  In	  addition	  patient	  motivation	  or	  comorbidity	  may	  prevent	  them	  from	  achieving	  hyperaemia	  through	  exercise.	  As	  a	  result	  pharmacologic	  agents	  are	  frequently	  used	  to	  achieve	  hyperaemia.	  Vasodilators	  (adenosine,	  dypirdamole)	  are	  the	  preferred	  agents	  however	  catecholamines	  (dobutamine)	  can	  also	  be	  useful.	  Adenosine	  is	  used	  most	  frequently	  and	  induces	  hyperaemia	  by	  A2A	  receptor	  mediated	  vasodilation	  of	  the	  smooth	  muscle	  cells	  of	  coronary	  vessels.	  Dipyridamole	  indirectly	  activates	  the	  same	  pathway	  by	  inhibiting	  the	  cellular	  uptake	  of	  adenosine	  and,	  consequently,	  increasing	  its	  interstitial	  concentrations.	  The	  excess	  adenosine	  nonselectively	  activates	  all	  adenosine	  receptor	  subtypes,	  including	  the	  A2A	  receptors,	  resulting	  in	  vasodilation.	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  Unfortunately	  adenosine	  is	  not	  a	  selective	  A2A	  receptor	  agonist	  and	  stimulation	  of	  A1,	  A2B,	  and	  A3	  receptors	  frequently	  results	  in	  adverse	  effects.	  These	  are	  usually	  self-­‐limiting	  and	  include	  flushing,	  chest	  pain,	  dyspnoea,	  dizziness,	  and	  nausea.	  However	  despite	  being	  medically	  trivial	  these	  symptoms	  can	  be	  distressing	  to	  the	  patient.	  Rarely,	  more	  serious	  adverse	  events,	  including	  bronchospasm	  (mediated	  by	  the	  A1,	  A2B,	  and	  A3	  receptors),	  atrioventricular	  block	  (A1	  receptor),	  and	  peripheral	  vasodilation	  (A2B	  receptor)	  resulting	  in	  hypotension	  can	  occur.	  Adenosine	  is	  thus	  contraindicated	  in	  subjects	  with	  asthma,	  advanced	  atrioventricular	  block	  or	  severe	  hypotension.	  	  	  Most	  published	  studies	  have	  used	  adenosine	  or	  dipyridamole	  however	  newer,	  more	  selective	  A2a	  agonists	  such	  as	  regadenoson	  appear	  to	  provide	  equivalent	  diagnostic	  information	  with	  an	  improved	  adverse	  effect	  profile39.	  	  
Qualitative	  versus	  quantitative	  assessment	  of	  perfusion	  Broadly,	  myocardial	  perfusion	  can	  be	  assessed	  qualitatively	  or	  quantitatively.	  Qualitative	  assessment	  relies	  on	  the	  presence	  of	  a	  normally	  perfused	  area	  of	  myocardium.	  Abnormal	  areas	  can	  then	  identified	  as	  they	  have	  relatively	  less	  perfusion	  in	  comparison.	  	  The	  main	  advantage	  of	  this	  approach	  is	  that	  it	  is	  simpler	  to	  implement	  and	  does	  not	  require	  complex	  image	  post-­‐processing	  allowing	  rapid	  interpretation	  and	  reporting	  of	  studies.	  	  However,	  in	  general,	  quantification	  of	  images	  results	  in	  more	  precise	  and	  user-­‐
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independent	  results40.	  Absolute	  quantification	  of	  myocardial	  perfusion	  involves	  calculating	  myocardial	   perfusion	   in	  ml/min/g	   and	   is	   therefore	  not	   dependent	  on	   the	   presence	   of	   a	   normally	   perfused	   region	   of	   myocardium.	   Full	  quantification	   has	   proven	   benefits	   and	   also	   potential	   advantages	   over	   non-­‐quantitative	  methods41.	  The	  benefits	  of	  quantitative	  perfusion	  have	  been	  largely	  confirmed	  by	  PET	  studies.	  The	  PET-­‐derived	  ratio	  of	  the	  absolute	  stress	  to	  rest	  perfusion	   values,	   known	   as	   the	   coronary	   flow	   reserve	   (CFR)	   or	   myocardial	  perfusion	   reserve	   (MPR),	   decreases	   in	   proportion	   to	   the	   coronary	   artery	  luminal	  diameter	  stenosis.	  CFR	  and	  MPR	  can	  thus	  be	  used	  for	  the	  diagnosis	  of	  CAD42	   43.	  Recent	  studies	  using	   13N-­‐ammonia	  PET	  have	  also	  demonstrated	   that	  an	   abnormal	   MPR	   is	   an	   independent	   predictor	   of	   an	   adverse	   prognosis44,	   45.	  Furthermore,	   quantitative	   data	   also	   provides	   unique	   information	   about	   the	  coronary	   microcirculation	   which	   is	   not	   available	   from	   non-­‐quantitative	  methods36.	  	  	  In	  addition	  to	  these	  proven	  benefits,	  more	  precise,	  user-­‐independent,	  quantitative	  measurements	  of	  myocardial	  perfusion	  should	  allow	  more	  robust	  assessment	  of	  perfusion	  in	  cases	  where	  visual	  assessment	  is	  difficult	  such	  as	  multivessel	  disease,	  severe	  left	  ventricular	  impairment	  and	  after	  CABG.	  Moreover,	  it	  may	  eventually	  allow	  the	  definition	  of	  thresholds	  of	  perfusion	  associated	  with	  myocardial	  ischaemia46	  	  and	  viability	  both	  of	  which	  are	  known	  to	  be	  important	  for	  selecting	  patients	  for	  revascularization	  procedures.	  	  However,	  in	  order	  to	  be	  clinically	  useful,	  techniques	  for	  non-­‐invasive	  quantification	  of	  myocardial	  perfusion	  must	  fulfil	  a	  number	  of	  criteria.	  Firstly	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they	  must	  be	  validated	  against	  gold-­‐standard	  techniques	  to	  ensure	  accuracy	  of	  the	  results.	  Secondly	  they	  must	  be	  reproducible-­‐intra	  and	  inter-­‐observer	  and	  inter-­‐study	  reproducibility	  must	  be	  within	  acceptable	  limits.	  Thirdly	  imaging	  and	  post-­‐processing	  methods	  must	  be	  widely	  available.	  Fourthly	  methods	  must	  be	  quick	  and	  automated	  insofar	  as	  possible.	  Overly	  time-­‐consuming	  methods	  will	  not	  be	  used	  or	  cost-­‐efficient.	  Finally	  they	  must	  be	  acceptable	  to	  the	  patient.	  	  The	  following	  section	  considers	  the	  different	  modalities	  available	  for	  non-­‐invasive	  assessment	  of	  myocardial	  perfusion.	  Each	  modality	  is	  outlined	  including:	  a	  description	  of	  the	  method,	  advantages,	  diagnostic	  and	  prognostic	  performance	  and	  finally	  their	  limitations.	  This	  comparison	  between	  the	  various	  methods	  is	  summarised	  in	  table	  1.1	  on	  page	  45.	  	  For	  the	  detection	  of	  CAD	  all	  of	  the	  imaging	  methods	  are	  reported	  to	  be	  very	  accurate	  with	  high	  sensitivity	  and	  specificity.	  However	  although	  these	  data	  are	  presented	  together	  caution	  is	  required	  when	  comparing	  methods.	  The	  accuracy	  of	  any	  test	  will	  vary	  depending	  on	  the	  prevalence	  of	  the	  condition	  under	  consideration	  and	  on	  other	  factors	  specific	  to	  the	  population	  being	  tested.	  Studies	  tend	  to	  include	  a	  high	  proportion	  of	  patients	  with	  CAD,	  which	  will	  often	  improve	  the	  accuracy	  of	  the	  imaging	  technique	  but	  may	  not	  reflect	  its	  performance	  in	  other	  cohorts	  of	  patients.	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Non-­‐invasive	  myocardial	  perfusion	  imaging	  
Nuclear	  perfusion	  techniques	  Nuclear	  perfusion	  techniques	  involve	  the	  administration	  of	  a	  radioisotope,	  which	  emits	  gamma	  photons	  by	  radioactive	  decay.	  Uptake	  of	  the	  radioisotope	  by	  the	  heart	  is	  related	  to	  myocardial	  perfusion.	  Detection	  of	  the	  radioisotopes	  by	  a	  gamma	  camera	  thus	  allows	  assessment	  of	  myocardial	  perfusion.	  	  
Single	  Photon	  Emission	  Tomography	  (SPECT)	  
Description	  and	  Advantages	  Cardiac	  SPECT	  uses	  radiotracers,	  which	  emit	  single	  photons,	  particularly	  thallium-­‐201,	  and	  technetium-­‐99m,	  which	  are	  extracted	  from	  the	  circulation	  as	  a	  function	  of	  blood	  flow.	  Comparison	  of	  stress	  and	  rest	  imaging	  allows	  the	  identification	  of	  regions	  of	  reduced	  perfusion	  compared	  to	  remote	  normal	  regions.	  Stress	  imaging	  can	  be	  performed	  during	  exercise,	  pharmacological	  stress	  or	  a	  combination	  of	  both.	  Modern	  gamma	  cameras	  have	  resulted	  in	  faster	  imaging	  and	  studies	  can	  now	  be	  completed	  within	  minutes.	  SPECT	  is	  widely	  available,	  well	  established	  and	  effective.	  It	  has	  a	  robust	  evidence	  base	  and	  most	  evidence	  today	  supporting	  the	  concept	  of	  ischaemia	  imaging	  as	  an	  essential	  part	  of	  the	  workup	  of	  these	  patients	  comes	  from	  SPECT	  imaging.	  	  	  
Diagnostic	  and	  Prognostic	  Performance	  There	  are	  a	  large	  number	  of	  studies	  evaluating	  the	  diagnostic	  performance	  of	  SPECT	  imaging.	  These	  studies	  have	  reported	  high	  sensitivity	  and	  moderate	  to	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high	  specificity	  for	  the	  detection	  of	  CAD.	  The	  reported	  sensitivity	  and	  specificity	  of	  exercise	  SPECT	  when	  compared	  with	  invasive	  angiography	  range	  between	  85–90%	  and	  70–75%,	  respectively47.	  Furthermore,	  there	  is	  a	  very	  extensive	  literature	  demonstrating	  that	  SPECT	  imaging	  provides	  prognostic	  information.	  In	  one	  meta-­‐analysis	  of	  39,173	  patients	  with	  a	  mean	  follow-­‐up	  of	  2.3	  years	  a	  normal	  scan	  was	  shown	  to	  predict	  a	  good	  outcome	  (0.6%	  annual	  rate	  of	  non-­‐fatal	  myocardial	  infarction	  or	  cardiac	  death).	  Conversely	  an	  abnormal	  scan	  predicts	  a	  significantly	  higher	  risk	  of	  myocardial	  infarction	  or	  death	  (5.9%	  annual	  event	  rate	  over	  3	  years	  in	  the	  same	  meta-­‐analysis)10.	  	  	  
Limitations	  Nuclear	  techniques	  involve	  the	  use	  of	  ionising	  radiation	  which	  is	  particularly	  important	  in	  younger	  patients	  or	  when	  repeated	  examinations	  are	  required.	  Spatial	  resolution	  of	  SPECT	  is	  also	  sub-­‐optimal-­‐in	  the	  region	  of	  10x10mm.	  This	  has	  been	  proven	  to	  be	  clinically	  relevant	  as	  it	  is	  less	  accurate	  for	  the	  detection	  of	  subendocardial	  myocardial	  infarction	  than	  CMR48.	  Lower	  spatial	  resolution	  also	  limits	  the	  detection	  of	  transmural	  differences	  in	  perfusion,	  which	  translates	  to	  a	  lower	  sensitivity	  for	  moderate	  stenoses	  compared	  to	  CMR49.	  	  
Positron	  Emission	  Tomography	  (PET)	  
Description	  and	  Advantages	  PET	  uses	  positron-­‐emitting	  radiotracers	  with	  physical	  properties	  identical	  to	  naturally	  occurring	  elements	  and	  emission-­‐computed	  tomography	  to	  produce	  images	  of	  myocardial	  perfusion	  (and	  also	  metabolism).	  Radiotracers	  emit	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positrons	  from	  their	  nuclei;	  these	  positrons	  collide	  with	  electrons	  and	  the	  ensuing	  annihilation	  reaction	  results	  in	  the	  emission	  of	  two	  photons	  travelling	  in	  opposite	  directions.	  The	  PET	  scanner	  detects	  photons	  and	  only	  registers	  events	  when	  paired	  photons	  are	  detected	  by	  opposing	  detectors	  (temporal	  coincidence).	  This	  temporal	  coincidence	  results	  in	  improved	  accuracy	  compared	  to	  SPECT.	  Myocardial	  perfusion	  is	  evaluated	  using	  13N-­‐ammonia,	  15O-­‐water	  or	  82Rubidium.	  	  	  Advantages	  of	  PET	  imaging	  include	  the	  ability	  to	  fully	  quantify	  myocardial	  perfusion,	  superior	  resolution	  to	  SPECT	  and	  a	  lower	  radiation	  dose	  than	  SPECT	  (see	  table	  1.1).	  	  	  
Diagnostic	  and	  Prognostic	  Performance	  PET	  has	  been	  shown	  to	  be	  more	  accurate	  than	  SPECT	  for	  the	  diagnosis	  of	  CAD50	  against	  coronary	  angiography	  with	  a	  meta	  analysis	  including	  1442	  patients	  demonstrating	  92%	  sensitivity	  and	  85%	  specificity.	  Furthermore,	  the	  prognostic	  value	  of	  PET	  myocardial	  perfusion	  imaging	  has	  also	  been	  demonstrated	  in	  several	  studies	  with	  abnormal	  scans	  associated	  with	  an	  increase	  in	  adverse	  cardiac	  events	  and	  mortality51	  52	  53.	  One	  study	  of	  685patients	  followed	  up	  for	  a	  mean	  of	  3.4	  years	  demonstrated	  that	  the	  prognostic	  utility	  is	  similar	  to	  SPECT.	  A	  normal	  PET	  study	  was	  associated	  with	  0.9%	  annual	  cardiac	  mortality	  and	  a	  4.3%	  rate	  in	  those	  with	  abnormal	  scans52.	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Limitations	  Disadvantages	  of	  PET	  include	  the	  use	  of	  ionizing	  radiation	  and	  inferior	  spatial	  resolution	  compared	  to	  CMR.	  The	  main	  limitation	  of	  PET-­‐imaging	  however	  is	  the	  requirement	  for	  an	  on-­‐site	  cyclotron	  to	  produce	  many	  of	  the	  radiotracers	  with	  resulting	  high	  costs	  and	  limited	  availability.	  
	  
Myocardial	  contrast	  echocardiography	  (MCE)	  Echocardiographic	  evaluation	  of	  ischaemia	  usually	  involves	  the	  identification	  of	  wall	  motion	  abnormalities,	  which	  occur	  during	  pharmacological	  or	  exercise	  stress.	  However	  perfusion	  can	  also	  be	  evaluated	  using	  MCE.	  	  
Description	  and	  Advantages	  Echocardiography	  contrast	  agents	  contain	  microbubbles.	  Contrast	  agent	  is	  infused	  intravenously	  until	  a	  steady	  state	  is	  reached	  within	  the	  circulation.	  The	  bubbles	  within	  the	  imaging	  field	  are	  then	  destroyed	  by	  high-­‐energy	  ultrasound.	  Microbubbles	  remain	  within	  the	  intravascular	  space	  and	  the	  rate	  of	  microbubble	  replenishment	  reflects	  myocardial	  perfusion.	  This	  method	  can	  be	  used	  with	  pharmacological	  stress	  to	  detect	  regions	  of	  hypoperfusion.	  Evaluation	  of	  this	  microbubble	  replenishment	  can	  be	  qualitative	  or	  quantitative.	  The	  rate	  of	  replenishment	  can	  be	  used	  to	  calculate	  blood	  velocity	  and	  subsequently	  absolute	  perfusion.	  MCE	  is	  a	  non-­‐ionising,	  relatively	  low-­‐cost	  technique	  with	  high	  spatio-­‐temporal	  resolution.	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Diagnostic	  and	  Prognostic	  Performance	  MCE	  also	  been	  reported	  to	  be	  accurate	  for	  the	  detection	  of	  CAD	  with	  a	  sensitivity	  of	  82%	  and	  specificity	  of	  80%	  in	  a	  combined	  analysis	  including	  1088	  patients54.	  Furthermore,	  there	  is	  evidence	  from	  a	  retrospective	  study	  that	  MCE	  can	  also	  provide	  prognostic	  information	  with	  abnormal	  perfusion	  associated	  with	  a	  higher	  rate	  of	  death	  and	  non-­‐fatal	  myocardial	  infarction	  in	  788	  patients	  followed	  up	  for	  1.7	  years55.	  	  
Limitations	  MCE	  can	  be	  limited	  by	  poor	  acoustic	  windows	  and	  endocardial	  definition.	  Despite	  the	  evidence	  behind	  MCE	  uptake	  of	  this	  technique	  has	  been	  limited	  due	  to	  difficulties	  performing	  the	  examinations	  compared	  to	  wall	  motion	  assessment	  and	  a	  lack	  of	  suitable	  expertise.	  	  
Computed	  Tomography	  	  
Description	  and	  Advantages	  Computed	  tomography	  (CT)	  is	  a	  rapidly	  emerging	  cardiovascular	  imaging	  modality	  and	  can	  assess	  left	  ventricular	  function56,	  and	  potentially	  perfusion	  and	  viability57.	  CT	  perfusion	  imaging	  is	  similar	  to	  CMR	  in	  that	  the	  first	  pass	  of	  a	  contrast	  agent	  into	  the	  myocardium	  is	  imaged.	  During	  hyperaemia	  perfusion	  of	  contrast	  into	  the	  myocardium	  subtended	  by	  vessels	  with	  flow-­‐limiting	  CAD	  does	  not	  increase	  as	  much	  as	  perfusion	  of	  contrast	  into	  myocardium	  supplied	  by	  normal	  vessels	  resulting	  in	  perfusion	  defects.	  In	  contrast	  to	  CMR	  perfusion	  imaging,	  which	  is	  dynamic,	  CT	  perfusion	  usually	  involves	  acquisition	  of	  a	  single	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image	  of	  the	  first	  pass	  of	  contrast	  agent	  in	  order	  to	  limit	  the	  dose	  of	  radiation.	  There	  are	  however	  small	  studies	  demonstrating	  the	  feasibility58	  and	  validity59	  of	  continuous	  imaging	  of	  the	  first	  pass	  and	  subsequent	  quantitative	  evaluation	  of	  perfusion.	  	  Advantages	  of	  CT	  perfusion	  imaging	  include	  rapid	  data	  acquisition	  at	  very	  high	  spatial	  resolution.	  Another	  potential	  advantage	  is	  the	  possibility	  of	  a	  single	  comprehensive	  cardiac	  examination	  incorporating	  anatomy	  (coronary	  angiography	  and	  scar)	  and	  function	  (LV	  function	  and	  perfusion).	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Diagnostic	  and	  Prognostic	  Performance	  Small	  single-­‐centre	  studies	  have	  recently	  demonstrated	  that	  CT	  perfusion	  is	  accurate	  compared	  to	  SPECT60,	  CMR61	  and	  coronary	  angiography57.	  	  
Limitations	  CT	  perfusion	  techniques	  are	  not	  currently	  well	  established	  and	  its	  main	  strength	  at	  present	  is	  coronary	  artery	  imaging.	  The	  major	  disadvantage	  of	  CT	  is	  its	  significant	  radiation	  exposure	  particularly	  if	  coronary	  angiography,	  function,	  perfusion	  and	  viability	  are	  all	  studied	  or	  when	  repeated	  examinations	  are	  required.	  The	  quality	  of	  CT	  data	  is	  also	  compromised	  by	  tachycardia,	  which	  can	  cause	  problems	  when	  pharmacologic	  stress	  is	  used.	  Furthermore	  the	  risk	  of	  contrast	  nephropathy	  with	  iodinated	  contrast	  agents	  limits	  its	  use	  in	  patients	  with	  renal	  dysfunction.	  	  
CMR	  perfusion	  imaging	  	  
Description	  and	  Advantages	  Magnetic	  resonance	  describes	  a	  property	  of	  elements	  with	  an	  uneven	  number	  of	  protons	  and	  neutrons	  to	  rotate	  or	  “spin”	  around	  their	  axis.	  In	  a	  strong	  magnetic	  field	  these	  spins	  align	  parallel	  or	  anti-­‐parallel	  to	  the	  external	  magnetic	  field.	  A	  small	  excess	  of	  spins	  align	  parallel	  to	  the	  field	  producing	  a	  detectable	  net	  magnetisation	  vector.	  For	  clinical	  magnetic	  resonance	  imaging	  hydrogen	  nuclei	  are	  imaged	  due	  to	  the	  abundance	  of	  these	  nuclei	  in	  human	  tissue.	  Radiofrequency	  waves	  are	  transmitted	  into	  the	  heart	  (RF	  pulse)	  and	  cause	  a	  brief	  excitation	  and	  subsequent	  relaxation	  of	  the	  hydrogen	  nuclei.	  Excitation	  of	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the	  hydrogen	  nuclei	  results	  in	  two	  important	  changes	  to	  the	  net	  magnetisation	  vector.	  Firstly	  it	  tips	  in	  the	  longitudinal	  direction	  out	  of	  alignment	  with	  the	  external	  magnetic	  field.	  Secondly	  the	  RF	  pulse	  causes	  the	  spins	  to	  rotate	  together	  or	  in	  phase	  in	  the	  transverse	  direction.	  Following	  this	  excitation	  the	  net	  magnetisation	  vector	  returns	  to	  baseline,	  which	  is	  termed	  relaxation.	  This	  relaxation	  is	  exponential	  and	  the	  rate	  of	  relaxation	  is	  defined	  by	  two	  parameters	  known	  as	  T1	  and	  T2.	  	  T1	  describes	  the	  time	  it	  takes	  for	  63%	  of	  the	  longitudinal	  magnetisation	  to	  recover	  after	  a	  90-­‐degree	  displacement.	  T2	  describes	  the	  transverse	  relaxation	  as	  the	  spins	  de-­‐phase.	  Relaxation	  is	  associated	  with	  energy	  release,	  which	  can	  be	  detected	  by	  receiver	  coils,	  which	  act	  like	  antennae.	  This	  can	  then	  be	  converted	  to	  images	  by	  Fourier	  transformation.	  T1	  and	  T2	  values	  vary	  according	  to	  the	  tissue	  composition	  and	  this	  can	  be	  exploited	  to	  produce	  an	  intrinsic	  contrast	  between	  different	  tissues.	  	  CMR	  first	  pass	  perfusion	  imaging	  was	  first	  introduced	  in	  1990.	  A	  bolus	  of	  contrast	  agent	  is	  injected	  into	  a	  peripheral	  vein	  and	  a	  series	  of	  images	  are	  acquired	  during	  the	  first	  pass	  of	  the	  contrast	  agent	  into	  the	  myocardium.	  High	  temporal	  resolution	  is	  required	  in	  order	  to	  image	  multiple	  regions	  of	  the	  heart	  repeatedly	  during	  transit	  of	  the	  contrast	  agent.	  Perfusion	  imaging	  is	  based	  on	  the	  same	  principles	  as	  described	  above.	  Modern	  perfusion	  imaging	  uses	  single-­‐shot	  fast	  gradient	  echo	  based	  sequences.	  A	  non-­‐selective	  90-­‐degree	  (saturation)	  RF	  pulse	  starts	  the	  sequence	  as	  this	  is	  independent	  of	  heart	  rate	  and	  magnetization	  history	  and	  also	  results	  in	  a	  heavily	  T1-­‐weighted	  image.	  This	  is	  important	  as	  the	  contrast	  agent	  contains	  chelated	  gadolinium,	  which	  shortens	  myocardial	  T1	  and	  therefore	  allows	  differentiation	  of	  tissues	  based	  on	  their	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gadolinium	  content	  during	  subsequent	  imaging.	  This	  process	  is	  repeated	  for	  each	  slice	  of	  myocardium	  imaged	  every	  1-­‐2	  heartbeats.	  During	  hyperaemia	  perfusion	  of	  contrast	  into	  the	  myocardium	  subtended	  by	  vessels	  with	  flow-­‐limiting	  CAD	  does	  not	  increase	  as	  much	  as	  perfusion	  of	  contrast	  into	  myocardium	  supplied	  by	  normal	  vessels.	  These	  regions	  contain	  less	  gadolinium	  and	  therefore	  less	  signal	  after	  the	  saturation	  pulse	  and	  are	  dark	  compared	  to	  the	  normally	  perfused	  regions,	  which	  are	  bright.	  In	  the	  clinical	  setting	  this	  is	  usually	  interpreted	  qualitatively	  as	  a	  defect	  in	  the	  contrast	  perfusion	  into	  the	  myocardial	  wall	  visible	  with	  stress	  but	  not	  at	  rest.	  However	  quantitative	  evaluation	  is	  also	  possible	  as	  discussed	  below.	  	  Advantages	   of	   CMR	   include	   freedom	   from	   ionising	   radiation,	   high	   quality	  images	   and	   most	   importantly,	   the	   generation	   of	   a	   complete	   workup	  incorporating	  LV	  volumes	  and	  function,	  myocardial	  viability	  and	  scar,	  as	  well	  as	  ischaemia	  within	  a	  single	  study	  lasting	  approximately	  one	  hour.	  	  
Diagnostic	  and	  Prognostic	  Performance	  There	  are	  a	  number	  of	  single-­‐centre	  studies	  and	  a	  few	  multi-­‐centre	  trials	  comparing	  CMR	  to	  established	  methods	  of	  detecting	  myocardial	  ischaemia.	  In	  a	  meta-­‐analysis31,	  perfusion	  CMR	  was	  assessed	  using	  data	  from	  24	  studies	  and	  1516	  patients	  resulting	  in	  a	  sensitivity	  of	  91%	  (95%	  CI	  88	  to	  94%)	  and	  a	  speciﬁcity	  of	  81%	  (95%	  CI	  77	  to	  85%)	  against	  X-­‐ray	  coronary	  angiography.	  	  	  MR-­‐IMPACT	  was	  the	  first	  multi-­‐centre	  perfusion	  CMR	  trial	  comparing	  CMR	  and	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SPECT	  for	  the	  detection	  of	  myocardial	  ischaemia65.	  Perfusion	  CMR	  was	  determined	  to	  be	  non-­‐inferior	  to	  SPECT	  for	  the	  detection	  of	  CAD	  with	  ≥50%	  stenosis	  on	  quantitative	  X-­‐ray	  coronary	  angiography	  as	  the	  reference	  standard.	  This	  was	  however	  a	  dose-­‐finding	  study	  and	  only	  42	  patients	  formed	  the	  CMR	  cohort	  on	  which	  this	  analysis	  was	  based.	  	  	  The	  larger	  and	  more	  recent	  CE-­‐MARC	  study66	  extended	  these	  findings	  and	  found	  CMR	  to	  be	  superior	  to	  SPECT	  for	  the	  diagnosis	  of	  CAD.	  628	  patients	  with	  suspected	  angina	  underwent	  SPECT,	  CMR	  and	  X-­‐ray	  coronary	  angiography.	  The	  CMR	  protocol	  included	  coronary	  angiography,	  functional,	  and	  scar	  imaging	  in	  addition	  to	  perfusion	  imaging.	  The	  sensitivity	  and	  negative	  predictive	  value	  of	  CMR	  were	  significantly	  better	  than	  SPECT	  imaging.	  Furthermore	  area	  under	  the	  receiver	  operating	  characteristic	  (ROC)	  curve	  was	  significantly	  higher	  for	  stress	  perfusion	  CMR	  compared	  to	  SPECT.	  	  One	  of	  the	  difficulties	  in	  validating	  all	  non-­‐invasive	  methods	  for	  the	  detection	  of	  myocardial	  ischaemia	  is	  the	  absence	  of	  a	  clear	  gold	  standard	  for	  comparison.	  The	  studies	  discussed	  above	  use	  coronary	  angiography	  as	  the	  gold	  standard	  with	  the	  limitations	  discussed	  previously	  in	  this	  article.	  For	  a	  more	  direct	  comparison	  of	  invasive	  versus	  non-­‐invasive	  physiological	  measurements,	  CMR	  has	  been	  validated	  against	  FFR.	  These	  studies	  have	  also	  revealed	  overall	  good	  agreement	  between	  the	  two	  methods	  with	  CMR	  perfusion	  sensitivities	  ranging	  from	  88%-­‐92.9%	  and	  specificities	  from	  56.7%-­‐94%67-­‐69.	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Jahnke	  et	  al12	  demonstrated	  that	  CMR	  perfusion	  imaging	  can	  also	  provide	  prognostic	  data.	  In	  a	  study	  of	  513	  patients	  an	  abnormal	  perfusion	  imaging	  was	  associated	  with	  a	  significantly	  higher	  incidence	  of	  cardiac	  death	  or	  non-­‐fatal	  myocardial	  infarction	  over	  a	  median	  2.3-­‐year	  follow-­‐up	  period.	  	  
Limitations	  CMR	  perfusion	  imaging	  has	  a	  number	  of	  limitations	  at	  present.	  The	  main	  disadvantages	  are	  that	  imaging	  is	  contraindicated	  in	  patients	  with	  certain	  implants	  e.g.	  pacemakers,	  limited	  availability	  and	  rarely	  reduction	  of	  imaging	  quality	  due	  to	  patient	  claustrophobia,	  poor	  gating	  or	  patient	  motion.	  Other	  limitations	  are	  specific	  to	  perfusion	  imaging.	  Most	  CMR	  images	  (for	  example	  cines	  and	  scar	  imaging)	  are	  reconstructed	  from	  a	  number	  of	  cardiac	  cycles	  using	  ECG	  gating.	  This	  is	  not	  possible	  with	  perfusion	  imaging	  as	  it	  is	  necessary	  to	  image	  the	  first	  passage	  of	  the	  contrast	  through	  the	  myocardium.	  As	  a	  consequence	  of	  the	  increased	  temporal	  resolution	  required	  to	  do	  this	  spatial	  resolution	  is	  reduced	  and	  imaging	  is	  more	  prone	  to	  artefacts.	  Dark	  rim	  artefacts	  (DRA)	  are	  the	  most	  problematic	  type	  of	  artefacts	  for	  perfusion	  imaging	  and	  are	  discussed	  in	  more	  detail	  in	  chapter	  3.	  	  
Quantification	  of	  myocardial	  perfusion	  with	  CMR	  Quantification	   of	   perfusion	   with	   CMR	   can	   be	   sub-­‐divided	   into	   semi	   and	   fully	  quantitative	  analysis.	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Semi-­‐quantitative	  analysis	  Initial	  progress	  towards	  quantification	  with	  CMR	  involved	  the	  use	  of	  semi-­‐quantitative	  methods.	  These	  techniques	  make	  use	  of	  the	  changes	  in	  signal	  intensity	  within	  a	  region	  of	  interest	  over	  time-­‐the	  time	  intensity	  curve.	  The	  myocardial	  time	  intensity	  curve	  is	  compared	  at	  stress	  and	  rest	  to	  calculate	  an	  index	  of	  perfusion	  reserve.	  The	  upslope	  of	  this	  curve	  is	  usually	  used	  for	  this	  calculation	  but	  the	  initial	  area	  under	  the	  curve	  and	  the	  amplitude	  have	  also	  been	  used.	  These	  methods	  have	  been	  validated	  in	  animal	  models70,	  71	  and	  can	  improve	  the	  diagnostic	  accuracy	  over	  visual	  analysis	  alone	  in	  humans72.	  Whilst	  these	  methods	  are	  widely	  accepted	  and	  available	  they	  are	  not	  routinely	  used	  outside	  clinical	  studies,	  probably	  as	  the	  post-­‐processing	  required	  is	  not	  felt	  to	  add	  sufficient	  value	  to	  visual	  assessment-­‐alone.	  	  	  
Fully	  quantitative	  analysis	  Full	  quantification	  also	  involves	  interrogation	  of	  signal	  intensity	  curves.	  Calculating	  absolute	  perfusion	  from	  these	  curves	  requires	  the	  use	  of	  complex	  mathematical	  models	  that	  fit	  the	  kinetics	  of	  the	  gadolinium	  contrast	  medium.	  	  Two	  main	  models	  for	  quantification	  of	  absolute	  myocardial	  perfusion	  have	  been	  described	  namely	  the	  linear	  time-­‐invariant	  model,	  including	  Fermi	  constrained	  deconvolution,	  and	  the	  compartment	  model.	  	  	  Both	  models	  make	   a	  number	  of	   assumptions	   that	  must	  be	  upheld	   in	   order	   to	  accurately	  calculate	  perfusion	  and	  sufficient	  myocardial	  contrast	  to	  noise	  ratio	  and	   reasonable	   linearity	   of	   signal	   intensity	   in	   the	   blood	   and	  myocardium	   are	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crucial	  with	  both	  methods	  for	  accurate	  quantification.	  	  	  This	  causes	  a	  problem,	  as	  at	  lower	  doses	  of	  contrast	  agent	  there	  is	  a	  linear	  relationship	  between	  contrast	  agent	  concentration	  and	  signal	  intensity.	  However	  at	  higher	  doses	  of	  contrast	  agent,	  which	  are	  required	  for	  visual	  analysis	  and	  high	  myocardial	  CNR,	  T1-­‐saturation	  effects	  occur	  with	  loss	  of	  this	  linearity73.	  Signal	  attenuation	  is	  particularly	  a	  problem	  in	  the	  LV	  cavity	  where	  the	  signal	  intensity-­‐time	  curve	  usually	  represents	  the	  arterial	  input	  function	  (AIF).	  Potential	  solutions	  to	  this	  problem	  are	  the	  use	  of:	  1. a	  low	  dose	  of	  contrast,	  e.g.	  0.025-­‐0.05	  mmol/L	  with	  a	  strongly	  T1-­‐weighted	  sequence	  for	  the	  whole	  perfusion	  study,	  2. one	  low-­‐dose	  and	  one	  high	  dose	  injection	  of	  contrast	  agent	  for	  each	  perfusion	  acquisition-­‐the	  dual	  bolus	  technique,	  3. or	  a	  hybrid	  perfusion	  sequence	  that	  obtains	  a	  separate	  image	  for	  the	  AIF	  on	  each	  heartbeat.	  	  Quantification	  with	  a	  low-­‐dose	  techniques	  have	  been	  demonstrated	  to	  be	  feasible	  and	  accurate74.	  However,	  this	  approach	  is	  limited	  by	  a	  low	  contrast	  to	  noise	  ratio	  (CNR)	  in	  the	  myocardium	  and	  images	  which	  are	  sub-­‐optimal	  for	  visual	  interpretation65.	  	  	  The	  dual	  bolus	  technique	  uses	  a	  low	  dose	  of	  contrast	  to	  calculate	  the	  AIF	  without	  signal	  saturation	  and	  a	  subsequent	  higher	  dose	  to	  preserve	  myocardial	  CNR.	  Christian	  et	  al	  demonstrated	  in	  dogs	  that	  this	  allows	  accurate	  measurement	  of	  absolute	  epicardial	  and	  endocardial	  perfusion	  across	  a	  wide	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range	  of	  blood	  flow	  rates75.	  In	  a	  subsequent	  comparison	  of	  single	  and	  dual	  bolus	  methods	  both	  single-­‐bolus	  (0.025	  mmol/kg)	  and	  dual-­‐bolus	  (0.0025	  mmol/kg	  and	  0.10	  mmol/kg)	  perfusion	  methods	  correlated	  closely	  with	  perfusion,	  but	  with	  greater	  signal	  and	  contrast	  in	  the	  dual-­‐bolus	  images76.	  Furthermore,	  the	  dual-­‐bolus	  method	  provided	  more	  accurate	  measurements	  when	  smaller	  myocardial	  regions	  were	  analyzed	  which	  is	  likely	  to	  be	  as	  a	  result	  of	  the	  higher	  myocardial	  signal.	  Another	  study77	  demonstrated	  that	  the	  dual-­‐bolus	  technique	  (0.005	  mmol/kg	  and	  0.05	  mmol/kg)	  was	  superior	  to	  a	  single-­‐	  bolus	  (0.05	  mmol/kg)	  protocol	  for	  the	  assessment	  of	  myocardial	  perfusion	  reserve	  (MPR)	  with	  the	  dual	  bolus	  associated	  with	  a	  reduced	  coefficient	  of	  variation.	  	  A	  hybrid	  perfusion	  sequence	  has	  also	  been	  shown	  to	  be	  an	  alternative	  method	  to	  overcome	  this	  problem78.	  However,	  experience	  with	  this	  method	  is	  much	  more	  limited.	  
Validation	  of	  CMR	  quantitative	  perfusion	  	  Fully	   quantitative	   measurement	   of	   myocardial	   perfusion	   by	   CMR	   has	   been	  validated	  in	  a	  number	  of	  animal	  and	  human	  studies	  however	  these	  studies	  have	  used	  a	  number	  of	  different	  methods	  for	  quantification.	  	  	  Animal	  models	  allow	  validation	  of	  measurements	  against	  microspheres,	  which	  are	  a	  pathological	  gold	  standard	  of	  regional	  perfusion.	  CMR	  perfusion	  measurements	  have	  been	  validated	  against	  microspheres	  using	  model-­‐independent	  deconvolution	  and	  low-­‐dose	  contrast	  agent	  and	  also	  Fermi	  function	  deconvolution	  and	  a	  dual	  bolus	  method75,	  76.	  CMR-­‐derived	  perfusion	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values	  in	  these	  studies	  correlated	  very	  strongly	  with	  microsphere	  measurements.	  	  	  In	  human	  studies	  validation	  has	  been	  performed	  in	  patients	  with	  CAD	  against	  FFR	  using	  high	  dose	  contrast	  agent	  and	  Fermi	  deconvolution68	  and	  also	  against	  CFR79	  using	  a	  dual	  bolus	  of	  contrast	  agent	  and	  a	  compartmental	  analysis	  method.	  The	  former	  study	  demonstrated	  that	  the	  MPR	  from	  quantitative	  CMR	  perfusion	  imaging	  detected	  significant	  CAD	  (FFR	  ≤0.75)	  with	  high	  sensitivity	  (93%)	  but	  only	  modest	  specificity	  (57%).	  The	  latter	  demonstrated	  a	  strong	  correlation	  between	  MPR	  and	  invasive	  Doppler	  derived	  CFR	  measurements	  and	  that	  MPR<2	  had	  high	  sensitivity	  and	  specificity	  (88%	  and	  90%	  respectively)	  for	  predicting	  CFR	  <2.	  	  	  Finally	  three	  previous	  studies	  have	  validated	  CMR	  and	  PET	  measures	  of	  quantitative	  perfusion	  in	  healthy	  volunteers	  as	  discussed	  in	  more	  detail	  in	  chapter	  4.	  Two	  of	  these	  studies	  used	  compartmental	  analysis	  to	  obtain	  quantitative	  CMR	  perfusion	  whilst	  the	  third	  used	  model	  independent	  deconvolution.	  	  	  Measurements	  obtained	  with	  CMR	  in	  all	  of	  these	  human	  studies	  both	  at	  rest	  and	  with	  adenosine	  stress	  are	  in	  the	  same	  ranges	  as	  published	  values	  from	  other	  methods	  of	  measuring	  myocardial	  perfusion80.	  	  However	  all	  of	  these	  studies	  are	  relatively	  small	  and	  important	  differences	  exist	  between	  the	  CMR	  techniques	  used	  including	  the	  use	  of	  different	  pulse	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sequences,	  contrast	  agents	  and	  delivery	  regimens,	  doses	  of	  gadolinium	  and	  models	  for	  quantification.	  As	  a	  consequence	  of	  the	  complexity	  of	  full	  quantification	  current	  techniques	  require	  expertise	  and	  time-­‐consuming	  post-­‐processing.	  We	  remain	  some	  considerable	  way	  from	  achieving	  methodological	  consensus	  and	  full	  quantification	  remains	  a	  new	  and	  developing	  application	  for	  CMR.	  	  This	  is	  in	  contrast	  to	  many	  other	  areas	  of	  CMR	  practice,	  that	  are	  performed	  routinely	  in	  clinical	  practice	  according	  to	  standardised	  international	  evidence-­‐based	  guidelines81.	  	  	  
CMR	  assessment	  of	  viability	  CMR	  is	  the	  gold	  standard	  for	  evaluation	  of	  LV	  volumes	  and	  function,	  which	  are	  routinely	  obtained	  during	  any	  CMR	  examination.	  CMR	  viability	  assessment	  is	  achieved	  using	  low	  dose	  dobutamine	  (functional	  response),	  late	  gadolinium	  enhancement	  (LGE)	  scar	  imaging	  (morphologic	  assessment	  of	  viability),	  or	  a	  combination	  of	  both	  methods.	  A	  comparison	  between	  PET	  and	  low	  dose	  dobutamine	  CMR	  demonstrated	  close	  agreement	  between	  the	  two	  techniques	  for	  the	  assessment	  of	  viability	  with	  CMR	  sensitivity	  of	  88%	  and	  specificity	  of	  87%	  compared	  to	  PET82.	  When	  contractile	  improvement	  post	  revascularisation,	  rather	  than	  PET,	  is	  considered	  to	  be	  the	  gold	  standard	  dobutamine	  CMR	  maintains	  a	  high	  specificity	  and	  sensitivity	  although	  the	  sensitivity	  may	  be	  reduced	  with	  more	  severely	  impaired	  baseline	  LV	  function83.	  	  	  LGE	  scar	  imaging	  correlates	  very	  closely	  with	  post	  mortem	  infarct	  assessment	  in	  animals84	  and	  also	  with	  PET	  data	  in	  humans85.	  When	  contractile	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improvement	  post	  revascularisation	  is	  taken	  as	  the	  gold	  standard	  LGE	  can	  predict	  viability	  as	  demonstrated	  in	  a	  seminal	  paper	  in	  200086.	  This	  study	  demonstrated	  that	  transmurality	  of	  LGE	  and	  the	  likelihood	  of	  functional	  recovery	  following	  revascularisation	  are	  inversely	  related.	  The	  positive	  and	  negative	  predictive	  values	  of	  this	  technique	  vary	  according	  to	  the	  extent	  of	  scar	  that	  is	  taken	  as	  a	  cut-­‐off	  value	  to	  define	  viability.	  These	  values	  also	  vary	  depending	  on	  whether	  all	  segments	  or	  only	  the	  most	  dysfunctional	  are	  considered.	  For	  example,	  using	  a	  cut-­‐off	  >25%	  transmurality	  of	  scar	  and	  considering	  all	  segments,	  the	  positive	  and	  negative	  predictive	  values	  are	  71%	  and	  79%.	  When	  only	  akinetic	  or	  dyskinetic	  segments	  are	  considered	  this	  increases	  to	  88%	  and	  89%.	  On	  the	  other	  hand	  if	  a	  50%	  cut	  off	  value	  is	  used	  and	  all	  segments	  considered,	  the	  negative	  predictive	  value	  increases	  to	  92%	  but	  the	  positive	  predictive	  value	  falls	  to	  66%.	  This	  is	  clinically	  important	  as	  patients	  with	  scar	  of	  intermediate	  transmurality	  (1-­‐50%)	  have	  an	  intermediate	  chance	  of	  recovery	  of	  function	  following	  revascularisation	  (figure	  1.5)	  so	  LGE-­‐alone	  is	  not	  a	  good	  discriminator	  in	  these	  patients.	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Figure	  1.5:	  Relationship	  between	  scar	  transmurality	  and	  the	  likelihood	  of	  
improved	  function	  after	  revascularization.	  	  
These	  data	  are	  based	  on	  all	  dysfunctional	  segments	  in	  a	  study	  of	  50	  patients.	  The	  ring	  draws	  attention	  to	  the	  fact	  that	  an	  intermediate	  extent	  of	  scar	  is	  associated	  with	  an	  intermediate	  likelihood	  of	  recovery.	  Adapted	  from86.	  
	  Wellnhofer	  at	  al87	  compared	  dobutamine	  and	  LGE	  CMR	  for	  the	  prediction	  of	  viability	  in	  29	  patients	  and	  found	  dobutamine	  CMR	  to	  be	  slightly	  superior	  in	  predicting	  recovery	  after	  revascularisation.	  LGE	  CMR	  predicted	  73%	  of	  hibernating	  segments	  correctly	  compared	  to	  85%	  correctly	  predicted	  by	  low-­‐dose	  dobutamine.	  This	  difference	  was	  particularly	  relevant	  for	  myocardial	  segments	  with	  an	  intermediate	  extent	  (1-­‐74%)	  of	  LGE	  (figure	  1.6).	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Figure	  1.6:	  Low-­‐dose	  dobutamine	  versus	  scar	  imaging	  for	  viability	  
assessment.	  
ROC	  curves	  demonstrate	  significantly	  higher	  area	  under	  the	  curve	  for	  predicting	  recovery	  after	  revascularisation	  with	  low	  dose	  dobutamine	  alone	  or	  low	  dose	  dobutamine	  and	  scar	  compared	  to	  using	  scar	  alone.	  These	  data	  are	  based	  on	  149	  dysfunctional	  segments	  in	  a	  study	  of	  29	  patients	  using	  a	  cut-­‐off	  of	  25%	  scar	  transmurality.	  Adapted	  from	  87.	  	  These	  findings	  are	  supported	  by	  another	  study	  of	  48	  patients	  which	  demonstrated	  that	  42%	  of	  segments	  with	  50-­‐75%	  LGE	  show	  contractile	  reserve	  during	  low	  dose	  dobutamine	  stimulation	  whereas	  58%	  did	  not88.	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LGE	  and	  low	  dose	  dobutamine	  are	  both	  therefore	  useful	  with	  some	  evidence	  from	  small	  studies	  to	  suggest	  that	  a	  combination	  of	  both	  is	  optimal.	  However	  both	  clearly	  also	  have	  limitations	  and,	  as	  with	  ischaemia	  testing,	  there	  is	  no	  clear	  gold	  standard	  for	  validation	  purposes.	  	  	  
Additional	  value	  from	  CMR	  imaging	  	  CMR	  examination	  of	  patients	  being	  worked-­‐up	  for	  coronary	  revascularisation	  frequently	  provides	  the	  clinician	  with	  other	  valuable	  data	  including	  prognostic	  information	  and	  even	  alternative	  diagnoses.	  High	  spatial	  resolution	  allows	  for	  analysis	  of	  the	  distribution	  of	  the	  scar	  within	  the	  myocardial	  wall	  and	  differentiation	  of	  ischaemic	  from	  dilated	  cardiomyopathy89.	  Such	  additional	  information	  obtained	  from	  CMR	  is	  clinically	  relevant	  as	  demonstrated	  in	  a	  registry	  of	  11,040	  patients90.	  A	  CMR	  examination	  for	  suspected	  coronary	  artery	  disease	  or	  ischaemia	  assessment	  resulted	  in	  a	  new,	  previously	  unsuspected	  diagnosis	  in	  19.6%	  of	  patients.	  Furthermore	  patient	  management	  was	  influenced	  in	  >70%	  of	  these	  patients.	  Similarly,	  23%	  of	  patients	  with	  suspected	  CAD	  but	  no	  history	  or	  ECG	  evidence	  of	  prior	  myocardial	  infarction	  have	  a	  myocardial	  infarction	  detected	  by	  LGE91.	  This	  has	  prognostic	  implications	  as	  detection	  of	  even	  a	  very	  small	  scar	  is	  associated	  with	  a	  >7-­‐fold	  increase	  in	  major	  adverse	  cardiovascular	  events.	  Finally,	  there	  are	  also	  data	  to	  suggest	  that	  scar	  detected	  by	  CMR	  is	  a	  stronger	  predictor	  of	  adverse	  clinical	  outcome	  than	  left	  ventricular	  ejection	  fraction	  and	  volumes92.	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CMR	  coronary	  angiography	  is	  also	  possible	  and	  the	  technique	  has	  evolved	  over	  the	  years93,	  94.	  It	  may	  form	  a	  useful	  component	  of	  a	  comprehensive	  CMR	  study	  for	  CAD66.	  However	  coronary	  artery	  imaging	  with	  CMR	  is	  still	  a	  cumbersome	  method	  with	  a	  higher	  failure	  rate,	  longer	  scan	  times	  and	  lower	  positive	  predictive	  than	  CT.	  	  	  
Clinical	  applications	  CMR	  provides	  the	  clinician	  with	  comprehensive	  and	  clinically	  relevant	  information	  about	  patients	  with	  CAD	  who	  are	  being	  considered	  for	  revascularisation.	  The	  first	  question	  that	  can	  be	  answered	  after	  the	  CMR	  examination	  is	  whether	  revascularisation	  should	  be	  undertaken	  at	  all.	  From	  the	  available	  evidence	  it	  is	  safe	  and	  probably	  preferable	  to	  defer	  revascularisation	  in	  the	  absence	  of	  demonstrable	  ischaemia	  or	  LV	  dysfunction	  with	  significant	  viability	  regardless	  of	  the	  coronary	  anatomy.	  	  The	  second	  question	  that	  can	  be	  answered	  is	  which	  vessel	  should	  be	  revascularised.	  Pre-­‐procedural	  CMR	  assessment	  in	  complex	  patients	  allows	  targeted	  PCI	  and	  avoids	  treatment	  of	  inappropriate	  lesions	  and	  therefore	  potentially	  will	  reduce	  complications	  whilst	  maximising	  benefit.	  	  
	  The	  CMR	  information	  will	  also	  be	  useful	  to	  a	  surgeon	  by	  determining	  the	  likely	  benefits	  from	  CABG	  and	  also	  in	  guiding	  the	  surgical	  approach	  for	  example	  targeting	  the	  best	  quality	  conduits	  and	  choosing	  between	  minimally	  invasive	  and	  open	  surgery.	  CMR	  data	  will	  be	  useful	  to	  retrospectively	  compare	  outcome	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in	  patients	  undergoing	  complete	  anatomic	  and	  complete	  functional	  revascularisation,	  although	  prospective	  randomized	  data	  on	  this	  are	  unlikely	  to	  be	  forthcoming	  in	  the	  near	  future.	  	  Finally,	  in	  addition	  to	  guiding	  the	  management	  strategy	  information	  obtained	  from	  a	  CMR	  examination	  allows	  more	  accurate	  risk	  stratification	  of	  patients	  with	  stable	  CAD.	  This	  is	  important	  for	  all	  patients	  with	  stable	  CAD,	  regardless	  of	  the	  treatment	  strategy,	  as	  it	  provides	  a	  platform	  for	  meaningful	  discussions	  about	  care	  with	  patients	  and	  their	  families.	  	  
	  
Summary	  and	  objectives	  Despite	  the	  advances	  in	  the	  treatment	  of	  CAD	  it	  remains	  an	  important	  disease	  and	  many	  patients	  continue	  to	  experience	  preventable	  morbidity	  and	  mortality.	  One	  of	  the	  main	  management	  decisions	  concerns	  which	  patients	  and	  lesions	  should	  be	  revascularised.	  Revascularisation	  carries	  a	  risk	  to	  patients	  and	  so	  it	  is	  important	  that	  in	  deciding	  whether	  it	  is	  appropriate	  we	  obtain	  as	  much	  information	  as	  possible.	  From	  the	  available	  evidence	  it	  is	  clear	  that	  information	  on	  coronary	  anatomy	  alone	  is	  often	  insufficient	  to	  make	  this	  decision	  and	  it	  is	  crucial	  to	  know	  also	  about	  myocardial	  ischaemia	  and	  viability.	  	  	  CMR	  provides	  a	  safe,	  non-­‐invasive	  and	  comprehensive	  assessment,	  which	  yields	  valid,	  reliable	  information	  on	  pathophysiology	  in	  patients	  with	  stable	  CAD.	  However,	  all	  current	  imaging	  modalities,	  including	  CMR,	  have	  limitations.	  CMR	  hardware	  and	  software	  continue	  to	  improve,	  allowing	  faster,	  higher-­‐resolution	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imaging	  and	  the	  potential	  for	  the	  development	  of	  new	  techniques.	  One	  such	  development	  is	  the	  emerging	  field	  of	  quantification	  of	  myocardial	  perfusion.	  Absolute	  quantification	  has	  been	  shown	  to	  be	  feasible	  and	  there	  are	  some	  data	  supporting	  its	  validity.	  However,	  thus	  far,	  it	  remains	  challenging	  and	  consequently	  the	  necessary	  expertise	  and	  availability	  are	  limited.	  Viability	  assessment	  may	  also	  benefit	  from	  the	  development	  of	  new	  techniques	  and	  also	  more	  data	  to	  define	  its	  exact	  role	  in	  patient	  care.	  	  	  The	  objective	  of	  this	  work	  was	  to	  evaluate	  and	  validate	  emerging	  CMR	  methods	  for	  guiding	  revascularization	  in	  a	  series	  of	  clinical	  studies	  with	  a	  particular	  focus	  on	  perfusion	  imaging.	  Firstly,	  we	  compared	  an	  advanced	  high-­‐resolution	  perfusion	  sequence	  with	  a	  standard	  sequence	  in	  a	  phantom,	  in	  volunteers	  and	  in	  patients	  and	  tested	  a	  number	  of	  different	  contrast	  agent	  doses.	  Visual	  and	  quantitative	  analysis	  of	  this	  sequence	  were	  subsequently	  used	  in	  validation	  studies	  against	  PET	  perfusion	  imaging	  and	  invasive	  coronary	  angiography.	  We	  have	  also	  examined	  the	  inter-­‐study	  reproducibility	  of	  quantitative	  perfusion	  imaging.	  In	  addition	  we	  have	  evaluated	  novel,	  non-­‐perfusion	  CMR	  techniques	  with	  potential	  applications	  in	  CAD.	  CMR	  feature	  tracking	  is	  a	  tool	  that	  permits	  quantitative	  analysis	  of	  wall	  motion	  and	  may	  have	  utility	  for	  functional	  assessment	  of	  both	  viability	  and	  ischaemia.	  A	  novel	  sequence	  for	  improved	  scar	  imaging	  has	  also	  been	  compared	  to	  the	  standard	  inversion	  recovery	  sequence.	  Finally	  a	  pilot	  study	  explored	  the	  feasibility	  of	  combined	  CMR	  imaging	  and	  invasive	  investigations	  and	  PCI	  in	  a	  hybrid	  laboratory.	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2	   GENERAL	  METHODS	  
Study	  participants	  All	  study	  participants	  involved	  in	  this	  work	  were	  recruited	  into	  a	  formal	  research	  study	  approved	  by	  the	  local	  ethics	  committee	  and	  all	  gave	  written	  informed	  consent	  to	  participate	  in	  research.	  Patient	  information	  sheets	  and	  consent	  forms	  from	  some	  of	  the	  studies	  are	  included	  in	  Appendix	  A.	  Inclusion	  criteria	  and	  study	  protocols	  varied	  for	  each	  study	  and	  are	  detailed	  in	  the	  relevant	  chapters.	  	  All	  patients	  undergoing	  stress	  perfusion	  examination	  were	  asked	  to	  abstain	  from	  caffeine	  and	  other	  adenosine	  antagonists	  including	  smoking	  for	  a	  minimum	  of	  24	  hours	  prior	  to	  the	  scan.	  Patients	  who	  admitted	  having	  food	  or	  drink	  containing	  caffeine	  or	  other	  adenosine	  antagonists	  during	  the	  24	  hours	  preceding	  imaging	  were	  rebooked	  if	  possible.	  However,	  patients	  who	  failed	  to	  abstain	  from	  smoking	  were	  included	  regardless	  as	  smokers	  are	  unlikely	  to	  manage	  complete	  abstention.	  	  	  General	  exclusion	  criteria,	  which	  applied	  to	  all	  studies,	  are	  listed	  below:	  
Exclusion	  criteria	  1. General	  exclusions	  a. Inability	  to	  consent	  b. Pregnancy/Breast	  feeding	  c. Medically	  unstable	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2. Contraindication	  to	  MRI	  a. implanted	  electronic	  devices,	  metallic	  foreign	  bodies,	  and	  others	  according	  to	  manufacturer’s	  recommendations	  and	  generally	  accepted	  guidelines	  b. known	  claustrophobia	  c. inability	  to	  lie	  flat	  	  3. Contraindication	  to	  gadolinium	  based	  contrast	  agent	  a. Estimated	  glomerular	  filtration	  rate	  <30ml/min/1.73m2.	  This	  level	  of	  renal	  impairment	  was	  chosen	  as	  Gadobutrol/Gadovist	  is	  a	  cyclic,	  non-­‐ionic	  agent	  with	  no	  reported	  cases	  of	  nephrogenic	  systemic	  sclerosis	  and	  is	  therefore	  classified	  as	  a	  low	  risk	  contrast	  agent.	  b. Known	  allergy	  to	  study	  drugs/contrast	  agents.	  	  4. Contraindication	  to	  adenosine	  for	  protocols	  including	  stress	  perfusion	  imaging	  a. Known	  significant	  bradycardia	  or	  high-­‐degree	  atrio-­‐ventricular	  block	  b. Asthma	  	  
CMR	  protocol	  All	  studies	  were	  performed	  on	  a	  Philips	  MRI	  1.5	  Tesla	  or	  a	  3	  Tesla	  Achieva	  scanner	  (Philips	  Healthcare,	  Best,	  The	  Netherlands)	  using	  a	  32-­‐channel	  coil	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phased	  array	  receiver	  coil	  and	  vectorcardiogram	  (VCG)	  gating.	  CMR	  assessment	  of	  volumes,	  function,	  scar	  and	  wall-­‐motion	  were	  performed	  using	  standard	  techniques	  and	  in	  accordance	  with	  internationally	  recognised	  guidelines	  published	  on	  behalf	  of	  the	  Society	  for	  Cardiovascular	  Magnetic	  Resonance81.	  	  	  A	  standard	  CMR	  protocol	  for	  all	  studies	  was	  defined	  and	  is	  shown	  in	  figure	  2.1.	  Any	  deviations	  from	  this	  protocol	  are	  described	  in	  the	  relevant	  chapters.	  	  
	  
Figure	  2.1:	  Standard	  CMR	  protocol.	  
The	  standard	  protocol	  used	  for	  the	  majority	  of	  patient	  studies.	  The	  images	  acquired	  with	  examples	  are	  shown	  with	  the	  specific	  information	  ascertained	  from	  each	  part	  summarised	  at	  the	  bottom.	  Details	  are	  provided	  in	  the	  text.	  For	  a	  comprehensive	  viability	  assessment	  low-­‐dose	  dobutamine	  can	  be	  added	  to	  the	  CMR	  protocol.	  However	  this	  was	  not	  included	  as	  part	  of	  these	  studies.	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  An	  initial	  survey	  and	  planning	  allowed	  the	  definition	  of	  appropriate	  planes	  for	  further	  imaging.	  	  	  
Functional	  imaging	  Long	  axis	  cines	  in	  2,	  3	  and	  4	  chamber	  orientations	  and	  short	  axis	  cines	  covering	  the	  entire	  left	  and	  right	  ventricles	  were	  acquired	  using	  a	  steady	  state	  free	  precession	  (SSFP)	  sequence.	  	  	  
Perfusion	  imaging	  Part	  of	  the	  objectives	  of	  this	  work	  was	  to	  compare	  and	  develop	  perfusion	  sequences	  and	  consequently	  these	  sequences	  are	  described	  in	  more	  detail	  in	  the	  appropriate	  chapters.	  	  	  Prior	  to	  entering	  the	  scanner	  room	  the	  breath-­‐holding	  routine	  was	  described	  to	  participants	  and	  the	  importance	  of	  following	  these	  commands	  emphasized.	  Perfusion	  imaging	  was	  planned	  from	  the	  systolic	  phase	  of	  the	  4	  and	  2-­‐chamber	  cines.	  3	  equally	  spaced	  short	  axis	  slices	  at	  basal,	  mid	  and	  apical	  left	  ventricular	  levels	  were	  acquired	  every	  heartbeat95.	  This	  allowed	  visualization	  of	  16	  of	  the	  17	  standard	  myocardial	  segments96	  during	  perfusion	  imaging.	  Ten-­‐second	  test	  scans	  without	  CA	  using	  both	  sequences	  were	  performed	  first	  and	  any	  problems	  identified	  were	  addressed	  (e.g.	  artefacts,	  breath-­‐holding	  or	  ECG	  problems).	  The	  imaging	  geometry	  and	  field	  of	  view	  were	  kept	  constant	  for	  stress	  and	  rest	  perfusion.	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For	  stress	  imaging	  140mcg/kg/minute	  of	  adenosine	  was	  administered	  via	  an	  intravenous	  cannula	  in	  the	  left	  antecubital	  fossa.	  Participants’	  heart	  rate	  were	  monitored	  continuously	  throughout	  the	  examination	  by	  VCG.	  Blood	  pressure	  was	  monitored	  non-­‐invasively	  via	  a	  sphygmomanometer	  on	  the	  subjects’	  right	  arm	  prior	  to	  commencing	  adenosine	  and	  every	  60	  seconds	  during	  the	  infusion	  except	  during	  contrast	  agent	  (CA)	  injection.	  Stress	  perfusion	  imaging	  was	  commenced	  3	  minutes	  into	  the	  adenosine	  infusion	  and	  continued	  for	  70	  seconds.	  The	  adenosine	  was	  routinely	  discontinued	  at	  the	  end	  of	  the	  perfusion	  sequence.	  Adenosine	  was	  discontinued	  immediately	  in	  the	  presence	  of	  intolerable	  or	  severe	  symptoms	  (for	  example	  significant	  chest	  pain,	  severe	  respiratory	  difficulty,	  at	  subjects’	  request),	  severe	  (<90	  mmHg	  systolic)	  or	  symptomatic	  hypotension	  or	  significant	  cardiac	  arrhythmias,	  e.g.	  severe	  bradycardia	  or	  high-­‐degree	  atrio-­‐ventricular	  block.	  	  	  Rest	  perfusion	  was	  performed	  at	  least	  10	  minutes	  after	  stress	  perfusion.	  CA	  administration	  during	  perfusion	  imaging	  is	  described	  in	  more	  detail	  below.	  
	  
First-­‐pass	  perfusion	  imaging	  contrast	  agent	  delivery-­‐the	  dual	  bolus	  technique	  A	  weight	  adjusted	  dose	  of	  the	  gadolinium	  based	  CA	  Gadobutrol	  (Gadovist,	  Schering,	  Germany)	  was	  used	  for	  all	  first-­‐pass	  perfusion	  imaging.	  	  As	  discussed	  in	  the	  introduction	  above,	  there	  is	  a	  conflict	  in	  selecting	  the	  optimal	  dose	  of	  CA,	  with	  doses	  producing	  high	  myocardial	  CNR	  resulting	  in	  signal	  saturation	  effects,	  particularly	  in	  the	  LV	  blood	  pool	  where	  the	  AIF	  is	  determined.	  We	  adopted	  the	  dual	  bolus	  method	  to	  overcome	  this	  problem.	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However	  since	  no	  simple	  method	  to	  deliver	  a	  dual-­‐bolus	  had	  been	  descried	  we	  devised	  a	  universal	  dual-­‐bolus	  scheme	  for	  simple	  and	  consistent	  CA	  administration	  and	  quantification	  of	  perfusion97.	  	  	  Important	  considerations	  in	  the	  design	  of	  the	  dual-­‐bolus	  method	  were75-­‐77,	  98:	  1) Both	  the	  main-­‐bolus	  of	  neat	  gadolinium	  contrast	  agent,	  and	  the	  dilute	  pre-­‐bolus	  should	  be	  of	  equal	  volume	  and	  administered	  at	  the	  same	  flow	  rate.	  2) Each	  bolus	  should	  be	  followed	  by	  an	  equal	  volume	  saline	  flush	  to	  maintain	  a	  compact	  contrast	  agent	  bolus	  in	  the	  LV	  chamber.	  3) The	  time	  delay	  between	  each	  bolus	  of	  CA	  can	  be	  controlled	  to	  minimise	  temporal	  overlap,	  this	  delay	  can	  also	  be	  adjusted	  to	  heart	  rate	  if	  required.	  4) The	  system	  should	  be	  easy	  to	  set	  up.	  5) The	  procedure	  is	  easy	  to	  perform	  and	  repeat	  within	  a	  routine	  clinical	  or	  research	  scan.	  	  The	  dual	  bolus	  set-­‐up	  involved	  the	  use	  of	  a	  saline-­‐filled	  double-­‐headed	  power	  injector	  connected	  to	  a	  15cm	  extension	  tube	  to	  hold	  the	  contrast	  agent.	  The	  extension	  tube	  was	  connected	  to	  participants	  via	  an	  intravenous	  cannula	  placed	  in	  the	  right	  antecubital	  fossa.	  A	  three-­‐way	  tap	  placed	  between	  the	  power-­‐injector	  and	  the	  extension	  tube	  allowed	  the	  contrast	  agent	  to	  be	  introduced	  into	  the	  system.	  This	  set-­‐up	  is	  shown	  in	  figure	  2.2.	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Figure	  2.2:	  Dual-­‐bolus	  set-­‐up	  
From	  left:	  Both	  syringes	  of	  the	  power	  injector	  (Spectris	  Solaris®	  EP,	  MEDRAD,	  INC.,	  USA)	  are	  filled	  with	  normal	  saline.	  A	  length	  of	  extendable	  tubing	  connects	  both	  injector	  syringes	  to	  a	  3-­‐way	  tap.	  The	  3-­‐way	  tap	  is	  connected	  to	  a	  15cm	  extension	  tube,	  which	  is	  then	  connected	  to	  the	  intravenous	  cannula.	  The	  3-­‐way	  tap	  was	  positioned	  outside	  the	  bore	  of	  the	  magnet	  for	  accessibility.	  A	  syringe	  is	  connected	  to	  the	  3-­‐way	  tap	  here	  to	  demonstrate	  how	  both	  the	  CA	  boluses	  were	  introduced	  into	  the	  system	  for	  perfusion	  imaging.	  	  Adapted	  from	  97.	  	  CA	  was	  prepared	  in	  advance	  of	  all	  perfusion	  studies.	  The	  dual	  bolus	  consisted	  of	  equal	  volumes	  of	  dilute	  and	  neat	  CA.	  The	  main	  bolus	  was	  a	  weight–adjusted	  volume	  of	  1	  mol/litre	  CA.	  Dilute	  (10%)	  CA	  was	  prepared	  by	  mixing	  CA	  with	  normal	  saline	  in	  a	  1:9	  ratio.	  Prior	  to	  the	  commencement	  of	  perfusion	  imaging	  the	  power	  injector	  was	  programmed	  to	  deliver	  2	  x	  20ml	  (or	  25ml)	  saline	  flushes	  at	  4ml/second	  separated	  by	  a	  20-­‐second	  (or	  25-­‐second)	  delay.	  In	  the	  initial	  studies	  (chapters	  3-­‐5)	  20ml	  and	  20-­‐seconds	  were	  used	  respectively.	  This	  was	  increased	  to	  25ml	  and	  25-­‐seconds	  for	  all	  subsequent	  studies	  to	  prevent	  any	  overlap	  in	  the	  pre	  bolus	  and	  main	  bolus	  SI	  curves	  which	  was	  observed	  rarely	  in	  the	  early	  studies.	  One	  of	  the	  investigators	  entered	  the	  scan	  room	  for	  perfusion	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studies	  and	  immediately	  prior	  to	  imaging	  injected	  the	  first	  bolus	  via	  the	  3-­‐way	  tap	  into	  the	  extension	  tubing.	  The	  participant	  was	  instructed	  to	  breathe	  gently	  then	  imaging	  was	  commenced.	  The	  power	  injector	  was	  then	  immediately	  activated	  to	  deliver	  the	  first	  saline	  flush.	  This	  flushed	  the	  first	  bolus	  into	  the	  participants’	  circulation.	  During	  the	  following	  pre-­‐programmed	  delay	  between	  power	  injections	  the	  main	  bolus	  of	  contrast	  agent	  was	  injected	  via	  the	  3-­‐way	  tap	  into	  the	  extension	  tubing.	  At	  the	  end	  of	  the	  interval	  the	  second	  saline	  flush	  given	  by	  the	  power	  injector	  delivered	  the	  main	  CA	  bolus.	  During	  this	  second	  flush	  participants	  were	  instructed	  to	  take	  a	  small	  breath	  in	  and	  hold	  their	  breath	  for	  as	  long	  as	  possible	  to	  minimise	  respiratory	  artefact.	  	  	  
Scar	  imaging	  Scar	  imaging	  was	  commenced	  10-­‐15	  minutes	  after	  a	  total	  dose	  of	  0.2mmol/kg	  of	  gadolinium	  and	  was	  performed	  using	  an	  inversion	  recovery	  turbo	  gradient	  echo	  sequence	  with	  the	  prepulse	  delay	  optimized	  for	  maximum	  suppression	  of	  myocardial	  signal.	  Acquired	  spatial	  resolution	  was	  1.6	  x	  1.8	  x	  10mm	  (1.5T)	  and	  1.75	  x	  1.75	  x	  8mm	  (3T)	  except	  where	  stated	  otherwise.	  	  	  
Invasive	  catheter	  laboratory	  investigations	  All	  invasive	  studies	  and	  interventions	  were	  clinically	  indicated	  apart	  from	  some	  of	  the	  pressure	  wire	  data	  in	  chapter	  9.	  	  	  X-­‐ray	  coronary	  angiography	  was	  performed	  from	  the	  right	  femoral	  artery	  according	  to	  the	  standard	  Judkin’s	  technique.	  Multiple	  projections	  of	  the	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coronary	  arteries	  were	  acquired,	  after	  administration	  of	  intracoronary	  isosorbide	  dinitrate,	  in	  at	  least	  two	  orthogonal	  views,	  to	  assess	  stenosis	  severity.	  	  PCI	  was	  performed	  using	  standard	  techniques,	  equipment	  and	  adjunctive	  therapy	  at	  the	  discretion	  of	  the	  operator.
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3A:	  PERFUSION	  IMAGING.	  Optimisation	  of	  the	  CMR	  Perfusion	  
Sequence-­‐Sequence	  Selection	  
Abstract	  
Objectives	  Compare	  image	  quality,	  signal	  to	  noise	  ratio	  (SNR)	  and	  contrast	  to	  noise	  ratio	  (CNR),	  dark	  rim	  and	  respiratory	  artefacts	  using	  a	  standard	  and	  an	  advanced,	  high-­‐resolution	  perfusion	  sequence	  and	  determine	  the	  perfusion	  sequence	  to	  be	  used	  for	  further	  studies.	  	  
Background	  Technical	  advances	  in	  CMR	  perfusion	  imaging,	  particularly	  accelerated	  data	  acquisition	  methods,	  allow	  myocardial	  perfusion	  imaging	  with	  unprecedented	  spatial	  resolution.	  However,	  it	  is	  not	  clear	  how	  implementation	  of	  these	  recent	  advances	  affects	  perfusion	  image	  quality,	  SNR	  and	  CNR	  and	  the	  occurrence	  of	  important	  artefacts.	  	  
	  
Methods	  A	  standard	  ultrafast	  gradient	  echo	  perfusion	  sequence	  (st-­‐GrE)	  was	  compared	  with	  an	  advanced	  kt-­‐accelerated	  steady	  state	  free	  precession	  sequence	  (kt-­‐SSFP)	  at	  1.5T	  in	  a	  perfusion	  phantom,	  healthy	  volunteers	  (n=16)	  and	  patients	  (n=32)	  with	  known	  or	  suspected	  coronary	  artery	  disease.	  Volunteers	  were	  imaged	  with	  both	  sequences	  at	  rest	  and	  patients	  underwent	  stress	  and	  rest	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perfusion	  imaging	  with	  either	  st-­‐GrE	  or	  kt-­‐SSFP	  prior	  to	  X-­‐ray	  coronary	  angiography.	  Phantom	  data	  were	  used	  to	  generate	  signal	  intensity	  curves	  for	  SNR	  and	  CNR	  analysis.	  	  	  A	  blinded	  expert	  scored	  image	  quality	  and	  respiratory	  artefact	  severity	  and	  also	  classified	  patients	  for	  the	  presence	  of	  CAD.	  The	  extent,	  transmurality	  and	  duration	  of	  dark	  rim	  artefacts	  (DRA)	  as	  well	  as	  SNR	  and	  CNR	  were	  quantified.	  	  
	  
Results	  	  In	  normal	  hearts	  kt-­‐SSFP	  imaging	  resulted	  in	  significantly	  improved	  image	  quality	  (p=0.003),	  SNR	  (21.0±6.7	  vs.	  18.8±6.6;	  p=0.009),	  CNR	  (15.4±6.1	  vs.	  14.0±6.0;	  p=0.034)	  and	  a	  reduced	  extent	  (p=<0.0001)	  and	  transmurality	  (p=0.0001)	  of	  DRA.	  In	  patients	  kt-­‐SSFP	  imaging	  resulted	  in	  significantly	  improved	  image	  quality	  (p=0.012),	  and	  a	  reduced	  extent	  	  (p=<0.0001),	  duration	  (p=0.004)	  and	  transmurality	  (p=<0.0001)	  of	  DRA.	  Sensitivity	  and	  specificity	  for	  the	  detection	  of	  CAD	  against	  X-­‐ray	  angiography	  was	  comparable	  with	  both	  sequences.	  There	  was	  a	  non-­‐significant	  trend	  towards	  increased	  respiratory	  artefacts	  with	  kt-­‐SSFP	  in	  both	  patients	  and	  volunteers.	  Phantom	  studies	  demonstrated	  comparable	  SNR	  and	  CNR	  for	  both	  sequences.	  	  	  
Conclusions	  Advanced	  high	  resolution	  CMR	  perfusion	  imaging	  using	  a	  kt-­‐accelerated	  SSFP	  technique	  results	  in	  significantly	  improved	  image	  quality,	  SNR	  and	  CNR	  and	  a	  reduction	  in	  the	  extent	  and	  transmurality	  of	  DRA	  compared	  to	  a	  standard	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sequence.	  These	  findings	  support	  the	  use	  of	  advanced	  perfusion	  sequences	  for	  clinical	  perfusion	  imaging	  and	  the	  kt-­‐SSFP	  sequence	  for	  subsequent	  studies.	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Background	  Detection	  of	  myocardial	  ischaemia	  is	  important,	  particularly	  in	  CAD,	  for	  diagnostic	  purposes,	  identification	  of	  patients	  with	  an	  adverse	  prognosis12	  and	  for	  guiding	  revascularization20,	  21	  as	  discussed	  above.	  CMR	  perfusion	  imaging	  has	  become	  established	  as	  a	  valuable,	  non-­‐invasive	  tool	  for	  ischaemia	  detection	  that	  is	  free	  of	  ionizing	  radiation	  and	  is	  at	  least	  as	  reliable	  other	  imaging	  techniques	  31,	  65,	  66,	  99,	  100.	  However,	  despite	  this,	  the	  requirement	  to	  acquire	  large	  amounts	  of	  data	  in	  a	  short	  duration	  means	  that	  perfusion	  imaging	  is	  technically	  challenging,	  and	  still	  has	  important	  limitations.	  These	  limitations	  are	  most	  notably	  that	  the	  requirement	  to	  maintain	  high	  temporal	  resolution	  constrains	  spatial	  resolution	  and	  there	  is	  an	  increased	  tendency	  for	  imaging	  to	  be	  affected	  by	  problematic	  artefacts.	  Artefacts	  occur	  both	  as	  a	  result	  of	  the	  competing	  constraints	  of	  spatial	  and	  temporal	  resolution	  and	  of	  the	  method	  of	  first	  pass	  imaging	  itself.	  Imaging	  during	  the	  arrival	  of	  a	  concentrated	  bolus	  of	  contrast	  agent	  (CA)	  into	  the	  left	  ventricle	  contributes	  to	  the	  occurrence	  of	  DRA.	  DRA	  are	  a	  particular	  concern	  as	  they	  can	  mimic	  or	  hide	  subendocardial	  defects	  resulting	  in	  diagnostic	  errors.	  These	  perfusion	  imaging	  related	  demands	  are	  in	  addition	  to	  the	  usual	  requirements	  for	  patient	  breath	  holding,	  and	  for	  precise	  gating	  with	  the	  cardiac	  cycle,	  both	  of	  which	  can	  be	  more	  difficult	  during	  vasodilator	  stress.	  Respiratory	  artefacts	  as	  a	  result	  of	  inadequate	  breath	  holding	  can	  also	  compromise	  study	  interpretation.	  	  Currently	  a	  number	  of	  types	  of	  sequence,	  each	  with	  different	  advantages	  and	  disadvantages,	  are	  used	  for	  perfusion	  imaging.	  Common	  sequences	  include	  ultrafast	  gradient	  echo	  sequences,	  single-­‐shot	  echo	  planar	  imaging,	  hybrid	  echo	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planar	  imaging	  and	  more	  recently	  steady-­‐state	  free	  precession	  (SSFP)	  sequences.	  	  Whilst	  some	  previous	  studies	  have	  compared	  perfusion	  sequences101-­‐105	  CMR	  hardware	  and	  software	  has	  continued	  to	  evolve	  rapidly	  and	  it	  is	  not	  known	  whether	  the	  implementation	  of	  more	  recent	  advances	  can	  address	  the	  current	  limitations	  associated	  with	  perfusion	  imaging.	  	  Parallel	  imaging	  techniques	  such	  as	  sensitivity	  encoding	  (SENSE)	  are	  now	  routinely	  used	  to	  accelerate	  perfusion	  imaging	  and	  this	  acceleration	  can	  be	  used	  to	  improve	  spatial	  resolution.	  However,	  in	  practice,	  this	  is	  limited	  to	  2-­‐fold	  acceleration	  due	  to	  associated	  artefact	  and	  noise	  penalties106.	  Advanced	  k-­‐t	  acceleration	  techniques	  allow	  higher	  degrees	  of	  acceleration	  than	  SENSE	  and	  have	  been	  proposed	  more	  recently	  as	  a	  useful	  technique	  to	  improve	  the	  spatial	  resolution	  of	  perfusion	  imaging	  even	  further	  whilst	  preserving	  temporal	  resolution	  and	  cardiac	  coverage107.	  	  	  The	  objective	  of	  this	  study	  was	  to	  compare	  a	  standard	  perfusion	  sequence	  with	  an	  advanced,	  high-­‐resolution	  method	  to	  determine	  whether	  there	  is	  a	  measurable	  difference	  in	  performance.	  We	  therefore	  compared	  a	  standard	  turbo	  field	  echo	  (st-­‐GrE)	  perfusion	  sequence	  (ultrafast	  gradient	  echo	  sequence),	  to	  an	  advanced,	  high-­‐resolution	  k-­‐t	  BLAST	  accelerated	  balanced	  turbo	  field	  echo	  sequence	  (kt-­‐SSFP),	  in	  normal	  hearts,	  in	  patients	  with	  known	  or	  suspected	  CAD	  and	  in	  a	  perfusion	  phantom.	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Methods	  	  The	  st-­‐GrE	  and	  kt-­‐SSFP	  perfusion	  sequences	  were	  compared	  in	  16	  volunteers,	  in	  32	  patients	  and	  in	  a	  perfusion	  phantom	  using	  the	  1.5T	  MRI	  scanner.	  The	  imaging	  parameters	  for	  both	  sequences	  are	  shown	  in	  table	  3.1.	  	  	  
Table	  3.1:	  Imaging	  parameters	  for	  the	  standard	  (st-­‐GrE)	  and	  high-­‐
resolution	  (kt-­‐SSFP)	  sequences.	  
Parameter	   st-­‐GrE	   kt-­‐SSFP	  
Acquired	  spatial	  resolution	   2.6	  x	  2.8	  x	  10mm	  	   1.7	  x	  1.9	  x	  10mm	  	  
Echo	  time	  (TE)	   shortest	  	  (range	  1.61-­‐1.91ms)	   shortest	  	  (range	  1.29-­‐1.59ms)	  
Repetition	  time	  (TR)	   shortest	  	  (range	  3.6-­‐3.9ms);	   shortest	  	  (range	  2.59-­‐3.18ms)	  
Flip	  angle	   18°	   50°	  
Prepulse	   90°	   90°	  
Prepulse	  delay*	  	   100ms	   100ms	  
Image	  acquisition	  time	   140-­‐152ms	   80-­‐99ms	  
Water-­‐fat	  shift	   0.438pixel	   0.165pixel	  
Bandwidth	   496Hz	   1316	  Hz	  
Acceleration	  technique	   SENSE:	  factor	  2	   kt-­‐BLAST	  factor	  5	  with	  11	  training	  profiles	  	  (effective	  k-­‐t	  factor	  3.8)	  *Prepulse	  delay:	  time	  between	  saturation	  preparation	  pulse	  and	  centre	  of	  k-­‐space	  acquisition.	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Study	  population	  
Volunteers	  Volunteers	  referred	  for	  a	  clinically	  indicated	  non-­‐perfusion	  CMR	  scan	  with	  a	  high	  pre-­‐test	  probability	  of	  a	  normal	  scan	  were	  recruited	  prospectively.	  General	  exclusion	  criteria	  are	  detailed	  in	  chapter	  2.	  	  
	  
Patients	  32	  patients	  with	  a	  history	  of	  stable	  angina,	  known	  or	  suspected	  CAD,	  and	  a	  clinical	  indication	  for	  a	  diagnostic	  X-­‐ray	  coronary	  angiography	  were	  recruited	  prospectively.	  These	  patients	  underwent	  a	  CMR	  examination	  including	  stress	  and	  rest	  perfusion	  prior	  to	  their	  angiogram.	  Exclusion	  criteria	  were	  the	  same	  as	  for	  volunteers	  and	  also	  an	  acute	  coronary	  syndrome	  within	  6	  weeks	  and	  contraindication	  to	  adenosine.	  	  	  
Data	  acquisition	  
Perfusion	  Imaging	  All	  perfusion	  imaging	  was	  performed	  using	  a	  dual	  bolus	  of	  weight-­‐adjusted	  gadolinium	  CA	  (Gadobutrol/Gadovist)	  injected	  at	  4ml/s	  by	  a	  power	  injector	  as	  described	  above.	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Human	  studies	  0.1mmol/kg	  of	  CA	  was	  used	  for	  all	  studies.	  Perfusion	  imaging	  was	  planned	  from	  the	  systolic	  phase	  of	  the	  4	  and	  2-­‐chamber	  cines.	  Three	  equally	  spaced	  short	  axis	  slices	  at	  basal,	  mid	  and	  apical	  left	  ventricular	  levels	  were	  acquired	  every	  heartbeat95.	  The	  imaging	  geometry	  and	  field	  of	  view	  were	  kept	  constant	  for	  each	  perfusion	  sequence.	  During	  the	  perfusion	  image	  acquisition	  the	  patient	  was	  instructed	  to	  breath	  gently	  until	  delivery	  of	  the	  main	  bolus	  of	  contrast	  agent	  commenced	  at	  which	  point	  the	  patient	  was	  instructed	  to	  take	  a	  small	  breath	  in	  and	  hold	  their	  breath for as long as possible. 	  	  
Volunteers	  Volunteers	  underwent	  rest	  perfusion	  imaging	  using	  both	  st-­‐GrE	  and	  kt-­‐SSFP	  in	  addition	  to	  the	  clinical	  scan	  protocol.	  The	  order	  of	  the	  perfusion	  sequences	  was	  alternated	  to	  control	  for	  the	  effect	  of	  higher	  baseline	  myocardial	  signal	  following	  the	  first	  administration	  of	  contrast	  agent.	  There	  were	  no	  deviations	  from	  the	  perfusion	  sequence	  parameters	  listed	  in	  table	  1.	  	  	  
Patient	  studies	  Patients	  were	  allocated	  sequentially	  to	  undergo	  either	  st-­‐GrE	  or	  kt-­‐SSFP	  perfusion	  imaging	  with	  the	  first	  16	  recruited	  to	  the	  st-­‐GrE	  group	  and	  the	  second	  16	  to	  the	  kt-­‐SSFP	  group.	  Patients	  underwent	  stress	  and	  rest	  perfusion,	  functional	  and	  scar	  imaging.	  Stress	  imaging	  always	  preceded	  rest	  imaging.	  In	  order	  to	  account	  for	  higher	  heart	  rates	  at	  stress,	  if	  required,	  the	  voxel	  size	  was	  increased	  stepwise,	  to	  maintain	  imaging	  at	  every	  heartbeat.	  This	  was	  required	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in	  3	  patients	  in	  the	  st-­‐GrE	  group	  (resulting	  in	  a	  spatial	  resolution	  of	  3.0	  x	  3.0	  in	  2	  patients	  and	  3.5	  x	  3.5	  in	  1	  patient).	  Conversely	  voxel	  size	  did	  not	  need	  to	  be	  increased	  in	  any	  patients	  in	  the	  kt-­‐SSFP	  group.	  	  
Phantom	  studies	  Our	  research	  group	  have	  designed	  and	  described	  a	  dedicated	  perfusion	  phantom	  which	  replicates	  the	  anatomy	  of	  a	  60kg	  person’s	  heart	  and	  great	  vessels	  and	  allows	  reproducible	  performance	  and	  imaging	  of	  dynamic	  first-­‐pass	  myocardial	  perfusion108.	  Perfusion	  imaging	  was	  performed	  with	  this	  phantom	  using	  both	  sequences	  with	  0.025,	  0.05,	  0.075	  and	  0.1mmol/kg	  equivalent	  concentrations	  of	  CA.	  Absolute	  signal	  intensity	  (SI)	  curves	  were	  generated	  from	  the	  left	  myocardial	  compartment	  at	  each	  CA	  dose.	  	  
X-­‐ray	  coronary	  angiography	  X-­‐ray	  coronary	  angiography	  was	  performed	  according	  to	  standard	  techniques.	  	  	  
Data	  analysis	  Data	  analysis	  was	  performed	  with	  the	  dedicated	  software	  CMR42	  (Circle,	  Calgary,	  Canada)	  except	  where	  specifically	  stated	  otherwise.	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Human	  studies	  
Image	  quality	  	  Image	  quality	  was	  assessed	  qualitatively	  in	  all	  participants	  and	  graded	  on	  a	  5-­‐point	  scale	  (4=excellent,	  3	  good,	  2	  moderate,	  1	  poor	  and	  0	  non	  diagnostic)	  by	  an	  expert	  observer	  blinded	  to	  the	  clinical	  details	  and	  the	  perfusion	  sequence	  used.	  The	  observer	  was	  blinded	  to	  the	  clinical	  data,	  to	  which	  sequence	  was	  used	  and	  to	  the	  purpose	  of	  the	  study	  at	  the	  time	  of	  analysis.	  Perfusion	  images	  were	  presented	  along	  with	  the	  corresponding	  LGE	  images.	  Areas	  of	  scar	  were	  not	  analysed	  since	  scar	  may	  affect	  perfusion	  image	  quality.	  
	  
Signal-­‐to-­‐noise	  and	  contrast-­‐to-­‐noise	  ratios	  SNR	  and	  CNR	  were	  calculated	  from	  the	  mid	  ventricular	  slice	  in	  all	  16	  volunteers.	  Epi	  and	  endocardial	  borders	  were	  manually	  traced	  on	  the	  first	  dynamic	  where	  the	  main	  bolus	  of	  CA	  was	  visible	  in	  the	  myocardium.	  The	  superior	  right	  ventricular	  insertion	  point	  was	  manually	  defined.	  This	  subsequently	  allowed	  6	  standard	  myocardial	  segments96	  to	  be	  automatically	  defined	  in	  each	  dynamic	  of	  the	  perfusion	  scan.	  This	  segmentation	  was	  manually	  corrected	  if	  required.	  Time	  versus	  SI	  curves	  were	  then	  generated	  for	  each	  segment.	  Subsequently,	  the	  mean	  SI	  and	  the	  standard	  deviation	  (SD)	  of	  the	  SI	  in	  each	  segment	  on	  the	  frame	  with	  peak	  myocardial	  enhancement	  were	  measured.	  Baseline	  segmental	  mean	  SI	  and	  SD	  measurements	  were	  obtained	  for	  both	  sequences	  prior	  to	  any	  contrast	  injection.	  From	  these	  measurements,	  the	  segmental	  baseline	  and	  peak	  SNR	  of	  the	  myocardium	  were	  calculated	  as	  follows103:	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   SNRbaseline	  =	  Mean	  SIbaseline/SDbaseline	  	  	   SNRpeak=	  Mean	  SIpeak/SDbaseline	  	  	  Then,	  CNR	  values	  were	  calculated	  as	  follows:	  	  	  	   CNR	  =	  SNRpeak	  –	  SNRbaseline	  
	  
Image	  artefacts	  The	  severity	  of	  respiratory	  artefacts	  was	  evaluated	  by	  the	  same	  blinded	  expert	  and	  graded	  as	  follows:	  4=nil	  significant,	  3=minor,	  2	  moderate	  1=severe,	  0=non-­‐diagnostic	  due	  to	  respiratory	  artefact.	  Respiratory	  artefacts	  were	  defined	  as	  any	  artefact	  due	  to	  respiratory	  motion	  that	  impaired	  visualisation	  of	  the	  myocardium	  during	  the	  first	  pass	  of	  CA.	  	  A	  second,	  unblinded	  expert	  observer	  evaluated	  the	  extent,	  transmurality	  and	  duration	  of	  DRA.	  The	  extent	  of	  DRA	  was	  defined	  as	  the	  percentage	  of	  segments	  affected.	  Transmurality	  was	  graded	  as	  1	  (1-­‐25%),	  2	  (26-­‐50%),	  3(51-­‐75%)	  or	  4	  (76-­‐100%).	  Duration	  was	  recorded	  as	  the	  number	  of	  frames	  (and	  therefore	  heartbeats)	  for	  which	  the	  artefact	  was	  present.	  Perfusion	  images	  were	  analysed	  in	  conjunction	  with	  LGE	  images.	  Perfusion	  defects,	  which	  occurred	  only	  in	  the	  area	  of	  scar,	  were	  not	  classified	  as	  DRA.	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Diagnosis	  of	  CAD	  Patient	  CMR	  studies	  and	  X-­‐ray	  angiograms	  were	  evaluated	  by	  independent	  experts	  blinded	  to	  the	  results	  of	  the	  other	  investigation.	  CMR	  perfusion	  and	  LGE	  data	  were	  analysed	  in	  conjunction	  by	  an	  experienced	  physician	  (8	  years	  CMR	  experience)	  and	  classified	  as	  positive	  or	  negative	  for	  CAD.	  The	  observer	  was	  blinded	  to	  the	  clinical	  data,	  to	  which	  sequence	  was	  used	  and	  to	  the	  purpose	  of	  the	  study	  at	  the	  time	  of	  analysis.	  Angiograms	  were	  analysed	  visually	  by	  a	  consultant	  cardiologist,	  blinded	  to	  the	  CMR	  and	  clinical	  data,	  and	  classified	  as	  positive	  or	  negative	  for	  the	  presence	  of	  at	  least	  one	  stenosis	  of	  ≥70%	  in	  a	  coronary	  artery	  ≥2mm	  in	  diameter	  to	  allow	  calculation	  of	  a	  sensitivity	  and	  specificity	  for	  the	  detection	  of	  CAD.	  	  
Phantom	  studies	  Since	  parallel	  imaging	  reconstruction	  affects	  the	  noise	  across	  the	  field	  of	  view,	  noise	  values	  were	  taken	  from	  noise	  maps.	  For	  this,	  reconstruction	  was	  modified	  to	  replace	  the	  under-­‐sampled	  data	  with	  white	  noise	  while	  retaining	  the	  training	  data	  signals	  and	  coil	  sensitivity	  information109.	  The	  standard	  deviation	  of	  the	  real	  part	  of	  the	  noise	  signal	  was	  determined	  in	  identical	  locations	  of	  the	  reconstructed	  noise	  images.	  SNR	  and	  CNR	  were	  then	  calculated	  using	  the	  above	  formulae	  for	  each	  dose	  of	  CA	  with	  both	  sequences.	  	  
Statistical	  analysis	  Statistical	  analysis	  was	  performed	  using	  IBM	  SPSS	  Statistics	  version	  19.	  Data	  are	  expressed	  as	  the	  mean	  ±	  SD.	  Differences	  between	  the	  two	  groups	  of	  patients	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were	  compared	  using	  unpaired	  t	  tests	  or	  Fisher’s	  exact	  test	  for	  normally	  distributed	  or	  non-­‐parametric	  data	  respectively.	  Image	  quality	  and	  respiratory	  artefacts	  scores	  were	  compared	  using	  the	  Wilcoxon	  signed	  ranks	  test	  or	  the	  two-­‐sample	  Kolmogorov-­‐Smirnov	  test	  in	  volunteers	  and	  patients	  respectively.	  Mean	  scores	  for	  SNR,	  CNR	  and	  DRA	  were	  compared	  using	  paired	  t	  tests	  for	  within	  group	  and	  unpaired	  t-­‐tests	  for	  between	  group	  comparisons.	  Significance	  was	  determined	  at	  <0.05.	  	  	  
Results	  
Human	  studies	  
Study	  population	  All	  volunteer	  studies	  were	  completed	  successfully.	  The	  CMR	  examination	  was	  normal	  in	  13	  volunteers.	  Three	  volunteers	  were	  found	  to	  have	  slightly	  abnormal	  scans:	  2	  had	  mildly	  impaired	  left	  ventricular	  function	  whilst	  1	  had	  a	  mildly	  dilated	  right	  ventricle.	  These	  were	  isolated	  abnormalities	  in	  each	  case.	  	  One	  patient	  from	  the	  st-­‐GrE	  group	  did	  not	  complete	  the	  protocol	  due	  to	  claustrophobia	  and	  was	  excluded.	  Participant	  characteristics	  are	  shown	  in	  table	  3.2.	  Patients	  in	  both	  the	  st-­‐GrE	  and	  kt-­‐SSFP	  arms	  were	  well	  matched	  for	  age,	  sex,	  body	  mass	  index	  and	  cardiovascular	  risk	  factors.	  There	  were	  significantly	  more	  patients	  who	  had	  undergone	  previous	  percutaneous	  coronary	  intervention	  (PCI)	  in	  the	  kt-­‐SSFP	  arm	  and	  these	  patients	  also	  had	  a	  lower	  systolic	  blood	  pressure	  at	  rest.	  However,	  heart	  rate,	  systolic	  blood	  pressure	  during	  stress	  and	  rate	  pressure	  product	  were	  not	  different.	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Table	  3.2:	  Sequence	  selection	  study	  participant	  characteristics. 
	   Volunteers	    Patients	  
	   (n=16)	    st-­‐GrE	  (n=15)	   kt-­‐SSFP	  (n=16)	   p	  value	  
Age	   43±20	   	   64±9	   64±11	   0.89	  
Male	   8	  (50%)	   	   10	  (67%)	   13	  (81%)	   0.3	  
Body	  Mass	  Index	  
(kg/m2)	  
24	  ±4	   	   30±5	   28±4	   0.21	  
Diabetes	   0	   	   6	  (40%)	   7	  (44%)	   1	  
Hypertension	   0	   	   12	  (80)	   9	  (56%)	   0.25	  
Smoker	   0	   	   2	  (13%)	   2	  (13%)	   1	  
Previous	  PCI	   0	   	   0	   4	  (25%)	   0.02	  
LVEF	  
RVEF	  
58±7%	   	   58	  ±12%	  59±8%	   63	  ±10%	  60±8%	   0.23	  0.67	  
CAD	   0	   	   12	  (80%)	   13	  (81%)	   1	  
Scar	  present	   0	   	   5	  (33%)	   2	  (13%)	   0.22	  
Haemodynamics	  HR	  rest	  	  	  	  	  	  	  	  stress	  SBP	  rest	  	  	  	  	  	  	  	  	  	  stress	  RPP	  rest	  	  	  	  	  	  	  	  	  	  stress	  
	  69±10	  	  	  
	   	  64±15	  85±20	  148±21	  142±21	  8851±2545	  10942±2319	  
	  65±11	  84±15	  132±17	  129±23	  8562±1950	  10823±2662	  
	  0.8	  0.93	  0.03	  0.15	  0.74	  0.91	  p	  values	  refer	  to	  differences	  between	  patients	  in	  the	  st-­‐GrE	  and	  the	  kt-­‐SSFP	  group.	  HR:	  heart	  rate	  (beat	  per	  minute);	  SBP:	  systolic	  blood	  pressure	  (mmHg);	  RPP:	  rate-­‐pressure	  product	  (HR	  x	  SBP).	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Image	  quality 
Qualitative	  assessment	  Image	  quality	  was	  significantly	  better	  with	  kt-­‐SSFP	  compared	  to	  st-­‐GrE	  in	  both	  volunteers	  (p=0.003)	  and	  in	  patients	  (p=0.012)	  (figure	  3.1).	  Image	  quality	  was	  good	  or	  excellent	  in	  19%	  of	  volunteers	  with	  st-­‐GrE	  compared	  to	  81%	  with	  kt-­‐SSFP.	  In	  patients	  50%	  of	  images	  were	  good	  or	  excellent	  with	  st-­‐GrE	  whereas	  the	  corresponding	  figure	  for	  kt-­‐SSFP	  was	  94%.
	  
Figure	  3.1:	  Image	  quality	  and	  respiratory	  artefact	  scores	  for	  volunteers	  
and	  patients	  with	  both	  sequences.	  
Scores	  for	  image	  quality	  (A)	  and	  respiratory	  artefacts	  (B)	  in	  volunteers	  and	  patients	  ranging	  from	  0	  to	  4	  (4=excellent,	  3	  good,	  2	  moderate,	  1	  poor	  and	  0	  non	  diagnostic	  for	  image	  quality;	  4=nil	  significant,	  3=minor,	  2	  moderate	  1=severe,	  0=non-­‐diagnostic	  due	  to	  respiratory	  artefact	  for	  respiratory	  artefacts)	  .	  Image	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quality	  scores	  were	  significantly	  higher	  with	  kt-­‐SSFP	  and	  there	  was	  a	  non-­‐significant	  trend	  towards	  fewer	  respiratory	  artefacts	  with	  st-­‐GrE.	  	  
SNR	  and	  CNR	  SNR	  and	  CNR	  were	  both	  significantly	  higher	  with	  the	  kt-­‐SSFP	  sequence	  (figure	  3.2).	  SNR	  was	  18.8±6.6	  with	  st-­‐GrE	  and	  21.0±6.7	  with	  kt-­‐SSFP	  (p=0.009).	  CNR	  was	  14.0±6.0	  with	  st-­‐GrE	  and	  15.4±6.1	  with	  kt-­‐SSFP	  (p=0.034).	  Myocardial	  signal	  intensity	  was	  lower	  with	  kt-­‐SSFP	  compared	  to	  st-­‐GrE	  but	  noise	  was	  reduced	  proportionately	  more	  resulting	  in	  increased	  SNR.	  Segmental	  signal	  intensity	  curves	  from	  a	  volunteer	  are	  shown	  in	  figure	  3.3.	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Figure	  3.2:	  Signal	  and	  contrast	  to	  noise	  ratios	  for	  volunteer	  rest	  perfusion	  
scans.	  
Boxplots	  showing	  segmental	  SNR	  and	  CNR	  values	  in	  the	  volunteers	  with	  each	  sequence.	  Both	  SNR	  and	  CNR	  were	  significantly	  higher	  with	  kt-­‐SSFP.	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Figure	  3.3:	  First	  pass	  rest	  perfusion	  images	  with	  segmental	  signal	  
intensity	  curves.	  
Segmented	  mid-­‐ventricular	  slice	  during	  first-­‐pass	  rest-­‐perfusion	  with	  the	  st-­‐GrE	  (left)	  and	  kt-­‐SSFP	  sequences	  (right)	  with	  corresponding	  signal	  intensity	  curves.	  A	  dual	  bolus	  of	  contrast	  is	  used	  as	  standard	  but	  full-­‐quantification	  was	  not	  performed	  as	  part	  of	  this	  study.	  The	  red	  curve	  is	  the	  left	  ventricular	  blood	  pool	  signal.	  All	  other	  colours	  represent	  the	  signal	  from	  each	  of	  the	  six	  standard	  segments.	  Baseline	  signal	  is	  lower	  with	  the	  st-­‐GrE	  sequence	  as	  this	  sequence	  was	  used	  first	  in	  this	  volunteer.	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Image	  artefacts	  
Respiratory	  artefacts	  There	  was	  a	  non-­‐significant	  trend	  for	  increased	  respiratory	  artefacts	  with	  the	  kt-­‐SSFP	  sequence	  in	  both	  volunteers	  (p=0.07)	  and	  patients	  (p=0.17)	  (figure	  3.1).	  No	  studies	  were	  non-­‐diagnostic	  due	  to	  respiratory	  artefact.	  No	  st-­‐GrE	  studies	  had	  severe	  respiratory	  artefacts	  in	  either	  patients	  or	  volunteers	  whereas	  with	  the	  kt-­‐SSFP	  sequence	  severe	  respiratory	  artefacts	  affected	  both	  rest	  and	  stress	  scans	  in	  one	  patient	  and	  also	  one	  volunteer	  scan.	  In	  volunteers	  38%	  of	  st-­‐GrE	  scans	  compared	  to	  19%	  of	  kt-­‐SSFP	  were	  free	  of	  any	  respiratory	  artefact.	  In	  patients	  the	  corresponding	  figures	  were	  50%	  and	  22%	  respectively.	  Respiratory	  artefacts	  consisted	  of	  ghosting	  in	  space	  and	  time	  due	  to	  rapid	  motion	  caused	  by	  respiration.	  	  
Dark	  rim	  artefacts	  The	  extent,	  and	  transmurality	  of	  DRA	  was	  significantly	  lower	  with	  kt-­‐SSFP	  in	  both	  volunteers	  and	  patients.	  The	  duration	  of	  DRA	  was	  also	  significantly	  less	  in	  patients	  with	  kt-­‐SSFP	  although	  there	  was	  no	  difference	  with	  volunteers.	  These	  findings	  are	  summarised	  in	  table	  3.3.	  DRA	  was	  apparent	  in	  39%	  of	  segments	  in	  volunteers	  and	  33%	  in	  patients	  with	  st-­‐GrE	  compared	  to	  15%	  and	  12%	  with	  kt-­‐SSFP.	  DRA	  involved	  the	  basal	  slice	  most	  frequently	  (64-­‐76%	  of	  affected	  segments),	  followed	  by	  the	  mid	  ventricular	  segments	  (24-­‐33%),	  and	  the	  apical	  segments	  least	  often	  (0-­‐5%).	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Table	  3.3:	  Dark	  rim	  artefacts.	  
	   Volunteers	   Patients	  
DRA	   st-­‐GrE	   kt-­‐SSFP	   p	  value	   st-­‐GrE	   kt-­‐SSFP	   p	  value	  Extent	  (%)	   39±13	   15±12	   <0.0001	   33±14	   12±10	   <0.0001	  Transmurality	   1.83±0.58	   1.02±0.06	   <0.0001	   1.57±0.40	   1.07±0.17	   <0.0001	  Duration	  	   10.6±3.56	   9.7±2.51	   0.373	   10.8±3.7	   8.0±2.7	   0.004	  
	   Volunteers	   Patients	  
	  
n	  
st-­‐GrE	  16	   kt-­‐SSFP	  16	   p	  value	   st-­‐GrE	  15	   kt-­‐SSFP	  16	   p	  value	  
DRA	  Extent	  (%)	   	  39±13	   	  15±12	   	  <0.0001	   	  33±14	   	  12±10	   	  <0.0001	  Transmurality	   1.83±0.58	   1.02±0.06	   <0.0001	   1.57±0.40	   1.07±0.17	   <0.0001	  Duration	  	   10.6±3.56	   9.7±2.51	   0.373	   10.8±3.7	   8.0±2.7	   0.004	  	  Extent	  refers	  to	  the	  percentage	  of	  segments	  affected.	  	  Transmurality	  was	  scored	  as	  1=1-­‐25%,	  2=26-­‐50%,	  3=51-­‐75%	  and	  4=76-­‐100%.	  Duration	  refers	  to	  the	  number	  of	  frames	  for	  which	  the	  defect	  was	  visible.	  	  The	  p	  values	  relate	  to	  the	  difference	  between	  the	  scores	  with	  st-­‐GrE	  and	  kt-­‐SSFP	  in	  both	  patients	  and	  volunteers.	  
	  
Diagnosis	  of	  CAD	  Sensitivity	  and	  specificity	  for	  the	  detection	  of	  CAD	  against	  X-­‐ray	  angiography:	  st-­‐GrE	  82%	  (48-­‐97%)	  and	  100%	  (31-­‐100%),	  kt-­‐SSFP	  78%	  (40-­‐96%)	  and	  80%	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(30-­‐99%)	  respectively.	  The	  95%	  confidence	  intervals	  for	  sensitivity	  and	  specificity	  are	  almost	  identical	  and	  therefore	  there	  is	  no	  significant	  difference	  between	  the	  sequences.	  Formal	  statistical	  comparison	  was	  not	  performed	  as	  the	  small	  sample	  size	  meant	  that	  the	  study	  was	  underpowered	  to	  detect	  such	  differences.	  An	  example	  of	  a	  perfusion	  defect	  in	  one	  patient	  from	  each	  group	  is	  shown	  in	  figure	  3.4.	  	  	  
	  
Figure	  3.4:	  Stress	  perfusion	  images	  from	  patients	  with	  coronary	  artery	  
disease	  using	  both	  sequences.	  
Still	  images	  from	  the	  first	  pass	  of	  contrast	  agent	  during	  adenosine	  stress	  from	  two	  different	  patients.	  4A	  is	  a	  st-­‐GrE	  image	  in	  a	  patient	  with	  angina.	  There	  is	  a	  perfusion	  defect	  in	  the	  inferior/inferoseptal	  wall	  (arrows).	  There	  is	  also	  dark	  rim	  artefact	  visible,	  particularly	  in	  the	  anteroseptal	  segment	  (arrowheads).	  The	  patient	  was	  subsequently	  found	  to	  have	  an	  occluded	  right	  coronary	  artery.	  4B	  is	  from	  another	  patient	  with	  angina.	  The	  lateral	  wall	  is	  thinned	  whilst	  the	  inferior/inferolateral	  wall	  is	  of	  normal	  thickness.	  There	  is	  a	  subendocardial	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perfusion	  defect	  in	  both	  of	  these	  regions	  (arrows).	  LGE	  revealed	  scar	  in	  the	  lateral	  wall	  but	  not	  the	  inferior/inferoseptal	  wall	  (not	  shown).	  This	  patient	  had	  a	  severe	  lesion	  in	  his	  proximal	  right	  coronary	  artery	  and	  an	  occluded	  circumflex	  artery.	  
Phantom	  data	  SNR	  and	  CNR	  values	  for	  both	  sequences	  are	  shown	  in	  table	  3.4.	  Despite	  the	  much	  higher	  spatial-­‐resolution	  the	  kt-­‐SSFP	  sequence	  had	  similar	  SNR	  and	  CNR	  to	  the	  st-­‐GrE	  sequence	  across	  the	  full	  range	  of	  CA	  doses.	  In	  keeping	  with	  the	  data	  from	  humans	  SI	  was	  greater	  with	  st-­‐GrE	  however	  the	  noise	  was	  also	  greater	  resulting	  in	  similar	  SNR	  and	  CNR.	  SI	  values	  are	  higher	  in	  the	  phantom	  than	  in	  humans	  as	  the	  coil	  is	  closer	  to	  the	  myocardial	  compartment.	  	  
Table	  3.4:	  SNR	  and	  CNR	  values	  in	  a	  perfusion	  phantom	  for	  both	  sequences	  
at	  increasing	  doses	  of	  CA.	  
CA	  dose	  (mmol/kg)	   SNR	   CNR	  
	   St-­‐GrE	   kt-­‐SSFP	   St-­‐GrE	   kt-­‐SSFP	  
0.025	   72.3	   67.5	   41.7	   36.4	  
0.05	   91.2	   91.0	   60.1	   59.7	  
0.075	   108.1	   103.5	   77.5	   72.4	  
0.1	   115.2	   119.2	   83.6	   88.0	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Discussion	  This	  study	  demonstrates	  that	  newer,	  advanced	  imaging	  techniques	  can	  improve	  the	  resolution	  of	  perfusion	  imaging	  and	  also	  result	  in	  significantly	  improved	  image	  quality,	  SNR	  and	  CNR	  and	  significantly	  reduced	  DRA	  in	  humans.	  	  CMR	  has	  emerged	  relatively	  recently	  as	  a	  valuable	  tool	  for	  the	  assessment	  of	  cardiac	  patients.	  However	  on-­‐going	  technical	  developments	  have	  resulted	  in	  continuing	  rapid	  evolution	  of	  CMR	  and	  perfusion	  techniques.	  It	  is	  difficult	  to	  predict	  the	  effects	  of	  sequence	  alterations	  on	  image	  quality	  and	  artefacts	  or	  diagnostic	  accuracy	  and	  as	  such	  it	  is	  necessary	  to	  continually	  evaluate	  new	  methods	  against	  those	  that	  have	  been	  previously	  established	  through	  clinical	  trials	  and	  practice.	  We	  therefore	  sought	  to	  compare	  the	  performance	  of	  a	  state-­‐of-­‐the	  art	  perfusion	  sequence	  with	  an	  optimised	  established	  sequence.	  We	  evaluated	  both	  sequences	  in	  a	  dedicated	  perfusion	  phantom,	  which	  enabled	  evaluation	  of	  each	  perfusion	  sequence	  at	  varying	  CA	  concentrations	  within	  a	  consistent	  set-­‐up,	  in	  normal	  hearts	  and	  in	  patients.	  This	  provided	  a	  comprehensive	  and	  clinically	  relevant	  assessment	  of	  image	  quality	  and	  artefacts,	  and	  also	  SNR	  and	  CNR.	  	  A	  number	  of	  different	  types	  of	  CMR	  sequence	  can	  be	  used	  for	  perfusion	  imaging	  and	  we	  have	  only	  compared	  two	  in	  this	  study.	  However,	  each	  sequence	  also	  has	  very	  many	  parameters,	  each	  of	  which	  can	  be	  adjusted	  to	  influence	  imaging.	  Consequently,	  a	  large	  number	  of	  permutations	  and	  combinations	  exist	  which	  cannot	  all	  realistically	  be	  compared.	  We	  therefore	  opted	  to	  comprehensively	  compare	  an	  optimised	  standard	  perfusion	  sequence	  to	  a	  state-­‐of-­‐the-­‐art	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sequence.	  An	  ultrafast	  gradient	  echo	  sequence	  was	  chosen	  as	  the	  standard	  sequence	  as	  it	  is	  very	  commonly	  used	  in	  the	  clinical	  setting	  and	  has	  been	  used	  in	  important	  recent	  CMR	  perfusion	  studies66.	  Our	  advanced	  sequence	  was	  not	  simply	  a	  modification	  of	  this	  but	  a	  sequence	  that	  we	  felt	  was	  most	  likely	  to	  produce	  results	  of	  the	  highest	  quality	  using	  technology	  that	  is	  widely	  available.	  	  	  Previous	  studies	  have	  evaluated	  k-­‐t	  acceleration	  techniques	  for	  improving	  perfusion	  imaging.	  In	  keeping	  with	  our	  findings	  a	  study	  by	  Maredia	  et	  al	  in	  10	  normal	  volunteers	  found	  reduced	  DRA	  with	  a	  k-­‐t	  SENSE	  accelerated	  gradient	  echo	  sequence	  compared	  to	  a	  reference	  SENSE	  accelerated	  sequence110.	  These	  authors	  used	  k-­‐t	  acceleration	  to	  improve	  spatial	  resolution,	  temporal	  resolution	  or	  a	  combination	  of	  both	  and	  found	  that	  maximizing	  spatial	  resolution	  produced	  the	  greatest	  reduction	  in	  DRA.	  	  	  Another	  study	  compared	  k-­‐t	  SENSE	  accelerated	  gradient	  echo	  sequences	  in	  14	  volunteers	  and	  in	  37	  patients	  at	  1.5	  and	  3T111.	  In	  addition	  a	  standard	  lower	  resolution	  SENSE	  accelerated	  gradient	  echo	  sequence	  was	  compared	  to	  a	  k-­‐t	  accelerated	  sequence	  at	  3T.	  This	  study	  also	  demonstrated	  improved	  image	  quality	  and	  reduced	  DRA	  with	  the	  k-­‐t	  accelerated	  sequence	  compared	  to	  the	  standard	  sequence.	  In	  keeping	  with	  our	  study	  they	  did	  not	  demonstrate	  improved	  diagnostic	  accuracy	  for	  CAD	  with	  the	  higher	  resolution	  sequence	  in	  this	  relatively	  small	  study.	  Our	  current	  study	  builds	  on	  these	  previous	  studies	  as	  we	  have	  demonstrated	  consistent	  findings	  using	  a	  k-­‐t	  BLAST	  accelerated	  balanced	  sequence,	  in	  both	  patients	  and	  volunteers,	  at	  1.5T.	  At	  present	  1.5T	  scanners	  are	  used	  most	  commonly	  for	  clinical	  perfusion	  imaging	  despite	  the	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potential	  advantages	  associated	  with	  imaging	  at	  3T.	  	  In	  this	  study	  the	  use	  of	  k-­‐t	  acceleration	  allowed	  higher	  resolution	  imaging	  with	  preservation	  of	  three-­‐slice	  coverage	  of	  the	  heart	  each	  heartbeat	  even	  at	  higher	  heart	  rates.	  Higher	  spatial	  resolution	  may	  improve	  the	  detection	  of	  sub-­‐endocardial	  perfusion	  defects	  and	  thus	  result	  in	  improved	  sensitivity	  for	  CAD.	  To	  date	  this	  has	  not	  been	  confirmed	  in	  clinical	  studies,	  however,	  limited	  early	  data	  support	  the	  possibility	  that	  high-­‐resolution	  techniques	  may	  be	  more	  accurate112.	  Furthermore,	  in	  patients	  with	  higher	  heart	  rates	  during	  stress	  perfusion	  imaging,	  the	  constraints	  of	  the	  sequence	  may	  make	  it	  necessary	  to	  reduce	  spatial	  resolution,	  cardiac	  coverage	  or	  temporal	  resolution	  by	  imaging	  on	  alternate	  heartbeats.	  This	  occurred	  in	  3	  patients	  in	  the	  st-­‐GrE	  group	  and	  spatial	  resolution	  had	  to	  be	  reduced	  further	  but	  higher	  speed-­‐up	  with	  k-­‐t	  acceleration	  meant	  that	  it	  did	  not	  occur	  in	  the	  kt-­‐SSFP	  group	  despite	  the	  higher	  spatial	  resolution	  of	  this	  sequence.	  Lower	  temporal	  resolution	  may	  also	  compromise	  diagnostic	  accuracy	  and,	  for	  example,	  is	  known	  to	  affect	  the	  calculation	  of	  a	  myocardial	  perfusion	  reserve	  index113.	  	  
	  
Image	  quality	  Although	  image	  quality	  was	  at	  least	  moderate	  in	  almost	  all	  volunteers	  and	  patients	  with	  both	  sequences	  kt-­‐SSFP	  images	  were	  significantly	  better	  and	  most	  were	  scored	  as	  good	  or	  excellent.	  Perfusion	  image	  quality	  is	  important,	  as	  good	  quality	  high-­‐resolution	  scans	  are	  required	  to	  accurately	  delineate	  regions	  of	  ischaemia.	  This	  is	  particularly	  required	  for	  evaluating	  epi-­‐endocardial	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differences	  in	  perfusion	  or,	  in	  combination	  with	  LGE	  imaging,	  for	  establishing	  whether	  there	  is	  peri-­‐infarct	  ischaemia.	  Such	  findings	  can	  be	  useful	  diagnostically	  and	  also	  for	  patient	  management,	  for	  example	  when	  decisions	  are	  made	  regarding	  revascularisation.	  This	  study	  was	  too	  small	  to	  demonstrate	  whether	  improved	  image	  quality	  results	  in	  a	  difference	  in	  diagnostic	  performance.	  However,	  previous	  work	  has	  demonstrated	  that	  sensitivity	  to	  perfusion	  defects	  and	  inter-­‐observer	  reproducibility	  are	  related	  to	  image	  quality	  and	  also	  to	  SNR114.	  	  
SNR	  and	  CNR	  The	  kt-­‐SSFP	  sequence	  voxel	  size	  was	  approximately	  half	  that	  of	  the	  st-­‐GrE	  sequence	  and	  consequently	  a	  reduction	  in	  SNR	  and	  CNR	  by	  a	  factor	  of	  2	  may	  have	  been	  expected.	  However,	  both	  the	  phantom	  and	  human	  data	  show	  that	  this	  is	  not	  the	  case.	  The	  use	  of	  a	  balanced	  sequence,	  which	  results	  in	  higher	  signal	  has	  compensated	  for	  the	  reduction	  in	  voxel	  size.	  Previous	  studies104,	  115	  have	  also	  found	  a	  higher	  SNR	  and	  CNR	  with	  a	  balanced	  SSFP	  sequence	  compared	  to	  a	  GRE	  perfusion	  sequence.	  	  	  Noise	  can	  vary	  greatly	  across	  the	  field	  of	  view	  with	  the	  use	  of	  parallel	  imaging116	  and	  thus	  SNR	  and	  CNR	  measurements	  can	  be	  difficult.	  In	  an	  attempt	  to	  overcome	  this,	  true	  noise	  measurements	  were	  obtained	  from	  noise	  maps	  in	  the	  perfusion	  phantom.	  The	  SNR	  and	  CNR	  values	  from	  the	  phantom	  are	  much	  higher	  than	  those	  from	  human	  studies	  due	  to	  the	  close	  proximity	  of	  the	  coil	  to	  the	  CA	  when	  using	  the	  phantom.	  In	  contrast	  to	  the	  human	  studies	  SNR	  and	  CNR	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were	  comparable	  with	  both	  sequences	  reflecting	  the	  different	  methodology	  used.	  In	  the	  human	  studies,	  signal	  and	  noise	  were	  measured	  from	  standard	  myocardial	  segments	  defined	  on	  the	  reconstructed	  images.	  These	  results	  demonstrated	  an	  improved	  SNR	  and	  CNR	  with	  the	  kt-­‐SSFP	  sequence.	  Whilst	  the	  SNR	  and	  CNR	  values	  obtained	  from	  the	  reconstructed	  images	  are	  not	  the	  same	  as	  the	  true	  values	  they	  remain	  relevant,	  as	  the	  reconstructed	  images	  are	  the	  ones	  used	  for	  clinical	  interpretation.	  SNR	  and	  CNR	  were	  not	  measured	  in	  patients	  given	  the	  heterogeneous	  nature	  of	  pathologic	  perfusion	  defects.	  We	  used	  the	  mid-­‐ventricular	  slice	  to	  minimise	  partial	  volume	  effects,	  which	  are	  more	  likely	  to	  occur	  in	  the	  basal	  and	  apical	  slices	  and	  also	  DRA,	  which	  occurred	  more	  frequently	  in	  the	  basal	  slice.	  In	  addition	  the	  use	  of	  automatically	  generated	  myocardial	  segments	  as	  regions	  of	  interest	  resulted	  in	  a	  standardised,	  less	  user-­‐dependent,	  approach.	  	  
Artefacts	  DRA	  is	  related	  to	  juxtaposition	  of	  the	  high	  signal	  from	  blood	  pool	  and	  low	  signal	  from	  myocardium	  and	  is	  often	  reported	  as	  transient.	  However	  if	  the	  blood	  pool	  remains	  bright,	  for	  example	  if	  the	  arrival	  of	  the	  bolus	  is	  dispersed,	  it	  can	  be	  persistent.	  DRA	  can	  therefore	  be	  particularly	  troublesome	  given	  that	  pathological	  perfusion	  also	  results	  in	  dark	  areas	  of	  myocardium	  and	  can	  make	  image	  interpretation	  difficult	  even	  for	  experienced	  observers.	  Furthermore	  quantitative	  analysis	  of	  perfusion	  relies	  on	  obtaining	  accurate	  myocardial	  SI	  curves	  and	  can	  also	  be	  severely	  compromised	  by	  the	  presence	  of	  DRA.	  Inclusion	  of	  DRA	  within	  regions	  of	  interest	  will	  result	  in	  incorrect	  perfusion	  values,	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particularly	  from	  the	  sub-­‐endocardium.	  Myocardial	  borders	  can	  be	  manually	  defined	  to	  exclude	  areas	  of	  DRA	  however	  automated	  algorithms	  for	  myocardial	  border	  detection	  are	  unlikely	  to	  be	  able	  to	  accurately	  differentiate	  DRA	  from	  true-­‐defects.	  In	  turn	  quantitative	  assessment	  of	  perfusion	  are	  unlikely	  to	  make	  the	  transition	  from	  research	  tool	  to	  clinically	  useful	  tool	  without	  robust	  and	  rapid	  automated	  methods.	  	  	  The	  causes	  of	  DRA	  are	  incompletely	  understood	  but	  cardiac	  motion	  during	  image	  acquisition	  and	  lower	  spatial	  resolution	  are	  suspected	  to	  contribute117.	  In	  this	  study	  DRA	  was	  significantly	  reduced	  with	  the	  kt-­‐SSFP	  sequence.	  This	  may	  be	  a	  result	  of	  increased	  spatial	  resolution	  reducing	  truncation	  artefacts	  and/or	  the	  shorter	  acquisition	  time	  and	  thus	  reduced	  cardiac	  motion	  during	  acquisition.	  	  However,	  it	  would	  have	  been	  difficult	  to	  predict	  this	  in	  advance,	  as	  the	  increased	  difference	  in	  signal	  between	  the	  blood	  pool	  and	  myocardium	  expected	  with	  a	  balanced	  SSFP	  sequence	  could	  have	  resulted	  in	  increased	  DRA.	  	  Respiratory	  artefacts	  can	  also	  compromise	  qualitative	  and	  quantitative	  perfusion	  imaging	  particularly	  stress	  imaging	  in	  patients	  with	  cardiac	  pathology,	  when	  breath	  holding	  in	  combination	  with	  adenosine	  stimulation	  can	  be	  more	  challenging.	  Temporal	  under-­‐sampling	  with	  the	  kt-­‐SSFP	  sequence	  would	  be	  expected	  to	  exacerbate	  this	  problem.	  Respiratory	  artefacts	  were	  seen	  as	  ghosting	  in	  space	  and	  time	  and	  were	  worst	  with	  large	  respiratory	  movements.	  Although	  correct	  breath	  holding	  resulted	  in	  fewest	  artefacts	  kt-­‐SSFP	  associated	  respiratory	  artefacts	  were	  usually	  only	  minor	  when	  subjects	  continued	  to	  take	  shallow	  breaths	  and	  in	  general	  were	  only	  slightly	  more	  severe	  than	  those	  we	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encountered	  during	  non-­‐k-­‐t	  perfusion	  imaging.	  However	  although	  there	  was	  a	  trend	  towards	  more	  respiratory	  artefact	  with	  kt-­‐SSFP	  it	  was	  not	  significant.	  The	  phase	  encoding	  direction	  with	  both	  sequences	  in	  this	  study	  was	  antero-­‐posterior	  and	  it	  may	  be	  possible	  to	  further	  reduce	  respiratory	  artefacts	  by	  using	  the	  head-­‐foot	  direction,	  although	  this	  may	  itself	  subsequently	  increase	  acquisition	  times.	  	  	  In	  principle	  ECG	  mistriggering	  could	  result	  in	  inconsistencies	  of	  data	  in	  xf-­‐space,	  which	  would	  lead	  to	  additional	  artefacts	  with	  the	  kt-­‐SSFP	  sequence.	  However	  we	  did	  not	  encounter	  any	  other	  significant	  artefacts,	  such	  as	  ECG	  mistriggering,	  with	  either	  sequence	  in	  this	  study.	  Methodical	  patient	  preparation	  and	  attention	  to	  the	  test	  scan	  allows	  prevention	  or	  correction	  of	  the	  majority	  of	  such	  problems	  prior	  to	  the	  perfusion	  imaging.	  	  There	  were	  more	  patients	  with	  scar	  in	  the	  st-­‐GrE	  group	  (n=5)	  compared	  to	  the	  kt-­‐SSFP	  (n=2)	  group,	  although	  this	  was	  not	  statistically	  significant	  (p=0.22)	  in	  this	  relatively	  small	  cohort.	  Potentially	  the	  presence	  of	  scar	  may	  have	  affected	  image	  quality	  or	  DRA	  assessment,	  for	  example,	  a	  perfusion	  defect	  related	  to	  LGE	  may	  be	  erroneously	  classified	  as	  DRA.	  However	  in	  order	  to	  minimise	  such	  effects	  perfusion	  images	  were	  always	  analysed	  in	  conjunction	  with	  LGE	  images	  in	  keeping	  with	  usual	  clinical	  practice.	  This	  allowed	  areas	  of	  LGE	  to	  be	  excluded	  from	  quality	  and	  artefact	  assessments.	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Limitations	  It	  may	  have	  been	  preferable	  to	  use	  both	  sequences	  in	  the	  same	  patients	  rather	  than	  two	  different	  groups.	  However	  our	  patients	  were	  well	  matched	  overall.	  Both	  sequences	  were	  compared	  in	  the	  same	  conditions	  in	  the	  same	  volunteers	  and	  phantom	  studies	  and	  the	  quantitative	  assessments	  were	  performed	  in	  these	  groups.	  Performing	  perfusion	  imaging	  with	  both	  sequences	  in	  patients	  also	  has	  problems;	  either	  stress	  perfusion	  has	  to	  be	  repeated	  on	  the	  same	  day	  (possibly	  at	  the	  expense	  of	  rest	  perfusion	  due	  to	  CA	  dose	  limitations)	  or	  patients	  have	  to	  attend	  on	  two	  occasions,	  when	  conditions	  such	  as	  myocardial	  perfusion	  or	  patient	  positioning	  in	  the	  magnet,	  may	  not	  be	  the	  same.	  	  	  The	  half-­‐life	  of	  the	  CA	  used	  is	  approximately	  90	  minutes	  (depending	  on	  renal	  function)118.	  Therefore	  in	  humans,	  after	  the	  first	  dose	  of	  CA,	  myocardial	  signal	  does	  not	  reduce	  to	  baseline	  within	  the	  timeframe	  of	  a	  single	  CMR	  examination	  (as	  seen	  in	  figure	  3.3).	  To	  account	  for	  this	  we	  alternated	  which	  perfusion	  sequence	  we	  used	  first	  in	  volunteers.	  Inadequate	  coil	  response	  non-­‐uniformity	  correction	  may	  also	  have	  resulted	  in	  variations	  in	  signal	  intensity	  the	  field	  of	  view	  in	  some	  cases.	  However	  since	  the	  same	  segments	  were	  compared	  with	  both	  sequences	  this	  would	  not	  have	  affected	  the	  overall	  result.	  	  Finally,	  a	  relatively	  small	  number	  of	  patients	  were	  included	  in	  the	  study,	  and	  the	  prevalence	  of	  CAD	  was	  very	  high	  (approximately	  80%)	  resulting	  in	  wide	  confidence	  intervals	  for	  the	  sensitivity	  and	  specificity	  of	  both	  sequences	  for	  the	  detection	  of	  CAD.	  Consequently	  it	  was	  not	  possible	  to	  determine	  whether	  there	  is	  a	  difference	  in	  diagnostic	  performance	  between	  the	  two	  sequences.	  However,	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each	  sequence	  was	  comprehensively	  assessed	  in	  a	  phantom	  and	  volunteers	  in	  addition	  to	  patients.	  This	  study	  therefore	  provides	  a	  platform	  for	  larger	  scale	  studies	  to	  evaluate	  whether	  CMR	  sequences	  using	  advanced	  techniques	  also	  improve	  diagnostic	  accuracy.	  	  
Conclusions	  Advanced,	  high-­‐resolution	  CMR	  perfusion	  imaging	  using	  a	  k-­‐t	  accelerated	  SSFP	  technique	  results	  in	  significantly	  improved	  image	  quality,	  signal	  and	  contrast	  to	  noise	  ratios	  and	  a	  reduction	  in	  dark-­‐rim	  artefacts	  in	  humans.	  These	  findings	  support	  the	  use	  of	  an	  advanced	  high-­‐resolution	  sequence	  in	  preference	  to	  a	  standard	  sequence	  for	  clinical	  myocardial	  perfusion	  imaging	  and	  for	  subsequent	  studies.	  Further	  studies	  exploring	  whether	  the	  use	  of	  advanced	  methods	  can	  be	  translated	  into	  superior	  diagnostic	  accuracy	  for	  coronary	  disease	  are	  desirable.	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3B	   PERFUSION	  IMAGING.	  Optimisation	  of	  the	  CMR	  
Perfusion	  Sequence-­‐Contrast	  Agent	  Dose	  Selection	  
Abstract	  
Objectives	  Compare	  CA	  doses	  in	  a	  phantom	  and	  in	  patients	  using	  the	  kt-­‐SSFP	  sequence	  to	  determine	  the	  dose	  to	  be	  used	  for	  further	  studies.	  	  
Background	  On	  the	  basis	  of	  the	  previous	  study	  the	  kt-­‐SSFP	  was	  used	  in	  further	  studies	  but	  there	  remains	  uncertainty	  regarding	  the	  optimal	  dose	  of	  CA	  for	  perfusion	  imaging.	  	  
Methods	  The	  perfusion	  phantom	  was	  used	  to	  generate	  signal	  intensity	  curves	  using	  0.025,	  0.05,	  0.075	  and	  0.1mmol/kg	  equivalent	  doses	  of	  CA	  at	  1,	  2.5	  and	  5ml/kg/min.	  Sixteen	  sequential	  patients	  with	  angina	  and	  suspected	  CAD	  referred	  for	  clinical	  perfusion	  imaging	  were	  enrolled.	  CMR	  imaging	  was	  identical	  to	  the	  first	  part	  of	  the	  study	  except	  that	  a	  CA	  dose	  of	  0.0075	  and	  0.075mmol/kg	  was	  used.	  Images	  were	  analysed	  for	  quality	  and	  artefacts	  as	  previously	  and	  compared	  to	  the	  previous	  results	  at	  0.1mmol/kg.	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Results	  The	  relationship	  between	  CA	  dose	  and	  SI	  was	  linear	  with	  CA	  doses	  up	  to	  approximately	  0.06mmol/kg.	  Signal	  saturation	  effects	  were	  seen	  at	  higher	  CA	  doses.	  There	  was	  no	  difference	  in	  image	  quality	  or	  artefacts	  between	  patients	  receiving	  0.1	  and	  0.075mmol/kg	  of	  CA.	  
	  
Conclusions	  Based	  on	  these	  findings	  and	  previous	  published	  dose-­‐finding	  studies	  0.1mmol/kg	  CA,	  with	  a	  dual	  bolus	  injection	  method,	  was	  selected	  for	  subsequent	  perfusion	  studies	  at	  1.5T.	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Background	  CMR	  perfusion	  imaging	  has	  developed	  rapidly	  over	  the	  past	  few	  years.	  This	  rapid	  growth	  and	  evolution	  has	  resulted	  in	  a	  lack	  of	  standardisation	  of	  CMR	  perfusion	  methodology.	  This	  is	  in	  contrast	  to	  nuclear	  imaging,	  which	  has	  been	  established	  for	  far	  longer	  and	  is	  more	  standardised.	  CMR	  perfusion	  studies	  and	  clinical	  practice	  is	  performed	  using	  various	  pulse	  sequences,	  CA,	  CA	  delivery	  regimens	  and	  field	  strengths.	  	  	  A	  limited	  number	  of	  studies	  have	  evaluated	  different	  CA	  doses65,	  119,	  120,	  however,	  results	  have	  been	  conflicting	  and	  much	  of	  the	  data	  relates	  to	  early	  perfusion	  techniques.	  Since	  the	  optimal	  dose	  of	  CA	  may	  well	  depend	  on	  the	  exact	  set-­‐up	  used	  evaluation	  of	  the	  optimal	  dose	  of	  CA	  is	  desirable.	  The	  optimal	  dose	  also	  depends	  on	  whether	  the	  images	  will	  be	  analysed	  visually	  or	  quantitatively	  as	  discussed	  in	  chapter	  1.	  
	  Having	  identified	  that	  the	  kt-­‐SSFP	  sequence	  was	  superior	  and	  would	  be	  used	  in	  subsequent	  work	  we	  compared	  different	  CA	  doses	  using	  this	  sequence	  in	  the	  perfusion	  phantom	  and	  in	  patients.	  	  	  
Methods	  
Phantom	  studies	  Perfusion	  imaging	  was	  performed	  using	  the	  kt-­‐SSFP	  and	  0.025,	  0.05,	  0.075	  and	  0.1mmol/kg	  equivalent	  concentrations	  of	  CA	  at	  perfusion	  rates	  of	  1,	  2.5	  and	  5ml/min/kg.	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Patient	  studies	  A	  further	  16	  sequential	  patients	  with	  angina	  and	  known	  or	  suspected	  CAD,	  who	  were	  referred	  for	  a	  clinically	  indicated	  CMR	  perfusion	  imaging,	  were	  recruited.	  Exclusion	  criteria	  were	  identical	  to	  the	  first	  part	  of	  the	  study.	  All	  imaging	  methods	  were	  identical	  to	  the	  first	  part	  of	  the	  study	  except	  that	  the	  dose	  of	  CA	  for	  perfusion	  imaging	  was	  changed	  to	  a	  dual	  bolus	  regimen	  of	  0.0075	  and	  0.075mmol/kg.	  	  
Data	  analysis	  Stress	  perfusion	  images	  were	  analysed	  and	  image	  quality	  and	  artefacts	  were	  graded	  in	  the	  same	  way	  as	  previously.	  Patients	  receiving	  0.075mmol/kg	  CA	  (kt-­‐SSFP	  0.075)	  were	  compared	  to	  those	  who	  received	  0.1mmol/kg	  (kt-­‐SSFP	  0.1)	  using	  the	  same	  statistical	  analytical	  methods	  as	  above.	  	  
Results	  
Phantom	  studies	  SI	  curves	  with	  increasing	  CA	  doses	  are	  shown	  in	  Figure	  3.5.	  SI	  increases	  progressively	  with	  increasing	  CA	  dose.	  At	  all	  3	  perfusion	  rates	  there	  is	  a	  linear	  relationship	  between	  CA	  dose	  and	  SI	  up	  to	  approximately	  0.06mmol/kg.	  Higher	  doses	  are	  associated	  with	  loss	  of	  linearity.	  	  
  107 
	  	  
Figure	  3.5:	  Signal	  intensity	  curves	  from	  the	  left	  myocardial	  compartment	  
of	  the	  perfusion	  phantom.	  
The	  broken	  grey	  lines	  are	  linear	  reference	  lines.	  SI	  is	  linearly	  related	  to	  CA	  dose	  up	  to	  approximately	  0.06mmol/kg.	  Signal	  saturation	  effects	  are	  evident	  at	  higher	  dose	  of	  CA.	  	  
	  
Patient	  studies	  One	  patient	  in	  the	  kt-­‐SSFP	  0.075	  was	  later	  excluded	  due	  to	  uncertainty	  regarding	  the	  dose	  of	  CA	  given.	  Patient	  characteristics	  in	  the	  two	  groups	  are	  shown	  in	  table	  3.5.	  Patients	  were	  well	  matched	  with	  no	  significant	  differences	  in	  these	  baseline	  characteristics.	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Table	  3.5:	  Baseline	  characteristics	  of	  the	  kt-­‐SSFP	  0.075	  and	  0.1	  patients.	  
	   kt-­‐SSFP	  0.075	  
(n=15)	  
kt-­‐SSFP	  	  0.1	  
(n=16)	  	  
p	  value	  
Age	   60±10	   64±11	   0.36	  
Male	   12	  (80%)	   13	  (81%)	   1	  
BMI	   28±5	   28±4	   0.82	  
DM	   2	  (13%)	   7	  (44%)	   0.11	  
Hypertension	   7	  (47%)	   9	  (56%)	   0.72	  
Smoker	   6	  (40%)	   2	  (13%)	  	   0.11	  
Previous	  PCI	   2	  (13%)	   4	  (25%)	   0.22	  
LVEF	   60±7	   63	  ±10%	   0.33	  
Haemodynamics	  HR	  rest	  	  	  	  	  	  	  	  stress	  SBP	  rest	  	  	  	  	  	  	  	  	  stress	  RPP	  rest	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  stress	  
	  65±11	  88±17	  132±17	  129±23	  8562±1950	  10823±2662	  
	  69±11	  84±15	  135±23	  131±26	  9582±3086	  12298±28700	  
	  0.47	  0.47	  0.72	  0.89	  0.34	  0.25	  
CAD	   9	  (60%)	   13	  (81%)	   0.25	  
Scar	  present	   6	  (40%)	   2	  (13%)	   0.11	  	  
Image	  quality	  Image	  quality	  was	  not	  significantly	  different	  at	  either	  CA	  dose	  (p=1.0).	  14/15	  (93%)	  and	  16/16	  (100%)	  of	  the	  studies	  were	  good	  or	  excellent	  in	  the	  kt-­‐SSFP	  0.75	  group	  and	  the	  kt-­‐SSFP	  0.1	  groups	  respectively	  (figure	  3.6).	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Figure	  3.6:	  Image	  quality	  and	  respiratory	  artefact	  scores	  with	  kt-­‐SSFP	  
0.075	  and	  kt-­‐SSFP	  0.1.	  	  
Scores	  for	  image	  quality	  (A)	  and	  respiratory	  artefacts	  (B)	  in	  patients	  ranging	  from	  0	  to	  4	  (4=excellent,	  3	  good,	  2	  moderate,	  1	  poor	  and	  0	  non	  diagnostic	  for	  image	  quality;	  4=nil	  significant,	  3=minor,	  2	  moderate	  1=severe,	  0=non-­‐diagnostic	  due	  to	  respiratory	  artefact	  for	  respiratory	  artefacts).	  There	  were	  no	  significant	  differences	  between	  the	  CA	  doses	  
	  
Image	  artefacts	  
Respiratory	  artefacts	  There	  was	  no	  significant	  difference	  in	  respiratory	  artefacts	  between	  the	  groups	  (p=0.96,	  figure	  3.6).	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Dark	  rim	  artefacts	  There	  was	  no	  difference	  in	  the	  extent,	  transmurality	  or	  duration	  of	  DRA	  between	  the	  groups	  (table	  3.6).	  	  
Table	  3.6:	  Dark	  rim	  artefacts	  at	  kt-­‐SSFP	  0.075	  and	  kt-­‐SSFP	  0.1.	  
Dark	  rim	  artefact	   kt-­‐SSFP	  0.075	  
(n=15)	  
kt-­‐SSFP	  0.1	  
(n=16)	  
p	  value	  
Extent	  (%)	   16±16	   13±10	   0.62	  
Transmurality	   1.14±0.31	   1.08±0.19	   0.54	  
Duration	  (frames)	   8.4±3.0	   8.0±2.0	   0.68	  The	  extent	  refers	  to	  the	  percentage	  of	  segments	  affected.	  Transmurality	  was	  scored	  as	  1=1-­‐25%,	  2=26-­‐50%,	  3=51-­‐75%	  and	  4=76-­‐100%.	  Duration	  refers	  to	  the	  number	  of	  frames	  (and	  therefore	  heartbeats)	  for	  which	  the	  defect	  was	  visible.	  The	  differences	  are	  not	  significant.	  	  
Discussion	  The	  perfusion	  phantom	  data	  demonstrate	  that	  across	  the	  full	  physiological	  range	  of	  myocardial	  perfusion	  signal	  saturation	  effects	  were	  evident	  in	  the	  myocardium	  with	  doses	  of	  CA	  above	  approximately	  0.06mmol/kg.	  In	  patients	  with	  known	  or	  suspected	  CAD	  there	  are	  no	  important	  differences	  in	  image	  quality	  or	  artefacts	  between	  0.075	  or	  0.1mmol/kg	  Gadobutrol/Gadovist	  CA	  with	  the	  kt-­‐SSFP	  sequence.	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Signal	  saturation	  effects	  are	  well	  known	  to	  occur	  at	  higher	  doses	  of	  CA.	  The	  perfusion	  phantom	  allowed	  these	  effects	  to	  be	  clearly	  demonstrated	  with	  loss	  of	  linearity	  between	  CA	  dose	  and	  SI	  occurring	  at	  approximately	  0.06mmol/kg.	  Notwithstanding	  the	  non-­‐physiological	  conditions	  associated	  with	  imaging	  a	  phantom	  extrapolation	  of	  these	  results	  to	  human	  subjects	  suggests	  that	  a	  dual	  bolus	  of	  CA	  is	  likely	  to	  be	  required	  for	  quantitative	  analysis	  regardless	  of	  whether	  0.075	  or	  0.1mmol/kg	  CA	  is	  used.	  	  Only	  limited	  and	  somewhat	  conflicting	  data	  are	  available	  to	  guide	  CA	  dose	  selection	  for	  perfusion	  imaging.	  3	  multi-­‐centre	  studies	  have	  compared	  area	  under	  the	  ROC	  curve	  (AUC)	  for	  the	  detection	  of	  CAD	  against	  QCA	  at	  different	  doses	  of	  CA.	  Giang	  et	  al119	  evaluated	  doses	  of	  0.05,	  0.1	  and	  0.15mmol/kg	  in	  80	  patients	  with	  known	  or	  suspected	  CAD	  and	  found	  0.1	  and	  0.15mmol/kg	  to	  be	  comparable	  and	  significantly	  better	  than	  0.05mmol/kg	  (AUC	  0.91	  ±	  0.07;	  0.86	  ±	  0.08	  and	  0.53±0.13	  respectively).	  In	  keeping	  with	  this	  Schwitter	  et	  al65	  evaluated	  212	  patients	  in	  the	  more	  recent	  multicentre	  MR-­‐IMPACT	  study	  and	  found	  that	  0.1mmol/kg	  CA	  performed	  better	  than	  0.01,	  0.025,	  0.05	  and	  0.075mmol/kg	  (AUC	  0.86±0.06	  vs.	  0.69±0.09,	  0.60±0.14,	  0.64±0.10	  and	  0.60±0.09,	  respectively).	  In	  contrast	  in	  a	  third	  multicentre	  evaluation	  of	  75	  patients	  Wolff	  et	  al120	  found	  0.05mmol/kg	  to	  be	  significantly	  better	  than	  0.1mmol/g	  and	  non-­‐significantly	  better	  than	  0.15mmol/kg	  (AUC	  0.90±0.04,	  0.72±0.09,	  and	  0.83±0.09	  respectively).	  All	  three	  studies	  were	  performed	  at	  1.5T.	  Giang	  et	  al.	  and	  Wolff	  et	  al.	  used	  an	  echo	  planar	  imaging	  perfusion	  sequence	  with	  Gd-­‐DTPA/Magnevist	  CA	  whilst	  the	  MR-­‐IMPACT	  used	  gradient	  echo	  and	  hybrid	  echo	  planar	  imaging	  sequences	  and	  Gd-­‐DTPA-­‐BMA/Omniscan.	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  Different	  CA	  doses	  would	  probably	  not	  be	  expected	  to	  result	  in	  changes	  in	  image	  quality	  and	  should	  not	  affect	  the	  severity	  of	  respiratory	  artefacts.	  Conversely,	  increased	  LV	  blood	  pool	  signal	  intensity	  with	  higher	  doses	  of	  CA	  may	  have	  resulted	  in	  increased	  DRA,	  but	  this	  was	  not	  seen	  at	  the	  doses	  of	  CA	  used	  here.	  Although	  diagnostic	  confidence	  in	  the	  images	  was	  not	  assessed	  directly	  confidence	  is	  a	  result	  of	  a	  combination	  of	  image	  quality	  and	  artefacts	  and	  sufficient	  SNR	  and	  CNR.	  Since	  image	  quality	  and	  artefacts	  were	  the	  same	  and	  there	  was	  only	  a	  small	  difference	  in	  CNR	  and	  SNR	  between	  the	  doses	  diagnostic	  confidence	  in	  the	  images	  is	  also	  likely	  to	  be	  similar	  at	  both	  doses.	  	  This	  study	  was	  too	  small	  to	  allow	  evaluation	  of	  the	  diagnostic	  accuracy	  of	  different	  doses	  of	  CA	  however	  this	  is	  related	  to	  image	  quality	  and	  artefacts	  as	  discussed	  above.	  Furthermore,	  it	  is	  not	  entirely	  clear	  how	  well	  the	  results	  of	  previous	  studies	  translate	  to	  perfusion	  imaging	  using	  a	  different	  set-­‐up.	  However,	  on	  balance,	  a	  number	  of	  factors	  favoured	  the	  use	  of	  0.1mmol/kg	  CA.	  Firstly	  myocardial	  SNR	  and	  CNR	  in	  the	  phantom	  were	  higher	  with	  0.1mmol/kg	  and	  both	  doses	  were	  associated	  with	  signal	  saturation	  effects.	  Secondly	  the	  higher	  SNR	  and	  CNR	  with	  0.1mmol/kg	  did	  not	  incur	  a	  penalty	  of	  increased	  DRA	  or	  reduction	  in	  image	  quality.	  Thirdly	  a	  dual	  bolus	  of	  CA	  will	  be	  required	  for	  quantitative	  analysis	  regardless	  of	  whether	  0.075	  or	  0.1mmol/kg	  CA	  is	  administered.	  Fourthly	  combining	  perfusion	  imaging	  with	  LGE	  scar	  imaging	  improves	  diagnostic	  accuracy121	  and	  our	  local	  protocol	  was	  to	  use	  0.2mmol/kg	  CA	  for	  LGE	  imaging.	  Therefore	  using	  0.1mmol/kg	  for	  stress	  and	  again	  for	  rest	  perfusion	  does	  not	  increase	  the	  CA	  dose	  to	  study	  participants.	  Finally	  the	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weight	  of	  previously	  published	  evidence	  supports	  this	  as	  two	  of	  the	  three	  studies;	  involving	  the	  overall	  majority	  of	  patients,	  found	  it	  to	  be	  the	  optimal	  dose	  for	  diagnostic	  purposes.	  	  
Limitations	  The	  same	  limitations	  regarding	  sample	  size	  and	  the	  use	  of	  different	  CA	  doses	  in	  different	  patients	  rather	  than	  both	  doses	  in	  all	  patients	  which	  are	  discussed	  in	  the	  first	  part	  of	  this	  study	  are	  also	  applicable	  to	  this	  dose-­‐comparison	  sub	  study.	  It	  would	  have	  been	  ideal	  to	  compare	  a	  number	  of	  different	  sequences	  and	  CA	  doses	  in	  the	  same	  patients.	  However	  this	  was	  not	  practical	  given	  the	  number	  of	  patients	  that	  would	  have	  required	  and	  the	  perfusion	  phantom	  did	  allow	  comparison	  of	  multiple	  perfusion	  rates	  and	  CA	  doses.	  	  
Conclusions	  Image	  quality	  and	  artefacts	  were	  the	  same	  in	  patients	  imaged	  with	  both	  0.075	  and	  0.1mmol/kg	  of	  CA	  using	  the	  kt-­‐SSFP	  sequence.	  Myocardial	  signal	  saturation	  effects	  were	  evident	  at	  both	  0.075	  and	  0.1mmol/kg	  CA.	  On	  the	  basis	  of	  these	  findings	  and	  previous	  dose-­‐finding	  studies	  0.1mmol/kg	  with	  a	  dual	  bolus	  regimen	  was	  used	  for	  subsequent	  perfusion	  studies.	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4	   PERFUSION	  IMAGING.	  Validation	  of	  Fully	  Quantitative	  
CMR	  Perfusion	  Against	  Positron	  Emission	  Tomography	  in	  
Patients	  with	  Coronary	  Artery	  Disease	  	  
Abstract	  
Objectives	  Compare	  fully	  quantitative	  CMR	  and	  PET	  myocardial	  perfusion	  and	  myocardial	  perfusion	  reserve	  (MPR)	  measurements	  in	  patients	  with	  CAD.	  
	  
Background	  Absolute	  quantification	  of	  myocardial	  perfusion	  and	  MPR	  using	  PET	  have	  proven	  diagnostic	  and	  prognostic	  roles	  in	  patients	  with	  CAD.	  Quantitative	  CMR	  perfusion	  imaging	  has	  been	  established	  more	  recently	  and	  has	  been	  validated	  against	  PET	  in	  normal	  hearts.	  However,	  there	  are	  no	  studies	  comparing	  fully	  quantitative	  CMR	  against	  PET	  perfusion	  imaging	  in	  patients	  with	  CAD.	  	  
Methods	  41	  patients	  with	  known	  or	  suspected	  CAD	  prospectively	  underwent	  quantitative	  13N-­‐ammonia	  PET	  and	  CMR	  perfusion	  imaging	  prior	  to	  coronary	  angiography.	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Results	  	  CMR-­‐derived	  MPR	  (MPRCMR)	  correlated	  well	  with	  PET-­‐derived	  measurements	  (MPRPET)	  (r=0.75,	  p=<0.0001).	  MPRCMR	  and	  MPRPET	  for	  the	  two	  lowest	  scoring	  segments	  in	  each	  coronary	  territory	  also	  correlated	  strongly	  (r=0.79,	  p=<0.0001).	  Absolute	  CMR	  perfusion	  values	  correlated	  significantly	  but	  weakly	  with	  PET	  values	  both	  at	  rest	  (r=0.32;	  p=0.002)	  and	  during	  stress	  (r=0.37;	  p=<0.0001).	  	  	  Area	  under	  the	  receiver-­‐operating	  characteristic	  curve	  for	  MPRPET	  to	  detect	  significant	  CAD	  was	  0.83	  (95%	  CI	  0.73-­‐0.94)	  and	  for	  MPRCMR	  was	  0.83	  (0.74-­‐0.92).	  MPRPET	  ≤1.44	  predicted	  significant	  CAD	  with	  82%	  sensitivity	  and	  87%	  specificity	  and	  MPRCMR	  ≤1.45	  with	  82%	  sensitivity	  and	  81%	  specificity.	  
	  
Conclusions	  There	  is	  good	  correlation	  between	  MPRCMR	  and	  MPRPET.	  For	  the	  detection	  of	  significant	  CAD	  MPRPET	  and	  MPRCMR	  appear	  comparable	  and	  accurate.	  However,	  absolute	  perfusion	  values	  from	  PET	  and	  CMR	  are	  only	  weakly	  correlated	  therefore	  although	  quantitative	  CMR	  is	  clinically	  useful	  further	  refinements	  are	  still	  required.	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Background	  Non-­‐invasive	  assessment	  of	  myocardial	  perfusion	  is	  clinically	  important,	  particularly	  for	  the	  detection	  and	  management	  of	  patients	  with	  CAD.	  Currently,	  clinical	  decision-­‐making	  is	  usually	  based	  on	  visual	  estimates	  of	  relative	  perfusion.	  However,	  this	  approach	  relies	  on	  the	  presence	  of	  a	  normally	  perfused	  region	  of	  myocardium.	  Quantification	  of	  perfusion	  addresses	  this	  limitation	  and	  PET	  studies	  have	  confirmed	  that	  it	  provides	  incremental	  value	  compared	  to	  non-­‐quantitative	  method122.	  	  PET	  can	  accurately	  quantify	  perfusion	  and	  MPR	  and	  is	  currently	  the	  non-­‐invasive	  reference-­‐standard.	  Fully	  quantitative	  methods	  are	  accurate	  for	  the	  detection	  of	  CAD122	  and	  can	  result	  in	  improved	  diagnostic	  accuracy	  compared	  to	  relative	  perfusion	  analysis123.	  Recent	  studies	  have	  also	  demonstrated	  that	  an	  abnormal	  quantitative	  MPR	  is	  an	  independent	  predictor	  of	  an	  adverse	  prognosis44,	  45.	  Furthermore,	  quantitative	  data	  provides	  unique	  information	  about	  the	  coronary	  microcirculation	  which	  is	  not	  available	  from	  non-­‐quantitative	  methods36.	  	  CMR	  has,	  relatively	  recently,	  established	  itself	  as	  an	  accurate	  and	  valuable	  tool	  for	  perfusion	  imaging31.	  Currently,	  visual	  assessment	  is	  standard,	  however	  absolute	  quantification	  of	  perfusion	  has	  also	  been	  demonstrated	  to	  be	  feasible	  and	  accurate74,	  75,	  124,	  125.	  Quantitative	  CMR	  methods	  have	  been	  validated	  against	  microspheres	  in	  animals75,	  coronary	  sinus	  flow	  in	  patients125	  and	  PET	  in	  healthy	  volunteers126-­‐128.	  However,	  to	  date,	  there	  is	  a	  lack	  of	  evidence	  comparing	  quantitative	  CMR	  with	  PET	  in	  patients	  with	  CAD.	  Patient	  studies	  are	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clinically	  more	  relevant	  given	  the	  inherent	  differences	  between	  patients	  and	  healthy	  volunteers.	  The	  primary	  aim	  of	  this	  study	  was	  therefore	  to	  compare	  quantitative	  assessment	  of	  myocardial	  perfusion	  and	  MPR	  using	  CMR	  and	  PET	  in	  a	  cohort	  of	  patients	  with	  known	  or	  suspected	  CAD.	  	  
Methods	  
Patient	  population	  and	  study	  design	  Patients	  with	  a	  history	  of	  stable	  angina	  and	  known	  or	  suspected	  CAD	  underwent	  CMR	  and	  PET	  perfusion	  imaging	  prior	  to	  planned	  X-­‐ray	  coronary	  angiography.	  Exclusion	  criteria:	  acute	  coronary	  syndrome	  <6	  weeks,	  previous	  CABG,	  previous	  ST-­‐elevation	  infarction,	  or	  a	  contraindication	  to	  MRI	  or	  adenosine.	  The	  UK	  Administration	  of	  Radioactive	  Substances	  Advisory	  Committee	  licensed	  radiation	  exposure.	  	  
Data	  acquisition	  
CMR	  imaging	  Data	  were	  acquired	  with	  the	  1.5T	  scanner.	  Examinations	  included	  high-­‐resolution	  perfusion,	  functional	  and	  scar	  imaging.	  Perfusion	  imaging	  was	  performed	  with	  the	  kt-­‐SSFP	  sequence	  and	  consisted	  of	  3	  short	  axis	  slices	  acquired	  every	  heartbeat	  covering	  16	  of	  the	  standard	  myocardial	  segments96	  (apex	  excluded).	  Stress	  imaging	  preceded	  rest	  by	  14±2	  minutes	  (range	  10-­‐19	  minutes).	  A	  dual	  bolus	  (equal	  volumes	  of	  0.01mmol/kg	  followed	  by	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0.1mmol/kg	  after	  a	  20	  second	  pause)	  of	  weight	  adjusted	  CA	  was	  injected	  as	  previously	  described.	  	  	  
PET	  imaging	  This	  was	  performed	  using	  a	  GE,	  Discovery	  VCT	  PET-­‐CT	  scanner	  (GE	  Healthcare,	  Wisconsin,	  USA)	  after	  administration	  of	  13N	  ammonia,	  with	  47	  transaxial	  slices	  reconstructed	  over	  an	  axial	  field	  of	  view	  of	  15cm.	  Acquired	  resolution	  4.8x4.8x4.9mm.	  CT	  scout	  data	  determined	  patient	  position	  and	  a	  low	  dose	  CT	  used	  for	  attenuation	  correction.	  Acquisition	  consisted	  of	  dynamic	  scans	  0	  -­‐	  6	  mins	  (12x10seconds,	  6x20seconds	  and	  2x60seconds)	  and	  then	  a	  single	  static	  scan	  frame	  for	  20	  minutes.	  For	  the	  rest	  study	  a	  total	  of	  550	  MBq	  of	  13N-­‐ammonia	  was	  injected	  intravenously.	  Approximately	  50	  minutes	  later	  stress	  imaging	  was	  performed	  following	  a	  second	  CT	  scan.	  140µg/kg/minute	  of	  adenosine	  was	  administered	  intravenously	  for	  6	  minutes	  with	  a	  second	  equivalent	  dose	  of	  13N-­‐ammonia	  administered	  2	  minutes	  into	  the	  infusion.	  Patients	  remained	  on	  the	  scanner	  table	  throughout	  the	  entire	  study	  however	  attenuation	  correction	  was	  repeated	  for	  the	  stress	  study.	  	  
X-­‐ray	  coronary	  angiography	  This	  was	  performed	  according	  to	  the	  standard	  Judkin’s	  technique.	  Multiple	  projections	  of	  the	  coronary	  arteries	  were	  acquired	  including	  at	  least	  two	  orthogonal	  views	  to	  assess	  stenosis	  severity.	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Data	  analysis	  
Visual	  analysis	  Studies	  were	  analysed	  by	  two	  independent	  experts	  blinded	  to	  all	  other	  data.	  PET	  scans	  were	  classified	  as	  positive	  for	  CAD	  in	  the	  presence	  of	  a	  stress-­‐induced	  perfusion	  defect	  involving	  ≥2	  myocardial	  segments	  and	  CMR	  scans	  in	  the	  presence	  of	  a	  stress-­‐induced	  perfusion	  defect,	  which	  was	  transmural	  or	  involved	  ≥2	  myocardial	  segments.	  In	  the	  case	  of	  disagreement	  between	  the	  observers	  the	  images	  were	  reviewed	  together	  and	  a	  consensus	  reached.	  	  
	  
Quantitative	  analysis	  	  Quantitative	  analysis	  was	  performed	  by	  one	  of	  the	  experts.	  Perfusion	  was	  quantified	  in	  16	  standard	  AHA	  segments.	  Segments	  were	  defined	  separately	  for	  the	  PET	  and	  CMR	  images	  using	  the	  RV	  insertion	  points	  for	  reference.	  Segment	  17	  was	  excluded.	  Myocardial	  border	  detection	  was	  automated	  and	  manually	  corrected	  where	  required.	  Segments	  unsuitable	  for	  analysis	  due	  to	  artefact	  or	  poor	  image	  quality	  were	  excluded.	  CMR	  segments	  demonstrating	  LGE	  and	  PET	  data	  from	  patients	  with	  >10mm	  movement	  between	  the	  CT	  and	  PET	  were	  considered	  unreliable	  and	  also	  excluded.	  Coronary	  territories	  were	  excluded	  if	  all	  relevant	  segments	  were	  unsuitable	  for	  analysis.	  	  	  
PET:	  Original	  dynamic	  raw	  PET	  scans	  were	  used	  to	  calculate	  arterial	  input	  function	  and	  mean	  segmental	  perfusion	  calculated	  over	  the	  linear	  portion	  of	  the	  curve	  from	  70-­‐210	  seconds,	  using	  Quick	  Cardiac	  (Hermes	  Medical	  Solutions,	  Stockholm,	  Sweden)	  in	  conjunction	  with	  software	  developed	  at	  our	  institution	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based	  on	  the	  Patlak	  method	  as	  previously	  described	  and	  validated.129	  	  	  
CMR:	  Mean	  segmental	  perfusion	  values	  were	  obtained	  using	  dedicated	  prototype	  ViewForum	  software	  (Philips,	  Best,	  The	  Netherlands).	  Myocardial	  border	  definition	  results	  in	  automated	  production	  of	  pixel-­‐wise	  signal	  intensity	  curves	  in	  the	  myocardium	  and	  an	  AIF	  from	  the	  blood	  pool	  of	  the	  basal	  slice.	  The	  observer	  defines	  the	  time	  points	  of	  AIF	  onset	  and	  offset	  and	  myocardial	  signal	  onset.	  Perfusion	  is	  then	  be	  calculated	  in	  120	  radial	  segments	  per	  slice	  using	  the	  previously	  validated	  Fermi	  deconvolution	  method75.	  These	  values	  are	  then	  translated	  into	  mean	  perfusion	  values	  for	  each	  standard	  segment.	  	  
PET	  and	  CMR:	  Each	  segment	  was	  assigned	  to	  the	  appropriate	  perfusion	  territory96,	  with	  segment	  15	  assigned	  to	  the	  dominant	  coronary	  artery	  (defined	  by	  the	  observer	  analysing	  the	  angiogram).	  MPR	  was	  defined	  as	  stress	  perfusion	  divided	  by	  rest	  perfusion	  and	  was	  calculated	  for	  each	  segment	  and	  territory.	  For	  CAD	  detection	  mean	  MPR	  of	  the	  2	  lowest	  scoring	  segments	  for	  each	  perfusion	  territory	  (MPR2)	  was	  used	  for	  further	  analysis	  as	  described	  previously130.	  	  
	  
X-­‐ray	  angiography:	  All	  coronary	  arteries	  >2	  mm	  in	  diameter	  were	  assessed	  by	  an	  independent	  cardiologist	  blinded	  to	  all	  other	  data.	  Stenoses	  <30%	  and	  >95%	  on	  visual	  analysis	  were	  judged	  to	  be	  non	  flow-­‐limiting	  or	  flow-­‐limiting	  respectively	  without	  further	  assessment.	  Quantitative	  coronary	  angiography	  (QCA)	  was	  performed	  for	  all	  arteries	  with	  a	  visual	  stenosis	  severity	  of	  30-­‐95%	  using	  a	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dedicated	  software	  programme	  (Medcon	  UK,	  Middlesex,	  UK).	  Mean	  diameter	  stenosis	  from	  2	  orthogonal	  views	  was	  recorded	  and	  ≥70%	  regarded	  as	  significant.	  Coronary	  territories	  subtended	  by	  a	  coronary	  artery	  with	  ≥70%	  stenosis	  were	  classified	  as	  stenotic	  territories	  and	  all	  others	  as	  remote.	  
	  
Statistical	  analysis	  IBM	  SPSS	  Statistics	  version	  19	  and	  Medcalc	  were	  used.	  Data	  are	  presented	  as	  mean±standard	  deviation	  except	  where	  stated.	  Shapiro-­‐Wilk	  analysis	  defined	  when	  non-­‐parametric	  tests	  were	  required.	  Agreement	  and	  correlations	  between	  PET	  and	  CMR	  were	  determined	  using	  Bland	  Altman	  plots	  and	  Spearman’s	  test	  of	  correlation	  with	  a	  two-­‐tailed	  test	  of	  significance	  respectively.	  Analyses	  were	  performed	  on	  a	  per	  observation	  basis.	  Since	  3	  perfusion	  territories	  were	  analysed	  per	  patient	  analyses	  were	  repeated	  within	  each	  territory	  to	  ensure	  that	  any	  strong	  correlations	  did	  not	  simply	  reflect	  high	  within-­‐subject	  correlations.	  Intra	  and	  inter-­‐observer	  reproducibility	  was	  determined	  by	  a	  coefficient	  of	  variation	  (CV):	  standard	  deviation	  of	  the	  differences	  divided	  by	  the	  mean.	  Paired	  and	  independent	  T-­‐tests	  were	  used	  for	  comparison	  of	  paired	  and	  unpaired	  mean	  data	  respectively.	  ROC	  analysis	  determined	  the	  accuracy	  of	  visual	  analysis,	  MPR2	  and	  stress	  perfusion	  values	  from	  PET	  and	  CMR	  for	  predicting	  a	  corresponding	  coronary	  artery	  stenosis	  of	  ≥70%	  on	  QCA.	  Areas	  under	  ROC	  curves	  were	  compared	  using	  the	  Hanley	  and	  McNeil	  method.	  Optimal	  cut-­‐offs	  were	  determined	  by	  the	  maximum	  Youden	  index.	  Logistic	  regression	  models	  were	  used	  to	  calculate	  the	  area	  under	  the	  ROC	  curve	  when	  information	  from	  both	  CMR	  and	  PET	  were	  combined	  and	  this	  was	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compared	  to	  the	  ROC	  curves	  when	  CMR	  or	  PET	  was	  used	  alone.	  Sensitivity	  and	  specificity	  were	  compared	  with	  McNemar’s	  test.	  Significance	  was	  determined	  at	  <0.05.	  	  	  
Results	  
Study	  population	  Forty-­‐one	  patients	  were	  recruited.	  Table	  4.1	  shows	  baseline	  characteristics.	  The	  study	  protocol	  was	  completed	  in	  38	  patients	  (exclusions:	  1	  AV	  block,	  1	  withdrawal	  of	  consent,	  1	  claustrophobia)	  and	  further	  analysis	  relates	  to	  these	  patients.	  Haemodynamics	  during	  imaging	  are	  shown	  in	  table	  4.2.	  Resting	  heart	  rate	  was	  significantly	  higher	  during	  CMR	  studies	  (66	  vs.	  63	  beats	  per	  minute	  respectively).	  There	  were	  no	  significant	  differences	  between	  rate	  pressure	  product,	  systolic	  blood	  pressure	  or	  stress	  heart	  rate	  during	  CMR	  and	  PET	  studies.	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Table	  4.1:	  Baseline	  characteristics	  of	  the	  41	  study	  participants.	  	  
Characteristic	  	   	  
Age	   63±9	  
Male	   32	  (78%)	  
BMI	   29±5	  
LVEF	   63±12%	  
Angina	  (CCS)	  	  Class	  1	  Class	  2	  Class	  3	  
	  11	  (27%)	  22	  (54%)	  8	  (20%)	  
Diabetes	   13	  (32%)	  
Hypertension	   30	  (73%)	  
Smoking	  current	  previous	  
	  5	  (12%)	  21	  (51%)	  
Family	  history	  CAD	   19	  (46%)	  
Cerebrovascular	  disease	   4	  (10%)	  
Previous	  PCI	   13	  (32%)	  
Previous	  myocardial	  infarct	   5	  (12%)	  
Medications	  Aspirin	  Clopidogrel	  Statin	  ACE	  inhibitor	  Angiotensin	  receptor	  blocker	  Betablocker	  Calcium	  channel	  blocker	  Nitrate	  
	  33	  (80%)	  18	  (44%)	  35	  (85%)	  22	  (54%)	  6	  (15%)	  21	  (51%)	  13	  (32%)	  7	  (17%)	  
Coronary	  disease	  ≥70%	  Left	  anterior	  descending	  	  Circumflex	  	  Right	  coronary	  artery	  
	  7	  	  (17%)	  12	  (29%)	  13	  (32%)	  	  	  
  124 
The	  interval	  between	  PET	  and	  CMR	  scans	  was	  3±6	  days;	  26(63%)	  patients	  underwent	  both	  on	  the	  same	  day.	  The	  coronary	  angiogram	  was	  17±19	  and	  17±21	  days	  after	  the	  CMR	  and	  PET	  respectively.	  Twenty-­‐five	  patients	  (61%)	  had	  ≥1	  stenosis	  of	  ≥70%	  diameter.	  Nineteen	  had	  single-­‐vessel	  disease,	  5	  two-­‐vessel	  disease	  and	  1	  three-­‐vessel	  disease.	  The	  affected	  coronary	  artery	  was	  dominant	  in	  3	  of	  the	  12	  patients	  with	  circumflex	  disease	  and	  12	  of	  the	  13	  patients	  with	  right	  coronary	  artery	  disease.	  Left	  ventricular	  ejection	  fraction	  (CMR)	  was	  63±12%.	  	  	  
Table	  4.2:	  Summary	  (mean±SD)	  of	  the	  haemodynamic	  data	  for	  all	  38	  
participants	  during	  the	  imaging	  studies.	  
	   Rest	   Stress	  
	   PET	   CMR	   p	   PET	   CMR	   p	  
HR	  (bpm)	   63±10	   66±11	   0.002	   84±15	   86±15	   0.14	  
SBP	  (mmHg)	   138±18	   137±17	   0.75	   128±21	   132±19	   0.164	  
RPP	  (HRxSBP)	   8734±336	   9122±329	   0.12	   10781±479	   11344±445	   0.08	  	  
Myocardial	  perfusion	  	  All	  perfusion	  studies	  were	  suitable	  for	  visual	  analysis.	  Quantitative	  MPR	  data	  were	  available	  for	  89%,	  84%	  and	  73%	  of	  territories	  with	  CMR,	  PET	  and	  both	  modalities	  respectively.	  Results	  are	  summarized	  in	  table	  4.3.	  In	  patients	  with	  CAD	  stress	  perfusion,	  MPR	  and	  MPR2	  were	  significantly	  lower	  in	  stenotic	  territories	  compared	  to	  remote	  territories	  with	  both	  PET	  and	  CMR.	  Conversely,	  rest	  perfusion	  was	  not	  significantly	  different.	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  MPR2PET	  was	  1.36±0.32	  and	  1.74±0.32	  in	  stenotic	  and	  remote	  territories	  respectively	  (p=<0.0001).	  MPR2CMR	  values	  were	  1.31±0.30	  and	  1.70±0.42	  (p=<0.0001).	  In	  patients	  without	  significant	  CAD	  there	  was	  a	  trend	  towards	  higher	  MPR	  and	  MPR2	  compared	  to	  remote	  territories	  in	  patients	  with	  CAD	  but	  this	  was	  not	  significant.	  In	  patients	  without	  CAD	  MPR2PET	  was	  1.92±0.39	  and	  MPR2CMR	  was	  1.93±0.53	  (p=0.14	  and	  p=0.16	  respectively	  compared	  to	  remote	  territories	  in	  patients	  with	  CAD).	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Table	  4.3:	  Quantitative	  perfusion	  values	  in	  patients	  with	  and	  without	  
significant	  CAD.	  	  
A	  stenotic	  territory	  is	  subtended	  by	  a	  coronary	  artery	  with	  ≥70%	  diameter	  stenosis	  and	  a	  remote	  territory	  by	  a	  coronary	  artery	  with	  <70%	  stenosis.	  
	   CAD	   No	  CAD	  
	   Stenotic	  
territory	  
(n=32)	  
Remote	  
territory	  
(n=43)	  
p	  value*	   All	  territories	  
	  
(n=39)	  
p	  value†	  
Stress	  perfusion	  
(ml/minute/g)	  PET	  CMR	  
	  	  1.24±0.49	  1.54±0.34	  
	  	  1.56±0.66	  1.94±0.59	  
	  	  <0.0001	  0.001	  
	  	  1.72±0.66	  2.03±0.63	  
	  	  0.49	  0.68	  
Rest	  perfusion	  
(ml/minute/g)	  PET	  CMR	  	  
	  	  0.77±0.24	  1.03±0.30	  
	  	  0.81±0.25	  1.06±0.33	  
	  	  0.08	  0.28	  
	  	  0.85±0.26	  0.98±0.29	  
	  	  0.71	  0.47	  
MPR	  PET	  CMR	  
	  1.57±0.31	  1.55±0.36	  
	  1.87±0.36	  1.90±0.48	  
	  <0.0001	  0.001	  
	  2.06±0.44	  2.20±0.56	  
	  0.20	  0.13	  
MPR2	  PET	  CMR	  
	   1.36±0.32	  1.31±0.30	  
	  1.74±0.32	  1.70±0.42	  
	   <0.0001	  <0.0001	  
	   1.92±0.39	  1.93±0.53	  
	   0.14	  0.16	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Myocardial	  perfusion-­‐agreement	  between	  CMR	  and	  PET	  There	  was	  good	  correlation	  between	  MPRCMR	  and	  MPRPET;	  r=0.75	  (p=<0.0001;	  figure	  4.1A)	  and	  between	  MPR2CMR	  and	  MPR2PET;	  r=0.79	  (p=<0.0001,	  figure	  4.1B).	  A	  Bland	  Altman	  plot	  demonstrates	  good	  agreement	  between	  MPRCMR	  and	  MPRPET	  (Figure	  4.2).	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Figure	  4.1:	  Scatter	  plots	  comparing	  CMR	  and	  PET	  derived	  MPR.	  
Scatter	  plots	  with	  fit	  lines	  comparing	  myocardial	  perfusion	  reserve	  values	  from	  cardiac	  magnetic	  resonance	  (MPRCMR)	  and	  positron	  emission	  tomography	  (MPRCMR)	  for	  the	  entire	  myocardial	  territory	  (A)	  and	  the	  mean	  of	  the	  lowest	  two	  segments	  in	  each	  territory	  (MPR2)	  (B).	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Figure	  4.2:	  Agreement	  between	  CMR	  and	  PET	  MPR.	  
Bland	  Altman	  plot	  showing	  the	  agreement	  between	  CMR	  and	  PET	  derived	  absolute	  MPR	  measurements.	  	  Absolute	  CMR	  perfusion	  values	  correlated	  significantly	  but	  weakly	  with	  PET	  values	  both	  at	  rest	  (r=0.32;	  p=0.002)	  and	  during	  stress	  (r=0.37;	  p=<0.0001)	  (figure	  3).	  Results	  were	  similar	  when	  analyses	  were	  repeated	  within	  each	  territory.	  MPRCMR	  correlated	  well	  with	  MPRPET	  in	  the	  LAD	  (r=0.79;	  p=<0.0001),	  circumflex	  (r=0.64;	  p=<0.0001)	  and	  RCA	  territories	  (r=0.77;	  p=<0.0001).	  Bland	  Altman	  limits	  of	  agreement	  for	  MPRCMR	  and	  MPRPET	  also	  remained	  similar	  in	  the	  LAD	  (-­‐0.71	  to	  0.58),	  circumflex	  (-­‐0.7	  to	  0.8)	  and	  RCA	  territories	  (-­‐0.62	  to	  0.48).	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Figure	  4.3:	  Correlation	  and	  agreement	  between	  CMR	  and	  PET	  derived	  
absolute	  perfusion	  values.	  
Scatter	  plots	  illustrating	  the	  correlation	  between	  absolute	  measures	  of	  myocardial	  perfusion	  at	  rest	  (4.3A)	  and	  during	  peak	  stress	  (4.3C),	  along	  with	  the	  corresponding	  Bland	  Altman	  plots	  (4.3B	  and	  4.3D	  respectively)	  with	  limits	  of	  agreement	  lines	  (2	  standard	  deviations).	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Reproducibility	  Intra-­‐observer	  CV	  for	  PET	  stress	  perfusion,	  rest	  perfusion	  and	  MPR	  were	  9%,	  12%	  and	  15%.	  Corresponding	  CV	  for	  inter-­‐observer	  reproducibility	  were	  17%,	  13%	  and	  18%.	  CMR	  intra-­‐observer	  CV	  were	  9%,	  14%	  and	  20%	  and	  inter-­‐observer	  CV	  16%,	  18%	  and	  22%.	  
	  
Diagnosis	  of	  CAD	  
Visual	  analysis:	  Sensitivity	  and	  specificity	  against	  QCA:	  PET	  92%	  (95%	  confidence	  interval	  72-­‐99%)	  and	  69%	  (41-­‐88%);	  CMR	  86%	  (64-­‐96%)	  and	  76%	  (50-­‐92%).	  CMR	  and	  PET	  sensitivity	  and	  specificity	  were	  not	  significantly	  different	  (p=0.65	  and	  0.71	  respectively).	  	  If	  only	  those	  patients	  with	  quantitative	  data	  suitable	  for	  analysis	  were	  considered	  sensitivity	  and	  specificity	  changed	  to	  94%	  (71-­‐99%)	  and	  67%	  (39-­‐87%)	  and	  85%	  (61-­‐96%)	  and	  79%	  (49-­‐94%)	  for	  PET	  and	  CMR	  respectively.	  	  	  
Quantitative	  analysis:	  AUC	  for	  MPR2PET	  to	  detect	  significant	  CAD	  was	  0.83	  (95%	  CI	  0.73-­‐0.94)	  and	  for	  MPR2CMR	  was	  0.83	  (0.74-­‐0.92)	  (p=0.96).	  Sensitivity	  and	  specificity	  against	  QCA:	  MPR2PET	  ≤1.44,	  82%	  and	  87%	  and	  MPRCMR	  ≤1.45	  82%	  and	  81%	  (figure	  4.4).	  An	  example	  case	  is	  shown	  in	  figure	  4.5.	  	  AUC	  was	  0.85	  (0.75-­‐0.95)	  for	  MPR2PET	  and	  MPR2CMR	  combined.	  There	  was	  no	  significant	  difference	  between	  AUC	  when	  MPR2PET	  and	  MPR2CMR	  were	  both	  included	  in	  the	  model	  and	  when	  MPR2PET	  (p=0.406)	  or	  MPR2CMR	  (p=0.4749)	  alone	  were	  used.	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Figure	  4.4:	  Diagnosis	  of	  significant	  CAD	  against	  QCA	  using	  quantitative	  
CMR	  and	  PET	  derived	  MPR.	  
Mean	  myocardial	  perfusion	  reserve	  of	  the	  lowest	  2	  segments	  (MPR2)	  in	  remote	  (<70%)	  and	  stenotic	  (≥70%)	  territories.	  The	  best	  cut-­‐off	  values	  for	  the	  detection	  of	  CAD	  (MPRCMR	  1.45	  and	  MPRPET	  1.44)	  are	  shown.	  
	  MPR2PET	  and	  MPR2CMR	  were	  inversely	  related	  to	  the	  severity	  of	  CAD	  by	  QCA.	  For	  QCA	  subgroups	  <30%;	  30-­‐49%;	  50-­‐69%;	  70-­‐95%	  and	  >95%	  MPR2PET	  and	  MPR2CMR	  were	  1.93±0.39	  and	  1.89±0.46;	  1.73±0.33	  and	  1.86±0.67;	  1.58±0.4	  and	  1.54±0.47;	  1.49±0.33	  and	  1.28±0.42	  and	  1.18±0.20	  and	  1.26±0.22	  respectively.	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AUC	  for	  absolute	  perfusion	  values	  during	  stress	  to	  detect	  significant	  CAD:	  PET	  0.69	  (0.56-­‐0.81)	  and	  CMR	  0.72	  (0.61-­‐0.83).	  This	  was	  significantly	  lower	  than	  MPR2	  AUC	  with	  PET	  (p=0.049)	  but	  not	  CMR	  (p=0.12).	  Optimal	  absolute	  stress	  perfusion	  cut-­‐offs	  were	  PET	  ≤1.48ml/min/g	  (sensitivity	  80%,	  specificity	  53%)	  and	  CMR	  ≤1.50ml/min/g	  (sensitivity	  63%,	  specificity	  76%).	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Figure	  4.5:	  Case	  example.	  
PET	  (top),	  CMR	  (middle)	  and	  the	  X-­‐ray	  angiogram	  of	  the	  left	  coronary	  artery	  of	  a	  54-­‐year-­‐old	  patient	  with	  diabetes	  and	  exertional	  angina.	  Basal,	  mid	  and	  apical	  slices	  have	  been	  taken	  from	  the	  PET	  study,	  which	  approximately	  correspond	  to	  the	  CMR	  slices.	  There	  is	  a	  stress-­‐induced	  perfusion	  defect	  in	  the	  infero-­‐lateral	  region	  from	  base	  to	  apex	  visible	  on	  both	  PET	  and	  CMR	  images.	  There	  is	  a	  corresponding	  severe	  (>95%)	  stenosis	  of	  the	  proximal	  circumflex	  artery.	  There	  was	  no	  other	  significant	  angiographic	  disease.	  MPR2	  for	  each	  territory	  are	  shown	  in	  the	  table.	  MPR2	  for	  the	  circumflex	  artery	  is	  below	  the	  cut-­‐off	  of	  1.44	  and	  1.45	  for	  both	  PET	  and	  CMR	  respectively.	  
	  
Diagnostic	  accuracy	  for	  each	  coronary	  artery	  ROC	  curves	  for	  each	  individual	  coronary	  artery	  are	  shown	  in	  figure	  4.6.	  Area	  under	  the	  ROC	  curve	  and	  sensitivity	  were	  highest	  for	  the	  RCA	  and	  lowest	  for	  the	  circumflex	  with	  both	  modalities	  (table	  4.4).	  This	  difference	  was	  significant	  with	  CMR	  (p=0.04)	  but	  not	  with	  PET	  (p=0.15).	  The	  difference	  between	  the	  area	  under	  the	  LAD	  and	  circumflex	  and	  the	  LAD	  and	  RCA	  ROC	  curves	  were	  not	  significant	  with	  CMR	  (p=0.1	  and	  0.6	  respectively)	  or	  PET	  (p=0.2	  and	  0.88	  respectively).	  Sensitivity	  was	  highest	  for	  the	  RCA	  with	  both	  modalities.	  Specificity	  was	  also	  highest	  for	  the	  RCA	  and	  lowest	  for	  the	  circumflex	  with	  CMR.	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Figure	  4.6:	  ROC	  curves	  for	  the	  identification	  of	  significant	  CAD	  in	  each	  
individual	  coronary	  artery	  using	  MPR2PET	  (left)	  and	  MPR2CMR	  (right).	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Table	  4.4:	  Area	  under	  the	  ROC	  curves	  (ROC	  AUC),	  optimal	  MPR2	  cut-­‐off	  
and	  sensitivity	  and	  specificity	  for	  detection	  of	  significant	  CAD	  in	  each	  
coronary	  territory.	  
PET	   ROC	  
AUC	  	  
95%	  CI	   Optimal	  	  
MPR2	  cut-­‐off	  
Sensitivity	   Specificity	  
PET	   	   	   	   	   	  Overall	   0.83	   0.73-­‐0.94	   ≤1.44	   82%	   7%	  LAD	   0.88	   0.73-­‐1.0	   ≤1.33	   80%	   93%	  Circumflex	   0.69	   0.43-­‐0.94	   ≤1.42	   57%	   92%	  RCA	   0.89	   0.78-­‐1.0	   ≤1.44	   100%	   82%	  
	   	   	   	   	   	  
CMR	   	   	   	   	   	  Overall	   0.83	   0.74-­‐0.92	   ≤1.45	   82%	   81%	  LAD	   0.88	   0.77-­‐1.0	   ≤1.35	   83%	   86%	  Circumflex	   0.69	   0.5-­‐0.89	   ≤1.45	   60%	   78%	  RCA	   0.92	   0.8-­‐1.0	   ≤1.45	   91%	   87%	  LAD	  n=7,	  circumflex	  n=12	  and	  RCA	  n=13.	  	  
Discussion	  We	  have	  demonstrated	  that	  in	  patients	  with	  known	  or	  suspected	  CAD	  there	  is	  good	  correlation	  between	  MPRPET	  and	  MPRCMR.	  MPR2CMR	  also	  appears	  to	  have	  a	  similar	  sensitivity	  and	  specificity	  to	  MPR2PET	  for	  the	  detection	  of	  significant	  coronary	  artery	  stenoses.	  However,	  the	  correlation	  between	  the	  absolute	  perfusion	  values	  from	  PET	  and	  CMR	  is	  relatively	  weak.	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  To	  our	  knowledge	  there	  are	  no	  previously	  published	  studies	  comparing	  quantitative	  CMR	  myocardial	  perfusion	  with	  PET	  in	  patients.	  Previous	  studies	  have	  been	  limited	  to	  semi-­‐quantitative	  analysis	  methods100,	  131	  or	  have	  involved	  healthy	  volunteers126-­‐128.	  Semi-­‐quantitative	  analysis	  has	  been	  shown	  to	  be	  useful72	  and	  to	  correlate	  well	  with	  MPRPET	  in	  patents	  with	  CAD100,	  131.	  However,	  unlike	  fully	  quantitative	  analysis,	  these	  methods	  only	  provide	  an	  index	  of	  perfusion	  reserve	  not	  a	  true	  MPR,	  and	  might	  substantially	  underestimate	  perfusion,	  particularly	  at	  higher	  perfusion	  values131.	  	  	  Studies	  using	  fully	  quantitative	  CMR	  methods	  are	  limited	  to	  small	  numbers	  of	  healthy	  volunteers.	  The	  results	  of	  these	  studies	  are	  inconsistent	  and	  difficult	  to	  compare	  as	  each	  study	  employed	  different	  PET	  and	  CMR	  methods.	  Parkka	  et	  al.127	  studied	  18	  healthy	  volunteers	  with	  15O-­‐water	  PET	  and	  CMR.	  They	  used	  compartmental	  modeling	  and	  found	  that	  MPR	  and	  stress	  perfusion	  values	  were	  significantly	  correlated	  (r=0.48	  and	  r=0.7	  respectively).	  However,	  rest	  perfusion	  values	  were	  not	  significantly	  correlated.	  Fritz-­‐Hansen	  et	  al.126	  studied	  10	  healthy	  volunteers	  with	  13N-­‐ammonia	  PET	  using	  the	  same	  CMR	  quantification	  method.	  Similar	  to	  our	  findings	  they	  demonstrated	  a	  significant	  correlation	  between	  global	  MPRPET	  and	  MPRCMR	  (r=0.7).	  They	  found	  an	  even	  stronger	  correlation	  for	  the	  change	  in	  myocardial	  perfusion	  between	  rest	  and	  stress	  (r=0.96).	  Both	  of	  these	  studies	  found	  a	  tendency	  for	  CMR	  to	  underestimate	  MPR	  compared	  to	  PET.	  In	  a	  smaller	  study	  of	  five	  volunteers	  Pack	  et	  al.128	  found	  that	  3T	  CMR	  and	  13N-­‐ammonia	  PET	  perfusion	  and	  MPR	  values	  are	  well	  correlated	  but	  that	  MPR	  may	  be	  in	  better	  agreement.	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  Both	  PET	  and	  CMR	  perfusion	  and	  MPR	  values	  in	  our	  study	  are	  physiologically	  plausible	  and	  in	  the	  same	  range	  as	  in	  some	  previous	  studies126,	  132-­‐136	  but	  lower	  than	  those	  reported	  by	  others137.	  Patients	  are	  known	  to	  have	  lower	  stress	  and	  rest	  perfusion	  than	  normal	  volunteers	  do	  even	  in	  remote	  territories133,	  134.	  The	  mean	  difference	  between	  PET	  and	  CMR	  perfusion	  values	  is	  small	  however;	  the	  limits	  of	  agreement	  are	  broad,	  particularly	  at	  higher	  stress	  perfusion	  values.	  The	  findings	  that	  MPR,	  a	  ratio	  of	  stress	  and	  rest	  perfusion	  values,	  correlates	  well	  but	  that	  the	  absolute	  perfusion	  values	  correlate	  relatively	  poorly	  suggests	  that	  the	  errors	  in	  quantification	  had	  a	  similar	  influence	  on	  both	  rest	  and	  stress	  perfusion	  values	  and	  were	  subsequently	  cancelled	  by	  the	  calculation	  of	  MPR.	  These	  errors	  may	  be	  a	  result	  of	  either	  methodological	  or	  physiological	  factors.	  	  
Methodological	  considerations	  Differences	  in	  voxel	  size	  and	  acquisition	  methods	  (3D	  segments	  were	  acquired	  with	  PET	  and	  10mm	  slices	  through	  the	  16	  segments	  with	  CMR)	  and	  the	  use	  of	  different	  post-­‐processing	  methods	  mean	  that	  despite	  calculating	  mean	  values	  in	  standard	  segments	  and	  territories	  there	  is	  likely	  to	  have	  been	  a	  small	  degree	  of	  misregistration	  between	  the	  modalities.	  Furthermore,	  whilst	  partial	  volume	  effects	  are	  corrected	  for	  using	  compartmental	  PET	  analysis129	  these	  were	  not	  taken	  into	  account	  with	  CMR.	  	  	  PET	  and	  CMR	  have	  both	  been	  validated	  against	  gold-­‐standard	  techniques	  however	  both	  still	  have	  limitations.	  PET	  studies	  have	  used	  different	  tracers	  (e.g.	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13N-­‐ammonia	  versus	  15O	  water),	  acquisition	  protocols	  and	  analysis	  methods	  (e.g.	  Patlak,	  compartmental).	  In	  the	  present	  study	  the	  method	  may	  underestimate	  absolute	  perfusion138-­‐an	  effect	  which	  would	  also	  be	  cancelled	  by	  the	  calculation	  of	  MPR.	  	  	  Quantitative	  CMR	  perfusion	  studies	  have	  used	  different	  magnetic	  field	  strengths,	  contrast	  agents,	  perfusion	  sequences	  and	  post	  processing	  algorithms.	  One	  of	  the	  main	  challenges	  faced	  by	  CMR	  quantification	  is	  that	  at	  higher	  concentrations	  of	  contrast	  agent	  there	  is	  a	  loss	  of	  linearity	  between	  contrast	  agent	  concentration	  and	  signal	  intensity.	  It	  is	  possible	  that	  these	  signal	  saturation	  effects	  influenced	  our	  CMR	  results.	  However,	  we	  used	  a	  dual	  bolus	  method	  to	  preserve	  signal	  linearity	  in	  the	  LV	  blood	  pool	  and	  allow	  calculation	  of	  the	  arterial	  input	  function.	  In	  addition,	  a	  previous	  study	  has	  demonstrated	  that	  myocardial	  signal	  intensity	  continues	  to	  increase	  at	  much	  higher	  doses	  of	  contrast	  agent	  (up	  to	  at	  least	  0.15mmol/kg)	  than	  those	  used	  here119,	  although	  this	  study	  was	  in	  normal	  hearts	  imaged	  using	  a	  hybrid	  echo	  planar	  pulse	  sequence.	  Furthermore,	  a	  14-­‐minute	  interval	  between	  stress	  and	  rest	  imaging	  is	  insufficient	  for	  complete	  dissipation	  of	  the	  contrast	  agent.	  We	  used	  a	  published	  method139	  of	  baseline	  correction	  to	  account	  for	  this	  however	  this	  may	  also	  have	  introduced	  some	  error	  into	  rest	  perfusion	  measurements.	  In	  contrast	  to	  the	  previous	  volunteer	  studies,	  we	  did	  not	  find	  any	  evidence	  of	  systematic	  errors	  for	  low	  or	  high	  values,	  indicating	  that	  CMR	  is	  valid	  for	  a	  wide	  range	  of	  perfusion	  values.	  	  	  It	   is	  also	  possible	   that	  systematic	  errors	  could	  relate	   to	   the	   fact	   that	  PET80,	  140	  and	   particularly	   CMR141	   have	   only	   moderate	   inter-­‐study	   reproducibility.	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Regional	  measurements	  of	  perfusion	  in	  particular	  tend	  to	  be	  less	  reproducible	  than	   global	   measurements.	   Since	   the	   reproducibility	   of	   data	   analysis	   was	  relatively	   high	   this	  may	  be	   partly	   also	   explained	  by	  physiological	   variation	   of	  perfusion.	  	  	  
Physiological	  considerations	  There	  are	  also	  likely	  to	  have	  been	  real	  changes	  in	  perfusion	  even	  though	  the	  interval	  between	  the	  PET	  and	  CMR	  scans	  was	  short.	  Little	  is	  known,	  for	  example,	  as	  to	  whether	  diurnal	  variation	  or	  changes	  in	  hydration	  affect	  myocardial	  perfusion.	  It	  is	  also	  possible	  that	  such	  differences	  are	  more	  pronounced	  in	  patients	  than	  in	  volunteers	  for	  example	  as	  a	  result	  of	  the	  use	  of	  medications	  which	  affect	  perfusion.	  	  	  
Clinical	  Implications	  The	  novel	  finding	  that	  MPRCMR	  correlates	  with	  MPRPET	  is	  important	  given	  the	  proven	  utility	  of	  MPRPET.	  MPRPET	  correlates	  inversely	  with	  the	  degree	  of	  coronary	  artery	  stenosis	  at	  angiography42.	  Furthermore,	  recent	  studies	  have	  demonstrated	  that	  MPRPET	  is	  an	  independent	  predictor	  of	  outcome	  and	  predicts	  major	  adverse	  cardiac	  events	  and	  cardiac	  death44	  in	  patients	  with	  suspected	  impaired	  perfusion	  and	  reduced	  survival	  in	  patients	  with	  left	  ventricular	  impairment45.	  	  	  In	  this	  study	  we	  identified	  MPR2CMR	  and	  MPR2PET	  cut-­‐off	  values	  that	  detected	  CAD	  with	  a	  high	  sensitivity	  and	  specificity.	  MPR	  was	  superior	  to	  absolute	  stress	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perfusion	  values	  for	  this	  purpose.	  MPR2PET	  AUC	  was	  significantly	  higher	  than	  absolute	  stress	  perfusion	  values	  AUC	  and	  there	  was	  also	  a	  trend	  towards	  significance	  with	  MPR2CMR.	  This	  was	  reflected	  by	  optimal	  cut-­‐off	  values	  for	  absolute	  stress	  perfusion	  values	  that	  would	  be	  clinically	  less	  useful	  due	  to	  modest	  sensitivity	  (CMR)	  or	  specificity	  (PET).	  This	  is	  in	  contrast	  to	  some	  limited	  recent	  PET	  data	  suggesting	  that	  a	  single	  absolute	  stress	  perfusion	  cut-­‐off	  value	  might	  be	  superior	  to	  MPR	  for	  the	  detection	  of	  CAD132.	  In	  addition,	  there	  does	  not	  appear	  to	  be	  any	  incremental	  value	  in	  combining	  MPR	  data	  from	  both	  PET	  and	  CMR	  for	  the	  diagnosis	  of	  CAD.	  	  The	  optimal	  MPR	  cut-­‐off	  was	  similar	  between	  both	  modalities	  in	  all	  3	  coronary	  arteries.	  It	  is	  noteworthy	  that	  the	  area	  under	  the	  ROC	  curve	  was	  lower	  for	  the	  detection	  of	  circumflex	  disease	  and	  this	  difference	  was	  significant	  with	  CMR	  (but	  not	  PET).	  Since	  this	  trend	  was	  seen	  with	  both	  PET	  and	  CMR	  it	  may	  be	  due	  to	  erroneous	  allocation	  of	  myocardial	  segments	  to	  coronary	  artery	  territories,	  as	  we	  used	  a	  standard	  method	  of	  allocation,	  even	  though	  there	  is	  known	  to	  be	  considerable	  inter-­‐individual	  variability142.	  We	  attempted	  to	  adjust	  for	  this,	  to	  some	  extent,	  by	  allocating	  segment	  15	  variably	  to	  the	  dominant	  coronary	  artery.	  However	  variability	  in	  blood	  supply	  also	  affects	  other	  segments	  and	  there	  is	  no	  reliable	  method	  to	  correct	  for	  all	  segments,	  although	  this	  can	  be	  attempted	  by	  examining	  the	  CMR	  and	  angiogram	  together.	  Moreover,	  evaluation	  of	  individual	  coronary	  arteries	  reduces	  the	  sample	  size	  considerably,	  and	  increases	  the	  confidence	  intervals	  (table	  4.1).	  It	  is	  therefore	  best	  to	  consider	  the	  overall	  results	  and	  study	  differences	  in	  diagnostic	  accuracy	  between	  the	  coronaries	  further	  in	  larger	  future	  studies.	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  Quantification	  of	  images	  in	  general	  results	  in	  more	  precise,	  reproducible	  and	  user-­‐independent	  results.	  Although	  in	  this	  study	  there	  was	  no	  incremental	  benefit	  over	  visual	  analysis	  non-­‐invasive	  quantification	  of	  perfusion	  may	  be	  particularly	  useful	  in	  cases	  where	  visual	  assessment	  is	  difficult	  such	  as	  multivessel	  disease,	  severe	  left	  ventricular	  impairment	  and	  after	  CABG.	  Moreover,	  it	  may	  eventually	  allow	  the	  definition	  of	  thresholds	  of	  perfusion	  associated	  with	  myocardial	  ischaemia46	  and	  viability	  both	  of	  which	  are	  known	  to	  be	  important	  for	  selecting	  patients	  for	  revascularization	  procedures.	  This	  study	  reinforces	  the	  evidence	  that	  quantitative	  CMR	  perfusion	  data	  can	  be	  useful	  for	  the	  assessment	  of	  patients	  with	  CAD	  and	  at	  present	  we	  can	  accurately	  differentiate	  normal	  from	  abnormal	  myocardial	  territories.	  However,	  further	  method	  refinement	  is	  required	  before	  the	  benefits	  can	  be	  fully	  realized.	  	  
Limitations	  The	  sample	  size	  in	  this	  study	  is	  modest.	  However,	  this	  is	  the	  first	  study	  in	  patients	  and	  larger	  than	  previous	  volunteer	  studies.	  Furthermore,	  this	  limitation	  applies	  more	  to	  the	  secondary	  objective	  of	  exploring	  diagnostic	  accuracy	  than	  to	  the	  primary	  aim	  of	  comparing	  quantitative	  perfusion.	  Large	  sample	  sizes	  will	  be	  required	  to	  demonstrate	  any	  significant	  differences	  in	  diagnostic	  accuracy.	  We	  compared	  functional	  tests	  against	  an	  anatomic	  reference	  standard	  (QCA)	  despite	  the	  well-­‐documented	  limitations	  of	  this	  approach.	  It	  may	  be	  better	  to	  use	  fractional	  flow	  reserve	  as	  a	  reference	  standard	  in	  future	  studies.	  However,	  X-­‐ray	  coronary	  angiography	  is	  widely	  used	  as	  the	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reference	  standard	  in	  both	  studies	  and	  in	  clinical	  practice,	  and	  does	  not	  affect	  the	  comparisons	  made	  between	  PET	  and	  CMR,	  which	  was	  the	  main	  goal	  of	  our	  study.	  	  	  The	  patients	  included	  in	  this	  study	  had	  overall	  good	  left	  ventricular	  function	  and	  it	  is	  not	  clear	  how	  well	  these	  methods	  translate	  into	  patients	  with	  left	  ventricular	  systolic	  dysfunction.	  Finally,	  the	  relatively	  high	  prevalence	  CAD	  and	  the	  exclusion	  of	  segments	  where	  image	  quality	  precluded	  quantitative	  assessment	  means	  that	  these	  results	  are	  likely	  to	  represent	  best	  possible	  results	  using	  currently	  available	  quantitative	  techniques.	  	  
Conclusions	  There	  is	  good	  correlation	  between	  MPR	  derived	  from	  quantitative	  CMR	  and	  PET	  data,	  which	  is	  important	  given	  the	  proven	  value	  of	  MPRPET	  for	  detection	  of	  CAD,	  prognostication	  and	  assessment	  of	  the	  microcirculation.	  MPRPET	  and	  MPRCMR	  seem	  to	  predict	  significant	  CAD	  equally	  well	  and	  accurately.	  However,	  in	  patients,	  the	  absolute	  perfusion	  values	  from	  PET	  and	  CMR	  are	  only	  weakly	  correlated	  suggesting	  that	  further	  refinement	  of	  quantitative	  techniques	  is	  required.	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5	   PERFUSION	  IMAGING.	  Comparison	  of	  CMR	  Ischaemic	  
Burden	  and	  the	  Angiographic	  Extent	  of	  Coronary	  Artery	  
Disease.	  
Abstract	  
Objectives	  Examine	  the	  relationship	  between	  the	  extent	  of	  angiographic	  CAD	  and	  myocardial	  ischaemic	  burden	  assessed	  with	  CMR.	  	  
Background	  It	  is	  increasingly	  recognised	  that	  angiographic	  and	  functional	  data	  are	  both	  important	  for	  determining	  patient	  management	  and	  planning	  revascularisation.	  Despite	  this	  little	  is	  known	  about	  the	  correlation	  between	  angiographic	  and	  functional	  measures	  of	  the	  extent	  of	  CAD.	  	  
Methods	  75	  patients	  with	  angina	  and	  known	  or	  suspected	  CAD	  referred	  for	  coronary	  angiography	  prospectively	  underwent	  high-­‐resolution	  CMR	  perfusion	  imaging.	  Correlation	  between	  the	  BCIS-­‐1	  Myocardial	  Jeopardy	  Score	  (BCIS-­‐JS)	  and	  CMR	  ischaemic	  burden	  and	  the	  accuracy	  with	  which	  the	  BCIS-­‐JS	  can	  predict	  a	  prognostic	  ischaemia	  threshold	  were	  evaluated.	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Results	  There	  was	  a	  strong	  correlation	  between	  the	  BCIS-­‐JS	  and	  myocardial	  ischaemic	  burden:	  r=0.75,	  p<0.0001.	  Area	  under	  the	  ROC	  curve	  for	  BCIS-­‐JS	  to	  detect	  ≥12%	  myocardial	  ischaemic	  burden	  was	  0.87	  (95%	  CI	  0.78-­‐0.96).	  BCIS-­‐JS	  ≥6	  predicted	  ≥12%	  myocardial	  ischaemic	  burden	  with	  a	  sensitivity	  of	  68%	  and	  a	  specificity	  of	  91%.	  	  
	  
Conclusions	  The	  BCIS-­‐JS	  correlates	  well	  with	  myocardial	  ischaemic	  burden.	  A	  BCIS-­‐JS	  ≥6	  predicts	  the	  prognostically	  important	  ischaemic	  threshold	  of	  12%	  with	  high	  specificity.	  These	  findings	  provide	  useful	  insight	  into	  the	  relationship	  between	  	  angiographic	  and	  functional	  measures	  of	  the	  extent	  of	  CAD.	  In	  addition	  they	  support	  the	  utility	  of	  the	  BCIS-­‐JS	  for	  classification	  of	  CAD	  burden	  in	  clinical	  trials	  and	  suggest	  it	  may	  have	  a	  potential	  role	  in	  managing	  patients	  with	  CAD.	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Background	  The	  literature	  on	  coronary	  revascularization	  is	  dominated	  by	  anatomical	  classifications	  of	  CAD	  and	  as	  such	  there	  are	  very	  many	  reports	  on	  the	  relationship	  between	  the	  extent	  of	  CAD	  and	  patient	  management	  or	  prognosis.	  	  The	  extent	  of	  CAD	  frequently	  influences	  whether	  a	  patient	  is	  treated	  medically	  or	  is	  considered	  for	  revascularization.	  Patients	  with	  more	  extensive	  disease	  have	  a	  worse	  prognosis8,	  143	  and	  are	  thought	  to	  derive	  the	  most	  benefit	  from	  revascularization.	  Furthermore,	  the	  extent	  of	  disease	  also	  correlates	  with	  an	  increased	  risk	  of	  complications	  during	  revascularization	  procedures144.	  Currently,	  the	  coronary	  angiogram	  remains	  the	  gold-­‐standard	  investigation	  for	  the	  diagnosis	  and	  quantification	  of	  CAD.	  	  	  However,	  more	  recently	  increasing	  recognition	  has	  been	  given	  to	  the	  limitations	  of	  anatomic	  investigations	  and	  the	  importance	  of	  assessing	  the	  functional	  consequences	  of	  CAD	  to	  guide	  revascularisation21.	  Myocardial	  ischaemia	  is	  also	  known	  to	  have	  an	  adverse	  affect	  on	  prognosis10,	  12.	  Furthermore,	  a	  myocardial	  ischaemic	  burden	  of	  approximately	  12%	  has	  been	  identified	  as	  an	  important	  threshold.	  Revascularization	  may	  confer	  a	  prognostic	  benefit	  over	  medical	  therapy	  in	  patients	  above	  this	  threshold	  whilst	  medical	  therapy	  may	  be	  superior	  in	  patients	  with	  little	  or	  no	  ischaemia13.	  	  Despite	  this	  recognition	  much	  less	  is	  known	  about	  the	  relationship	  between	  the	  extent	  of	  angiographic	  CAD	  and	  myocardial	  ischaemia.	  The	  primary	  aim	  of	  this	  study	  was	  therefore	  to	  examine	  this	  relationship	  in	  a	  contemporary	  cohort	  of	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patients	  with	  CAD	  by	  assessing	  the	  correlation	  between	  the	  angiographic	  BCIS-­‐1	  Myocardial	  Jeopardy	  Score	  (BCIS-­‐JS)	  and	  CMR	  myocardial	  ischaemic	  burden.	  	  The	  recently	  described	  BCIS-­‐JS145	  provides	  a	  semi-­‐quantitative	  estimate	  of	  the	  extent	  of	  CAD	  and	  was	  used	  initially	  in	  a	  large	  multicentre	  study	  to	  define	  high-­‐risk	  patients	  with	  a	  large	  amount	  of	  myocardium	  at	  risk146.	  This	  angiographic	  score	  is	  a	  modification	  of	  the	  Duke	  Jeopardy	  Score147,	  which	  allows	  classification	  of	  a	  broader	  range	  of	  anatomy,	  including	  left	  main	  coronary	  disease	  and	  coronary	  artery	  bypass	  grafts.	  Two	  points	  each	  are	  ascribed	  for	  disease	  in	  each	  of	  6	  major	  proximal	  coronary	  segments	  and	  the	  score	  adjusted	  to	  account	  for	  functioning	  bypass	  grafts;	  the	  overall	  score	  ranges	  from	  0	  (for	  no	  jeopardy)	  to	  12	  (reflecting	  maximum	  jeopardy).	  For	  the	  full	  BCIS-­‐JS	  see	  Appendix	  B.	  This	  broader	  anatomical	  applicability	  is	  particularly	  relevant	  given	  the	  heterogeneity	  of	  patients	  seen	  in	  contemporary	  practice.	  There	  are	  increasing	  numbers	  of	  patients	  with	  previous	  CABG148	  and	  increasingly	  complex	  anatomy	  is	  being	  considered	  for	  revascularization.	  In	  contrast	  to	  other	  scores149-­‐152,	  the	  BCIS-­‐JS	  can	  be	  simply	  calculated	  by	  visual	  analysis	  of	  the	  coronary	  angiogram.	  	  
Methods	  	  
Patient	  population	  and	  study	  design	  Patients	  with	  a	  history	  of	  stable	  angina	  and	  known	  or	  suspected	  CAD	  referred	  for	  diagnostic	  X-­‐ray	  coronary	  angiography	  were	  prospectively	  included.	  Exclusion	  criteria	  were:	  an	  acute	  coronary	  syndrome	  within	  6	  weeks,	  and	  left	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ventricular	  ejection	  fraction	  <30%	  in	  addition	  to	  the	  general	  criteria	  in	  chapter	  2.	  Patients	  enrolled	  underwent	  CMR	  examination	  within	  90	  days	  of	  X-­‐ray	  angiography	  either	  as	  part	  of	  their	  routine	  care	  or	  as	  an	  additional	  research	  investigation.	  Patients	  were	  randomly	  assigned	  to	  undergo	  CMR	  imaging	  at	  either	  1.5T	  or	  3T	  (2:1	  ratio)	  to	  reflect	  the	  interchangeable	  use	  of	  both	  field	  strengths	  in	  clinical	  practice	  and	  in	  order	  to	  complete	  the	  study	  prior	  to	  a	  planned	  upgrade	  to	  the	  3T	  system.	  	  	  
Data	  acquisition	  X-­‐ray	  coronary	  angiography	  was	  performed	  according	  to	  the	  standard	  techniques.	  	  	  CMR	  imaging	  was	  performed	  using	  standard	  techniques	  All	  examinations	  included	  high-­‐resolution	  k-­‐t	  accelerated	  perfusion	  imaging,	  long	  and	  short	  axis	  cine	  and	  scar	  imaging.	  The	  kt-­‐SSFP	  sequence	  was	  used	  at	  1.5T.	  The	  following	  parameters	  were	  used	  for	  perfusion	  imaging	  at	  3T:	  k-­‐t	  Turbo	  Field	  Echo	  sequence	  with	  shortest	  echo	  time	  (range	  0.9-­‐0.95ms),	  shortest	  repetition	  time	  (range	  2.54-­‐2.67ms),	  flip	  angle	  20°;	  90°	  prepulse,	  120ms	  prepulse	  delay	  and	  typical	  acquired	  resolution	  of	  1.3	  x	  1.3	  x	  10mm.	  CA	  was	  administered	  as	  a	  dual	  bolus.	  The	  dose	  was	  optimized	  for	  visual	  assessment	  according	  to	  local	  protocols	  (0.1mmol/kg	  at	  1.5T	  and	  0.075mmol/kg	  at	  3T).	  Scar	  imaging	  was	  commenced	  10-­‐15	  minutes	  after	  a	  total	  dose	  of	  0.2mmol/kg	  of	  gadolinium	  and	  was	  performed	  using	  an	  inversion	  recovery	  turbo	  gradient	  echo	  sequence	  with	  the	  prepulse	  delay	  optimized	  for	  maximum	  suppression	  of	  myocardial	  signal.	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Data	  analysis	  Expert	  observers	  blinded	  to	  all	  other	  clinical	  and	  imaging	  data	  performed	  the	  data	  analysis.	  X-­‐ray	  coronary	  angiograms	  were	  assigned	  a	  BCIS-­‐JS	  as	  previously	  described145	  (Appendix	  B).	  	  	  CMR	  perfusion	  and	  scar	  images	  were	  segmented	  according	  to	  the	  standard	  AHA	  model96	  and	  16	  segments	  analysed	  (true	  apex	  excluded).	  Each	  segment	  was	  further	  subdivided	  into	  equal	  endocardial	  and	  epicardial	  sub-­‐segments	  with	  each	  sub-­‐segment	  considered	  to	  represent	  3%	  of	  the	  myocardium.	  Sub-­‐segments	  were	  analysed	  visually	  and	  classified	  as	  normal,	  ischaemic	  or	  scar.	  Scar	  was	  defined	  as	  LGE	  typical	  of	  myocardial	  infarction	  affecting	  >50%	  of	  the	  sub-­‐segment	  thickness.	  Ischaemia	  was	  defined	  as	  >50%	  sub-­‐segment	  thickness	  affected	  by	  a	  perfusion	  defect	  present	  only	  during	  stress	  and	  also	  <50%	  of	  the	  sub-­‐segment	  affected	  by	  scar.	  All	  other	  sub-­‐segments	  were	  classified	  as	  normal.	  This	  method	  permitted	  the	  calculation	  of	  the	  myocardial	  scar	  and	  ischaemic	  burden	  expressed	  as	  a	  percentage.	  In	  addition	  we	  also	  calculated	  the	  combined	  percentage	  of	  myocardium	  that	  was	  affected	  by	  either	  scar	  or	  ischaemia.	  	  
Statistical	  analysis	  This	  was	  performed	  using	  IBM	  SPSS	  Statistics	  version	  19.	  Correlation	  between	  the	  BCIS-­‐JS	  and	  CMR	  ischaemic	  burden	  and	  also	  the	  combined	  burden	  of	  ischaemia	  and	  scar	  were	  determined	  using	  Pearson’s	  test	  of	  correlation	  with	  a	  two-­‐tailed	  test	  of	  significance.	  ROC	  analysis	  was	  performed	  to	  determine	  the	  accuracy	  of	  the	  BCIS-­‐JS	  for	  predicting	  a	  myocardial	  ischaemic	  burden	  of	  ≥12%.	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Haemodynamic	  data	  were	  compared	  using	  a	  paired	  t-­‐test.	  Significance	  was	  determined	  at	  <0.05.	  Data	  are	  presented	  as	  mean	  ±	  standard	  deviation	  except	  where	  stated	  otherwise.	  
	  
Results	  75	  patients	  were	  enrolled	  in	  the	  study.	  7	  patients	  were	  later	  excluded	  from	  the	  analysis,	  5	  from	  the	  1.5T	  arm	  and	  2	  from	  the	  3T	  arm.	  Reasons	  for	  exclusion	  included	  complete	  heart	  block	  during	  adenosine	  infusion	  (1	  patient),	  LVEF	  <30%	  (1	  patient),	  protocol	  violation	  (1	  patient),	  claustrophobia	  (1	  patient)	  and	  X-­‐ray	  coronary	  angiography	  not	  performed	  within	  90	  days	  of	  CMR	  (3	  patients).	  Patients	  included	  in	  the	  final	  analysis	  were	  66±10	  years	  old.	  Table	  5.1	  summarizes	  patient	  characteristics	  and	  BCIS-­‐JS.	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Table	  5.1:	  Characteristics	  of	  the	  patients	  included	  in	  the	  analysis.	  
Characteristic	  (n=68)	   Number	  (%)	  of	  patients	  
Male	   58	  (85%)	  
Diabetes	   19	  (28%)	  
Previous	  CABG	   13	  (19%)	  
Previous	  PCI	   24	  (35%)	  
Previous	  MI	   12	  (18%)	  
Hypertension	   46	  (68%)	  
Recent/Current	  smoking	  	   25	  (37%)	  
Family	  history	  of	  premature	  CAD	   24	  (35%)	  
Hypercholesterolaemia	   41	  (60%)	  
BCIS-­‐JS	  0	  2	  4	  6	  8	  10	  12	  
	  12	  (18%)	  8	  (12%)	  14	  (21%)	  13	  (19%)	  11	  (16%)	  5	  (7%)	  5	  (7%)	  
LVEF	  >55%	  30-­‐54%	  
	  49	  (72%)	  19	  (28%)	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CMR	  During	  adenosine	  stress	  there	  was	  a	  significant	  increase	  in	  heart	  rate	  and	  a	  reduction	  in	  diastolic	  blood	  pressure	  (table	  5.2).	  	  
Table	  5.2:	  Haemodynamics	  during	  CMR	  perfusion	  imaging.	  
	   Rest	   Stress	   p	  value	  	  
Heart	  rate	   66±11	   87±12	   <0.0001	  
Systolic	  blood	  pressure	   136±20	   131±20	   0.06	  
Diastolic	  blood	  pressure	   75±7	   69±11	   <0.0001	  	  	  Left	  ventricular	  ejection	  fraction	  was	  60±12%	  (range	  30-­‐78%).	  CMR	  ischaemic	  burden	  was	  19±15%.	  Combined	  ischaemia/scar	  burden	  was	  25±20%.	  Scar	  burden	  was	  5±8%	  in	  the	  study	  population	  overall	  and	  13±8%	  of	  the	  myocardium	  in	  those	  with	  scar.	  Mean	  ischaemia	  and	  scar	  burden	  across	  the	  range	  of	  BCIS-­‐JS	  are	  shown	  in	  figure	  5.1.	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Figure	  5.7:	  Mean	  LV	  myocardial	  ischaemia	  and	  scar	  burden	  according	  to	  
BCIS-­‐JS	  	  
Black	  bars	  are	  +1	  standard	  deviation.	  Ischaemic	  burden	  increases	  with	  higher	  BCIS-­‐JS	  in	  contrast	  to	  scar	  burden.	  	  Scar	  was	  present	  on	  CMR	  imaging	  in	  every	  one	  of	  the	  18%	  of	  patients	  who	  reported	  a	  previous	  myocardial	  infarction.	  In	  addition	  another	  20%	  with	  no	  history	  of	  myocardial	  infarction	  also	  had	  scar,	  indicative	  of	  prior	  infarction,	  on	  CMR	  imaging.	  Scar	  was	  therefore	  present	  in	  38%	  of	  patients	  overall.	  	  
Coronary	  angiography	  The	  interval	  between	  CMR	  and	  coronary	  angiography	  was	  23±24	  days.	  No	  patients	  reported	  unstable	  cardiac	  symptoms	  requiring	  hospital	  admission	  during	  this	  interval.	  56	  (82%)	  patients	  had	  significant	  CAD.	  The	  whole	  range	  of	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CAD	  severity	  and	  BCIS-­‐JS	  were	  covered	  as	  detailed	  in	  table	  5.1.	  Figure	  5.2	  shows	  the	  coronary	  angiogram	  and	  CMR	  data	  with	  associated	  BCIS-­‐JS	  and	  ischaemic	  burden	  from	  an	  example	  case.	  	  
	  
Figure	  5.2:	  X-­‐ray	  coronary	  angiogram	  and	  CMR	  stress	  perfusion	  and	  scar	  
imaging	  from	  one	  patient.	  
The	  left	  anterior	  descending	  artery	  is	  proximally	  occluded	  and	  the	  circumflex	  is	  non-­‐dominant	  and	  free	  from	  significant	  disease	  (1a).	  The	  right	  coronary	  artery	  is	  dominant	  and	  there	  is	  a	  severe	  proximal	  lesion.	  The	  BCIS-­‐JS	  is	  therefore	  10.	  High-­‐resolution	  CMR	  stress	  perfusion	  short	  axis	  views	  of	  the	  basal	  (1c),	  mid	  (1d)	  and	  apical	  (1e)	  LV	  demonstrate	  anterior,	  anterolateral,	  inferior,	  inferolateral	  and	  apical	  perfusion	  defects.	  There	  is	  no	  scar	  in	  the	  corresponding	  slices	  (1f-­‐1h).	  The	  myocardial	  ischaemic	  burden	  was	  calculated	  as	  48%.	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Correlation	  between	  BCIS-­‐JS	  and	  myocardial	  ischaemic	  burden	  There	  was	  a	  strong	  correlation	  between	  the	  BCIS-­‐JS	  and	  myocardial	  ischaemic	  burden:	  Pearson’s	  r=0.75,	  p<0.0001	  (figure	  5.3).	  The	  BCIS-­‐JS	  also	  correlated	  well	  with	  the	  combined	  burden	  of	  scar	  and	  ischaemia:	  r	  =	  0.77,	  p<0.0001.	  
	  
Figure	  5.3:	  Correlation	  between	  the	  BCIS-­‐JS	  and	  myocardial	  ischaemic	  
burden	  
The	  graph	  shows	  the	  correlation	  between	  the	  angiographic	  BCIS-­‐JS	  and	  ischaemic	  burden	  obtained	  using	  high-­‐resolution	  CMR	  perfusion	  imaging.	  Patients	  without	  previous	  myocardial	  infarction	  (MI),	  defined	  as	  the	  presence	  of	  typical	  scar	  on	  CMR,	  are	  shown	  as	  open	  blue	  squares	  and	  those	  with	  previous	  MI	  as	  open	  red	  circles.	  Patients	  with	  previous	  CABG	  are	  denoted	  by	  the	  filled	  in	  points.	  Markers	  are	  offset	  slightly	  at	  points	  of	  overlap.	  The	  dashed	  line	  highlights	  the	  prognostically	  important	  threshold	  of	  12%	  ischaemic	  burden.	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  Area	  under	  the	  ROC	  curve	  for	  BCIS-­‐JS	  to	  detect	  ≥12%	  myocardial	  ischemic	  burden	  was	  0.87,	  95%	  confidence	  interval	  0.78-­‐0.96.	  A	  BCIS-­‐JS	  of	  ≥6	  predicted	  ≥12%	  myocardial	  ischaemic	  burden	  with	  68%	  sensitivity	  and	  91%	  specificity	  (figure	  5.4).	  	  
	  
Figure	  5.4:	  ROC	  curve	  for	  BCIS-­‐JS	  to	  detect	  myocardial	  ischaemic	  burden	  
≥12%.	  	  
BCIS-­‐JS	  ≥6	  detected	  this	  threshold	  with	  sensitivity	  68%	  and	  specificity	  91%.	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Discussion	  This	  study	  demonstrates	  that	  the	  BCIS-­‐JS	  correlates	  well	  with	  myocardial	  ischaemic	  burden	  in	  patients	  with	  stable	  angina.	  Furthermore,	  a	  BCIS-­‐JS	  ≥6	  predicts	  the	  prognostically	  important	  threshold	  of	  ≥12%	  myocardial	  ischaemia	  with	  high	  specificity.	  This	  ischaemic	  threshold	  is	  important	  as	  it	  differentiates	  patients	  who	  are	  likely	  to	  gain	  a	  survival	  benefit	  from	  revascularization	  from	  those	  who	  are	  not13.	  	  Treatment	  of	  CAD	  has	  historically	  been	  based	  on	  anatomic	  criteria,	  but	  more	  recently	  increasing	  recognition	  is	  being	  given	  to	  the	  importance	  of	  also	  assessing	  the	  associated	  myocardial	  pathophysiology.	  Despite	  this	  little	  is	  known	  about	  the	  functional	  relevance	  of	  angiographic	  scores.	  Some	  recent	  studies	  have	  examined	  the	  correlation	  between	  angiographic	  scores	  and	  CMR	  findings.	  However,	  these	  studies	  have	  focused	  on	  CMR	  methods	  for	  the	  determination	  of	  myocardial	  area	  at	  risk	  in	  patients	  with	  acute	  myocardial	  infarction.	  These	  studies	  also	  found	  significant	  correlations	  between	  CMR	  measures	  of	  myocardial	  oedema	  and	  scar	  burden	  and	  the	  Duke	  Jeopardy153,	  the	  myocardial	  jeopardy	  index	  from	  the	  Bypass	  Angioplasty	  Revascularization	  Investigation	  (BARI)142	  and	  the	  Alberta	  Provincial	  Project	  for	  Outcome	  Assessment	  in	  Coronary	  Heart	  Disease	  (APPROACH)142,	  153,	  154	  scores.	  In	  contrast,	  the	  goal	  of	  this	  study	  was	  to	  combine	  functional	  and	  anatomic	  data	  in	  stable	  patients,	  and	  examine	  the	  ability	  of	  an	  angiographic	  score	  to	  predict	  ischaemic	  burden.	  To	  our	  knowledge,	  this	  has	  not	  been	  described	  previously.	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BCIS-­‐JS	  Extensive	  CAD	  is	  known	  to	  be	  a	  marker	  of	  poor	  prognosis	  and	  a	  number	  of	  angiographic	  scores	  have	  been	  developed	  to	  quantify	  the	  extent	  of	  CAD.	  	  We	  used	  the	  BCIS-­‐JS	  in	  preference	  to	  other	  scores	  as	  it	  has	  a	  number	  of	  advantages	  which	  made	  it	  the	  most	  suitable	  for	  this	  study.	  Firstly,	  the	  purpose	  of	  the	  BCIS-­‐JS	  is	  to	  quantify	  the	  anatomic	  extent	  of	  CAD.	  Secondly,	  it	  is	  universally	  applicable	  and	  can	  be	  used	  in	  patients	  with	  left	  main	  stem	  disease	  and	  CABG.	  Consequently	  it	  was	  not	  necessary	  to	  exclude	  patients	  on	  the	  basis	  of	  their	  coronary	  anatomy,	  which	  is	  a	  better	  reflection	  of	  clinical	  practice.	  Thirdly,	  the	  BCIS-­‐JS	  can	  be	  quickly	  and	  easily	  calculated	  from	  the	  coronary	  angiogram	  and	  may	  therefore	  be	  more	  applicable	  in	  clinical	  practice.	  Finally,	  we	  have	  also	  recently	  validated	  the	  score	  as	  an	  independent	  predictor	  of	  outcome155.	  	  	  Many	  other	  angiographic	  scoring	  systems	  have	  been	  shown	  to	  be	  useful	  and	  to	  provide	  prognostic	  information	  over	  and	  above	  simple	  descriptions	  of	  anatomy.	  The	  Duke	  Jeopardy	  Score,	  BARI,	  APPROACH151	  and	  other	  scoring	  systems150	  have	  all	  been	  found	  to	  be	  independent	  predictors	  of	  mortality.	  Similarly	  high	  SYNTAX	  scores	  have	  been	  associated	  with	  an	  increased	  risk	  of	  major	  adverse	  cardiovascular	  or	  cerebrovascular	  adverse	  events	  in	  patients	  treated	  with	  PCI,	  although	  the	  same	  is	  not	  true	  for	  patients	  undergoing	  CABG.	  However,	  these	  scoring	  systems	  vary	  in	  their	  primary	  purpose,	  ease	  of	  use	  and	  applicability	  across	  different	  groups	  of	  patients	  and	  were	  less	  suited	  to	  this	  study.	  The	  Duke	  Jeopardy	  score,	  for	  example,	  cannot	  be	  used	  in	  patients	  with	  left	  main	  stem	  disease	  or	  CABG.	  Similarly	  the	  SYNTAX	  score149	  cannot	  be	  used	  in	  patients	  with	  CABG,	  is	  complex	  and	  was	  designed	  to	  reflect	  the	  technical	  complexity	  of	  CAD	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from	  a	  revascularization	  perspective	  rather	  than	  simply	  quantify	  the	  extent	  of	  CAD.	  In	  addition,	  the	  complexity	  of	  some	  scores	  limits	  their	  use	  in	  routine	  practice149-­‐152.	  
	  
Clinical	  Implications	  This	  study	  has	  implications	  for	  coronary	  disease	  classification	  in	  clinical	  trials	  and	  also	  suggests	  that	  the	  BCIS-­‐JS	  could	  inform	  management	  in	  routine	  clinical	  practice.	  The	  BCIS-­‐JS	  correlates	  with	  the	  amount	  of	  myocardium	  at	  risk,	  and	  as	  such	  is	  a	  potentially	  valuable	  tool	  for	  use	  in	  clinical	  trials	  of	  patients	  with	  CAD,	  undergoing	  any	  form	  of	  revascularization,	  medical	  or	  device	  therapy.	  Furthermore,	  the	  finding	  that	  the	  BCIS-­‐JS	  score	  can	  be	  used	  as	  a	  marker	  of	  myocardial	  ischaemia	  in	  patients	  with	  angina,	  confirms	  that	  the	  BCIS-­‐JS	  can	  be	  a	  useful	  tool	  in	  the	  catheter	  laboratory.	  A	  BCIS-­‐JS	  ≥6	  is	  likely	  to	  be	  associated	  with	  a	  high	  ischaemic	  burden	  and	  thus	  may	  support	  a	  decision	  to	  perform	  revascularization.	  However,	  whilst	  the	  BCIS-­‐JS	  might	  be	  used	  to	  influence	  management,	  revascularization	  is	  unlikely	  to	  be	  guided	  by	  the	  BCIS-­‐JS	  alone.	  Moreover	  the	  prognostic	  significance	  of	  the	  12%	  ischaemic	  burden	  threshold	  is	  derived	  from	  SPECT	  data	  and	  it	  remains	  unproven	  whether	  this	  threshold	  can	  be	  applied	  in	  CMR	  imaging.	  	  It	  is	  important	  to	  note	  that	  the	  sensitivity	  of	  a	  BCIS-­‐JS	  ≥6	  for	  predicting	  ≥12%	  ischaemia	  was	  modest	  at	  68%	  and	  therefore	  around	  a	  third	  of	  patients	  with	  an	  ischaemic	  burden	  above	  this	  threshold	  have	  a	  BCIS-­‐JS	  <6.	  This	  is	  also	  reflected	  in	  figure	  1,	  as	  the	  mean	  ischaemic	  burden	  in	  patients	  with	  BCIS-­‐JS	  2-­‐4	  was	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14±9%	  and	  figure	  3	  where	  similar	  numbers	  of	  patients	  with	  a	  BCIS-­‐JS	  2	  or	  4	  lie	  either	  side	  of	  the	  12%	  threshold.	  	  	  This	  modest	  sensitivity	  is	  likely	  to	  be	  the	  result	  of	  a	  number	  of	  factors.	  Firstly,	  predicting	  the	  haemodynamic	  significance	  of	  CAD	  from	  the	  coronary	  angiogram	  can	  be	  difficult,	  and	  is	  likely	  to	  have	  been	  incorrect	  in	  some	  cases.	  In	  patients	  with	  fewer	  lesions,	  and	  thus	  lower	  BCIS-­‐JS,	  the	  relative	  importance	  of	  each	  lesion	  increases.	  Consequently	  incorrect	  assessment	  of	  a	  lesions’	  haemodynamic	  significance	  will	  have	  a	  greater	  effect	  in	  patients	  with	  lower	  BCIS-­‐JS.	  Secondly,	  the	  BCIS-­‐JS	  simply	  involves	  scoring	  the	  proximal	  coronary	  tree	  segments	  and	  does	  not	  directly	  measure	  the	  size	  of	  the	  myocardial	  territory	  supplied	  by	  each	  vessel.	  For	  example,	  a	  patient	  with	  single	  vessel	  disease	  involving	  a	  dominant	  right	  coronary	  artery	  has	  a	  BCIS-­‐JS	  of	  4	  whether	  this	  lesion	  is	  at	  the	  ostium	  of	  the	  vessel	  or	  just	  proximal	  to	  the	  origin	  of	  the	  posterior	  descending	  artery,	  even	  though	  the	  ostial	  lesion	  will	  result	  in	  a	  larger	  ischaemic	  burden.	  However,	  whilst	  more	  precise	  scoring	  systems	  exist,	  they	  do	  not	  have	  the	  same	  attributes	  of	  simplicity	  and	  universal	  applicability.	  Finally,	  subgroups	  of	  patients	  with	  angina,	  detectable	  myocardial	  ischaemia	  and	  normal	  epicardial	  arteries	  have	  been	  well	  described156.	  Whilst	  this	  is	  less	  common	  than	  epicardial	  CAD	  there	  were	  patients	  with	  significant	  myocardial	  ischaemia	  and	  a	  low	  BCIS-­‐JS.	  Such	  patients	  may	  be	  identified	  more	  frequently	  by	  high-­‐resolution	  imaging	  techniques.	  As	  high-­‐resolution	  CMR	  becomes	  more	  widespread	  it	  is	  likely	  these	  patients	  will	  be	  better	  characterized	  in	  future.	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It	  is	  also	  noteworthy	  that	  a	  small	  number	  of	  patients	  with	  higher	  BCIS-­‐JS	  also	  had	  an	  ischaemic	  burden	  close	  to	  the	  12%	  threshold	  although	  these	  patients	  were	  predominantly	  from	  the	  group	  with	  previous	  myocardial	  infarction	  as	  discussed	  in	  more	  detail	  below.	  All	  of	  the	  above	  considerations	  are	  also	  likely	  to	  account	  for	  the	  fact	  that	  the	  correlation	  between	  the	  BCIS-­‐JS	  and	  ischaemic	  burden,	  despite	  being	  good,	  is	  imperfect.	  These	  limitations	  underscore	  the	  fact	  that	  functional	  investigations	  continue	  to	  be	  important	  for	  appropriate	  management	  of	  many	  of	  these	  patients.	  	  	  Myocardial	  scar	  is	  also	  relevant	  in	  many	  patients	  with	  established	  CAD	  and	  also	  influences	  both	  management86	  and	  prognosis91.	  It	  is	  interesting	  that	  whilst	  only	  18%	  of	  patients	  in	  this	  cohort	  had	  a	  history	  of	  known	  myocardial	  infarction	  38%	  of	  patients	  had	  CMR	  evidence	  of	  infarction.	  This	  finding	  is	  in	  keeping	  with	  a	  previous	  study91,	  which	  found	  that	  there	  is	  a	  high	  prevalence	  of	  scar	  in	  patients	  with	  known	  or	  suspected	  CAD	  but	  without	  a	  known	  prior	  myocardial	  infarction.	  Given	  the	  importance	  of	  scar	  we	  also	  examined	  the	  correlation	  between	  BCIS-­‐JS	  and	  combined	  ischaemia	  and	  scar	  burden.	  Addition	  of	  scar	  data	  however	  had	  little	  effect	  on	  the	  correlation	  with	  the	  BCIS-­‐JS.	  This	  is	  likely	  to	  be	  partly	  due	  to	  the	  relatively	  low	  scar	  burden	  (5±8%)	  and	  preserved	  LV	  function	  (mean	  ejection	  fraction	  60±12%)	  in	  this	  study	  cohort.	  This	  is	  also	  likely	  partly	  due	  to	  the	  fact	  that,	  in	  contrast	  to	  ischaemia,	  scar	  has	  a	  variable	  relationship	  with	  severe	  coronary	  stenoses.	  An	  infarct	  related	  artery,	  subtending	  a	  region	  of	  scar,	  may	  or	  may	  not	  be	  severely	  diseased;	  revascularization	  or	  spontaneous	  recanalization	  may	  alter	  the	  culprit	  lesion,	  while	  infarcts	  are	  also	  known	  to	  occur	  at	  the	  site	  of	  non	  flow-­‐limiting	  stenoses.	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Therefore,	  in	  patients	  with	  lower	  ejection	  fraction,	  a	  high	  BCIS-­‐JS	  may	  not	  reflect	  a	  high	  ischaemic	  burden,	  as	  some	  of	  these	  patients	  will	  have	  extensive	  scar	  and	  little	  or	  no	  ischaemia.	  In	  this	  study	  patients	  with	  LVEF<30%	  were	  excluded	  in	  order	  to	  limit	  these	  potentially	  confounding	  effects	  of	  scar.	  A	  cut-­‐off	  of	  30%	  was	  chosen,	  rather	  than	  including	  only	  patients	  with	  normal	  LVEF,	  as	  patients	  with	  more	  severe	  ischaemia	  may	  have	  impaired	  LV	  function	  in	  the	  absence	  of	  scar.	  Functional	  investigation	  also	  remains	  particularly	  important	  in	  patients	  with	  extensive	  CAD	  and	  significant	  LV	  impairment.	  These	  patients	  probably	  need	  an	  assessment	  of	  hibernation	  and	  ischaemia	  to	  complement	  the	  anatomic	  information	  before	  a	  decision	  on	  revascularization	  can	  be	  made26.	  	  	  It	  may	  have	  been	  preferable	  to	  perform	  the	  CMR	  and	  the	  angiogram	  on	  the	  same	  day	  and	  use	  FFR	  to	  determine	  the	  significance	  of	  all	  lesions.	  However,	  the	  study	  was	  designed	  to	  represent	  a	  real	  world	  scenario	  where	  there	  is	  usually	  an	  interval	  between	  non-­‐invasive	  and	  invasive	  investigations	  and	  FFR	  is	  not	  routinely	  used.	  The	  mean	  interval	  between	  the	  CMR	  and	  the	  X-­‐ray	  coronary	  angiogram	  was	  23	  days,	  which	  is	  a	  short	  duration	  in	  the	  natural	  history	  of	  CAD.	  Given	  that	  there	  were	  no	  adverse	  cardiac	  events	  reported	  by	  participants	  during	  this	  interval	  it	  is	  unlikely	  to	  have	  had	  a	  significant	  impact	  on	  our	  findings.	  Nevertheless	  it	  would	  be	  of	  interest	  to	  incorporate	  routine	  FFR	  assessment	  as	  part	  of	  future	  studies	  exploring	  the	  relationship	  between	  invasive	  and	  non-­‐invasive	  assessment	  of	  CAD.	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Limitations	  The	  main	  limitation	  of	  this	  study	  is	  the	  modest	  number	  of	  patients	  included.	  However,	  despite	  this	  limitation,	  enough	  patients	  were	  included	  to	  demonstrate	  a	  highly	  significant	  correlation.	  All	  participants	  had	  a	  history	  of	  angina	  and	  as	  a	  result	  the	  prevalence	  of	  CAD	  was	  high.	  It	  is	  not	  clear	  whether	  these	  findings	  can	  be	  applied	  in	  populations	  with	  a	  lower	  incidence	  of	  CAD	  and	  to	  patients	  without	  angina.	  	  There	  are	  small	  differences	  between	  perfusion	  imaging	  at	  1.5T	  and	  3T.	  Higher	  resolution	  imaging	  at	  3T	  may	  mean	  that	  ischaemic	  or	  scar	  burden	  estimation	  may	  vary	  according	  to	  field	  strength.	  This	  may	  be	  particularly	  relevant	  in	  the	  presence	  of	  scar	  where	  higher	  resolution	  perfusion	  imaging	  may	  allow	  identification	  of	  peri-­‐infarct	  ischaemia.	  However,	  to	  date,	  in	  contrast	  to	  SPECT	  imaging,	  little	  is	  known	  about	  ischaemic	  burden	  measured	  by	  CMR.	  In	  this	  study	  we	  classified	  each	  sub-­‐segment	  (50%	  of	  every	  myocardial	  segment)	  as	  normal,	  ischaemic	  or	  scar.	  In	  order	  to	  be	  classified	  as	  ischaemic	  or	  scar	  these	  sub-­‐segments	  had	  to	  be	  at	  least	  50%	  abnormal	  themselves	  (i.e	  at	  least	  25%	  transmural	  scar	  or	  ischaemia).	  Since	  abnormalities	  of	  this	  magnitude	  were	  well	  within	  the	  resolution	  of	  imaging	  at	  both	  field	  strengths	  we	  anticipated	  that	  any	  differences	  would	  therefore	  be	  small	  and	  will	  not	  have	  influenced	  the	  overall	  findings.	  	  However	  we	  did	  not	  systematically	  assess	  for	  differences	  between	  the	  field	  strengths	  as	  part	  of	  this	  study.	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Conclusions	  The	  anatomic	  BCIS-­‐JS	  correlates	  well	  with	  myocardial	  ischaemic	  burden	  measured	  using	  CMR	  perfusion	  imaging.	  A	  BCIS-­‐JS	  ≥6	  also	  predicts	  the	  prognostically	  important	  ischaemic	  threshold	  of	  12%	  with	  high	  specificity.	  These	  findings	  provide	  insight	  into	  the	  relationship	  between	  anatomic	  and	  functional	  measures	  of	  CAD	  severity.	  Furthermore,	  they	  support	  the	  use	  of	  the	  BCIS-­‐JS	  for	  classification	  of	  CAD	  burden	  in	  clinical	  trials	  and	  for	  assisting	  in	  the	  clinical	  management	  of	  patients.	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6	   PERFUSION	  IMAGING.	  Inter-­‐Study	  Reproducibility	  of	  
Quantitative	  CMR	  Myocardial	  Perfusion	  Imaging.	  
Abstract	  
Objectives	  Evaluate	  the	  inter-­‐study	  reproducibility	  of	  hyperaemic	  and	  rest	  myocardial	  perfusion	  and	  MPR	  and	  whether	  these	  parameters	  vary	  during	  the	  day.	  
	  
Background	  Absolute	  quantification	  of	  myocardial	  perfusion	  with	  CMR	  is	  increasingly	  available	  and	  can	  potentially	  improve	  current	  qualitative	  and	  semi-­‐quantitative	  analysis.	  The	  absence	  of	  ionising	  radiation	  makes	  CMR	  ideal	  for	  serial	  examinations	  for	  patient	  management	  or	  in	  clinical	  trials.	  Inter-­‐study	  reproducibility	  is	  crucial	  for	  serial	  examinations	  but	  data	  for	  quantitative	  CMR	  perfusion	  are	  very	  limited.	  
	  
Methods	  Sixteen	  healthy	  volunteers	  underwent	  high-­‐resolution	  3T	  perfusion	  imaging	  three	  times	  during	  a	  single	  day	  to	  evaluate	  inter-­‐study	  reproducibility	  and	  for	  effects	  of	  daytime	  variation.	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Absolute	  perfusion	  was	  determined	  in	  each	  coronary	  artery	  territory	  and	  globally	  by	  Fermi	  constrained	  deconvolution	  of	  myocardial	  signal	  intensity	  curves.	  LV	  volumes	  and	  function	  were	  also	  calculated.	  	  
Results	  Eleven	  full	  datasets	  were	  suitable	  for	  quantitative	  perfusion	  analysis.	  Inter-­‐study	  reproducibility	  was	  reasonable	  with	  rest	  perfusion	  more	  reproducible	  than	  stress	  and	  global	  better	  than	  territorial.	  The	  coefficient	  of	  variation	  (CV)	  for	  global	  stress	  and	  rest	  perfusion	  and	  MPR	  was	  26.8%,	  16.0%	  and	  23.9%	  respectively.	  Corresponding	  territorial	  CV	  were	  35.2%,	  27.5%	  and	  33.5%.	  The	  reproducibility	  of	  left	  ventricular	  volumes	  and	  function	  was	  excellent	  (CV	  4%,	  7.7%	  and	  4.6%	  for	  end	  diastolic	  volume,	  end-­‐systolic	  volume	  and	  ejection	  fraction	  respectively).	  There	  were	  no	  significant	  detectable	  changes	  in	  perfusion	  or	  LV	  volumes	  and	  function	  during	  the	  day.	  
	  
Conclusions	  The	  inter-­‐study	  reproducibility	  of	  quantitative	  myocardial	  perfusion	  is	  reasonable	  and	  best	  for	  global	  rest	  perfusion.	  No	  significant	  daytime	  variation	  in	  perfusion	  was	  observed.	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Introduction	  Evaluation	  of	  myocardial	  perfusion	  is	  a	  key	  function	  of	  CMR	  imaging157.	  As	  previously	  discussed	  quantification	  of	  myocardial	  perfusion	  may	  be	  superior	  to	  visual	  analysis	  as	  it	  eliminates	  the	  requirement	  for	  the	  presence	  of	  a	  normally	  perfused	  region	  of	  myocardium.	  Moreover	  it	  should	  allow	  more	  robust	  calculation	  of	  ischaemic	  burden	  and	  more	  precise	  characterisation	  of	  changes	  in	  perfusion	  due	  to	  physiological	  variation,	  disease	  and	  therapeutic	  interventions.	  One	  of	  the	  main	  advantages	  of	  CMR	  over	  other	  imaging	  modalities	  is	  that	  the	  absence	  of	  ionising	  radiation	  makes	  it	  ideal	  for	  serial	  examinations.	  Serial	  examinations	  have	  an	  important	  place	  both	  in	  clinical	  practice	  and	  in	  studies.	  However,	  in	  order	  for	  quantitative	  CMR	  perfusion	  imaging	  to	  be	  a	  useful	  tool	  for	  repeated	  studies,	  inter-­‐study	  reproducibility	  must	  be	  acceptable.	  	  	  Data	  on	  the	  reproducibility	  of	  myocardial	  perfusion	  imaging	  are	  limited.	  PET	  studies	  have	  reported	  reasonably	  good	  inter-­‐study	  reproducibility	  in	  volunteers158.	  However	  the	  inter-­‐study	  reproducibility	  of	  fully	  quantitative	  CMR	  has	  only	  previously	  been	  reported	  in	  terms	  of	  MPR159	  or	  with	  long	  intervals	  between	  studies141.	  Furthermore,	  cardiovascular	  function	  is	  affected	  by	  diurnal	  variation	  and	  changes	  in	  heart	  rate,	  blood	  pressure	  and	  ischaemic	  threshold	  during	  the	  course	  of	  the	  day	  are	  well	  recognised160.	  Previous	  studies	  have	  not	  assessed	  whether	  myocardial	  perfusion	  varies	  during	  the	  course	  of	  the	  day	  despite	  the	  fact	  that	  this	  is	  important	  in	  determining	  whether	  serial	  measurements	  need	  to	  be	  performed	  under	  the	  same	  conditions	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The	  objectives	  of	  this	  study	  were	  therefore	  to	  evaluate	  the	  inter-­‐study	  reproducibility	  of	  hyperaemic	  and	  rest	  myocardial	  perfusion	  and	  MPR	  and	  also	  whether	  these	  changed	  during	  the	  course	  of	  the	  day.	  
	  
Methods	  
Population	  Sixteen	  healthy	  volunteers	  were	  recruited	  by	  University	  email.	  Volunteers	  underwent	  3	  stress	  and	  3	  rest	  perfusion	  scans	  on	  the	  same	  day.	  Exclusion	  criteria	  were:	  known	  cardiac,	  respiratory	  or	  renal	  disease	  or	  a	  contraindication	  to	  MRI.	  	  	  
Data	  acquisition	  CMR	  imaging	  was	  performed	  on	  the	  3	  Tesla	  clinical	  MRI	  scanner.	  Participants	  were	  asked	  to	  abstain	  from	  caffeine	  and	  smoking	  for	  24	  hours	  prior	  to	  any	  imaging	  and	  to	  fast	  from	  midnight	  on	  the	  day	  of	  the	  scans.	  Those	  who	  did	  not	  were	  excluded.	  Participants	  then	  underwent	  3	  CMR	  examinations	  as	  close	  as	  possible	  to	  09:00	  (Scan	  A),	  09:30	  (Scan	  B)	  and	  14:00	  (Scan	  C).	  Between	  scan	  2	  and	  3	  participants	  left	  the	  department	  and	  were	  allowed	  to	  eat	  and	  drink	  freely	  apart	  from	  the	  restrictions	  on	  adenosine	  antagonists	  described	  above.	  Scan	  A	  and	  B	  were	  used	  to	  evaluate	  perfusion	  inter-­‐study	  reproducibility	  under	  the	  same	  conditions.	  Scan	  C	  was	  used	  to	  evaluate	  whether	  variations	  in	  perfusion	  could	  be	  detected,	  due	  to	  circadian	  rhythms,	  changes	  in	  subject	  hydration	  or	  any	  other	  cause.	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Each	  CMR	  scan	  lasted	  approximately	  30-­‐minutes	  and	  followed	  the	  same	  protocol	  as	  follows:	  
• survey,	  coil	  reference	  scan	  and	  planning	  to	  define	  imaging	  planes	  
• 4-­‐chamber	  cine	  
• 2-­‐chamber	  cine	  
• test	  perfusion	  	  
• stress	  perfusion	  
• short	  axis	  stack	  to	  cover	  entire	  LV	  
• 3-­‐chamber	  cine	  
• rest	  perfusion	  	  
Cine	  images	  were	  acquired	  using	  a	  standard	  balanced	  steady	  state	  free	  precession	  (SSFP)	  sequence.	  Perfusion	  imaging	  was	  performed	  using	  the	  same	  high-­‐resolution	  k-­‐t	  accelerated	  gradient	  echo	  sequence	  described	  in	  chapter	  5	  (shortest	  echo	  time	  {range	  0.85-­‐0.99ms},	  shortest	  repetition	  time	  {range	  2.45-­‐2.75ms},	  20°	  flip	  angle;	  90°	  prepulse,	  120ms	  prepulse	  delay	  and	  acquired	  resolution	  of	  1.3	  x	  1.3	  x	  10mm).	  Perfusion	  imaging	  was	  planned	  according	  to	  standard	  methods	  and	  images	  acquired	  every	  heartbeat.	  The	  imaging	  geometry	  and	  field	  of	  view	  were	  kept	  constant	  for	  each	  perfusion	  sequence.	  In	  order	  to	  account	  for	  higher	  heart	  rates	  at	  stress,	  if	  required,	  the	  voxel	  size	  was	  increased	  stepwise,	  to	  maintain	  imaging	  at	  every	  heartbeat.	  (This	  was	  required	  in	  3	  subjects;	  2	  were	  imaged	  at	  1.6	  x	  1.6	  x	  10mm	  and	  1	  at	  1.9	  x	  1.9	  x	  10mm).	  Hyperaemia	  was	  induced	  with	  the	  standard	  adenosine	  regimen.	  For	  this	  study	  the	  dual	  bolus	  consisted	  of	  equal	  volumes	  of	  0.0045mmol/kg	  followed	  by	  0.045mmol/kg	  of	  CA	  separated	  by	  a	  25-­‐second	  pause.	  This	  allowed	  six	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perfusion	  scans	  to	  be	  performed	  and	  limited	  the	  total	  dose	  of	  CA	  to	  <0.3mmol/kg.	  During	  perfusion	  image	  acquisition	  participants	  help	  their	  breath	  at	  end-­‐expiration	  during	  both	  contrast	  agent	  boluses	  and	  breathed	  gently	  during	  the	  pause.	  Participants	  were	  removed	  from	  the	  scanner	  between	  each	  exam.	  	  
Data	  analysis	  
Myocardial	  Perfusion	  	  Quantitative	  analysis	  was	  performed	  by	  a	  blinded	  observer	  using	  dedicated	  prototype	  software	  (ViewForum,	  Philips	  Healthcare,	  Best,	  The	  Netherlands).	  The	  mid	  myocardial	  slice	  was	  used	  for	  further	  analysis.	  The	  data	  were	  analysed	  visually	  initially	  and	  any	  studies	  affected	  by	  severe	  artefact	  during	  the	  first	  pass	  of	  the	  main	  bolus	  of	  contrast	  agent,	  such	  that	  reliable	  signal	  intensity	  curves	  would	  not	  be	  produced,	  were	  excluded.	  Myocardial	  border	  detection	  was	  automated	  and	  manually	  corrected	  where	  required.	  Global	  myocardial	  perfusion	  and	  perfusion	  in	  each	  of	  the	  3	  myocardial	  territories	  according	  to	  a	  standard	  definition96	  were	  determined	  using	  Fermi	  deconvolution75.	  Cases	  where	  deconvolution	  was	  not	  possible	  were	  also	  excluded.	  MPR	  was	  defined	  as	  the	  ratio	  of	  stress	  to	  rest	  perfusion.	  
	  
Left	  ventricular	  volumes	  and	  function	  Images	  were	  analysed	  in	  a	  random	  order	  by	  a	  blinded	  experienced	  observer	  using	  CMR42	  (Circle,	  Calgary,	  Canada).	  The	  mitral	  valve	  plane	  and	  apex	  were	  identified	  from	  the	  4-­‐chamber	  view	  in	  end-­‐diastole	  and	  end-­‐systole.	  The	  LV	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endocardial	  border	  was	  automatically	  defined	  in	  the	  corresponding	  end-­‐systolic	  and	  end-­‐diastolic	  SA	  slices	  and	  was	  manually	  corrected	  where	  required.	  Papillary	  muscles	  were	  excluded.	  	  	  
Statistical	  analysis	  Statistical	  analysis	  was	  performed	  using	  Microsoft	  Excel	  and	  IBM	  SPSS	  Statistics	  version	  19.	  For	  inter-­‐study	  reproducibility	  evaluation	  a	  coefficient	  of	  variation	  (CV),	  and	  Bland	  Altman	  plots	  were	  calculated	  in	  keeping	  with	  previous	  reproducibility	  studies161.	  Mean	  segmental	  and	  global	  perfusion	  and	  MPR	  values	  and	  the	  intra-­‐subject	  differences	  between	  exam	  A	  and	  B	  were	  calculated.	  The	  CV	  was	  defined	  as	  the	  standard	  deviation	  of	  these	  differences	  divided	  by	  the	  mean.	  Analyses	  were	  all	  performed	  on	  a	  per	  observation	  basis.	  The	  Shapiro-­‐Wilk	  test	  determined	  that	  the	  data	  were	  normally	  distributed.	  Mean	  values	  from	  Scans	  A,	  B	  and	  C	  were	  compared	  with	  ANOVA	  with	  repeated	  measures.	  Post	  hoc	  tests	  using	  the	  Bonferroni	  correction	  were	  used	  for	  pairwise	  comparisons.	  Continuous	  data	  are	  presented	  as	  mean	  ±	  standard	  deviation.	  Significance	  was	  determined	  as	  p<0.05.	  	  
Results	  Sixteen	  volunteers	  were	  included.	  Five	  were	  later	  excluded	  and	  11	  full	  datasets	  included	  in	  the	  final	  analysis.	  Reasons	  for	  exclusion	  were:	  1	  subject	  withdrawal,	  1	  failure	  of	  scanner	  gradients	  prior	  to	  test	  completion	  and	  in	  3	  subjects	  1	  or	  more	  perfusion	  scans	  were	  unsuitable	  for	  quantitative	  analysis	  due	  to	  artefact.	  Of	  those	  excluded	  due	  to	  artefact	  one	  volunteer	  failed	  to	  hear	  the	  breath-­‐hold	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commands	  during	  two	  perfusion	  sequences	  due	  to	  intermittent	  headphone	  failure	  and	  one	  volunteer	  failed	  to	  breath	  hold	  adequately	  during	  the	  rest	  perfusion	  sequence	  of	  Scan	  B.	  The	  third	  volunteer	  was	  excluded	  as	  during	  the	  rest	  perfusion	  scan	  from	  Scan	  B	  there	  was	  no	  increase	  in	  myocardial	  signal	  intensity	  and	  deconvolution	  was	  not	  possible.	  	  Participants	  included	  in	  the	  final	  analysis	  were	  27±5	  years	  old	  and	  five	  were	  male.	  Body	  mass	  index	  was	  28.0±7.4	  (median	  26.2;	  range	  20-­‐48).	  They	  were	  all	  non-­‐smokers	  with	  no	  significant	  medical	  problems	  and	  were	  not	  taking	  any	  medications.	  	  
Perfusion	  imaging	  There	  were	  ≥10	  minutes	  between	  all	  perfusion	  scans.	  During	  Scans	  A	  and	  B	  the	  interval	  between	  CA	  injections	  was	  13.9±2.8	  minutes	  and	  during	  Scan	  C	  it	  was	  16	  ±3.7	  minutes.	  The	  interval	  between	  Scans	  B	  and	  C	  was	  236.9±29.3	  minutes.	  	  	  A	  representative	  stress	  perfusion	  study	  with	  territorial	  segmentation	  is	  shown	  in	  figure	  6.1.	  Myocardial	  perfusion	  and	  haemodynamics	  for	  all	  three	  studies,	  and	  the	  significance	  of	  associated	  differences,	  are	  shown	  in	  table	  6.1.	  Stress	  heart	  rate	  and	  rate	  pressure	  product	  (RPP)	  were	  significantly	  higher	  in	  scan	  A.	  There	  was	  a	  trend	  for	  rest	  and	  stress	  perfusion	  to	  be	  lower	  in	  Scan	  B	  than	  in	  Scan	  A	  although	  this	  did	  not	  meet	  statistical	  significance.	  No	  significant	  daytime	  variation	  in	  perfusion	  could	  be	  detected.	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Figure	  6.1:	  Stress	  perfusion	  image	  with	  territorial	  segmentation.	  	  
Still	  image,	  from	  a	  representative	  study,	  showing	  a	  single	  frame	  from	  the	  first	  pass	  of	  the	  main	  bolus	  of	  contrast	  agent.	  The	  standard	  coronary	  artery	  territories	  used	  for	  the	  study	  are	  demonstrated.	  LAD-­‐left	  anterior	  descending	  artery;	  RCA-­‐right	  coronary	  artery.	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Table	  6.1:	  Myocardial	  perfusion	  and	  haemodynamics	  for	  the	  11	  subjects	  
during	  each	  of	  the	  three	  scans.	  	  
	   Scan	  A	   Scan	  B	   Scan	  C	   p	  value	  
Perfusion-­‐
Territorial	  
(ml/min/g)	  
Stress	  	  Mean	  
LAD	  
Circumflex	  
RCA	  
Rest	  Mean	  
	  LAD	  
Circumflex	  
RCA	  
	  	  	  	  2.5±0.8	  
2.5±0.9	  
2.2±0.7	  
2.7±0.8	  	  0.6±0.2	  
0.6±0.1	  
0.5±0.1	  
0.7±0.2	  
	  	  	  	  2.1±0.6	  
2.2±0.6	  
2.0±0.7	  
2.1±0.7	  	  0.5±0.1	  
0.5±0.1	  
0.5±0.1	  
0.6±0.2	  
	  	  	  	  2.2±0.8	  
2.2±0.8	  
2.0±0.6	  
2.4±0.9	  	  0.5±0.2	  
0.6±0.1	  
0.5±0.1	  
0.6±0.2	  
	  	  	  	  0.05	  	  	  	  	  0.05	  
Perfusion-­‐global	  
(ml/min/g)	  Stress	  Rest	  
	  	  2.5±0.5	  0.6±0.1	  
	  	  2.1±0.5	  0.5±0.2	  
	  	  2.2±0.7	  0.5±0.2	  
	  	  0.19	  0.1	  
MPR	  Territorial	  	  Global	   	  4.3±1.3	  4.3±0.9	   	  4.3±1.4	  4.2±1.2	   	  4.1±1.1	  4.0±0.6	   	  0.34	  0.37	  
Heart	  rate	  (bpm)	  Stress	  Rest	   	  111±14	  74±10	   	  105±16	  73±9	   	  106±17	  73±14	   	  0.03	  0.92	  
SBP	  (mmHg)	  Stress	  Rest	   	  121±16	  119±21	   	  120±14	  119±16	   	  122±16	  120±23	   	  0.54	  0.92	  
RPP	  (HR.SBP)	  Stress	  Rest	   	  13550±2747	  8919±2639	   	  12696±2592	  8764±1698	   	  13009±2758	  8789±2377	   	  0.046	  0.90	  
DBP	  (mmHg)	  Stress	  Rest	   	  73±7	  69±9	   	  70±11	  66±6	   	  70±8	  64±9	   	  0.24	  0.06	  Data	  are	  mean	  ±	  standard	  deviation.	  Small	  differences	  in	  the	  average	  values	  are	  due	  to	  rounding.	  	  SBP=systolic	  blood	  pressure;	  RPP=rate	  pressure	  product;	  DBP=diastolic	  blood	  pressure.	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The	  mean	  differences	  between	  perfusion	  in	  Scan	  A	  and	  B	  with	  associated	  CV	  are	  shown	  in	  table	  6.2	  and	  between	  Scan	  A	  and	  C	  in	  table	  6.3.	  These	  demonstrate	  reasonable	  inter-­‐study	  reproducibility.	  Global	  perfusion	  is	  more	  reproducible	  than	  territorial	  perfusion	  and	  rest	  perfusion	  more	  reproducible	  than	  stress	  perfusion.	  Bland	  Altman	  plots	  for	  territorial	  rest	  and	  stress	  perfusion	  and	  MPR	  are	  shown	  in	  figure	  6.2.	  	  	  
Table	  6.2:	  Inter-­‐study	  reproducibility	  of	  perfusion	  imaging	  (Scan	  A	  vs	  B).	  
	   	   Territorial	  
(n=33)	  
Global	  
(n=11)	  
Stress	  perfusion	  
(ml/min/g)	  
	  
Mean	  Difference±SD	   0.35±0.81	   0.36±0.62	  Coefficient	  of	  Variation	   35.2%	   26.8%	  
Rest	  perfusion	  
(ml/min/g)	  
	  
Mean	  Difference±SD	   0.07±0.16	   0.07±0.09	  Coefficient	  of	  Variation	   27.5%	   16.0%	  
MPR	   Mean	  Difference±SD	   0.07±1.43	   0.07±1.03	  Coefficient	  of	  Variation	   33.5%	   23.9%	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Table	  6.3:	  Inter-­‐study	  reproducibility	  between	  Scans	  A	  and	  C.	  
	   	  
Territorial	  
(n=33)	  
Global	  
(n=11)	  
Stress	  perfusion	  
(ml/min/g)	  
	  
Mean	  Difference±SD	   0.28±0.82	   0.28±0.69	  Coefficient	  of	  Variation	   34.9%	   29.0%	  
Rest	  perfusion	  
(ml/min/g)	  
	  
Mean	  Difference±SD	   0.04±0.17	   0.04±0.11	  Coefficient	  of	  Variation	   29.6%	   19.0%	  
MPR	   Mean	  Difference±SD	   0.19±1.54	   0.23±1.04	  Coefficient	  of	  Variation	   36.3%	   25.2%	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Figure	  6.2:	  Perfusion	  imaging	  inter-­‐study	  agreement	  
Bland	  Altman	  plots	  showing	  the	  inter-­‐study	  agreement	  between	  stress	  and	  rest	  perfusion	  and	  MPR	  between	  Scans	  A	  and	  B.	  The	  mean	  difference	  and	  limits	  of	  agreement	  (1.96	  standard	  deviations)	  are	  shown.	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Left	  ventricular	  volumes	  and	  function	  LV	  mean	  volumes	  and	  ejection	  fractions,	  mean	  differences	  between	  Scan	  A	  and	  B	  and	  associated	  CV	  are	  shown	  in	  table	  6.4.	  There	  were	  no	  significant	  changes	  in	  LV	  volumes	  or	  function	  between	  scans.	  Inter-­‐study	  reproducibility	  was	  excellent	  with	  low	  CV	  for	  all	  parameters.	  
	  
Table	  6.4:	  Mean	  values,	  intra-­‐subject	  differences	  and	  inter-­‐study	  
reproducibility	  	  for	  LV	  volumes	  and	  function.	  
	   Scan	   	   Mean	  
difference	  
±	  SD	  
CV*	  
	   A	   B	   C	   p	  
LVEDV	  	   161.7±33.3ml	   162.5±37.0ml	   161.2±39.7ml	   0.76	   -­‐2.1±6.7	   4.0%	  
LVESV	   67.5±17.3ml	   68.9±20.0ml	   64.9±18.3ml	   0.28	   -­‐1.9±5.5	   7.7%	  
LVEF	   58.5±3.2%	   58.0±4.3%	   59.6±4.5%	   0.86	   0.55±2.7	   4.6%	  *CV=coefficient	  of	  variation	  based	  on	  scans	  A	  and	  B.	  LVEDV=left	  ventricular	  end-­‐diastolic	  volume;	  LVESV=	  left	  ventricular	  end-­‐systolic	  volume;	  LVEF=left	  ventricular	  ejection	  fraction.	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Discussion	  This	  study	  demonstrates	  that	  fully	  quantitative	  CMR	  perfusion	  analysis	  has	  moderate	  inter-­‐study	  reproducibility	  in	  normal	  hearts.	  Global	  perfusion	  is	  more	  reproducible	  than	  territorial	  and	  rest	  more	  reproducible	  than	  stress.	  Furthermore,	  with	  current	  techniques,	  daytime	  variations	  in	  perfusion	  are	  not	  detectable.	  	  
The	  value	  of	  inter-­‐study	  reproducibility	  CMR	  does	  not	  use	  ionising	  radiation	  and	  there	  are	  no	  known	  long-­‐term	  adverse	  sequelae	  as	  a	  result	  of	  repeated	  examinations.	  Consequently	  CMR	  is	  an	  ideal	  modality	  for	  serial	  examinations.	  Many	  diseases	  affecting	  myocardial	  perfusion	  are	  chronic	  and	  patients	  require	  serial	  examinations.	  This	  may	  be	  in	  order	  to	  monitor	  disease	  progression	  or	  to	  determine	  the	  timing	  or	  efficacy	  of	  therapeutic	  interventions.	  This	  is	  applicable	  to	  patients	  with	  CAD	  but	  also	  to	  other	  patient	  groups,	  for	  example,	  PET	  studies	  have	  demonstrated	  that	  quantitative	  perfusion	  can	  provide	  additional	  information	  about	  the	  coronary	  microcirculation36.	  Quantitative	  perfusion	  therefore	  also	  has	  a	  potential	  role	  in	  the	  characterisation	  and	  management	  of	  patients	  with	  microvascular	  disease,	  such	  as	  those	  with	  hypertension,	  diabetes	  and	  angina	  with	  normal	  epicardial	  coronary	  arteries.	  In	  addition	  to	  routine	  clinical	  practice	  serial	  examinations	  and	  surrogate	  end-­‐points	  are	  required	  for	  clinical	  trials.	  Quantitative	  perfusion	  could	  potentially	  detect	  changes	  in	  perfusion,	  which	  cannot	  be	  detected	  by	  non-­‐quantitative	  analysis.	  Furthermore	  inter-­‐study	  reproducibility	  is	  related	  to	  the	  number	  of	  subjects	  required	  for	  studies	  to	  detect	  significant	  results.	  Improved	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reproducibility	  means	  fewer	  subjects	  and	  studies	  that	  are	  easier	  and	  less	  expensive	  to	  complete.	  It	  is,	  therefore,	  crucially	  important	  to	  know	  the	  inter-­‐study	  reproducibility	  to	  understand	  the	  potential	  role	  for	  CMR	  imaging	  in	  these	  clinical	  and	  research	  settings.	  	  
Inter-­‐study	  reproducibility	  of	  quantitative	  perfusion	  imaging	  The	  degree	  of	  variability	  between	  measurements,	  and	  hence	  the	  magnitude	  of	  the	  CV,	  which	  is	  acceptable	  will	  vary	  depending	  on	  what	  is	  clinically	  relevant.	  It	  is	  therefore	  important	  to	  interpret	  these	  findings	  in	  the	  context	  of	  the	  magnitude	  of	  changes	  that	  need	  to	  be	  detected.	  For	  example,	  studies	  in	  patients	  with	  coronary	  artery	  disease42,	  43	  have	  shown	  that	  stress	  perfusion	  differs	  by	  approximately	  100%	  or	  more	  between	  coronary	  territories	  subtended	  by	  normal	  arteries	  and	  severely	  diseased	  arteries.	  In	  keeping	  with	  this	  stress	  perfusion	  values	  in	  the	  normal	  volunteers	  in	  this	  study	  were	  also	  approximately	  100%	  greater	  than	  those	  in	  stenotic	  territories	  of	  patients	  included	  in	  the	  PET	  comparison	  study	  in	  chapter	  4.	  MPR	  was	  also	  approximately	  200%	  greater	  in	  these	  volunteers.	  Therefore,	  based	  on	  the	  reproducibility	  findings	  reported	  here,	  it	  would	  be	  expected	  that	  stress	  perfusion	  imaging	  could	  reliably	  detect	  changes	  of	  this	  magnitude.	  Conversely,	  large	  studies	  would	  be	  required	  to	  detect	  smaller	  changes	  in	  perfusion,	  such	  as	  those	  that	  may	  be	  expected	  as	  a	  result	  of	  drug	  therapy.	  Of	  note	  in	  the	  previous	  PET	  comparison	  study	  differences	  of	  approximately	  26%	  in	  stress	  perfusion	  between	  stenotic	  and	  remote	  territories	  were	  described	  with	  CMR.	  However	  in	  this	  study	  remote	  territories	  were	  not	  normal	  and	  were	  subtended	  by	  arteries	  with	  diameter	  stenosis	  of	  0-­‐69%.	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  To	  date	  there	  are	  very	  limited	  data	  on	  the	  inter-­‐study	  reproducibility	  of	  quantitative	  CMR	  perfusion.	  A	  previous	  study	  by	  Elkington	  et	  al.	  analysed	  the	  inter-­‐study	  reproducibility	  of	  quantitative	  CMR	  perfusion159	  in	  a	  combined	  cohort	  of	  volunteers	  and	  patients	  with	  coronary	  artery	  disease.	  They	  performed	  two	  perfusion	  studies	  at	  a	  mean	  interval	  of	  13±18	  days,	  and	  also	  quantified	  perfusion	  from	  a	  single	  a	  midventricular	  slice,	  acquired	  at	  high-­‐resolution,	  using	  Fermi	  deconvolution.	  However,	  in	  contrast	  to	  our	  study,	  they	  did	  not	  report	  absolute	  perfusion	  values.	  They	  reported	  a	  CV	  for	  global	  MPR	  of	  21%	  and	  CVs	  for	  regional	  perfusion	  of	  26-­‐35%.	  These	  values	  are	  very	  similar	  to	  the	  corresponding	  global	  and	  territorial	  values	  in	  our	  study	  (23.9%	  and	  27.5-­‐35.2%	  respectively).	  They	  also	  found	  absolute	  quantification	  to	  be	  more	  reproducible	  than	  semi-­‐quantitative	  analysis.	  Important	  differences	  between	  the	  previous	  study	  and	  ours	  include	  the	  fact	  that	  our	  study	  was	  performed	  at	  3T	  using	  a	  k-­‐t	  accelerated	  perfusion	  technique	  whereas	  the	  former	  was	  performed	  at	  1.5T	  using	  a	  spoiled	  gradient	  echo	  (FLASH)	  sequence.	  It	  is	  therefore	  noteworthy	  that	  these	  differences	  do	  not	  appear	  to	  result	  in	  superior	  reproducibility.	  	  A	  sub-­‐study	  of	  the	  Multi-­‐Ethnic	  Study	  of	  Atherosclerosis141	  evaluated	  inter-­‐study	  reproducibility	  of	  quantitative	  CMR	  perfusion.	  This	  study	  also	  demonstrated	  reasonable	  reproducibility	  and,	  in	  agreement	  with	  our	  study,	  they	  also	  found	  global	  and	  rest	  perfusion	  to	  be	  the	  most	  reproducible.	  However	  the	  interval	  between	  the	  two	  examinations	  was	  very	  long	  (mean	  334	  days)	  as	  reproducibility	  assessment	  was	  not	  the	  primary	  aim	  of	  the	  main	  study.	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Semi-­‐quantitative	  analysis	  of	  CMR	  perfusion	  has	  also	  been	  found	  to	  have	  moderate	  to	  good	  reproducibility	  in	  another	  study	  of	  a	  mixed	  cohort	  of	  normal	  volunteers	  and	  patients	  with	  coronary	  artery	  disease162.	  The	  reproducibility	  of	  a	  semi-­‐quantitative	  index	  of	  MPR	  derived	  from	  normalised	  upslope	  analysis	  was	  also	  comparable	  to	  ours.	  However	  although	  of	  a	  similar	  magnitude,	  they	  reported	  consistently	  lower	  CV	  than	  we	  found	  for	  fully	  quantitative	  MPR.	  Furthermore	  there	  was	  also	  less	  of	  a	  difference	  between	  global	  (17.6%)	  and	  territorial	  (17.6-­‐20.7%)	  CV.	  	  Data	  on	  the	  inter-­‐study	  reproducibility	  of	  quantitative	  PET	  myocardial	  perfusion	  are	  also	  limited.	  One	  recent	  study	  performed	  serial	  82-­‐Rubidium	  PET	  perfusion	  imaging	  in	  volunteers	  without	  cardiac	  disease	  at	  a	  median	  interval	  of	  22	  days158.	  This	  study	  reported	  repeatability	  coefficients	  (1.96	  x	  standard	  deviation	  of	  differences	  divided	  by	  mean)	  in	  56	  true	  normal	  subjects	  of	  35%,	  34%	  and	  38%	  for	  global	  rest	  and	  stress	  perfusion	  and	  MPR	  respectively.	  The	  equivalent	  repeatability	  coefficients	  for	  this	  study	  are	  32%,	  53%	  and	  47%	  suggesting	  that	  CMR	  may	  be	  less	  reproducible	  than	  PET	  at	  present.	  However,	  it	  is	  noteworthy	  that	  in	  this	  PET	  study	  reproducibility	  was	  significantly	  worse	  in	  subjects	  who	  were	  retrospectively	  classified	  as	  not	  normal	  on	  the	  basis	  extensive	  clinical,	  biochemical	  and	  ECG	  screening.	  This	  is	  by	  far	  the	  largest	  PET	  study	  of	  inter-­‐study	  reproducibility.	  Previous	  studies	  have	  been	  similar	  to	  ours	  involving	  relatively	  small	  cohorts	  of	  normal	  subjects51,	  80,	  140,	  163,	  164.	  Follow-­‐up	  perfusion	  studies	  were	  performed	  either	  immediately,	  as	  in	  our	  study,	  or	  after	  a	  short	  interval.	  These	  studies	  reported	  similar	  reproducibility	  to	  the	  82-­‐Rb	  study	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described	  above	  and	  some	  also	  found	  that	  reproducibility	  was	  best	  for	  global	  and	  rest	  perfusion80.	  	  	  In	  this	  study	  we	  found	  that	  there	  was	  a	  significant	  reduction	  in	  stress	  RPP	  between	  Scans	  A	  and	  B	  despite	  using	  the	  same	  adenosine	  protocol.	  Furthermore	  there	  was	  a	  trend	  towards	  reduced	  territorial	  stress	  and	  rest	  perfusion	  although	  this	  did	  not	  reach	  significance	  (p=0.05	  for	  both).	  Inter-­‐individual	  variation	  in	  the	  response	  to	  adenosine	  is	  well	  reported165	  and	  significant	  reductions	  in	  heart	  rate	  response	  are	  seen	  when	  adenosine	  infusion	  is	  repeated	  after	  caffeine	  intake166.	  However,	  in	  this	  study	  it	  may	  be	  that	  familiarisation	  with	  the	  protocol	  meant	  that	  subjects	  were	  less	  anxious	  during	  the	  second	  administration	  of	  adenosine.	  This	  change	  in	  RPP	  could	  explain	  the	  trend	  towards	  reduced	  stress	  perfusion	  between	  Scans	  A	  and	  B	  but	  does	  not	  account	  for	  the	  trend	  towards	  reduced	  rest	  perfusion.	  Quantitative	  CMR	  perfusion	  relies	  on	  myocardial	  signal	  intensity	  analysis.	  The	  half-­‐life	  of	  the	  contrast	  agent	  used	  in	  this	  study	  is	  approximately	  90-­‐minutes	  whereas	  the	  interval	  between	  perfusion	  imaging	  between	  Scans	  A	  and	  B	  was	  much	  shorter.	  Consequently	  the	  baseline	  myocardial	  signal	  continues	  to	  increases	  after	  each	  dose	  of	  contrast	  agent.	  The	  signal	  intensity	  in	  a	  region	  of	  interest	  at	  the	  start	  of	  each	  perfusion	  scan	  was	  subtracted	  for	  baseline	  correction	  of	  each	  signal	  curve.	  However,	  this	  correction	  may	  result	  in	  an	  under-­‐estimation	  of	  perfusion	  in	  subsequent	  studies.	  This	  finding	  has	  implications	  for	  quantitative	  analysis	  of	  serial	  perfusion	  studies	  repeated	  at	  a	  short	  interval.	  For	  example,	  both	  in	  clinical	  practice	  and	  in	  studies	  it	  is	  common	  to	  perform	  both	  stress	  and	  rest	  perfusion	  during	  the	  same	  examination.	  Moreover	  both	  stress	  and	  rest	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perfusion	  are	  clearly	  required	  for	  calculation	  of	  MPR.	  It	  is	  therefore	  important	  that	  this	  observation	  is	  evaluated	  further	  in	  future	  studies.	  	  A	  number	  of	  different	  CMR	  techniques	  and	  perfusion	  sequences	  are	  used	  for	  clinical	  and	  research	  perfusion	  imaging.	  For	  this	  study	  we	  used	  our	  standard	  3	  Tesla	  clinical	  perfusion	  sequence,	  which	  includes	  three	  slices	  at	  basal,	  mid	  and	  apical	  left	  ventricular	  levels,	  in	  order	  to	  establish	  reproducibility	  of	  a	  sequence	  and	  methods	  in	  routine	  clinical	  use.	  Since	  this	  study	  only	  included	  normal	  volunteers	  we	  do	  not	  expect	  that	  there	  are	  important	  differences	  in	  the	  reproducibility	  of	  perfusion	  estimates	  between	  slices	  and	  therefore	  selected	  segments	  to	  represent	  all	  three	  coronary	  territories	  from	  the	  mid-­‐slice	  for	  analysis.	  However	  it	  would	  be	  interesting	  to	  assess	  whether	  there	  are	  any	  systematic	  differences	  in	  perfusion	  and	  perfusion	  reproducibility	  between	  slices	  in	  an	  appropriately	  powered	  prospective	  study.	  	  Myocardial	  perfusion	  values	  reported	  here	  are	  lower	  than	  some	  studies	  have	  previously	  reported167	  and	  may	  therefore	  represent	  an	  underestimate.	  However,	  they	  are	  very	  similar	  to	  values	  previously	  reported	  for	  healthy	  volunteers	  in	  previous	  13N-­‐ammonia	  PET	  studies140,	  168.	  Discrepancies	  in	  normal	  perfusion	  ranges	  seen	  in	  studies	  may	  arise	  due	  to	  small	  sample	  sizes.	  Alternatively	  they	  may	  arise	  as	  a	  result	  of	  differences	  in	  study	  populations,	  scanners,	  tracers	  or	  contrast	  agents,	  methods	  of	  sampling	  arterial	  input	  function	  or	  myocardial	  regions	  of	  interest,	  or	  mathematical	  perfusion	  models169,	  
170.	  Since	  MPR	  is	  a	  ratio	  of	  stress	  to	  rest	  perfusion	  this	  corrects	  for	  many	  of	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these	  differences	  and	  the	  MPR	  values	  found	  in	  this	  study	  are	  in	  keeping	  with	  previous	  literature.	  	  
Diurnal	  variation	  Many	  biological	  processes	  exhibit	  circadian	  rhythms	  and	  heart	  rate	  and	  blood	  pressure	  changes	  are	  well	  known171.	  Consequently	  studies	  are	  often	  designed	  to	  minimise	  the	  effects	  of	  physiological	  variation	  either	  as	  a	  result	  of	  circadian	  rhythms	  or	  changes	  in	  participants’	  volume	  status	  and	  therefore	  ventricular	  volumes161.	  However,	  data	  on	  whether	  detectable	  diurnal	  changes	  in	  left	  ventricular	  volumes	  and	  function	  actually	  occur	  are	  limited172,	  173.	  Previous	  echocardiographic	  studies	  have	  suggested	  that	  there	  are	  no	  diurnal	  variations	  in	  LV	  volumes	  and	  systolic	  function.	  Nonetheless	  variations	  in	  some	  parameters	  reflecting	  diastolic	  function	  have	  been	  demonstrated	  in	  healthy	  volunteers172,	  
174.	  In	  keeping	  with	  these	  studies,	  and	  despite	  designing	  the	  study	  to	  try	  and	  maximise	  variation	  between	  Scan	  A	  and	  C,	  we	  could	  not	  detect	  any	  significant	  changes	  in	  LV	  volumes	  or	  function	  or	  myocardial	  perfusion	  during	  the	  course	  of	  the	  day.	  This	  suggests	  that	  daytime	  variations	  in	  perfusion	  are	  not	  important	  for	  study	  design	  or	  clinical	  practice	  at	  present.	  However	  it	  is	  also	  important	  to	  note	  that	  small	  differences	  in	  perfusion	  are	  unlikely	  to	  have	  been	  detectable	  using	  current	  methods.	  It	  is	  also	  noteworthy	  that	  we	  only	  measured	  perfusion	  at	  two	  different	  times	  of	  day	  and	  if	  we	  had	  examined	  participants	  at	  more	  time	  points,	  particularly	  during	  the	  night,	  it	  may	  have	  been	  possible	  to	  detect	  diurnal	  variation.	  However	  most	  perfusion	  CMR	  imaging	  takes	  place	  during	  working	  hours,	  in	  keeping	  with	  the	  times	  used	  here,	  and	  therefore	  the	  findings	  are	  of	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practical	  relevance.	  Finally	  this	  study	  confirms	  the	  excellent	  inter-­‐study	  reproducibility	  of	  CMR	  LV	  volumes	  and	  function	  described	  in	  previous	  studies175.	  
	  
Limitations	  The	  main	  limitations	  of	  the	  study	  are	  the	  small	  sample	  size	  and	  inclusion	  of	  healthy	  volunteers	  rather	  than	  patients.	  However	  there	  are	  no	  previously	  reported	  quantitative	  CMR	  perfusion	  studies	  reporting	  absolute	  perfusion	  values	  from	  multiple	  examinations	  performed	  within	  a	  short	  space	  of	  time.	  Furthermore,	  the	  equivalent	  PET	  literature	  consists	  of	  a	  modest	  number	  of	  studies,	  most	  which	  have	  small	  sample	  sizes	  and	  involve	  normal	  volunteers.	  	  	  The	  k-­‐t	  accelerated	  sequence	  is	  susceptible	  to	  respiratory	  artefacts,	  which	  can	  be	  problematic	  for	  quantification.	  Three	  subjects	  were	  excluded	  as	  a	  result	  of	  the	  unsuitability	  of	  one	  or	  more	  of	  the	  perfusion	  scans	  for	  quantitative	  analysis.	  However	  this	  relatively	  high	  exclusion	  rate	  also	  reflects	  the	  fact	  that	  three	  stress	  and	  three	  rest	  scans	  were	  required	  for	  each	  subject	  whereas	  usually	  fewer	  scans	  would	  be	  required	  for	  clinical	  care	  or	  studies.	  	  
Conclusions	  Quantitative	  CMR	  myocardial	  perfusion	  analysis	  has	  reasonable	  inter-­‐study	  reproducibility	  using	  current	  methods.	  Global	  perfusion	  is	  more	  reproducible	  than	  territorial	  perfusion	  and	  rest	  perfusion	  more	  reproducible	  than	  stress.	  No	  significant	  daytime	  variation	  in	  myocardial	  perfusion	  could	  be	  detected.	  On-­‐
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going	  refinement	  of	  quantitative	  post-­‐processing	  methods	  should	  result	  in	  further	  improvements	  in	  inter-­‐study	  reproducibility	  in	  the	  future.	  	   	  
  188 
7	   MYOCARDIAL	  VIABILITY	  AND	  ISCHAEMIA.	  Evaluation	  of	  
the	  Inter-­‐Study	  Reproducibility	  of	  CMR	  Feature	  Tracking	  	  
Abstract	  
Objectives	  Determine	  the	  inter-­‐study	  reproducibility	  of	  CMR	  feature	  tracking	  and	  whether	  strain	  analysis	  using	  feature	  tracking	  changes	  during	  the	  course	  of	  the	  day	  .	  	  
Background	  Cardiovascular	  magnetic	  resonance	  myocardial	  feature	  tracking	  (CMR-­‐FT)	  is	  a	  recently	  described	  method	  of	  post	  processing	  routine	  cine	  acquisitions	  which	  aims	  to	  provide	  quantitative	  measurements	  of	  circumferentially	  and	  radially	  directed	  ventricular	  wall	  strain.	  Inter-­‐study	  reproducibility	  is	  important	  for	  serial	  assessment	  however	  has	  not	  been	  defined	  for	  CMR-­‐FT.	  	  
Methods	  Sixteen	  healthy	  volunteers	  were	  imaged	  three	  times	  within	  a	  single	  day.	  The	  first	  examination	  was	  performed	  at	  0900	  after	  fasting	  and	  was	  immediately	  followed	  by	  the	  second.	  The	  third,	  non-­‐fasting	  scan,	  was	  performed	  at	  1400.	  	  	  CMR-­‐FT	  measures	  of	  	  segmental	  and	  global	  strain	  parameters	  were	  calculated.	  LV	  circumferential	  and	  radial	  strain	  were	  determined	  in	  the	  short	  axis	  orientation	  (EccSAX	  and	  ErrSAX	  respectively).	  LV	  and	  right	  ventricular	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longitudinal	  strain	  and	  LV	  radial	  strain	  were	  determined	  from	  the	  4-­‐chamber	  orientation	  (EllLV,	  EllRV,	  and	  ErrLAX	  respectively).	  LV	  volumes	  and	  function	  were	  also	  analysed.	  	  Inter-­‐study	  reproducibility	  and	  study	  sample	  sizes	  required	  to	  demonstrate	  5%	  changes	  in	  absolute	  strain	  were	  determined	  by	  comparison	  of	  the	  first	  and	  second	  exams.	  The	  third	  exam	  was	  used	  to	  determine	  whether	  daytime	  variation	  in	  CMR-­‐FT	  derived	  strain	  affected	  reproducibility.	  	  
Results	  CMR-­‐FT	  strain	  analysis	  inter-­‐study	  reproducibility	  was	  variable.	  Global	  strain	  assessment	  was	  more	  reproducible	  than	  segmental	  analysis.	  Overall	  EccSAX	  was	  the	  most	  reproducible	  measure	  of	  strain:	  coefficient	  of	  variation	  (CV)	  38%	  and	  20.3%	  and	  intraclass	  correlation	  coefficient	  (ICC)	  0.68	  (0.55-­‐0.78)	  and	  0.7	  (0.32-­‐0.89)	  for	  segmental	  and	  global	  analysis	  respectively.	  The	  least	  reproducible	  segmental	  measure	  was	  EllRV:	  CV	  60%	  and	  ICC	  0.56	  (0.41-­‐0.69)	  whilst	  the	  least	  reproducible	  global	  measure	  was	  ErrLAX:	  CV	  33.3%	  and	  ICC	  0.44	  (0-­‐0.77).	  Variable	  reproducibility	  was	  also	  reflected	  in	  the	  calculated	  sample	  sizes,	  which	  ranged	  from	  11	  (global	  EccSAX)	  to	  156	  subjects	  (segmental	  EllRV).	  The	  reproducibility	  of	  LV	  volumes	  and	  function	  was	  excellent.	  There	  was	  no	  variation	  in	  global	  strain	  or	  LV	  volumetric	  measurements	  during	  the	  day.	  
	  
Conclusions	  Inter-­‐study	  reproducibility	  of	  CMR-­‐FT	  varied	  between	  different	  parameters,	  as	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summarized	  above	  and	  was	  better	  for	  global	  rather	  than	  segmental	  analysis.	  It	  was	  not	  measurably	  affected	  by	  daytime	  variation.	  CMR-­‐FT	  may	  have	  potential	  for	  quantitative	  wall	  motion	  analysis	  with	  applications	  in	  patient	  management	  and	  clinical	  trials.	  However,	  inter-­‐study	  reproducibility	  was	  relatively	  poor	  for	  segmental	  and	  long	  axis	  analyses	  of	  strain,	  which	  have	  yet	  to	  be	  validated,	  and	  may	  benefit	  from	  further	  development.	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Background	  Myocardial	  wall	  motion	  analysis	  is	  key	  for	  assessment	  of	  LV	  and	  right	  ventricular	  (RV)	  function.	  It	  is	  important	  for	  the	  evaluation	  of	  viability	  and	  ischaemia	  during	  dobutamine	  stress	  in	  patients	  with	  CAD176	  and	  for	  identification	  of	  cardiomyopathies177.	  CMR	  is	  an	  established	  method	  for	  wall	  motion	  assessment	  as	  it	  provides	  excellent	  endocardial	  border	  definition	  and	  can	  be	  combined	  with	  other	  techniques	  for	  a	  comprehensive,	  radiation-­‐free,	  cardiac	  assessment	  in	  a	  single	  session157.	  Currently	  visual	  assessment	  of	  wall	  motion	  is	  standard	  however	  this	  is	  limited	  by	  inter-­‐observer	  variability178.	  To	  date	  quantitative	  techniques	  for	  assessment	  of	  wall	  motion,	  such	  as	  myocardial	  tagging,	  have	  not	  been	  widely	  adopted	  due	  to	  the	  requirement	  to	  perform	  additional	  scans	  and	  the	  associated	  complex	  and	  time-­‐consuming	  post-­‐processing179,	  180.	  Novel	  methods,	  which	  allow	  more	  robust	  and	  user-­‐independent	  quantitative	  wall	  motion	  assessment,	  are	  therefore	  desirable.	  	  CMR	  myocardial	  feature	  tracking	  (CMR-­‐FT)	  has	  been	  recently	  described181,	  182	  and	  is	  a	  method	  of	  quantitative	  wall	  motion	  assessment,	  which	  is	  analogous	  to	  echocardiographic	  speckle-­‐tracking.	  Standard	  CMR	  cine	  images	  are	  analysed	  off-­‐line	  and	  acquisition	  of	  additional	  sequences	  is	  therefore	  not	  required.	  CMR-­‐FT	  aims	  to	  provide	  measurements	  of	  circumferentially,	  radially	  and	  longitudinally	  directed	  ventricular	  wall	  strain.	  However,	  in	  order	  to	  be	  robust	  and	  useful,	  analytical	  techniques	  must	  be	  sufficiently	  reproducible.	  Reasonable	  inter	  and	  intra-­‐observer	  reproducibility	  of	  feature	  tracking	  has	  already	  been	  demonstrated183,	  184.	  The	  aim	  of	  this	  study	  therefore	  was	  to	  evaluate	  the	  inter-­‐
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study	  reproducibility	  of	  CMR-­‐FT	  and	  ascertain	  whether	  this	  is	  affected	  by	  detectable	  physiological	  variation.	  	  
Methods	  
Population	  	  The	  same	  16	  healthy	  volunteers	  recruited	  for	  the	  previous	  study	  (chapter	  6)	  formed	  this	  study	  cohort.	  	  
Data	  acquisition	  CMR	  protocols	  were	  as	  described	  in	  the	  previous	  chapter	  (page	  166).	  Cine	  images	  were	  acquired	  using	  a	  standard	  balanced	  steady	  state	  free	  precession	  (SSFP)	  sequence.	  Planning	  and	  acquisition	  were	  as	  follows:	  A	  pseudo	  2-­‐chamber	  cine	  was	  planned	  from	  the	  axial	  survey	  images	  and	  this	  was	  subsequently	  used	  to	  plan	  a	  pseudo	  4-­‐chamber	  cine.	  Systolic	  frames	  from	  the	  pseudo	  2	  and	  4-­‐chamber	  cines	  were	  then	  used	  to	  plan	  3	  short	  axis	  cine	  slices	  of	  the	  basal,	  mid	  and	  apical	  LV.	  Diastolic	  frames	  from	  preceding	  cines	  were	  then	  used	  to	  plan	  definitive	  views.	  The	  pseudo	  2-­‐chamber	  and	  short	  axis	  views	  were	  used	  to	  plan	  the	  4-­‐chamber	  cine.	  This	  4-­‐chamber	  view	  and	  the	  pseudo	  short	  axis	  slices	  were	  used	  to	  plan	  the	  2-­‐chamber	  cine.	  The	  2	  and	  4-­‐chamber	  views	  were	  used	  to	  plan,	  contiguous	  short	  axis	  (SA)	  cine	  slices	  covering	  the	  entire	  LV,	  and	  the	  4-­‐chamber	  and	  short	  axis	  views	  to	  plan	  a	  3-­‐chamber	  cine.	  SSFP	  cine	  in-­‐plane	  resolution	  was	  1.8	  x	  2mm	  and	  slice	  thickness	  8mm.	  The	  protocol	  was	  the	  same	  for	  all	  three	  scans	  and	  for	  all	  participants.	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Data	  analysis	  
Feature	  tracking	  Images	  were	  analysed	  in	  a	  random	  order	  by	  a	  blinded	  experienced	  observer.	  CMR-­‐FT	  strain	  analysis	  was	  performed	  using	  dedicated	  prototype	  software	  (Diogenes	  MRI,	  Tomtec,	  Unterschleissheim,	  Germany).	  Endocardial	  contours	  were	  manually	  drawn	  in	  all	  views	  included	  in	  the	  analysis.	  The	  4-­‐chamber	  view	  was	  used	  to	  determine	  RV	  and	  LV	  longitudinal	  strain	  and	  LV	  radial	  strain	  (EllRV	  and	  EllLV	  and	  ErrLAX).	  LV	  short	  axis	  circumferential	  (EccSAX)	  and	  radial	  strains	  (ErrSAX)	  were	  calculated	  from	  a	  mid-­‐ventricular	  short-­‐axis	  view	  containing	  both	  papillary	  muscles.	  The	  RV	  upper	  septal	  insertion	  point	  was	  manually	  defined	  to	  allow	  accurate	  segmentation	  according	  to	  a	  recognized	  standard	  model96.	  All	  parameters	  were	  analysed	  for	  all	  three	  exams.	  Strain	  values	  (%	  change	  from	  baseline)	  were	  obtained	  for	  each	  segment	  and	  global	  values	  defined	  as	  the	  mean	  of	  all	  segmental	  values.	  
	  
Left	  ventricular	  volumes	  and	  function	  Images	  were	  analysed	  in	  a	  random	  order	  by	  a	  blinded	  experienced	  observer	  using	  CMR42	  (Circle,	  Calgary,	  Canada)	  as	  described	  in	  the	  previous	  chapter.	  	  
Statistical	  analysis	  Statistical	  analysis	  was	  performed	  using	  Microsoft	  Excel	  and	  IBM	  SPSS	  Statistics	  version	  19.	  For	  inter-­‐study	  reproducibility	  evaluation	  a	  CV,	  intraclass	  correlation	  coefficient	  (ICC)	  and	  Bland	  Altman	  plots	  were	  calculated.	  The	  CV	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was	  defined	  as	  the	  standard	  deviation	  of	  the	  differences	  divided	  by	  the	  mean	  as	  previously.	  Analyses	  were	  all	  performed	  on	  a	  per	  observation	  basis.	  	  The	  significance	  of	  differences	  in	  reproducibility	  between	  exam	  A	  and	  B	  (reproducibility	  AB)	  and	  exam	  A	  and	  C	  (reproducibility	  AC)	  was	  evaluated	  by	  comparing	  the	  squared	  differences	  between	  the	  observations.	  These	  were	  compared	  directly	  with	  a	  paired	  t	  test	  if	  normally	  distributed	  (LV	  volumes	  and	  function)	  or	  after	  natural	  log	  transformation	  if	  not	  normally	  distributed	  (strain)161.	  The	  Shapiro-­‐Wilk	  test	  determined	  normality.	  The	  mean	  values	  for	  each	  strain	  parameter	  from	  Scan	  A,	  B	  and	  C	  were	  not	  normally	  distributed	  and	  therefore	  were	  compared	  using	  the	  Friedman	  test.	  Left	  ventricular	  volumes	  and	  function	  were	  compared	  using	  ANOVA	  with	  repeated	  measures	  as	  described	  in	  the	  previous	  chapter.	  	  Study	  sample	  sizes	  required	  to	  show	  a	  5%	  absolute	  change	  in	  strain	  with	  a	  power	  of	  90%	  and	  an	  α	  error	  of	  0.05	  were	  calculated	  as	  follows161:	  	  𝑛 = 𝑓 α,P .𝜎!. 2 𝛿! 	  	  where	  n	  is	  the	  sample	  size,	  f	  =10.5	  for	  α	  0.05	  and	  P	  0.9,	  σ	  the	  inter-­‐study	  standard	  deviation	  and	  δ	  the	  magnitude	  of	  the	  difference	  to	  be	  detected.	  	  Continuous	  data	  are	  presented	  as	  mean	  ±	  standard	  deviation.	  Significance	  was	  determined	  as	  p<0.05.	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Results	  
Participant	  details	  Participant	  age	  was	  27.9±5.7	  and	  body	  mass	  index	  26.2±6.8.	  Eight	  were	  male	  and	  eight	  female.	  One	  participant	  chose	  not	  to	  re-­‐attend	  for	  Scan	  C	  after	  Scans	  A	  and	  B.	  All	  other	  participants	  completed	  the	  protocol.	  The	  CMR	  data	  of	  one	  other	  participant	  was	  found	  to	  be	  incompatible	  with	  the	  CMR-­‐FT	  software	  (transient	  high	  signal	  in	  the	  pulmonary	  arteries	  affected	  the	  grey	  scaling	  obscuring	  endocardial	  border	  tracking).	  This	  participant	  was	  therefore	  only	  included	  in	  the	  volumetric	  assessments.	  Image	  quality	  was	  otherwise	  good	  or	  excellent	  in	  all	  subjects.	  	  
Feature	  tracking	  Mean	  segmental	  and	  global	  strain	  parameters	  for	  all	  three	  exams	  are	  summarised	  in	  table	  7.1.	  Mean	  segmental	  ErrSAX	  was	  significantly	  different	  (p=0.04)	  between	  the	  scans	  although	  the	  largest	  difference	  was	  between	  Scans	  A	  and	  B.	  There	  were	  no	  significant	  differences	  in	  any	  of	  the	  other	  strain	  parameters.	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Table	  7.1:	  Strain	  values	  for	  the	  combined	  study	  population.	  	  
	   Scan	   p	  value	  	   A	   B	   C	   	  
Segmental	  	  
(n=90)	  
	   	   	   	  
ErrSAX	   22.4±9.6	   19.2±8.0	   20.9±9.0	   0.04*	  EccSAX	   -­‐17.6±8.1	   -­‐16.6±8.4	   -­‐18.2±8.9	   0.06	  ErrLAX	   16.2±10.2	   17.7±10.3	   17.9±10.5	   0.25	  EllLV	   -­‐21.0±11.0	   -­‐20.0±11.0	   -­‐19.2±12.8	   0.23	  EllRV	   -­‐23.7±16.4	   -­‐21.7±13.5	   -­‐20.6±14.7	   0.25	  
Global	  
(n=15)	  
	   	   	   	  
ErrSAX	   22.6±7.9	   19.4±6.7	   20.5±5.2	   0.40	  EccSAX	   -­‐17.6±5.0	   -­‐16.6±4.4	   -­‐18.1±4.3	   0.81	  ErrLAX	   16.2±5.6	   17.7±5.6	   17.9±3.8	   0.29	  EllLV	   -­‐21.0±5.1	   -­‐20.0±5.3	   -­‐19.2±5.3	   0.06	  EllRV	   -­‐23.8±9.9	   -­‐21.8±5.7	   -­‐19.1±8.7	   0.26	  Values	  are	  in	  %.	  p	  values	  refer	  to	  the	  significance	  of	  differences	  between	  the	  mean	  values	  from	  Scans	  A,	  B	  and	  C.	  	  
Inter-­‐study	  reproducibility	  CV,	  ICCs	  and	  sample	  size	  calculations	  for	  each	  strain	  parameter	  are	  summarised	  in	  table	  7.2.	  Reproducibility	  was	  highly	  variable.	  Global	  strain	  assessment	  was	  more	  reproducible	  than	  segmental	  analysis.	  Overall	  EccSAX	  was	  the	  most	  
  197 
reproducible	  measure	  of	  strain;	  CV	  38%	  and	  20.3%	  and	  ICC	  0.68	  (0.55-­‐0.78)	  and	  0.7	  (0.32-­‐0.89)	  for	  segmental	  and	  global	  analysis	  respectively.	  The	  least	  reproducible	  segmental	  measure	  was	  EllRV:	  CV	  60%	  and	  ICC	  0.56	  (0.41-­‐0.69)	  whilst	  the	  least	  reproducible	  global	  measure	  was	  ErrLAX:	  CV	  33.3%	  and	  ICC	  0.44	  (0-­‐0.77).	  Bland-­‐Altman	  plots	  demonstrate	  the	  reproducibility	  of	  segmental	  EccSAX	  and	  EllRV	  (figure	  1).	  	  	  
	   	  
  198 
Table	  7.2:	  The	  inter-­‐study	  reproducibility	  of	  CMR-­‐FT	  strain.	  	  
	   Mean	  
difference±SD	  
Coefficient	  of	  
Variation	  
ICC	  (95%CI)	   Sample	  
size	  
Segmental	  
(n=90)	  	  
	   	   	   	  
ErrSAX	   -­‐3.5±7.5%	   35.9%	   0.57	  (0.35-­‐0.71)	   48	  EccSAX	   1.2±6.5%	   38.0%	   0.68	  (0.55-­‐0.78)	   36	  ErrLAX	   1.5±9.2%	   53.2%	   0.62	  (0.47-­‐0.73)	   72	  EllLV	   -­‐1.0±11.3	   55.4%	   0.59	  (0.44-­‐0.71)	   108	  EllRV	   -­‐1.9±13.6	   60.0%	   0.56	  (0.41-­‐0.69)	   156	  
Global	  
(n=15)	  
	   	   	   	  
ErrSAX	   -­‐3.2±5.7%	   27.2%	   0.61	  (0.15-­‐0.85)	   28	  EccSAX	   1.0±3.5%	   20.3%	   0.70	  (0.32-­‐0.89)	   11	  ErrLAX	   1.5±5.8%	   33.3%	   0.44	  (0-­‐0.77)	   29	  EllLV	   -­‐1.08±5.4%	   26.4%	   0.44	  (0-­‐0.77)	   25	  EllRV	   -­‐1.9±6.8%	   29.9%	   0.62	  (0.20-­‐0.85)	   39	  ICC=Intraclass	  correlation	  coefficient;	  CI=Confidence	  Interval.	  Sample	  size	  required	  to	  detect	  an	  absolute	  change	  of	  5%	  with	  90%	  power	  and	  an	  α	  error	  of	  0.05.	  Sample	  size	  numbers	  must	  be	  doubled	  for	  studies	  comparing	  active	  treatment	  vs.	  placebo.	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Figure	  78.1:	  Inter-­‐study	  agreement	  of	  CMR-­‐FT	  segmental	  strain	  analysis	  
Bland	  Altman	  plots	  with	  limits	  of	  agreement	  (95%	  confidence	  intervals)	  demonstrating	  the	  inter-­‐study	  reproducibility	  of	  CMR-­‐FT	  segmental	  LV	  circumferential	  and	  RV	  longitudinal	  strain.	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This	  variable	  reproducibility	  is	  reflected	  in	  the	  sample	  size	  calculations.	  5%	  changes	  in	  absolute	  global	  strain	  can	  be	  detected	  in	  follow-­‐up	  studies	  with	  relatively	  few	  patients	  whilst	  many	  more	  are	  required	  for	  some	  segmental	  strain	  parameters.	  Sample	  sizes	  for	  global	  strain	  parameters	  ranged	  from	  11	  	  (EccSAX)	  to	  39	  (EllRV)	  and	  for	  segmental	  strain	  from	  36	  (EccSAX)	  to	  156	  (EllRV).	  	  
Comparison	  of	  inter-­‐study	  reproducibility	  AB	  with	  AC	  Inter-­‐study	  reproducibility	  AC	  was	  not	  significantly	  different	  from	  reproducibility	  AB	  for	  any	  segmental	  or	  global	  parameters	  (p>0.05	  for	  all).	  
	  
LV	  volumes	  and	  function	  
Inter-­‐study	  reproducibility	  Mean	  LV	  volumes	  and	  function	  are	  shown	  in	  table	  7.3.	  There	  were	  no	  significant	  differences	  in	  LV	  volumes	  or	  function	  between	  the	  three	  scans.	  Inter-­‐study	  reproducibility	  was	  excellent	  overall.	  CV	  and	  ICC	  for	  LV	  end-­‐diastolic	  volume,	  end-­‐systolic	  volume	  and	  ejection	  fraction	  were	  4.2%	  and	  0.98;	  8.3%	  and	  0.95;	  and	  4.6%	  and	  0.75	  respectively	  (table	  7.4).	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Table	  7.3:	  Mean	  LV	  volumes	  and	  function	  for	  the	  entire	  study	  population.	  	  
	   Scan	   p	  n=16	   A	   B	   C	   	  
LVEDV	  	   161.7±33.3ml	   162.5±37.0ml	   161.2±39.7ml	   0.76	  
LVESV	   67.5±17.3ml	   68.9±20.0ml	   64.9±18.3ml	   0.28	  
LVEF	   58.5±3.2%	   58.0±4.3%	   59.6±4.5%	   0.86	  p	  values	  refer	  to	  the	  significance	  of	  differences	  between	  Scans	  A,	  B	  and	  C.	  LVEDV=left	  ventricular	  end-­‐diastolic	  volume;	  LVESV=left	  ventricular	  end-­‐systolic	  volume;	  LVEF=left	  ventricular	  ejection	  fraction	  	  
	  
Table	  7.4:	  Inter-­‐study	  reproducibility	  of	  LV	  volumes	  and	  function.	  
	  
n=16	  
Mean	  difference±SD	   Coefficient	  of	  
Variation	  
Intraclass	  correlation	  
coefficient	  (95%CI)	  
LVEDV	   -­‐2.1±6.7	   4.0%	   0.98	  (0.97-­‐1.0)	  
LVESV	   -­‐1.9±5.5	   7.7%	   0.95	  (0.88-­‐0.98)	  
LVEF	   0.55±2.7	   4.6%	   0.75	  (0.43-­‐0.91)	  	  	  
Comparison	  of	  inter-­‐study	  reproducibility	  AB	  with	  AC	  There	  were	  no	  significant	  differences	  between	  reproducibility	  AB	  and	  AC	  for	  LV	  volumes	  or	  function	  (p>0.05	  for	  all).	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Discussion	  This	  study	  demonstrates	  that	  the	  inter-­‐study	  reproducibility	  of	  CMR-­‐FT	  parameters	  is	  highly	  variable	  and	  is	  better	  for	  global	  rather	  than	  segmental	  measures.	  EccSAX	  is	  the	  most	  reproducible	  whilst	  others	  such	  as	  EllRV	  and	  ErrLAX	  are	  less	  reproducible.	  Furthermore	  there	  was	  no	  measurable	  variation	  during	  the	  day.	  
	  
CMR	  Feature	  Tracking	  Abnormalities	  or	  inter-­‐study	  changes	  in	  myocardial	  strain	  can	  occur	  without	  any	  detectable	  changes	  in	  LV	  volumes	  or	  function.	  This	  has	  been	  demonstrated,	  for	  example,	  in	  studies	  examining	  the	  treatment	  effect	  of	  stem	  cells	  in	  myocardial	  infarction185,	  186.	  Myocardial	  strain	  imaging	  may	  therefore	  allow	  early	  detection	  of	  abnormalities	  and	  subsequently	  allow	  early	  diagnosis	  and	  intervention.	  However,	  despite	  this	  imaging	  techniques	  for	  strain	  analysis	  have	  not	  been	  widely	  adopted.	  CMR-­‐FT	  has	  been	  described	  in	  detail	  previously182	  and	  appears	  to	  be	  a	  promising	  new	  tool	  for	  quantitative	  assessment	  of	  wall	  motion	  analysis.	  Borders	  within	  the	  image,	  such	  as	  the	  border	  between	  the	  LV	  endocardium	  and	  LV	  blood,	  are	  identified	  and	  then	  tracked	  from	  frame	  to	  frame.	  This	  relies	  on	  quantification	  of	  changes	  in	  signal	  intensity	  within	  voxels	  from	  one	  frame	  to	  the	  next.	  Frame-­‐to-­‐frame	  displacement	  of	  these	  signal	  changes	  is	  used	  to	  calculate	  local	  myocardial	  velocity	  and	  deformation	  or	  strain.	  	  	  The	  accuracy	  of	  CMR-­‐FT	  is	  likely	  to	  depend	  on	  the	  orientations	  and	  dimensions	  of	  the	  relevant	  border	  or	  features	  relative	  to	  voxels	  of	  the	  slice.	  Furthermore,	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CMR-­‐	  FT	  software	  derives	  strain	  measurements	  from	  the	  apparent	  in-­‐plane	  movements.	  However,	  the	  apparent	  movements	  of	  features	  in	  2D	  cine	  images	  may	  be	  caused	  by	  through-­‐plane	  displacements	  of	  oblique	  or	  tapering	  structures,	  and	  not	  only	  by	  in-­‐plane	  movements.	  This	  potential	  limitation	  of	  the	  technique	  may	  explain	  some	  of	  the	  variability	  seen	  in	  reproducibility	  in	  this	  study.	  	  Global	  EccSAX	  from	  the	  mid	  LV	  slice	  has	  been	  shown	  to	  correlate	  strongly	  with	  myocardial	  tagging	  using	  Harmonic	  Phase	  Imaging	  (HARP)	  in	  patients	  with	  Duchene	  Muscular	  Dystrophy	  and	  varying	  LV	  dysfunction	  and	  also	  in	  normal	  volunteers187.	  EccSAX	  has	  also	  been	  compared	  with	  a	  complementary	  spatial	  modulation	  of	  magnetization	  (CSPAMM)	  myocardial	  tagging	  reference	  method	  in	  a	  subsequent	  study188;	  agreement	  was	  modest	  and	  notably	  segmental	  strain	  measurements	  were	  less	  good	  than	  global	  EccSAX	  measurements.	  However,	  to	  date,	  other	  CMR-­‐FT	  parameters	  have	  not	  been	  validated	  against	  a	  reference	  standard	  for	  the	  evaluation	  of	  myocardial	  strain.	  Further	  validation	  of	  CMR-­‐FT	  strain	  measurements,	  particularly	  segmental	  measurements,	  is	  therefore	  desirable.	  
	  
Inter-­‐study	  reproducibility	  To	  our	  knowledge	  this	  is	  the	  first	  assessment	  of	  CMR-­‐FT	  inter-­‐study	  reproducibility.	  However,	  previous	  studies	  by	  our	  group	  have	  suggested	  that	  inter	  and	  intra	  observer	  reproducibility	  is	  higher	  for	  EccSAX	  than	  for	  ErrSAX	  both	  in	  volunteers	  and	  in	  patients	  with	  ischaemic	  cardiomyopathy183,	  184.	  Inter-­‐study	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variability	  was	  of	  a	  similar	  magnitude	  to	  the	  intra-­‐observer	  and	  inter-­‐observer	  variability	  reported	  previously	  although	  intra	  and	  inter-­‐observer	  reproducibility	  may	  be	  superior	  to	  inter-­‐study	  reproducibility.	  	  Inter-­‐study	  reproducibility	  of	  a	  technique	  is	  key	  where	  repeated	  examinations	  are	  required	  as	  discussed	  in	  detail	  in	  the	  previous	  chapter.	  Wall	  motion	  assessment	  with	  CMR-­‐FT	  could	  therefore	  potentially	  be	  useful	  for	  serial	  examinations	  of	  ventricular	  function	  to	  assess	  disease	  progression,	  treatment	  efficacy	  or	  determine	  the	  timing	  of	  therapy.	  Serial	  examinations	  are	  important	  in	  a	  multitude	  of	  clinical	  conditions	  and	  also	  form	  a	  key	  component	  of	  many	  studies.	  Higher	  reproducibility	  means	  that	  smaller	  changes	  can	  be	  detected	  with	  increased	  reliability.	  This	  also	  results	  in	  cost-­‐efficiencies,	  as	  fewer	  subjects	  are	  required	  in	  clinical	  trials175.	  	  	  Our	  sample	  size	  calculations	  demonstrate	  that	  relatively	  small	  sample	  sizes	  are	  required	  to	  detect	  5%	  changes	  in	  global	  strain	  parameters,	  particularly	  EccSAX.	  However,	  a	  5%	  change	  might	  be	  a	  relatively	  large	  effect,	  and	  larger	  sample	  sizes	  would	  be	  required	  if	  subtle	  changes	  in	  strain	  were	  likely	  to	  be	  clinically	  relevant.	  Furthermore,	  lower	  reproducibility	  of	  some	  segmental	  strain	  parameters	  means	  that	  large	  sample	  sizes	  would	  be	  required	  to	  detect	  differences	  in	  these.	  This	  is	  likely	  to	  be	  particularly	  relevant	  for	  assessing	  patients	  with	  CAD	  when	  regional	  analysis	  is	  crucial.	  Therefore	  whilst	  this	  new	  technique	  is	  promising	  for	  quantitative	  wall	  motion	  assessment	  its	  utility	  would	  be	  greater	  if	  further	  method	  developments	  improved	  reproducibility.	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This	  study	  included	  normal	  volunteers	  and	  image	  quality	  was	  good	  to	  excellent	  in	  all	  cases.	  Reproducibility	  and	  sample	  sizes	  may	  therefore	  be	  different	  in	  patient	  studies	  or	  when	  image	  quality	  is	  reduced.	  However,	  in	  previous	  studies	  of	  volunteers183	  and	  patients	  with	  ischaemic	  cardiomyopathy184,	  CMR-­‐FT	  intra-­‐	  and	  inter-­‐observer	  reproducibility	  were	  no	  worse	  during	  low-­‐dose	  dobutamine	  infusion	  than	  at	  rest,	  even	  though	  dobutamine	  is	  often	  associated	  with	  a	  deterioration	  in	  image	  quality.	  Furthermore,	  CMR-­‐FT	  reproducibility	  in	  patients	  with	  ischaemic	  cardiomyopathy	  appeared	  to	  be	  comparable	  to	  that	  of	  healthy	  volunteers	  despite	  reduced	  LV	  function	  in	  the	  patients.	  These	  observations	  suggest	  that	  the	  findings	  of	  this	  study	  can	  be	  applied	  to	  patients.	  However,	  it	  is	  important	  to	  note	  that	  in	  the	  patient	  study	  13%	  of	  segments	  were	  excluded,	  mainly	  due	  to	  breathing	  artefacts.	  	  This	  study	  also	  confirms	  the	  excellent	  inter-­‐study	  reproducibility	  of	  CMR	  for	  evaluating	  LV	  volumes	  and	  function	  demonstrated	  in	  previous	  studies161,	  175.	  In	  keeping	  with	  these	  studies,	  using	  CV	  as	  a	  measure	  of	  inter-­‐study	  reproducibility,	  we	  also	  found	  LV	  end-­‐systolic	  volume	  to	  be	  slightly	  less	  reproducible	  than	  both	  LV	  end-­‐diastolic	  volume	  and	  LV	  ejection	  fraction.	  However,	  ICC	  was	  lower	  for	  ejection	  fraction	  than	  for	  LV	  volumes,	  emphasizing	  the	  fact	  that	  multiple	  measures	  of	  inter-­‐study	  reproducibility	  exist,	  and	  the	  potential	  difficulties	  in	  comparing	  results	  from	  studies	  using	  different	  statistical	  methods.	  We	  have	  reported	  multiple	  measures	  of	  reproducibility	  in	  order	  to	  be	  comprehensive.	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Physiological	  variation	  In	  keeping	  with	  the	  previous	  study	  we	  did	  not	  detect	  any	  changes	  in	  LV	  volumes	  and	  function	  or	  in	  LV	  or	  RV	  myocardial	  strain	  during	  the	  day.	  Furthermore,	  the	  inter-­‐study	  reproducibility	  of	  LV	  volume	  and	  function	  and	  strain	  measurements	  was	  not	  measurably	  affected	  by	  daytime	  variation.	  These	  findings	  suggest	  that	  daytime	  variations	  are	  not	  currently	  important	  considerations	  when	  repeated	  studies	  are	  performed	  for	  CMR-­‐FT	  and/or	  volumetric	  analysis.	  However,	  it	  is	  important	  to	  note	  that	  the	  higher	  variability	  of	  the	  strain	  measurements	  means	  that	  small	  changes	  are	  unlikely	  to	  have	  been	  detected.	  The	  sample	  size	  calculations	  suggest	  that	  our	  sample	  was	  large	  enough	  to	  detect	  a	  5%	  change	  in	  EccSAX.	  	  
Comparison	  with	  speckle	  tracking	  Speckle	  tracking	  with	  echocardiography	  is	  a	  more	  established	  technique	  than	  CMR-­‐FT189.	  Previous	  echocardiography	  based	  studies	  have	  shown	  the	  clinical	  utility	  of	  speckle	  tracking	  for	  LV	  viability	  assessment	  and	  planning	  of	  revascularisation.	  Speckle	  tracking	  also	  has	  a	  role	  in	  the	  assessment	  of	  patients	  with	  acute	  myocardial	  infarction	  and	  heart	  failure	  with	  normal	  ejection	  fraction	  and	  as	  an	  early	  marker	  of	  LV	  dysfunction	  in	  patients	  with	  Tetralogy	  of	  Fallot190-­‐
194.	  Data	  on	  the	  inter-­‐study	  reproducibility	  of	  strain	  analysis	  speckle	  tracking	  is	  limited	  and	  it	  is	  therefore	  difficult	  to	  draw	  comparisons	  with	  the	  CMR	  findings	  of	  this	  study.	  Reasonable	  inter-­‐study	  reproducibility	  of	  left	  ventricular	  rotation	  parameters	  (as	  opposed	  to	  strain)	  has	  been	  demonstrated195	  using	  different	  measures	  of	  reproducibility.	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  Echocardiographic	  global	  longitudinal	  speckle	  strain	  was	  recently	  shown	  to	  be	  an	  independent	  predictor	  of	  mortality	  in	  a	  population	  of	  546	  consecutive	  patients	  undergoing	  echocardiography	  for	  left	  ventricular	  assessment196.	  Global	  longitudinal	  strain	  was	  a	  stronger	  predictor	  than	  both	  ejection	  fraction	  and	  wall	  motion	  scoring.	  This	  raises	  the	  possibility	  that	  the	  analogous	  global	  longitudinal	  LV	  feature	  tracking	  strain	  measured	  in	  this	  study,	  and	  possibly	  other	  strain	  parameters,	  may	  also	  be	  useful	  prognostic	  markers	  and	  our	  data	  show	  reasonably	  good	  reproducibility	  of	  global	  parameters.	  Larger	  scale	  long-­‐term	  CMR	  studies	  are	  required	  to	  test	  this	  hypothesis.	  	  Comparative	  studies	  between	  CMR-­‐FT	  and	  speckle	  tracking	  have	  not	  yet	  been	  performed.	  Both	  techniques	  have	  potential	  advantages.	  Reliable	  endocardial	  border	  detection	  is	  key	  for	  strain	  imaging	  and	  superior	  image	  quality	  and	  endocardial	  border	  definition	  with	  CMR	  may	  be	  an	  advantage.	  Echocardiography	  has	  different	  axial	  and	  lateral	  resolutions	  and	  can	  also	  be	  affected	  by	  limited	  acoustic	  windows.	  Border	  tracking	  may	  therefore	  be	  more	  reliable	  with	  better	  image	  quality.	  Conversely	  although	  CMR	  provides	  relatively	  good	  contrast	  to	  noise	  at	  most	  epi	  and	  endocardial	  boundaries	  it	  may	  not	  be	  able	  to	  detect	  similar	  intra-­‐myocardial	  features,	  and	  therefore	  intra-­‐myocardial	  strain,	  as	  well	  as	  speckle	  tracking.	  CMR	  myocardial	  tagging	  imaging	  techniques	  may	  also	  be	  superior	  to	  CMR-­‐FT	  in	  this	  respect.	  Moreover,	  echocardiography	  has	  superior	  temporal	  resolution,	  which	  may	  translate	  into	  an	  advantage	  for	  speckle	  tracking	  over	  CMR-­‐FT.	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Limitations	  The	  main	  limitations	  of	  this	  study	  are	  its	  small	  size	  and	  the	  inclusion	  of	  normal	  volunteers	  rather	  than	  patients.	  	  However	  it	  is	  common	  to	  evaluate	  emerging	  techniques	  in	  volunteers	  initially	  and	  these	  studies	  are	  important	  platforms	  for	  further	  method	  improvement	  and	  subsequent	  patient	  studies.	  Moreover	  limited	  previously	  published	  data	  suggest	  that	  volunteer	  and	  patient	  reproducibility	  may	  well	  be	  similar	  as	  discussed	  above.	  	  
Conclusions	  The	  inter-­‐study	  reproducibility	  of	  CMR-­‐FT	  is	  highly	  variable.	  At	  present	  reproducibility	  is	  best	  for	  global	  measurements	  and	  LV	  circumferential	  strain	  is	  the	  most	  reproducible	  strain	  parameter.	  CMR-­‐FT	  strain	  analysis	  is	  not	  measurably	  influenced	  by	  variation	  during	  the	  day.	  CMR	  myocardial	  strain	  analysis	  with	  feature	  tracking	  may	  have	  potential	  clinical	  and	  research	  applications.	  However	  the	  technique,	  particularly	  segmental	  and	  long	  axis	  analyses	  of	  strain,	  would	  benefit	  from	  improved	  inter-­‐study	  reproducibility	  and	  also	  further	  validation	  studies.	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8	   MYOCARDIAL	  VIABILITY.	  Evaluation	  of	  a	  Novel	  Dual	  
Inversion	  Recovery	  Sequence	  for	  Improved	  Visualization	  of	  
Myocardial	  Infarction	  	  
Abstract	  
Objectives	  Evaluate	  whether	  a	  dual	  inversion	  recovery	  (dual-­‐IR)	  pre-­‐pulse	  improves	  scar-­‐to-­‐blood	  contrast	  and	  observer	  confidence	  and	  consistency	  in	  the	  detection	  and	  evaluation	  of	  scar	  in	  late	  gadolinium	  enhancement	  (LGE)	  images.	  	  
Introduction	  Accurate	  assessment	  of	  the	  extent	  and	  transmurality	  of	  scar	  is	  key	  for	  guiding	  revascularisation	  in	  patients	  with	  CAD	  and	  previous	  myocardial	  infarction.	  The	  standard	  inversion	  recovery	  (IR)	  technique	  for	  scar	  imaging	  can	  be	  limited	  by	  poor	  scar-­‐to-­‐blood	  contrast,	  which	  can	  compromise	  accurate	  assessment	  of	  scar	  size	  and	  identification	  of	  small	  sub-­‐endocardial	  scars.	  A	  dual-­‐IR	  pre-­‐pulse	  may	  overcome	  this	  limitation	  by	  reducing	  signal	  from	  the	  blood	  pool.	  	  
Methods	  Twelve	  patients	  with	  known	  scar	  secondary	  to	  myocardial	  infarction	  were	  imaged	  at	  10,	  20	  and	  30	  minutes	  post	  contrast	  administration	  with	  both	  the	  IR	  sequence	  and	  the	  dual-­‐IR	  sequence	  with	  delays	  optimized	  for	  T1min	  of	  50,	  100,	  200	  and	  300ms	  and	  T1max	  of	  1400ms.	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Results	  Scar-­‐to-­‐blood	  CNR	  was	  significantly	  improved	  with	  the	  dual-­‐IR	  technique	  compared	  to	  the	  standard	  IR	  method	  for	  all	  time	  points	  (p<0.05).	  Experienced	  readers	  gave	  higher	  confidence	  scores	  for	  infarct	  detection	  and	  transmurality	  assessment	  to	  dual-­‐IR	  images.	  The	  dual-­‐IR	  sequence	  also	  resulted	  in	  more	  consistent	  assessment	  of	  scar	  size	  and	  transmurality	  between	  readers	  compared	  to	  the	  IR	  technique.	  	  	  	  
Conclusion	  In	  this	  preliminary	  patient	  study,	  the	  novel	  dual-­‐IR	  pre-­‐pulse	  improved	  scar-­‐to-­‐blood-­‐contrast	  compared	  to	  the	  IR	  technique.	  Dual-­‐IR	  imaging	  also	  resulted	  in	  improved	  expert	  confidence	  and	  reduced	  differences	  between	  readers	  in	  scar	  transmurality	  and	  size	  assessment.	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Introduction	  LGE	  imaging	  permits	  visualization	  of	  areas	  of	  cellular	  necrosis	  and	  extracellular	  fibrosis	  (scar)	  and	  is	  the	  basis	  of	  CMR	  imaging	  of	  acute	  and	  chronic	  myocardial	  infarction.	  LGE	  imaging	  is	  key	  for	  viability	  assessment	  prior	  to	  revascularization,	  and	  is	  also	  a	  valuable	  diagnostic177,	  197	  and	  prognostic	  tool91,	  177.	  It	  is	  a	  strength	  of	  CMR	  imaging	  that	  is	  unequalled	  by	  other	  modalities.	  	  	  Current	  imaging	  sequences	  exploit	  the	  kinetics	  of	  extracellular	  gadolinium	  based	  contrast	  agents.	  Following	  intravenous	  administration	  the	  contrast	  agent	  rapidly	  reaches	  all	  cardiac	  tissue	  with	  a	  normal	  blood	  supply	  but	  is	  delayed	  in	  reaching	  areas	  with	  a	  reduced	  supply.	  This	  forms	  the	  basis	  of	  perfusion	  imaging.	  There	  is	  an	  intermediate	  stage	  1-­‐2	  minutes	  after	  injection	  when	  contrast	  agent	  has	  started	  to	  wash	  out	  of	  normal	  myocardium	  but	  still	  has	  not	  reached	  areas	  of	  microvascular	  obstruction.	  This	  is	  used	  to	  detect	  areas	  of	  microvascular	  obstruction.	  Finally	  approximately	  5-­‐60	  minutes	  after	  injection	  a	  late	  stage	  is	  reached	  where	  most	  of	  the	  contrast	  has	  washed	  out	  of	  normal	  myocardium	  but	  has	  accumulated	  in	  areas	  of	  cellular	  necrosis	  and	  interstitial	  fibrosis	  due	  to	  the	  higher	  volume	  of	  distribution	  and	  delayed	  wash	  out	  in	  in	  these	  regions.	  During	  this	  late	  phase	  contrast	  agent	  has	  therefore	  accumulated	  in	  areas	  of	  both	  acute	  and	  chronic	  myocardial	  infarction.	  	  In	  order	  to	  image	  these	  areas	  of	  myocardial	  injury	  inversion	  recovery	  (IR)	  gradient	  echo	  sequences	  are	  used	  as	  standard.	  T1	  reduces	  with	  increasing	  tissue	  contrast	  agent	  concentration	  and	  this	  allows	  differentiation	  of	  scar	  from	  normal	  myocardium	  following	  a	  non-­‐selective	  180-­‐degree	  (inversion)	  RF	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prepulse.	  Imaging	  is	  performed	  at	  a	  pre-­‐selected	  time	  point	  after	  the	  prepulse	  (TI)	  when	  there	  is	  no	  signal	  from	  normal	  myocardium	  (nulled	  myocardium)	  but	  there	  is	  signal	  from	  areas	  of	  necrosis	  and	  scar	  (figure	  8.1).	  
	  
Figure	  8.1:	  The	  inversion	  recovery	  technique	  
a)	  Inversion	  recovery	  curves	  of	  normal	  and	  infarcted	  myocardium.	  The	  time	  at	  which	  the	  magnetization	  of	  normal	  myocardium	  reaches	  zero	  is	  defined	  as	  the	  inversion	  time	  to	  “null”	  normal	  myocardium	  (312	  msec	  in	  this	  example).	  b)	  Image	  intensities	  resulting	  from	  an	  inversion	  prepulse	  with	  various	  inversion	  delay	  times.	  c)	  Difference	  in	  image	  intensities	  between	  infarcted	  and	  normal	  myocardium	  as	  a	  function	  of	  inversion	  time.	  The	  optimal	  inversion	  time	  is	  when	  the	  maximum	  intensity	  difference	  occurs.	  From198	  .	  	  LGE	  scar	  imaging	  has	  been	  validated	  against	  histology	  in	  dogs	  and	  areas	  of	  LGE	  correspond	  very	  closely	  to	  area	  of	  scar84.	  Furthermore	  areas	  of	  scar	  are	  1080%	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times	  brighter	  than	  areas	  of	  normal	  myocardium199.	  However,	  the	  IR	  sequence	  only	  nulls	  normal	  myocardium,	  therefore	  although	  differentiating	  scar	  from	  normal	  myocardium	  is	  rarely	  a	  problem	  in	  CAD,	  high	  signal	  from	  blood	  can	  make	  differentiation	  of	  blood	  pool	  and	  scar	  difficult.	  In	  some	  cases,	  this	  can	  make	  accurate	  delineation	  of	  the	  endocardial	  border	  difficult,	  which	  in	  turn	  can	  compromise	  accurate	  assessment	  of	  scar	  size	  and	  identification	  of	  small	  sub-­‐endocardial	  scars.	  	  	  A	  modified	  IR	  sequence	  was	  developed	  by	  other	  researchers	  within	  our	  department	  to	  address	  this	  problem.	  This	  novel	  sequence	  included	  the	  addition	  of	  a	  second	  inversion	  prepulse	  prior	  to	  imaging	  (dual-­‐IR).	  The	  second	  prepulse	  results	  in	  the	  nulling	  of	  all	  tissues	  except	  those	  with	  very	  short	  T1	  values	  (figure	  8.2).	  Provided	  blood	  has	  lower	  signal	  than	  scarred	  myocardium	  it	  should	  be	  possible	  to	  null	  blood	  as	  well	  as	  myocardium	  but	  preserve	  the	  signal	  from	  infarct.	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Figure:	  8.2:	  Schematic	  representation	  of	  the	  inversion	  recovery	  (IR)	  (a)	  
and	  dual	  inversion	  recovery	  (dual-­‐IR)	  (b)	  sequences.	  	  
TD=trigger	  delay.	  TI=inversion	  time.	  The	  dual-­‐IR	  sequence	  contains	  two	  inversion	  prepulses	  and	  two	  inversion	  times	  TI1	  and	  TI2.	  The	  plots	  below	  show	  the	  evolution	  of	  the	  steady	  state	  longitudinal	  magnetization	  (Mz)	  for	  T1=100,	  200,	  400	  and	  1000ms	  for	  the	  IR	  (c)	  and	  dual-­‐IR	  (d)	  sequence.	  The	  second	  inversion	  prepulse	  results	  in	  nulling	  of	  all	  except	  very	  short	  T1	  values.	  	  The	  aim	  of	  this	  study	  was	  to	  compare	  the	  dual-­‐IR	  to	  the	  standard	  IR	  sequence	  for	  scar	  imaging	  in	  patients	  with	  CAD	  and	  prior	  myocardial	  infarction.	  We	  sought	  to	  investigate	  the	  effect	  on	  the	  contrast	  between	  scar	  and	  blood	  and	  whether	  confidence	  and	  consistency	  in	  the	  detection	  and	  evaluation	  of	  scar	  could	  be	  improved.	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Methods	  
Data	  acquisition	  Sixteen	  patients	  with	  a	  history	  of	  myocardial	  infarction,	  at	  least	  3	  months	  prior,	  and	  who	  were	  known	  to	  have	  scar	  from	  previous	  clinical	  IR	  images	  were	  recruited	  and	  imaged	  at	  3T.	  Three	  patients	  were	  used	  to	  optimize	  the	  MR	  protocol.	  The	  remaining	  patients	  were	  then	  imaged	  as	  follows:	  	  
• Survey,	  coil	  reference	  scan	  and	  planning	  to	  define	  imaging	  planes	  
• 0.2mmol/kg	  of	  Gadobutrol/Gadovist	  administered	  
• 5	  minutes	  post	  contrast:	  	  
o look	  locker	  
o short	  axis	  (SA)	  breath-­‐hold	  IR	  gradient-­‐echo	  (TFE)	  scans	  in	  expected	  scar	  location	  until	  suitable	  slice	  identified.	  
• All	  further	  imaging	  performed	  using	  the	  slice	  identified	  above.	  
• Starting	  10,	  20	  and	  30	  minutes	  post	  contrast:	  	  
o look	  locker	  
o IR	  TFE	  
o dual-­‐IR	  x4	  with	  T1min	  50,	  100,	  200	  and	  300ms	  (see	  below).	  	  Imaging	  parameters	  included:	  
IR-­‐TFE:	  spatial	  resolution=1.5x1.5x10mm,	  repetition	  time	  3.8ms,	  echo	  time	  2ms,	  flip	  angle	  25°,	  imaging	  every	  other	  heartbeat.	  TFE	  factor	  adjusted	  to	  achieve	  a	  12	  second	  breath-­‐hold	  for	  each	  patient.	  	  The	  TI	  was	  set	  to	  null	  the	  myocardium	  according	  to	  the	  preceding	  Look	  Locker	  scan.	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Dual-­‐IR:	  spatial	  resolution,	  repetition	  time,	  echo	  time,	  flip	  angle,	  the	  same	  as	  IR-­‐TFE,	  imaging	  every	  heartbeat	  with	  the	  TFE	  factor	  adjusted	  to	  achieve	  a	  12	  second	  breath-­‐hold	  for	  each	  patient.	  The	  T1	  and	  T2	  delays	  were	  optimised	  (depending	  on	  the	  heart	  rate)	  to	  suppress	  the	  signal	  within	  a	  user	  defined	  T1	  range:	  T1min-­‐T1max.	  T1min	  was	  varied	  between	  50,	  100,	  200	  and	  300ms	  with	  T1max	  always	  set	  at	  1400ms.	  There	  were	  therefore	  4	  dual-­‐IR	  scans	  at	  each	  time	  point.	  The	  order	  of	  the	  dual-­‐IR	  scans	  was	  randomized	  for	  each	  patient	  prior	  to	  the	  start	  of	  the	  imaging	  session.	  	  	  In	  five	  of	  the	  patients,	  additional	  2	  or	  4	  chamber	  views	  were	  also	  acquired	  at	  25	  or	  35	  minutes	  post-­‐contrast.	  	  
Data	  analysis	  Data	  analysis	  was	  performed	  with	  Osirix	  Imaging	  Software.	  	  
Blinded	  expert	  analysis:	  	  All	  IR	  and	  dual-­‐IR	  scar	  images	  were	  presented	  one	  at	  a	  time	  in	  a	  random	  order	  to	  two	  blinded	  experts.	  They	  were	  asked	  to	  i)	  identify	  whether	  myocardial	  scar	  was	  present;	  ii)	  grade	  transmurality	  as	  0-­‐25,	  26-­‐50,	  51-­‐75	  and	  76-­‐100%;	  iii)	  outline	  scar	  border	  and	  iv)	  assign	  a	  confidence	  score	  from	  1)	  negative	  low	  confidence,	  2)	  negative	  medium	  confidence,	  3)	  negative	  high	  confidence,	  4)	  positive	  low	  confidence,	  5)	  positive	  medium	  confidence	  to	  6)	  positive	  high	  confidence	  for	  both	  the	  presence	  and	  transmurality	  of	  scar.	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Signal	  and	  Contrast	  to	  noise	  analysis	  Mean	  signal	  values	  were	  taken	  from	  regions	  of	  interest	  in	  scar,	  remote	  myocardium	  and	  left	  ventricular	  blood	  pool.	  The	  signal	  standard	  deviation	  from	  a	  region	  of	  interest	  in	  the	  lung	  was	  taken	  to	  be	  noise.	  SNR	  of	  blood	  pool,	  myocardium	  and	  scar	  and	  CNR	  of	  scar-­‐to-­‐blood,	  scar-­‐to-­‐myocardium	  and	  blood-­‐to-­‐myocardium	  CNR	  were	  calculated	  for	  all	  short-­‐axis	  images	  at	  all	  time	  points.	  
	  
Statistical	  analysis:	  	  Prism	  software	  (GraphPad	  Software,	  California,	  USA)	  was	  used	  to	  compare	  SNR	  and	  CNR	  measurements	  at	  each	  time	  point	  with	  a	  one-­‐way	  Analysis	  of	  Variance	  between	  groups	  (ANOVA)	  comparison	  followed	  by	  a	  post-­‐hoc	  Newman-­‐Keuls	  paired	  t-­‐test.	  	  The	  differences	  between	  the	  confidence	  scores	  were	  compared	  using	  a	  Wilcoxon	  matched-­‐pairs	  signed	  ranks	  test.	  The	  percentage	  of	  infarcts	  where	  the	  experts	  gave	  a	  different	  transmurality	  assessment	  was	  compared	  using	  a	  student	  t-­‐test.	  Inter-­‐observer	  variability	  for	  the	  scar	  size	  was	  assessed	  using	  the	  Bland	  Altman	  test.	  	  
Results	  15	  patients	  completed	  the	  protocol	  successfully.	  One	  patient	  was	  excluded	  as	  he	  did	  not	  fit	  in	  the	  scanner	  with	  the	  32	  channel-­‐coil	  (previous	  clinical	  imaging	  performed	  with	  6-­‐channel	  coil).	  Patient	  characteristics	  are	  shown	  in	  table	  8.1.	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Table	  8.1:	  Characteristics	  of	  the	  12	  patients	  included	  in	  the	  analysis	  
Characteristic	  (mean	  ±	  SD)	   	  
Age	  	   63	  ±	  8	  years	  
Weight	   84	  ±	  12	  kg	  
Heart	  rate	   60	  ±	  8	  bpm	  
Time	  since	  infarct	   60	  ±	  74	  months	  
LVEF*	  	   44	  ±	  9	  %.	  	  
Male	   100%	  
Diabetes	   17%	  
Hypertension	   83%	  
Smokers	   42%	  
Hypercholesterolemia	   58%	  
Previous	  PCI	   83%	  
Previous	  CABG	   42%	  
Scar	  location*	  Anterior/Septal	  Inferior	  Lateral	  	  
	  4	  (33%)	  7	  (58%)	  2	  (17%)	  *Determined	  from	  clinical	  scan.	  One	  patient	  had	  2	  discrete	  infarcts.	  	  	  The	  dual-­‐IR	  technique	  achieved	  blood	  signal	  reduction	  in	  all	  patients.	  Representative	  images	  from	  a	  patient	  are	  shown	  in	  figure	  8.3.	  The	  dual-­‐IR	  sequence	  results	  in	  reduced	  blood	  signal	  compared	  to	  the	  IR	  sequence	  at	  all	  3	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time	  points	  post	  contrast	  administration.	  The	  degree	  to	  which	  the	  signal	  from	  blood	  is	  reduced	  depends	  on	  the	  T1min	  value.	  	  
	  
Figure	  8.3:	  Dual	  IR	  and	  standard	  IR	  scar	  images	  from	  a	  patient	  with	  
transmural	  scar	  in	  the	  LAD	  territory.	  	  
Top	  panel:	  Images	  in	  a	  short	  axis	  view	  acquired	  at	  10	  minutes	  (top	  row),	  20	  minutes	  (middle	  row)	  and	  30	  minutes	  (bottom	  row)	  after	  CA	  administration.	  	  From	  left	  to	  right:	  IR,	  dual	  IR	  with	  T1min=50ms,	  dual	  IR	  with	  T1min=100ms,	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dual-­‐IR	  with	  T1min=200ms,	  and	  dual-­‐IR	  with	  T1min=300ms.	  	  Bottom	  panel:	  2-­‐chamber	  view	  using	  p)	  IR,	  q)	  dual-­‐IR	  T1min=50ms,	  r),	  dual-­‐IR	  T1min=100ms,	  s)	  dual-­‐IR	  T1min=200ms	  and	  t)	  dual-­‐IR	  T1min=300ms.	  Dual-­‐IR	  images	  show	  reduced	  blood	  signal	  compared	  to	  the	  IR	  images	  at	  all	  3	  time	  points	  post	  CA	  administration.	  As	  the	  time	  from	  CA	  increases	  there	  is	  less	  signal	  from	  the	  blood	  at	  a	  given	  T1min	  value	  as	  the	  T1	  of	  blood	  increases.	  	  IR	  images	  and	  dual-­‐IR	  images	  taken	  at	  20	  minutes	  post-­‐contrast	  with	  a	  T1min	  of	  200ms	  in	  two	  patients	  with	  different	  scar	  location	  and	  transmurality	  are	  shown	  in	  figure	  8.4.	  	  
	  
Figure	  8.4:	  Standard	  versus	  dual-­‐IR	  scar	  images.	  
Short	  axis	  IR	  (left)	  and	  dual-­‐IR	  (right)	  images	  from	  a	  patient	  with	  partial	  thickness	  lateral	  wall	  scar	  (a,	  b)	  and	  a	  second	  patient	  with	  a	  full-­‐thickness	  anterior	  and	  partial	  thickness	  septal	  scar	  (c,	  d).	  Images	  were	  acquired	  20	  minutes	  post	  contrast	  administration.	  A	  T1min	  of	  200ms	  was	  used	  for	  the	  dual-­‐IR	  images.	  The	  blood	  pool	  is	  darker	  in	  the	  dual-­‐IR	  images,	  which	  improves	  the	  appreciation	  of	  the	  presence	  of	  scar	  and	  also	  transmurality	  assessment.	  
b) c) d) a) 
g) e) f) h) 
j) k) l) i) 
o) m) n) p) 
s) q) r) t) 
a b 
d c 
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Four-­‐chamber	  views	  taken	  at	  25	  minutes	  post-­‐contrast	  and	  a	  two-­‐chamber	  view	  taken	  at	  35	  minutes	  post-­‐contrast	  administration	  (figure	  8.5)	  also	  show	  reduced	  blood	  signal	  with	  dual-­‐IR	  technique	  and	  areas	  of	  contrast	  uptake	  are	  shown	  more	  clearly.	  	  	  
	  
Figure	  8.5:	  Long	  axis	  scar	  imaging	  using	  the	  IR	  and	  dual	  IR	  techniques.	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Four-­‐chamber	  views	  of	  a	  patient	  with	  a	  subendocardial	  basal	  to	  mid	  lateral	  wall	  scar	  using	  a)	  the	  IR	  and	  b)	  the	  dual-­‐IR	  sequence	  with	  a	  T1min	  of	  200ms	  at	  25	  minutes.	  Four-­‐chamber	  view	  of	  a	  different	  patient	  with	  a	  transmural	  basal	  to	  mid	  lateral	  wall	  scar	  using	  c)	  the	  IR	  and	  d)	  the	  dual-­‐IR	  sequence	  with	  a	  T1min	  of	  200ms	  at	  25	  minutes.	  Two-­‐chamber	  view	  of	  a	  patient	  with	  a	  transmural	  basal	  to	  mid	  inferior	  wall	  scar	  and	  a	  small	  basal	  anterior	  wall	  scar	  using	  e)	  the	  IR	  and	  f)	  the	  dual-­‐IR	  sequence	  with	  a	  T1min	  of	  200ms	  taken	  at	  35	  minutes	  post-­‐contrast	  administration.	  	  
	  
Expert	  observer	  quantitative	  and	  qualitative	  analysis	  Scar	  presence	  (figure	  8.6a)	  and	  transmurality	  assessment	  (figure	  8.6b)	  confidence	  scores	  were	  higher	  with	  the	  dual-­‐IR	  sequence	  (with	  T1min	  of	  100,	  200	  and	  300ms)	  compared	  to	  the	  IR	  sequence	  for	  both	  experts.	  The	  differences	  in	  transmurality	  confidence	  scores	  were	  significant	  for	  expert	  1	  when	  the	  IR	  sequence	  was	  compared	  to	  the	  dual-­‐IR	  sequence	  with	  T1min	  of	  100,	  200	  and	  300ms	  (p<0.05).	  Differences	  for	  expert	  2	  were	  not	  significant.	  With	  the	  dual-­‐IR	  sequence,	  there	  were	  fewer	  differences	  in	  transmurality	  assessment	  between	  the	  two	  experts	  compared	  to	  the	  IR	  sequence	  (figure	  8.6c).	  	  This	  was	  significant	  for	  the	  dual-­‐IR	  technique	  with	  a	  T1min	  of	  100ms	  and	  300ms	  (p<0.05).	  There	  was	  also	  a	  trend	  towards	  better	  agreement	  in	  scar	  size	  assessment	  with	  the	  dual-­‐IR	  sequence	  with	  T1min	  values	  of	  100ms,	  200s	  and	  300ms	  as	  shown	  in	  the	  Bland	  Altman	  plots	  (figure	  8.7).	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Figure:	  8.6:	  Expert	  observer	  confidence	  scores.	  
a)	  Scar	  presence	  and	  b)	  transmurality	  assessment	  confidence	  scores	  from	  the	  two	  independent	  experts	  (1	  and	  2).	  c)	  Percentage	  of	  scars	  in	  which	  there	  was	  a	  difference	  of	  25%	  in	  the	  transmurality	  between	  the	  two	  experts.	  The	  bars	  show	  the	  statistically	  significant	  differences	  (p<0.05).	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Figure	  8.7:	  Agreement	  between	  observers	  for	  scar	  size	  assessment	  with	  IR	  
and	  dual-­‐IR	  scar	  imaging.	  
Bland	  Altman	  plots	  demonstrating	  the	  agreement	  between	  scar	  size	  assessment	  by	  the	  two	  experts	  for	  a)	  IR	  images,	  b)	  dual	  IR	  images	  with	  T1min=50ms,	  c)	  dual	  IR	  images	  with	  T1min=100ms,	  d)	  dual	  IR	  images	  with	  T1min=200ms	  and	  e)	  dual	  IR	  images	  with	  T1min=300ms.	  	  Solid	  line	  indicates	  the	  mean	  of	  the	  differences	  and	  the	  dashed	  lines	  indicate	  1.96	  standard	  deviations	  above	  and	  below	  the	  mean	  of	  the	  differences.	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In	  order	  to	  make	  a	  direct	  comparison	  between	  the	  sequences,	  data	  presented	  in	  figures	  8.6	  and	  8.7	  are	  based	  on	  the	  analysis	  of	  the	  14	  scars,	  which	  were	  identified	  by	  both	  experts	  in	  all	  the	  images.	  There	  were	  discrepant	  results	  in	  4	  patients	  with	  either	  one	  expert	  reporting	  a	  scar	  whilst	  the	  other	  did	  not	  or	  the	  identification	  of	  scar	  in	  some	  images	  but	  not	  in	  others	  from	  the	  same	  patient	  by	  one	  or	  both	  observers.	  In	  one	  patient	  expert	  1	  defined	  an	  anterior	  infarct	  in	  all	  dual-­‐IR	  images,	  which	  he	  had	  not	  identified	  on	  IR	  images.	  In	  two	  patients	  expert	  2	  identified	  antero-­‐lateral	  infarcts	  on	  the	  IR	  image,	  which	  he	  excluded	  as	  blood	  pool	  in	  all	  dual-­‐IR	  images.	  Finally	  in	  one	  patient	  expert	  1	  identified	  enhancement	  as	  an	  infero-­‐lateral	  infarct	  whereas	  expert	  2	  excluded	  it	  as	  papillary	  muscle	  enhancement.	  	  	  
SNR	  and	  CNR	  	  Mean	  SNR	  of	  blood	  was	  significantly	  higher	  for	  the	  IR	  sequence	  compared	  to	  the	  dual-­‐IR	  sequence	  for	  all	  T1min	  values	  and	  at	  all	  time	  points	  (p<0.05).	  Scar	  SNR	  was	  significantly	  higher	  with	  IR	  than	  with	  dual-­‐IR	  at	  20	  minutes	  post	  CA	  with	  a	  T1min	  of	  50ms	  and	  at	  30	  minutes	  with	  a	  T1min	  of	  50ms	  and	  100ms.	  There	  were	  no	  significant	  differences	  for	  all	  other	  T1min	  and	  imaging	  time	  point	  combinations.	  	  Scar-­‐to-­‐blood	  CNR	  was	  found	  to	  be	  significantly	  higher	  in	  the	  dual-­‐IR	  sequence	  with	  all	  T1min	  values	  compared	  to	  the	  IR	  sequence	  at	  all	  time	  points	  (p<0.05)	  except	  for	  a	  T1min	  of	  50ms	  at	  30	  minutes.	  There	  was	  no	  significant	  difference	  in	  scar–to-­‐myocardium	  CNR	  between	  the	  sequences	  for	  all	  time	  points	  except	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for	  a	  T1min	  of	  50ms	  at	  20	  and	  30	  minutes	  IR	  CNR	  significantly	  higher).	  The	  blood-­‐to-­‐myocardium	  CNR	  was	  found	  to	  be	  significantly	  higher	  in	  the	  IR	  sequence	  compared	  to	  the	  dual-­‐IR	  sequence	  with	  all	  T1min	  values	  at	  all	  time	  points	  (p<0.05).	  	  	  
Discussion	  These	  pilot	  data	  demonstrate	  that,	  compared	  to	  the	  standard	  IR	  sequence,	  a	  novel	  dual-­‐IR	  sequence	  improves	  scar-­‐to-­‐blood	  contrast	  and	  also	  improves	  confidence	  in	  the	  assessment	  of	  the	  presence	  and	  transmurality	  of	  myocardial	  infarct	  scar.	  Furthermore	  consistency	  between	  observers	  for	  scar	  size	  and	  transmurality	  assessment	  was	  also	  improved	  with	  the	  dual-­‐IR	  sequence.	  	  	  The	  ability	  to	  differentiate	  irreversibly	  damaged	  from	  normal	  myocardium	  is	  a	  key	  advantage	  of	  MR	  over	  other	  imaging	  modalities.	  LGE	  IR	  scar	  imaging	  is	  the	  CMR	  gold	  standard	  for	  viability	  assessment	  and	  assessment	  of	  scar	  transmurality	  is	  crucial	  for	  guiding	  revascularisation	  as	  discussed	  previously.	  Scar	  imaging	  also	  allows	  differentiation	  of	  ischaemic	  from	  non-­‐ischaemic	  cardiomyopathy.	  	  	  Assessment	  of	  scar	  transmurality	  and	  detection	  of	  small	  sub-­‐endocardial	  scar	  can	  be	  hindered	  by	  the	  poor	  scar-­‐to-­‐blood	  contrast	  in	  IR	  images.	  Potential	  solutions	  to	  this	  limitation	  have	  been	  proposed.	  It	  is	  possible	  to	  delineate	  the	  endocardial	  border	  on	  SSFP	  cine	  images198	  or	  T2	  weighted	  images200	  	  which	  can	  then	  be	  used	  as	  a	  visual	  aid	  to	  interpret	  the	  IR	  image.	  However,	  this	  can	  be	  time-­‐
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consuming	  and	  inaccurate,	  as	  the	  two	  images	  should	  ideally	  be	  overlaid.	  	  Alternatively,	  a	  new	  LGE	  sequence	  was	  recently	  described	  which	  employs	  an	  additional	  slice	  selective	  pulse	  to	  prepare	  the	  blood	  and	  myocardium	  magnetization	  differently	  in	  order	  to	  achieve	  black	  blood	  properties201.	  However,	  this	  relies	  on	  sufficient	  blood	  flow	  between	  the	  slice-­‐selective	  and	  non-­‐selective	  inversion	  pulses	  and	  it	  was	  found	  to	  work	  less	  reliably	  in	  patients	  with	  an	  ejection	  fraction	  of	  less	  than	  40%.	  	  Furthermore,	  this	  approach	  still	  relies	  on	  the	  exact	  timing	  of	  inversion	  pulses	  to	  suppress	  the	  two	  individual	  T1	  values	  of	  blood	  and	  of	  tissue.	  	  The	  dual-­‐IR	  sequence	  is	  a	  modification	  of	  the	  quadruple	  inversion	  recovery	  (QIR)	  sequence	  which	  was	  developed	  to	  achieve	  T1-­‐independent	  blood	  suppression	  in	  carotid	  plaque	  imaging202.	  Whereas	  with	  the	  QIR	  sequence,	  the	  aim	  was	  to	  null	  only	  the	  blood	  signal,	  we	  have	  shown	  that	  the	  dual-­‐IR	  sequence	  achieves	  blood	  and	  tissue	  signal	  suppression	  within	  the	  defined	  T1-­‐range.	  It	  is	  not	  dependent	  on	  out-­‐flow	  of	  blood	  from	  the	  imaging	  slice	  and	  should	  therefore	  be	  applicable	  to	  patients	  with	  impaired	  LV	  function	  which	  is	  clearly	  crucial	  for	  imaging	  patients	  with	  myocardial	  scar.	  In	  this	  study	  the	  highest	  confidence	  scores	  were	  given	  to	  the	  dual-­‐IR	  sequence	  with	  a	  T1min	  of	  200ms,	  which	  may	  be	  due	  to	  a	  combination	  of	  sufficient	  left	  ventricular	  blood	  reduction	  combined	  with	  good	  visualization	  of	  the	  myocardium.	  Shorter	  T1min	  values	  resulted	  in	  lower	  blood	  signal	  whereas	  longer	  T1min	  values	  provided	  higher	  blood-­‐to-­‐myocardium	  CNR,	  which	  improved	  myocardium	  visualization	  and	  border	  definition.	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In	  addition	  to	  viability	  assessment	  in	  patients	  with	  CAD	  the	  dual-­‐IR	  technique	  may	  also	  have	  other	  clinical	  applications	  such	  as	  imaging	  diffuse	  fibrosis,	  for	  example	  as	  seen	  in	  amyloidosis	  or	  severe	  aortic	  stenosis	  where	  diffuse	  contrast	  uptake	  can	  make	  the	  correct	  choice	  of	  TI	  difficult.	  These	  exciting	  possibilities	  remain	  to	  be	  tested.	  	  
Limitations	  This	  study	  successfully	  demonstrates	  proof-­‐of-­‐concept	  but	  it	  has	  the	  usual	  limitations	  associated	  with	  pilot	  studies.	  We	  only	  investigated	  12	  patients	  with	  a	  wide	  range	  of	  scar	  chronicity.	  Instead	  of	  covering	  the	  entire	  left	  ventricle,	  we	  only	  tested	  the	  sequence	  in	  a	  single	  slice	  with	  confirmed	  scar	  on	  the	  IR	  sequence.	  However	  this	  approach	  minimized	  the	  time	  between	  the	  IR	  and	  dual-­‐IR	  sequence	  in	  order	  to	  allow	  comparison	  of	  both	  sequences	  at	  different	  times	  points	  post	  contrast	  injection.	  We	  also	  used	  identical	  read-­‐out	  parameters	  for	  the	  IR	  and	  dual-­‐IR	  sequences	  to	  minimize	  the	  impact	  of	  the	  imaging	  sequence	  on	  image	  contrast.	  In	  order	  to	  achieve	  an	  identical	  12-­‐second	  breath-­‐hold	  for	  the	  IR	  and	  dual-­‐IR	  images,	  the	  TFE	  factor	  and	  the	  acquisition	  time	  were	  approximately	  double	  for	  the	  IR	  images,	  which	  may	  have	  increased	  image	  blurring.	  SENSE	  acceleration	  is	  frequently	  used	  with	  IR	  sequences,	  to	  reduce	  the	  acquisition	  time,	  but	  was	  not	  employed	  in	  order	  to	  allow	  an	  accurate	  calculation	  of	  the	  SNR	  and	  CNR	  values.	  However,	  shorter	  acquisition	  times	  may	  have	  improved	  IR	  image	  quality	  and	  confidence	  scores.	  Apart	  from	  these	  specific	  adjustments	  the	  parameters	  of	  the	  standard	  IR	  sequence	  were	  not	  adjusted	  in	  this	  study.	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  We	  tested	  the	  dual-­‐IR	  sequence	  using	  Gadovist	  with	  a	  dose	  of	  0.2mmol/kg.	  This	  is	  consistent	  with	  both	  our	  clinical	  practice	  and	  with	  accepted	  international	  guidelines	  for	  LGE	  imaging81.	  However,	  with	  the	  IR	  sequence,	  little	  reduction	  in	  blood	  pool	  signal	  was	  observed	  in	  the	  30	  minutes	  post	  CA	  injection	  in	  most	  patients	  (figure	  8.1).	  This	  was	  unexpected	  as,	  although	  we	  have	  limited	  experience	  of	  imaging	  late	  after	  gadovist	  administration,	  the	  half-­‐life	  of	  all	  gadolinium	  based	  CA	  is	  reported	  to	  be	  similar118.	  A	  lower	  dose	  of	  CA	  may	  have	  produced	  less	  marked	  differences	  in	  blood	  signal	  between	  the	  two	  sequences,	  and	  increased	  confidence	  scores	  in	  the	  IR	  sequences,	  especially	  at	  later	  time	  points	  after	  administration.	  Future	  work	  should	  include	  an	  investigation	  of	  different	  contrast	  agents,	  doses,	  and	  field	  strengths	  and	  include	  a	  range	  of	  infarct	  ages.	  Finally,	  further	  studies	  should	  possibly	  include	  animal	  studies	  so	  that	  the	  new	  dual-­‐IR	  sequence	  can	  be	  validated	  against	  a	  histological	  gold	  standard.	  	  
Conclusion	  In	  conclusion,	  we	  have	  tested	  a	  novel	  dual-­‐IR	  sequence,	  which	  achieves	  adjustable	  tissue	  suppression	  over	  a	  wide	  T1	  range.	  Preliminary	  patient	  data	  show	  an	  improvement	  in	  scar-­‐to-­‐blood	  CNR,	  higher	  expert	  confidence	  with	  regard	  to	  the	  presence	  of	  scar	  and	  the	  assessment	  of	  transmurality	  and	  more	  consistent	  assessment	  of	  scar	  size	  and	  transmurality	  between	  experts	  compared	  to	  the	  IR	  technique.	  	   	  
  230 
9	   MYOCARDIAL	  PERFUSION	  AND	  VIABILITY.	  Feasibility	  of	  
Combined	  CMR	  Imaging	  and	  PCI	  in	  a	  Hybrid	  Laboratory	  	  
Abstract	  
Objectives	  Determine	  the	  feasibility	  of	  performing	  CMR	  studies	  combined	  with	  coronary	  angiography,	  pressure	  wire	  studies	  and	  PCI	  in	  a	  hybrid	  X-­‐ray	  and	  MRI	  (XMR)	  laboratory.	  	  
Background	  The	  relationship	  between	  anatomy	  and	  associated	  pathophysiology	  in	  CAD	  is	  complex	  and	  incompletely	  understood,	  yet	  is	  important	  for	  patient	  management.	  This	  information	  cannot	  be	  comprehensively	  provided	  by	  a	  single	  investigative	  modality.	  A	  hybrid	  XMR	  laboratory	  will	  potentially	  overcome	  this	  limitation.	  However,	  the	  feasibility	  of	  combined	  invasive	  and	  non-­‐invasive	  studies	  and	  PCI	  in	  an	  XMR	  laboratory	  is	  unknown.	  	  
Methods	  10	  patients	  with	  angina	  scheduled	  for	  coronary	  angiography	  or	  PCI	  underwent	  combined	  procedures	  in	  a	  3	  Tesla	  XMR	  laboratory.	  These	  procedures	  included	  serial	  non-­‐invasive	  high-­‐resolution	  perfusion,	  functional	  and	  scar	  imaging	  and	  invasive	  angiography,	  FFR	  measurements	  and	  PCI.	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Results	  All	  studies	  were	  well	  tolerated	  without	  complication.	  Eight	  patients	  underwent	  both	  CMR	  and	  invasive	  studies.	  Six	  patients	  had	  single	  vessel	  PCI.	  FFR	  and	  stress	  perfusion	  imaging	  were	  both	  performed	  in	  14	  coronary	  territories	  (4	  post	  PCI).	  Management	  was	  guided	  by	  functional	  information	  in	  8	  patients.	  	  
Conclusions	  Combined	  CMR	  and	  interventional	  coronary	  procedures	  are	  feasible	  and	  well	  tolerated	  in	  an	  XMR	  laboratory.	  This	  set-­‐up	  has	  many	  exciting	  potential	  research	  and	  clinical	  applications,	  which	  should	  improve	  the	  understanding	  and	  management	  of	  CAD.	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Background	  Optimal	  management	  and	  revascularisation	  of	  patients	  with	  CAD	  requires	  accurate	  anatomic	  and	  functional	  information.	  The	  relationship	  between	  these	  is	  clinically	  very	  important	  but	  is	  difficult	  to	  predict203,	  204	  and	  frequently	  poorly	  understood.	  To	  date,	  no	  single	  investigation	  can	  comprehensively	  assess	  coronary	  artery	  anatomy	  and	  coronary	  and	  myocardial	  physiology.	  Moreover,	  since	  direct	  assessment	  of	  important	  functional	  parameters,	  such	  as	  myocardial	  ischaemia,	  is	  not	  possible	  the	  available	  investigations	  target	  a	  number	  of	  different	  surrogate	  markers.	  Our	  understanding	  of	  the	  exact	  relationship	  between	  these	  different	  methods	  for	  assessing	  ischaemia	  is	  also	  incomplete.	  Improving	  understanding	  of	  the	  underlying	  disease	  pathophysiology	  and	  of	  how	  results	  from	  different	  investigative	  modalities	  relate	  to	  each	  other	  should,	  in	  turn,	  improve	  patient	  assessment	  and	  management.	  	  	  X-­‐ray	  coronary	  angiography	  is	  the	  reference	  standard	  for	  the	  assessment	  of	  CAD	  and	  allows	  precise	  evaluation	  of	  coronary	  anatomy,	  invasive	  assessment	  of	  coronary	  physiology	  and	  is	  a	  precursor	  to	  PCI.	  However,	  it	  is	  invasive,	  uses	  ionising	  radiation	  and	  does	  not	  permit	  adequate	  evaluation	  of	  the	  myocardium.	  CMR	  imaging	  allows	  comprehensive	  evaluation	  of	  myocardial	  function,	  perfusion	  and	  scar	  without	  using	  ionising	  radiation.	  However,	  CMR	  cannot	  adequately	  assess	  coronary	  blood	  flow	  or	  pressures,	  nor	  can	  it	  be	  used	  for	  coronary	  intervention.	  	  	  Ideally	  acquisition	  of	  all	  anatomic	  and	  functional	  data	  should	  be	  simultaneous.	  This	  eliminates	  any	  temporal	  changes	  related	  to	  disease	  progression,	  intrinsic	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diurnal	  variation	  or	  treatment	  effects.	  However	  simultaneous	  acquisition	  of	  data	  from	  different	  modalities	  is	  usually	  not	  practical.	  Hybrid	  XMR	  laboratories	  have	  been	  described205	  and	  are	  ideal	  for	  the	  acquisition	  of	  high-­‐quality	  anatomic	  and	  functional	  data	  during	  a	  single	  examination.	  An	  XMR	  laboratory	  will	  also	  allow	  assessment	  of	  changes	  in	  myocardial	  perfusion,	  both	  in	  the	  target	  and	  remote	  territories,	  immediately	  after	  PCI.	  This	  may	  be	  clinically	  important	  but	  data	  are	  very	  limited.	  To	  date,	  combined	  invasive	  and	  non-­‐invasive	  studies	  of	  patients	  with	  CAD	  and	  PCI	  in	  an	  XMR	  laboratory	  have	  not	  been	  described.	  We	  therefore	  sought	  to	  determine	  the	  feasibility	  of	  patient	  assessment	  and	  treatment	  in	  an	  XMR	  set-­‐up.	  	  	  
Methods	  
XMR	  laboratory	  The	  XMR	  laboratory	  consists	  of	  a	  Philips	  Healthcare	  3	  Tesla	  Achieva	  MRI	  scanner	  and	  an	  Allura	  Xper	  single	  plane	  X-­‐ray	  catheter	  system	  (figure	  9.1).	  Both	  components	  can	  operate	  independently	  as	  well	  as	  in	  combination.	  The	  floating	  tabletop	  allows	  direct	  transfer	  of	  patients	  between	  the	  X-­‐ray	  and	  MRI	  components	  of	  the	  laboratory	  without	  the	  need	  for	  patient	  movement.	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Figure	  9.1:	  The	  XMR	  laboratory.	  
In	  the	  foreground	  there	  is	  a	  fully	  equipped	  single-­‐plane	  interventional	  cardiac	  catheter	  laboratory.	  The	  red	  line	  on	  the	  floor	  is	  the	  5-­‐Gauss	  line	  and	  behind	  this	  there	  is	  a	  clinical	  3T	  MRI	  scanner.	  The	  catheter	  and	  MRI	  tables	  can	  be	  moved	  together	  allowing	  the	  floating	  table	  top,	  and	  the	  patient,	  to	  slide	  directly	  from	  one	  modality	  to	  another.	  Doors	  between	  the	  catheterisation	  and	  MRI	  sections	  can	  be	  closed	  and	  shield	  radiofrequency.	  	  
Safety	  Patient,	  staff	  and	  equipment	  safety	  are,	  of	  course,	  extremely	  important	  within	  the	  XMR	  environment	  as	  particular	  hazards	  are	  posed	  by	  the	  use	  of	  ferromagnetic	  materials	  in	  close	  proximity	  to	  the	  MRI	  scanner.	  Prior	  to	  the	  commencement	  of	  studies	  comprehensive	  safety	  protocols	  were	  implemented	  involving	  staff	  training,	  safety	  checks,	  restricted	  access	  to	  the	  laboratory,	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labelling	  equipment	  according	  to	  MR-­‐compatibility	  and	  tethering	  of	  ferromagnetic	  objects	  to	  the	  floor.	  	  
Patient	  recruitment	  10	  patients	  with	  angina	  and	  known	  or	  suspected	  CAD	  and	  a	  clinical	  indication	  for	  PCI	  or	  a	  coronary	  angiogram	  with	  ad	  hoc	  PCI	  were	  recruited	  to	  participate	  in	  the	  first	  pilot	  study.	  	  
Data	  acquisition	  The	  first	  3	  patients	  were	  used	  to	  test	  the	  XMR	  set-­‐up	  and	  procedures.	  Subsequent	  patients	  underwent	  an	  initial	  CMR	  examination	  followed,	  as	  indicated,	  by:	  an	  invasive	  angiogram,	  coronary	  artery	  pressure	  wire	  interrogation	  and	  FFR	  measurement,	  PCI,	  repeat	  pressure	  wire	  assessment	  and	  repeat	  CMR	  examination.	  Patients	  were	  moved	  directly	  on	  the	  floating	  tabletop	  between	  modalities.	  The	  arterial	  sheath	  was	  left	  in	  situ	  throughout	  but	  all	  other	  equipment	  was	  removed	  from	  the	  sheath	  prior	  to	  transfer	  to	  the	  CMR.	  The	  cardiac	  coils	  were	  removed	  from	  under	  the	  patient	  prior	  to	  X-­‐ray	  examinations	  to	  prevent	  artefacts	  from	  interfering	  with	  X-­‐ray	  screening;	  this	  was	  achieved	  by	  rolling	  the	  patient	  to	  one	  side.	  	  
CMR	  examination	  The	  CMR	  examination	  was	  performed	  with	  either	  a	  6-­‐channel	  (4	  patients)	  or	  a	  32-­‐channel	  (4	  patients)	  cardiac	  phased-­‐array	  receiver	  coil.	  A	  survey,	  coil	  reference	  scan	  and	  planning	  were	  performed	  at	  the	  start	  of	  each	  separate	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examination.	  The	  first	  examination	  included	  SSFP	  long	  axis	  cines	  and	  a	  short	  axis	  stack	  to	  cover	  the	  entire	  LV	  and	  high-­‐resolution	  k-­‐t	  accelerated	  stress	  perfusion	  imaging.	  Rest	  perfusion	  and	  LGE	  imaging	  were	  performed	  as	  indicated.	  Subsequent	  examinations	  included	  stress	  perfusion	  and	  also	  functional,	  rest	  perfusion	  and/or	  scar	  imaging	  as	  indicated.	  	  Perfusion	  imaging	  was	  performed	  as	  previously	  described	  using	  the	  same	  k-­‐t	  accelerated	  ultrafast	  gradient	  echo	  sequence	  described	  previously	  (acquired	  resolution	  of	  1.3	  x	  1.3	  x	  10mm),	  a	  dual	  bolus	  of	  0.0075	  then	  0.075mmol/kg	  of	  CA	  and	  adenosine	  stress.	  	  	  Scar	  imaging	  was	  performed	  using	  an	  inversion	  recovery	  turbo	  gradient	  echo	  sequence	  with	  the	  prepulse	  delay	  optimized	  for	  maximum	  suppression	  of	  myocardial	  signal	  and	  an	  acquired	  spatial	  resolution	  of	  1.75	  x	  1.75	  x	  8mm.	  	  
Invasive	  examinations	  X-­‐ray	  coronary	  angiography	  was	  performed	  from	  the	  right	  femoral	  artery	  according	  to	  the	  standard	  techniques.	  For	  calculation	  of	  FFR	  adenosine	  was	  infused	  using	  the	  same	  protocol	  as	  above.	  FFR	  was	  defined	  as	  (Pd	  –	  Pv)	  /	  Pv	  during	  hyperaemia	  where	  Pd,	  Pa,	  Pv	  	  are	  mean	  distal	  coronary,	  and	  aortic	  pressures	  respectively.	  FFR	  <0.75	  was	  considered	  to	  be	  positive.	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Percutaneous	  coronary	  intervention	  	  PCI	  was	  guided	  by	  functional	  data	  and	  performed	  when	  clinically	  indicated,	  using	  standard	  techniques,	  at	  the	  discretion	  of	  the	  operator.	  	  	  
Results	  Four	  females	  and	  six	  males	  with	  mean	  age	  73	  (range	  51-­‐86)	  were	  included.	  All	  procedures	  were	  completed	  and	  well	  tolerated	  with	  no	  complications	  or	  patient	  withdrawals.	  Seven	  patients	  had	  both	  CMR	  imaging	  and	  invasive	  studies.	  Two	  of	  the	  first	  three	  patients	  who	  were	  used	  to	  test	  XMR	  procedures	  underwent	  invasive	  procedures	  only	  and	  angiography	  was	  no	  longer	  indicated	  after	  CMR	  in	  one	  patient	  (see	  below).	  Mean	  study	  duration	  in	  patients	  who	  underwent	  both	  invasive	  and	  non-­‐invasive	  studies	  was	  117	  minutes	  (range	  36-­‐208).	  Four	  patients	  had	  single	  vessel	  CAD;	  three	  had	  2-­‐vessel	  disease;	  two	  3-­‐vessel	  disease	  and	  one	  minor	  disease.	  Details	  of	  all	  of	  the	  procedures	  and	  outcomes	  are	  shown	  in	  table	  9.1.	  Six	  patients	  had	  single	  vessel	  PCI	  and	  four	  patients	  were	  treated	  medically.	  Four	  patients	  had	  a	  CMR	  both	  pre	  and	  post	  PCI.	  Fourteen	  coronary	  territories	  in	  six	  patients	  had	  FFR	  with	  corresponding	  stress	  perfusion	  imaging;	  four	  of	  these	  territories	  were	  post	  PCI.	  	   	  
  238 
Table	  9.1:	  Patient	  characteristics	  and	  summary	  of	  XMR	  cases.	  	  
Patient	  
number	  
Age	   Sex	   Coronary	  
disease	  
Perfusion	  
imaging	  
FFR	   Outcome	  Pre	  PCI	   Post	  PCI	  
1	   65	   F	   Minor	   N/A	   N/A	   	   Medical	  
2	   77	   M	   LAD	  Cx	   Negative	  Negative	   N/A	   	   Medical	  
3	   71	   M	   RCA	   N/A	   N/A	   	   PCI	  RCA	  
4	   76	   F	   LAD	   Positive	   0.68	   	   PCI	  LAD	  
5	   79	   M	   LAD	   Positive	   0.38	   0.92	   PCI	  LAD	  
6	   79	   F	   LAD	  Cx	   Negative	  Negative	   0.73	  0.90	   0.83	   PCI	  LAD	  
7	   86	   F	   LAD	   Scar	   N/A	   	   Medical	  
8	   61	   M	   Cx	  RCA	   Positive	  Negative	   0.55	  0.29	   0.95	   PCI	  Cx	  
9	   75	   M	   LAD	  Cx	  RCA	  
Negative	  Negative	  Negative	  
0.83	  	  0.91	  
	   Medical	  
10	   51	   M	   LAD	  Cx	  RCA	  
+	  -­‐	  +	  
0.45	  0.96	   0.98	   PCI	  LAD	  
M=male;	  F=female;	  LAD=left	  anterior	  descending	  artery;	  Cx=circumflex	  artery;	  RCA=right	  coronary	  artery;	  Med=medical	  therapy,	  +/-­‐	  =presence/absence	  of	  a	  stress	  induced	  perfusion	  defect	  in	  the	  corresponding	  territory.	  	  
  239 
Results	  from	  3	  patients	  are	  shown	  in	  figures	  9.2-­‐9.5.	  
Figure	  9.2	  
	  	  
Figure	  9.3	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Figure	  9.2	  and	  9.9:	  CMR	  and	  X-­‐ray	  coronary	  angiogram	  from	  patient	  10.	  
Coronary	  angiography	  demonstrated	  severe	  disease	  at	  the	  origin	  of	  the	  posterior	  descending	  artery	  (2A)	  and	  in	  the	  proximal	  LAD	  (2B).	  FFR	  of	  the	  LAD	  lesion	  was	  0.45.	  	  Prior	  to	  PCI	  the	  CMR	  demonstrated	  an	  anterior/anteroseptal	  wall	  motion	  abnormality	  visible	  from	  the	  end-­‐diastolic	  (2C)	  and	  end-­‐systolic	  (2D;	  red	  arrows)	  frames	  from	  the	  short	  axis	  cine.	  Stress	  perfusion	  imaging	  demonstrated	  a	  severe	  perfusion	  defect	  in	  the	  LAD	  territory	  from	  base	  to	  apex	  (3A-­‐C;	  blue	  arrows)	  and	  a	  defect	  in	  the	  RCA	  territory	  (3D;	  green	  arrows).	  	  Following	  PCI	  to	  the	  LAD	  FFR	  increased	  to	  0.98,	  there	  was	  an	  immediate	  improvement	  in	  wall	  motion	  (2F-­‐G)	  and	  stress	  perfusion	  was	  significantly	  improved	  (3D-­‐F).	  The	  RCA	  territory	  defect	  remained	  (3D;	  green	  arrows)	  but	  there	  was	  also	  persistent	  hypoperfusion	  in	  the	  mid	  anterior	  slice	  (3E;	  blue	  arrow)	  and	  apical	  lateral	  wall	  (3F;	  blue	  arrow)	  despite	  the	  absence	  of	  scar	  on	  LGE	  imaging	  (3G-­‐I).	  No	  clear	  angiographic	  reason	  for	  this	  was	  identified	  although	  it	  may	  have	  been	  due	  to	  disease	  in	  smaller	  diagonal	  or	  obtuse	  marginal	  vessels.	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Figure:	  9.4:	  Coronary	  angiogram	  and	  stress	  perfusion	  images	  from	  patient	  
9.	  
Stress	  perfusion	  did	  not	  reveal	  any	  significant	  defects	  (A-­‐C).	  The	  X-­‐ray	  coronary	  angiogram	  demonstrated	  moderate	  disease	  in	  the	  proximal	  LAD	  (D),	  with	  a	  corresponding	  FFR	  of	  0.83,	  in	  the	  proximal	  dominant	  right	  coronary	  artery	  (E)	  with	  an	  FFR	  of	  0.91	  and	  also	  in	  the	  obtuse	  marginal	  and	  a	  small	  circumflex	  artery.	  The	  patient	  was	  treated	  medically.	  	  	  
  242 
	  
Figure	  9.5:	  Coronary	  angiogram	  and	  stress	  perfusion	  images	  pre	  and	  post	  
PCI.	  
Mid	  and	  apical	  LV	  stress	  perfusion	  images	  from	  patient	  5	  demonstrated	  an	  obvious	  perfusion	  defect	  in	  the	  mid	  to	  apical	  anterior	  wall	  and	  anteroseptum	  (B,	  C,).	  There	  is	  also	  a	  more	  subtle	  defect	  in	  the	  inferolateral	  wall	  (blue	  arrows	  B).	  Coronary	  angiography	  revealed	  diffuse	  coronary	  artery	  disease	  with	  focal	  severe	  lesions	  in	  the	  mid-­‐distal	  LAD	  (A	  arrow)	  and	  proximal	  circumflex	  artery	  (A	  arrowhead).	  FFR	  was	  0.38	  in	  the	  LAD	  lesion	  and	  increased	  to	  0.92	  post	  PCI.	  Post	  PCI	  perfusion	  during	  stress	  improved	  in	  the	  anterior	  wall/anteroseptum	  but	  it	  also	  improved	  in	  the	  inferolateral	  wall	  (E,	  F)	  despite	  no	  other	  coronary	  intervention.	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FFR	  and	  stress	  perfusion	  results	  were	  concordant	  in	  10	  of	  12	  vessels	  pre	  PCI.	  Of	  the	  2	  patients	  with	  discordant	  results	  one	  (patient	  6)	  had	  mid	  LAD	  disease	  with	  an	  FFR	  of	  0.73	  and	  no	  perfusion	  defect.	  One	  had	  severe	  disease	  in	  the	  LV	  branch	  of	  the	  RCA,	  an	  FFR	  of	  0.29	  and	  no	  perfusion	  defect.	  	  One	  subject	  (patient	  7)	  had	  predominantly	  breathlessness	  on	  exertion	  with	  some	  chest	  tightness.	  A	  previous	  coronary	  angiogram	  had	  demonstrated	  severe	  disease	  of	  the	  proximal	  LAD	  and	  she	  attended	  for	  PCI.	  The	  initial	  CMR	  demonstrated	  that	  the	  LAD	  territory	  was	  predominantly	  transmural	  scar	  with	  no	  significant	  ischaemia.	  On	  the	  basis	  of	  these	  findings	  PCI	  was	  not	  felt	  to	  be	  in	  her	  best	  interests	  and	  she	  was	  treated	  medically.	  	  
Discussion	  This	  pilot-­‐study	  demonstrates	  the	  feasibility	  of	  acquiring	  near-­‐simultaneous	  invasive	  coronary	  anatomic	  and	  physiological	  data	  and	  non-­‐invasive	  myocardial	  structural	  and	  functional	  data	  in	  an	  XMR	  laboratory.	  It	  was	  also	  possible	  to	  deliver	  targeted	  coronary	  revascularisation	  in	  this	  setting.	  The	  procedures	  were	  well	  tolerated	  by	  all	  subjects	  and	  all	  the	  required	  data	  collection	  and	  treatments	  were	  completed	  successfully.	  	  
Interventional	  Cardiovascular	  Magnetic	  Resonance	  X-­‐ray	  guided	  percutaneous	  interventional	  cardiology	  has	  gained	  huge	  momentum	  over	  recent	  years.	  PCI	  is	  now	  by	  far	  the	  dominant	  method	  for	  coronary	  revascularisation.	  However,	  X-­‐ray	  guidance	  is	  limited	  by	  poor	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visualisation	  of	  soft-­‐tissues	  and	  an	  inability	  to	  adequately	  assess	  the	  myocardium.	  MR-­‐guided	  interventions	  were	  initially	  proposed	  more	  than	  15	  years	  ago206	  as	  a	  possible	  method	  to	  overcome	  some	  of	  these	  limitations.	  Since	  then	  MR-­‐guided	  diagnostic	  cardiac	  catheterisation205,	  pulmonary	  valve	  dilatation207,	  and	  peripheral	  arterial	  stent	  placement208	  have	  been	  described	  in	  humans	  using	  dedicated	  MR-­‐compatible	  catheters	  and	  equipment.	  These	  preliminary	  studies	  are	  encouraging,	  and	  highlight	  areas	  where	  MR-­‐guided	  procedures	  are	  likely	  to	  have	  an	  increasing	  clinical	  role.	  	  	  Importantly,	  although	  MR-­‐guided	  coronary	  intervention	  has	  been	  described	  in	  an	  animal	  model209,	  it	  has	  not	  been	  performed	  in	  humans.	  Furthermore	  MR-­‐guided	  PCI	  is	  unlikely	  to	  be	  feasible	  in	  the	  near	  future	  for	  two	  main	  reasons.	  Firstly,	  there	  is	  no	  commercially	  available	  MR-­‐compatible	  equipment	  for	  PCI.	  Secondly,	  PCI	  requires	  very	  precise	  manipulation	  of	  equipment	  in	  small	  vessels	  and,	  unlike	  X-­‐ray	  technology,	  at	  present	  MRI	  does	  not	  have	  sufficient	  spatial	  or	  temporal	  resolution	  to	  permit	  this.	  Consequently,	  for	  patients	  with	  CAD,	  the	  main	  advantage	  of	  the	  XMR	  laboratory	  is	  the	  availability	  of	  sequential,	  complimentary	  multimodal	  data	  rather	  than	  using	  MRI	  to	  perform	  the	  PCI.	  CMR	  data	  is	  rapidly	  available	  before,	  after,	  and	  at	  any	  point	  during	  the	  procedure.	  	  
XMR	  laboratory	  applications	  The	  set-­‐up	  we	  describe	  here	  has	  both	  clinical	  and	  research	  applications.	  Sequential	  CMR	  and	  invasive	  assessment	  will	  improve	  our	  understanding	  of	  the	  relationship	  between	  coronary	  pressure	  and	  flow	  and	  myocardial	  perfusion.	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The	  advent	  of	  specialised	  Doppler	  and	  pressure	  sensor-­‐tipped	  coronary	  guidewires	  in	  recent	  years	  has	  allowed	  calculation	  of	  hyperaemic	  microvascular	  resistance,	  CFR	  and	  FFR.	  High-­‐resolution	  CMR	  imaging	  allows	  perfusion	  imaging	  with	  unprecedented	  spatial	  resolution	  permitting	  differentiation	  of	  endocardial	  and	  epicardial	  perfusion	  and	  scar	  from	  peri-­‐infarct	  ischaemia.	  Quantitative	  perfusion	  assessment	  allows	  calculation	  of	  absolute	  perfusion	  and	  true	  MPR.	  These	  tools	  are	  available	  and	  can	  be	  used	  to	  analyse	  data	  from	  the	  XMR	  laboratory	  to	  assist	  our	  understanding	  of	  the	  relationship	  between	  MPR,	  CFR	  and	  FFR,	  how	  revascularisation	  affects	  perfusion	  and	  whether	  this	  changes	  over	  time.	  In	  patients	  with	  multivessel	  CAD	  it	  is	  likely	  that	  revascularisation	  of	  one	  territory	  affects	  perfusion	  in	  other	  territories,	  as	  suggested	  by	  the	  data	  in	  figure	  5	  in	  this	  study.	  Furthermore,	  although	  perfusion	  is	  known	  to	  improve	  post	  PCI136	  full	  improvement	  may	  not	  be	  immediate	  as	  suggested	  by	  figure	  9.3	  above.	  	  	  In	  this	  study	  there	  were	  two	  territories	  in	  two	  patients	  with	  discordant	  FFR	  and	  CMR	  perfusion	  results.	  In	  the	  first	  patient	  the	  FFR	  was	  just	  below	  the	  threshold	  of	  positivity	  (0.73)	  and	  it	  is	  likely	  to	  be	  have	  been	  a	  false	  negative	  perfusion	  scan.	  Quantification	  of	  perfusion	  or	  detailed	  analysis	  of	  the	  epi-­‐endocardial	  perfusion	  gradients	  may	  allow	  us	  to	  understand	  such	  discordant	  results	  better.	  The	  second	  patient	  had	  disease	  in	  a	  distal	  branch	  of	  the	  right	  coronary	  artery.	  The	  FFR	  was	  strongly	  positive	  (0.29)	  however	  the	  distal	  nature	  of	  the	  disease	  probably	  explains	  the	  lack	  of	  a	  perfusion	  defect.	  MPR	  would	  have	  been	  informative	  in	  these	  patients	  but	  we	  did	  not	  have	  rest	  perfusion	  data	  in	  either	  case.	  In	  this	  study	  since	  data	  was	  not	  collected	  according	  to	  a	  systematic	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protocol	  retrospective	  ad	  hoc	  data	  analysis	  was	  avoided	  as	  it	  could	  be	  misleading.	  On	  the	  basis	  of	  the	  CMR	  scan	  the	  patient	  had	  a	  PCI	  to	  a	  proximal	  circumflex	  lesion,	  which	  was	  associated	  with	  a	  perfusion	  defect,	  but	  not	  to	  the	  right	  coronary	  artery	  and	  was	  free	  of	  angina	  at	  a	  6-­‐week	  follow-­‐up.	  	  The	  immediate	  availability	  of	  CMR	  data	  after	  PCI	  means	  that	  the	  XMR	  is	  an	  ideal	  set-­‐up	  to	  investigate	  the	  relationship	  between	  anatomy	  and	  physiology	  and	  between	  the	  different	  physiological	  parameters.	  In	  addition	  to	  patients	  with	  epicardial	  CAD	  the	  XMR	  laboratory	  has	  potential	  applications	  in	  other	  patient	  groups.	  For	  example	  the	  combination	  of	  high-­‐resolution	  perfusion	  imaging	  and	  estimation	  of	  microvascular	  resistance	  from	  Doppler	  pressure	  wire	  data	  will	  allow	  improved	  characterisation	  of	  patients	  with	  microvascular	  disease.	  	  	  The	  catheter	  laboratory	  component	  is	  fully	  equipped	  and	  allows	  the	  whole	  PCI	  procedure	  to	  be	  performed,	  therefore	  routine	  clinical	  cases	  can	  also	  be	  performed	  in	  the	  XMR	  set-­‐up	  with	  the	  added	  advantage	  of	  the	  immediate	  availability	  of	  state-­‐of-­‐the-­‐art	  CMR	  imaging.	  Furthermore,	  since	  the	  system	  registers	  the	  position	  of	  the	  patient	  this	  allows	  image	  fusion210	  whereby	  CMR	  images	  can	  be	  superimposed	  on	  the	  X-­‐ray	  images	  in	  real	  time.	  The	  soft	  tissues	  can	  therefore	  also	  be	  visualised	  during	  interventions	  and	  this	  approach	  has	  been	  utilised	  for	  cardiac	  resynchronisation	  therapy	  device	  implantation211.	  The	  disadvantage	  of	  using	  the	  XMR	  set-­‐up	  for	  clinical	  cases	  is	  that	  each	  patient	  treated	  requires	  the	  presence	  of	  both	  catheter	  and	  MRI	  staff	  throughout	  the	  procedure	  and	  only	  one	  modality	  can	  operate	  at	  a	  time	  which	  is	  less	  efficient	  than	  operating	  both	  modalities	  in	  parallel	  in	  separate	  laboratories.	  Therefore	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even	  though	  routine	  clinical	  work	  can	  be	  performed	  in	  the	  XMR	  laboratory	  realistically	  its	  predominant	  use	  will	  be	  for	  research	  applications	  or	  as	  a	  single	  modality	  laboratory	  for	  routine	  work.	  	  
Limitations	  This	  was	  a	  pilot	  study	  to	  allow	  us	  to	  test	  the	  feasibility	  of	  the	  XMR	  set-­‐up	  and	  as	  such	  the	  equipment	  used	  and	  data	  collected	  deliberately	  varied	  and	  were	  tailored	  to	  individual	  patients.	  Further	  studies	  are	  underway	  using	  systematic	  methods	  and	  materials.	  	  
Conclusion	  We	  have	  demonstrated	  that	  advanced	  CMR	  imaging	  can	  be	  combined	  with	  invasive	  X-­‐ray-­‐guided	  coronary	  angiography,	  pressure	  wire	  interrogation	  and	  intervention	  in	  a	  hybrid	  XMR	  laboratory.	  The	  procedures	  were	  well	  tolerated	  by	  patients.	  This	  set-­‐up	  allows	  acquisition	  of	  high-­‐quality,	  sequential	  data	  on	  coronary	  anatomy	  and	  coronary	  and	  myocardial	  physiology	  and	  has	  many	  exciting	  research	  and	  clinical	  applications.	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10	   DISCUSSION	  AND	  CONCLUSIONS	  
Discussion	  CMR	  imaging	  is	  already	  established	  as	  a	  valuable	  tool	  for	  assessment	  of	  patients	  with	  CAD	  and	  for	  guiding	  revascularisation.	  However	  on-­‐going	  research	  and	  development	  in	  both	  image	  acquisition	  and	  post-­‐processing	  methods	  means	  that	  its	  role	  is	  continues	  to	  evolve.	  As	  new	  techniques	  become	  available	  it	  is	  important	  that	  they	  are	  evaluated	  carefully	  in	  clinical	  studies.	  The	  objective	  of	  this	  work	  was	  to	  perform	  some	  of	  this	  evaluation	  and	  to	  identify	  strengths	  and	  limitations	  with	  some	  emerging	  CMR	  methods	  with	  potential	  utility	  in	  guiding	  revascularisation.	  	  
Quantification	  of	  perfusion	  with	  CMR	  Absolute	  quantification	  of	  myocardial	  perfusion	  with	  CMR	  is	  an	  exciting	  emerging	  technique.	  There	  are	  a	  number	  of	  clinical	  situations	  where	  it	  is	  anticipated	  that	  quantification	  will	  be	  advantageous	  although	  to	  date	  data	  to	  support	  this	  are	  very	  limited.	  Currently	  quantitative	  analysis	  is	  not	  widely	  available,	  prone	  to	  errors	  and	  the	  effects	  of	  artefacts,	  time-­‐consuming	  and	  lacks	  standardization.	  The	  techniques	  used	  here,	  and	  previously	  published	  data	  suggest	  that,	  at	  present,	  inter-­‐study	  reproducibility	  is	  modest.	  Furthermore	  the	  comparison	  with	  PET,	  the	  non-­‐invasive	  reference	  standard,	  had	  mixed	  results	  as	  reported	  in	  chapter	  4.	  Much	  of	  this	  is	  in	  contrast	  to	  visual	  analysis	  of	  perfusion,	  which	  is	  now	  a	  routine	  clinical	  tool.	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A	  number	  of	  different	  factors	  are	  likely	  to	  contribute	  to	  the	  current	  problems	  associated	  with	  quantitative	  CMR	  perfusion	  imaging	  all	  of	  which	  will	  need	  to	  be	  addressed	  in	  order	  to	  overcome	  the	  current	  limitations.	  	  
	  
Data	  acquisition	  
Image	  quality	  and	  artefacts	  Quantitative	  analysis	  is	  reliant	  on	  the	  generation	  of	  high	  quality	  myocardial	  SI	  curves.	  Despite	  the	  early	  work	  (chapter	  3)	  to	  identify	  and	  use	  the	  best	  possible	  perfusion	  sequence	  and	  CA	  dose	  myocardial	  SI	  curves	  were	  not	  always	  sufficiently	  robust	  for	  quantitative	  analysis.	  This	  is	  reflected	  in	  the	  fact	  that	  the	  data	  from	  11%	  of	  coronary	  territories	  in	  the	  comparison	  with	  PET	  (chapter	  4)	  and	  3	  of	  the	  16	  volunteers	  included	  in	  the	  inter-­‐study	  reproducibility	  analysis	  (chapter	  6)	  were	  not	  suitable	  for	  quantitative	  analysis.	  In	  contrast	  all	  studies	  and	  territories	  were	  suitable	  for	  visual	  analysis.	  Inadequate	  SI	  curves	  were	  a	  result	  of	  respiratory	  artefacts	  or	  insufficient	  myocardial	  CNR.	  Further	  improvements	  in	  perfusion	  sequences	  to	  achieve	  even	  higher	  SNR	  and	  CNR	  and	  reduce	  respiratory	  artefacts	  (and	  also	  DRA)	  are	  therefore	  desirable.	  	  	  
Temporal	  resolution	  Currently	  images,	  and	  therefore	  the	  myocardial	  SI	  curve,	  are	  acquired	  for	  only	  part	  of	  the	  cardiac	  cycle	  thus	  the	  first-­‐pass	  of	  CA	  is	  sampled	  rather	  than	  acquired	  in	  its	  entirety.	  This	  is	  a	  likely	  to	  be	  a	  source	  of	  error	  for	  absolute	  quantification,	  as	  curves	  generated	  by	  this	  method	  will	  vary	  depending	  on	  the	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exact	  time	  points	  sampled.	  Image	  acquisition	  during	  the	  entire	  cardiac	  cycle	  will	  eliminate	  this	  error.	  However	  this	  will	  necessitate	  the	  acquisition	  of	  multiple	  slices	  simultaneously	  rather	  than	  in	  series	  as	  is	  currently	  standard.	  	  
Contrast	  agent	  The	  properties	  of	  the	  CA	  currently	  in	  use	  for	  perfusion	  imaging	  are	  not	  ideal	  for	  quantitative	  analysis.	  Firstly,	  as	  previously	  discussed,	  the	  relationship	  between	  CA	  concentration	  and	  SI	  is	  non-­‐linear	  at	  higher	  doses	  of	  CA.	  Secondly,	  the	  CA	  are	  extravascular	  and	  therefore	  the	  SI	  is	  influenced	  by	  both	  the	  arrival	  of	  new	  CA	  and	  the	  effects	  of	  extravascular	  CA	  already	  in	  the	  myocardial	  tissue.	  Thirdly,	  the	  myocardial	  extraction	  fraction	  is	  typically	  0.3-­‐0.6	  and	  varies	  at	  different	  myocardial	  perfusion	  rates212.	  	  	  CA	  with	  a	  linear	  relationship	  between	  SI	  and	  myocardial	  concentration	  would	  be	  preferable	  to	  avoid	  errors	  due	  to	  signal	  saturation	  effects.	  Intravascular	  CA	  may	  be	  preferable	  and	  are	  available	  but	  experience	  of	  their	  use	  in	  myocardial	  perfusion	  imaging	  is	  lacking.	  Alternatively,	  an	  extravascular	  CA	  with	  high	  and	  consistent	  first	  pass	  uptake	  will	  at	  least	  overcome	  the	  limitations	  related	  to	  the	  variable	  and	  relatively	  low	  extraction	  of	  CA.	  	  	  
Post-­‐processing	  software	  A	  number	  of	  factors	  related	  to	  the	  post	  processing	  software	  currently	  limit	  the	  reliability	  of	  quantitative	  perfusion	  analysis.	  Many	  of	  these	  are	  generally	  applicable	  to	  all	  software	  programmes	  however	  the	  heterogeneous	  nature	  of	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the	  tools	  available	  means	  that	  some	  are	  more	  specific	  to	  the	  methods	  used	  for	  this	  work.	  	  	  One	  of	  the	  main	  sources	  of	  variability	  and	  error	  is	  user	  interaction	  with	  post-­‐processing	  software.	  At	  present	  automated	  post-­‐processing	  is	  not	  sufficiently	  robust	  to	  remove	  the	  requirement	  for	  input	  from	  users.	  SI	  curves	  are	  affected	  by	  myocardial	  border	  placement.	  It	  is	  important	  therefore	  to	  define	  these	  borders	  carefully	  to	  prevent	  contamination	  from	  the	  ventricular	  blood	  pool	  and	  consistently	  include	  equivalent	  segments	  of	  myocardium	  in	  the	  regions	  of	  interest.	  However	  automated	  border	  detection	  is	  sub-­‐optimal	  and	  manual	  correction	  of	  myocardial	  borders	  is	  frequently	  required.	  	  Quantitative	  analysis	  is	  also	  extremely	  dependent	  on	  obtaining	  an	  accurate	  arterial	  input	  function	  (AIF)	  and	  subsequently	  accurate	  definition	  of	  the	  onset	  and	  offset	  of	  the	  AIF	  and	  the	  onset	  of	  the	  myocardial	  response.	  LV	  signal,	  and	  thus	  AIF,	  is	  likely	  to	  vary	  depending	  on	  whether	  it	  is	  taken	  from	  the	  basal,	  mid	  or	  apical	  LV.	  In	  this	  work	  the	  AIF	  was	  automatically	  defined,	  using	  a	  defined	  area	  within	  the	  endocardial	  border	  of	  the	  basal	  slice.	  However,	  manual	  correction	  was	  required,	  for	  example	  in	  the	  presence	  of	  significant	  respiratory	  motion	  or	  the	  presence	  of	  papillary	  muscle	  in	  the	  region	  of	  interest.	  AIF	  onset	  and	  offset	  and	  the	  onset	  of	  the	  myocardial	  signal	  were	  also	  manually	  defined.	  Although	  this	  was	  done	  by	  blinded	  observers	  in	  a	  consistent	  manner	  automated	  algorithms	  to	  define	  these	  time	  points	  would	  be	  preferable.	  It	  is	  unlikely	  that	  user-­‐interaction	  with	  post	  processing	  methods	  can	  be	  completely	  abolished	  in	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the	  near	  future	  but	  improving	  automated	  algorithms	  and	  minimising	  this	  interaction	  will	  improve	  consistency.	  	  Quantification	  of	  perfusion	  with	  the	  post-­‐processing	  software	  used	  for	  these	  studies	  is	  based	  on	  deconvolution	  of	  SI	  curves	  derived	  from	  pixel-­‐wise	  analysis	  of	  the	  myocardium.	  Whilst	  this	  method	  is	  extremely	  sensitive	  for	  perfusion	  abnormalities	  it	  is	  also	  susceptible	  to	  the	  effects	  of	  noise	  and	  artefact.	  Averaging	  SI	  within	  a	  given	  region	  or	  segment	  and	  excluding	  extreme	  outliers	  as	  artefact	  prior	  to	  deconvolution	  may	  therefore	  improve	  reliability.	  	  Finally	  as	  discussed	  in	  chapters	  4	  and	  6	  difficulties	  in	  accurately	  correcting	  for	  baseline	  SI	  may	  reduce	  the	  accuracy	  of	  quantitative	  analysis,	  particularly	  after	  repeated	  administration	  of	  CA.	  	  
Lack	  of	  a	  true	  gold-­‐standard	  for	  validation	  Another	  problem	  currently	  limiting	  the	  development	  of	  quantitative	  methods	  is	  the	  absence	  of	  an	  obvious	  gold	  standard	  as	  it	  is	  not	  possible	  to	  measure	  true	  myocardial	  perfusion	  in	  human	  subjects.	  Simulations,	  phantoms,	  animal	  studies	  and	  human	  studies	  can	  all	  be	  used	  as	  reference	  standards.	  Simulated	  data	  have	  been	  used	  previously213,	  214	  and	  allow	  precise	  control	  over	  the	  conditions	  of	  perfusion.	  However	  simulations	  are	  not	  standardised	  and	  non-­‐physiological.	  	  	  Animal	  models	  are	  physiological	  and	  allow	  the	  use	  of	  microspheres	  for	  histological	  evaluation	  of	  perfusion.	  However	  these	  are	  limited	  by	  availability,	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cost	  and	  ethical	  considerations.	  Furthermore	  microspheres	  are	  only	  a	  surrogate	  marker	  of	  perfusion.	  An	  isolated,	  perfused,	  pig-­‐heart	  model	  has	  been	  described	  by	  our	  research	  group	  to	  allow	  exact	  control	  of	  perfusion215	  however	  it	  remains	  limited	  by	  cost	  and	  availability.	  The	  perfusion	  phantom	  described	  above	  allows	  precise	  control	  over	  perfusion	  and	  overcomes	  the	  cost	  and	  ethical	  restraints	  associated	  with	  animal	  models,	  however,	  it	  is	  non-­‐physiological.	  	  	  Human	  studies	  are	  the	  most	  relevant	  for	  validation	  and	  PET	  or	  invasive	  measurement	  of	  coronary	  flow	  using	  Doppler	  probe	  tipped	  guidewires	  can	  be	  used	  as	  the	  perfusion	  reference	  standard.	  However	  quantitative	  PET	  methods	  are	  also	  affected	  by	  many	  of	  the	  same	  problems	  that	  affect	  CMR.	  These	  methods	  are	  not	  standardised	  and	  use	  a	  number	  of	  mathematical	  models,	  each	  with	  potential	  limitations.	  It	  is	  recognised	  that	  different	  tracers	  provide	  different	  normal	  and	  abnormal	  perfusion	  ranges122.	  This	  is	  reflected	  in	  the	  paucity	  of	  published	  data	  using	  quantitative	  PET	  and	  the	  lack	  of	  consensus	  regarding	  normal	  ranges	  for	  perfusion158.	  Finally,	  invasive	  methods	  can	  de	  used	  to	  measure	  coronary	  flow	  and	  the	  XMR	  set-­‐up	  is	  ideal	  for	  comparison	  of	  CMR	  and	  invasive	  measurements.	  However	  these	  methods	  are	  an	  indirect	  measure,	  estimate	  coronary	  flow	  rather	  than	  perfusion	  and	  are	  not	  routinely	  available.	  	  	  Further	  developments	  should	  allow	  many	  of	  these	  limitations	  to	  be	  overcome	  eventually.	  However,	  calculation	  of	  a	  quantitative	  MPR	  will	  correct	  many	  of	  these	  differences,	  which	  occur	  as	  a	  result	  of	  the	  lack	  of	  method	  standardisation.	  MPR	  may	  therefore	  be	  more	  robust	  than	  absolute	  values	  as	  suggested	  in	  the	  comparison	  with	  PET	  reported	  here.	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Novel	  CMR	  methods	  for	  guiding	  revascularisation	  Although	  the	  focus	  of	  this	  work	  was	  perfusion	  and	  quantitative	  CMR	  perfusion	  two	  other	  novel	  CMR	  methods	  with	  potential	  applications	  for	  guiding	  revascularisation	  were	  evaluated.	  CMR	  endocardial	  border	  definition	  and	  image	  quality	  are	  unrivalled	  by	  other	  imaging	  modalities	  and	  as	  a	  result	  CMR	  has	  become	  accepted	  as	  the	  gold	  standard	  for	  wall	  motion	  analysis.	  The	  potential	  to	  accurately	  quantify	  wall	  motion	  in	  a	  user-­‐independent	  fashion	  with	  CMR	  feature	  tracking	  is	  therefore	  extremely	  promising	  as	  it	  may	  then	  allow	  improved	  selection	  of	  territories	  and	  patients	  for	  revascularisation	  procedures.	  In	  addition	  to	  this	  feature	  tracking	  has	  potential	  applications	  for	  early	  detection	  and	  monitoring	  of	  cardiomyopathies	  and	  monitoring	  disease	  progression,	  for	  example	  in	  patients	  taking	  cardiotoxic	  chemotherapeutic	  agents	  or	  prior	  to	  or	  after	  therapeutic	  interventions.	  Moreover	  CMR-­‐FT	  derived	  parameters	  could	  be	  used	  as	  surrogate	  end-­‐points	  in	  research	  studies,	  particularly	  if	  reproducibility	  can	  be	  improved.	  	  The	  early	  work	  with	  the	  dual-­‐IR	  sequence	  was	  also	  extremely	  promising.	  LGE	  imaging	  is	  one	  of	  the	  main	  strengths	  of	  CMR	  imaging	  both	  for	  guiding	  revascularisation	  and	  for	  other	  applications	  such	  as	  identifying	  the	  aetiology	  of	  cardiomyopathies.	  Despite	  the	  obvious	  successes	  of	  this	  method	  it	  is	  sometimes	  limited	  by	  inadequate	  contrast	  between	  LGE	  and	  blood	  and	  this	  novel	  sequence	  appears	  useful	  in	  these	  situations.	  Further	  studies	  using	  both	  of	  these	  techniques	  are	  supported	  by	  the	  results	  of	  this	  work	  and	  are	  now	  warranted.	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Future	  perspectives	  In	  addition	  to	  further	  development	  of	  the	  techniques	  discussed	  above	  the	  role	  of	  CMR	  in	  guiding	  revascularisation	  in	  future	  is	  likely	  to	  be	  influenced	  by	  improved	  hardware	  and	  software,	  new	  clinical	  studies	  and	  multimodal	  cardiac	  imaging.	  	  
Technical	  advances	  Technical	  advances	  will	  result	  in	  many	  future	  developments.	  As	  an	  example,	  Blood	  Oxygen	  Level-­‐Dependent	  (BOLD)	  magnetic	  resonance	  allows	  CMR	  perfusion	  imaging	  to	  be	  performed	  without	  CA	  administration	  as	  SI	  changes	  are	  detected	  as	  the	  ratio	  of	  oxygenated	  and	  deoxygenated	  haemoglobin	  in	  the	  myocardium	  changes.	  This	  method	  appears	  to	  allow	  visualisation	  of	  true	  ischaemia	  rather	  than	  a	  surrogate216.	  However,	  at	  present,	  BOLD	  techniques	  are	  not	  available	  for	  routine	  clinical	  use.	  	  
Clinical	  studies	  A	  number	  of	  important	  clinical	  questions	  remain	  unanswered	  and	  are	  the	  focus	  of	  current	  clinical	  trials.	  With	  respect	  to	  ischaemia	  it	  remains	  unclear	  whether	  reducing	  myocardial	  ischaemic	  burden	  per	  se	  is	  of	  prognostic	  benefit.	  It	  is	  also	  of	  interest	  whether	  a	  non-­‐invasive	  test,	  and	  specifically	  CMR,	  can	  guide	  revascularisation	  in	  the	  same	  way	  that	  FFR	  can.	  An	  international,	  multi-­‐centre	  study	  is	  currently	  recruiting	  to	  address	  this	  question	  (MR-­‐INFORM;	  clinical	  trials	  number	  NCT01236807).	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Despite	  publication	  of	  the	  much-­‐anticipated	  STICH	  study	  prospective	  imaging-­‐guided	  revascularisation	  outcome	  studies	  are	  still	  lacking.	  Much	  of	  the	  CMR	  viability	  work	  published	  previously	  has	  focused	  on	  patients	  with	  moderate	  LV	  systolic	  dysfunction.	  The	  accuracy	  of	  CMR	  for	  predicting	  viability	  in	  more	  severe	  LV	  dysfunction	  is	  less	  well	  established.	  In	  addition	  the	  mechanism	  of	  how	  prognosis	  is	  improved	  by	  revascularisation	  in	  the	  absence	  of	  an	  improvement	  in	  LV	  function	  remains	  unanswered.	  It	  is	  likely	  that	  the	  application	  of	  novel	  techniques	  and	  high	  spatial	  resolution	  imaging	  will	  be	  used	  to	  better	  understand	  these	  issues.	  	  
Multimodality	  Imaging	  	  Each	  imaging	  modality	  has	  its	  own	  advantages	  and	  limitations	  and	  no	  single	  modality	  can	  adequately	  provide	  all	  the	  information	  required	  to	  guide	  revascularisation.	  There	  is	  increasing	  interest	  in	  combining	  modalities	  to	  achieve	  even	  better	  results217.	  This	  can	  involve	  simultaneous	  dual	  modality	  imaging	  in	  hybrid	  scanners	  or	  sequential	  multimodality	  imaging	  with	  or	  without	  retrospective	  image	  fusion	  as	  described	  in	  chapter	  9.	  This	  approach	  has	  been	  successfully	  applied	  in	  the	  field	  of	  oncology	  where	  images	  from	  different	  modalities	  are	  fused	  for	  the	  diagnosis	  and	  staging	  of	  cancers.	  There	  has	  been	  some	  early	  limited	  success	  in	  the	  application	  of	  this	  approach	  to	  cardiac	  imaging.	  For	  example	  PET	  perfusion	  imaging	  and	  CT	  angiography	  have	  been	  successfully	  combined	  in	  a	  hybrid	  scanner	  to	  improve	  detection	  of	  flow-­‐limiting	  CAD218.	  The	  possibility	  of	  combining	  CMR	  with	  CT,	  for	  example,	  is	  also	  an	  appealing	  prospect	  and	  an	  area	  of	  current	  research.	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Conclusions	  In	  patients	  with	  CAD	  decisions	  regarding	  revascularization	  are	  central	  to	  patient	  management	  as	  revascularisation	  can	  improve	  both	  symptoms	  and	  prognosis	  in	  certain	  sub-­‐groups	  of	  patients.	  From	  the	  available	  evidence,	  it	  is	  clear	  that	  information	  on	  coronary	  anatomy	  alone	  is	  often	  insufficient	  to	  make	  this	  decision,	  and	  it	  is	  crucial	  to	  know	  also	  about	  myocardial	  ischaemia	  and	  viability.	  CMR	  can	  already	  provide	  much	  of	  the	  relevant	  functional	  information	  to	  guide	  revascularisation.	  However	  CMR	  techniques	  and	  clinical	  practice	  continue	  to	  evolve	  and	  some	  of	  these	  changes	  will	  ultimately	  result	  in	  improved	  patient	  and	  lesion	  selection.	  Quantitative	  analysis	  of	  perfusion	  is	  an	  exciting	  prospect	  with	  great	  potential	  and	  has	  demonstrated	  clinically	  utility,	  however	  its	  application	  remains	  challenging.	  Novel	  scar	  and	  strain	  imaging	  techniques	  with	  the	  potential	  to	  guide	  revascularisation	  have	  also	  shown	  promising	  results.	  Further	  method	  refinement	  and	  subsequent	  clinical	  studies	  will	  allow	  the	  full	  potential	  of	  these	  tools	  to	  be	  realised	  and	  consolidate	  the	  role	  of	  CMR	  at	  the	  forefront	  of	  guiding	  coronary	  revascularisation.	  	  	   	  
  258 
References	  
1.	   WorldHealthOrganization.	  http://www.Who.Int/mediacentre/factsheets/fs310/en/index.Html.	  
2008	  
2.	   BritishHeartFoundation.	  Http://www.Bhf.Org.Uk/heart-­‐health/statistics/mortality.Aspx.	  2011	  
3.	   Gould	  KL,	  Lipscomb	  K,	  Hamilton	  GW.	  Physiologic	  basis	  for	  assessing	  critical	  
coronary	  stenosis.	  Instantaneous	  flow	  response	  and	  regional	  distribution	  
during	  coronary	  hyperemia	  as	  measures	  of	  coronary	  flow	  reserve.	  The	  
American	  Journal	  of	  Cardiology.	  1974;33:87-­‐94	  
4.	   White	  CW,	  Wright	  CB,	  Doty	  DB,	  Hiratza	  LF,	  Eastham	  CL,	  Harrison	  DG,	  
Marcus	  ML.	  Does	  visual	  interpretation	  of	  the	  coronary	  arteriogram	  predict	  
the	  physiologic	  importance	  of	  a	  coronary	  stenosis?	  N	  Engl	  J	  Med.	  
1984;310:819-­‐824	  
5.	   Meijboom	  WB,	  Van	  Mieghem	  CAG,	  van	  Pelt	  N,	  Weustink	  A,	  Pugliese	  F,	  
Mollet	  NR,	  Boersma	  E,	  Regar	  E,	  van	  Geuns	  RJ,	  de	  Jaegere	  PJ,	  Serruys	  PW,	  
Krestin	  GP,	  de	  Feyter	  PJ.	  Comprehensive	  assessment	  of	  coronary	  artery	  
stenoses:	  Computed	  tomography	  coronary	  angiography	  versus	  
conventional	  coronary	  angiography	  and	  correlation	  with	  fractional	  flow	  
reserve	  in	  patients	  with	  stable	  angina.	  Journal	  of	  the	  American	  College	  of	  
Cardiology.	  2008;52:636-­‐643	  
6.	   Silber	  S,	  Albertsson	  P,	  Avilés	  FF,	  Camici	  PG,	  Colombo	  A,	  Hamm	  C,	  Jørgensen	  
E,	  Marco	  J,	  Nordrehaug	  JE,	  Ruzyllo	  W,	  Urban	  P,	  Stone	  GW,	  Wijns	  W.	  
Guidelines	  for	  percutaneous	  coronary	  interventions.	  The	  task	  force	  for	  
  259 
percutaneous	  coronary	  interventions	  of	  the	  european	  society	  of	  cardiology.	  
Eur	  Heart	  J.	  2005;26:804-­‐847	  
7.	   Serruys	  PW,	  Morice	  MC,	  Kappetein	  AP,	  Colombo	  A,	  Holmes	  DR,	  Mack	  MJ,	  
Ståhle	  E,	  Feldman	  TE,	  van	  den	  Brand	  M,	  Bass	  EJ,	  Van	  Dyck	  N,	  Leadley	  K,	  
Dawkins	  KD,	  Mohr	  FW.	  Percutaneous	  coronary	  intervention	  versus	  
coronary-­‐artery	  bypass	  grafting	  for	  severe	  coronary	  artery	  disease.	  N	  Engl	  
J	  Med.	  2009	  
8.	   Yusuf	  S,	  Zucker	  D,	  Peduzzi	  P,	  Fisher	  LD,	  Takaro	  T,	  Kennedy	  JW,	  Davis	  K,	  
Killip	  T,	  Passamani	  E,	  Norris	  R.	  Effect	  of	  coronary	  artery	  bypass	  graft	  
surgery	  on	  survival:	  Overview	  of	  10-­‐year	  results	  from	  randomised	  trials	  by	  
the	  coronary	  artery	  bypass	  graft	  surgery	  trialists	  collaboration.	  Lancet.	  
1994;344:563-­‐570	  
9.	   Mark	  DB,	  Shaw	  L,	  Harrell	  FE,	  Jr.,	  Hlatky	  MA,	  Lee	  KL,	  Bengtson	  JR,	  McCants	  
CB,	  Califf	  RM,	  Pryor	  DB.	  Prognostic	  value	  of	  a	  treadmill	  exercise	  score	  in	  
outpatients	  with	  suspected	  coronary	  artery	  disease.	  N	  Engl	  J	  Med.	  
1991;325:849-­‐853	  
10.	   Shaw	  L.	  Prognostic	  value	  of	  gated	  myocardial	  perfusion	  spect.	  Journal	  of	  
Nuclear	  Cardiology.	  2004;11:171-­‐185	  
11.	   Sicari	  R,	  Pasanisi	  E,	  Venneri	  L,	  Landi	  P,	  Cortigiani	  L,	  Picano	  E.	  Stress	  echo	  
results	  predict	  mortality:	  A	  large-­‐scale	  multicenter	  prospective	  
international	  study.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2003;41:589-­‐595	  
12.	   Jahnke	  C,	  Nagel	  E,	  Gebker	  R,	  Kokocinski	  T,	  Kelle	  S,	  Manka	  R,	  Fleck	  E,	  
Paetsch	  I.	  Prognostic	  value	  of	  cardiac	  magnetic	  resonance	  stress	  tests:	  
  260 
Adenosine	  stress	  perfusion	  and	  dobutamine	  stress	  wall	  motion	  imaging.	  
Circulation.	  2007;115:1769-­‐1776	  
13.	   Hachamovitch	  R,	  Kang	  X,	  Amanullah	  A,	  Abidov	  A,	  Hayes	  S,	  Friedman	  J,	  
Cohen,	  Thomson	  L,	  Germano	  G,	  Berman	  D.	  Comparison	  of	  the	  short-­‐term	  
survival	  benefit	  associated	  with	  revascularization	  compared	  with	  medical	  
therapy	  in	  patients	  with	  no	  prior	  coronary	  artery	  disease	  undergoing	  
stress	  myocardial	  perfusion	  single	  photon	  emission	  computed	  tomography.	  
Circulation.	  2003;107:2900-­‐2907	  
14.	   Davies	  RF,	  Goldberg	  AD,	  Forman	  S,	  Pepine	  CJ,	  Knatterud	  GL,	  Geller	  N,	  
Sopko	  G,	  Pratt	  C,	  Deanfield	  J,	  Conti	  CR.	  Asymptomatic	  cardiac	  ischemia	  
pilot	  (ACIP)	  study	  two-­‐year	  follow-­‐up:	  Outcomes	  of	  patients	  randomized	  to	  
initial	  strategies	  of	  medical	  therapy	  versus	  revascularization.	  Circulation.	  
1997;95:2037-­‐2043	  
15.	   Erne	  P,	  Schoenenberger	  A,	  Burckhardt	  D,	  Zuber	  M,	  Kiowski	  W,	  Buser	  P,	  
Dubach	  P,	  Resink	  T,	  Pfisterer	  M.	  Effects	  of	  percutaneous	  coronary	  
interventions	  in	  silent	  ischemia	  after	  myocardial	  infarction:	  The	  SWISSI	  II	  
randomized	  controlled	  trial.	  JAMA:	  The	  Journal	  of	  the	  American	  Medical	  
Association.	  2007;297:1985-­‐1991	  
16.	   Boden	  WE,	  O'Rourke	  RA,	  Teo	  KK,	  Hartigan	  PM,	  Maron	  DJ,	  Kostuk	  WJ,	  
Knudtson	  M,	  Dada	  M,	  Casperson	  P,	  Harris	  CL,	  Chaitman	  BR,	  Shaw	  L,	  
Gosselin	  G,	  Nawaz	  S,	  Title	  LM,	  Gau	  G,	  Blaustein	  AS,	  Booth	  DC,	  Bates	  ER,	  
Spertus	  JA,	  Berman	  DS,	  Mancini	  GB,	  Weintraub	  WS,	  Group	  CTR.	  Optimal	  
medical	  therapy	  with	  or	  without	  PCI	  for	  stable	  coronary	  disease.	  N	  Engl	  J	  
Med.	  2007;356:1503-­‐1516	  
  261 
17.	   Shaw	  L,	  Berman	  D,	  Maron	  D,	  Mancini	  G,	  Hayes	  S,	  Hartigan	  P,	  Weintraub	  W,	  
O'rourke	  R,	  Dada	  M,	  Spertus	  J,	  Chaitman	  B,	  Friedman	  J,	  Slomka	  P,	  Heller	  G,	  
Germano	  G,	  Gosselin	  G,	  Berger	  P,	  Kostuk	  W,	  Schwartz	  R,	  Knudtson	  M,	  
Veledar	  E,	  Bates	  E,	  Mccallister	  B,	  Teo	  K,	  Boden	  W.	  Optimal	  medical	  therapy	  
with	  or	  without	  percutaneous	  coronary	  intervention	  to	  reduce	  ischemic	  
burden:	  Results	  from	  the	  clinical	  outcomes	  utilizing	  revascularization	  and	  
aggressive	  drug	  evaluation	  (COURAGE)	  trial	  nuclear	  substudy.	  Circulation.	  
2008;117:1283-­‐1291	  
18.	   van	  den	  Brand	  MJ,	  Rensing	  BJ,	  Morel	  MA,	  Foley	  DP,	  de	  Valk	  V,	  Breeman	  A,	  
Suryapranata	  H,	  Haalebos	  MM,	  Wijns	  W,	  Wellens	  F,	  Balcon	  R,	  Magee	  P,	  
Ribeiro	  E,	  Buffolo	  E,	  Unger	  F,	  Serruys	  PW.	  The	  effect	  of	  completeness	  of	  
revascularization	  on	  event-­‐free	  survival	  at	  one	  year	  in	  the	  arts	  trial.	  
Journal	  of	  the	  American	  College	  of	  Cardiology.	  2002;39:559-­‐564	  
19.	   Hannan	  E.	  Racz	  M,	  Holmes	  DR,	  King,	  III	  SB,	  Walford	  G,	  Ambrose	  JA,	  Sharma	  
S,	  Katz	  S,	  Clark	  LT,	  Jones	  RH.Impact	  of	  completeness	  of	  percutaneous	  
coronary	  intervention	  revascularization	  on	  long-­‐term	  outcomes	  in	  the	  
stent	  era.	  Circulation.	  2006;113:2406-­‐2412	  
20.	   Pijls	  NH,	  van	  Schaardenburgh	  P,	  Manoharan	  G,	  Boersma	  E,	  Bech	  JW,	  van't	  
Veer	  M,	  Bär	  F,	  Hoorntje	  J,	  Koolen	  J,	  Wijns	  W,	  De	  Bruyne	  B.	  Percutaneous	  
coronary	  intervention	  of	  functionally	  nonsignificant	  stenosis:	  5-­‐year	  
follow-­‐up	  of	  the	  DEFER	  study.	  Journal	  of	  the	  American	  College	  of	  
Cardiology.	  2007;49:2105-­‐2111	  
21.	   Tonino	  PA,	  De	  Bruyne	  B,	  Pijls	  NH,	  Siebert	  U,	  Ikeno	  F,	  van'	  t	  	  Veer	  M,	  Klauss	  
V,	  Manoharan	  G,	  Engstrøm	  T,	  Oldroyd	  KG,	  Ver	  Lee	  PN,	  MacCarthy	  PA,	  
  262 
Fearon	  WF,	  Investigators	  FS.	  Fractional	  flow	  reserve	  versus	  angiography	  
for	  guiding	  percutaneous	  coronary	  intervention.	  N	  Engl	  J	  Med.	  
2009;360:213-­‐224	  
22.	   De	  Bruyne	  B,	  Pijls	  NH,	  Kalesan	  B,	  Barbato	  E,	  Tonino	  PA,	  Piroth	  Z,	  Jagic	  N,	  
Mobius-­‐Winckler	  S,	  Rioufol	  G,	  Witt	  N,	  Kala	  P,	  Maccarthy	  P,	  Engström	  T,	  
Oldroyd	  KG,	  Mavromatis	  K,	  Manoharan	  G,	  Verlee	  P,	  Frobert	  O,	  Curzen	  N,	  
Johnson	  JB,	  Jüni	  P,	  Fearon	  WF.	  Fractional	  Flow	  Reserve-­‐Guided	  PCI	  versus	  
Medical	  Therapy	  in	  Stable	  Coronary	  Disease..	  N	  Engl	  J	  Med	  2012;367:991-­‐
1001.	  	  
23.	   Barner	  H.	  Operative	  treatment	  of	  coronary	  atherosclerosis.	  The	  Annals	  of	  
Thoracic	  Surgery.	  2008;85:1473-­‐1482	  
24.	   Sharir	  T,	  Germano	  G,	  Kang	  X,	  Lewin	  HC,	  Miranda	  R,	  Cohen	  I,	  Agafitei	  RD,	  
Friedman	  JD,	  Berman	  DS.	  Prediction	  of	  myocardial	  infarction	  versus	  
cardiac	  death	  by	  gated	  myocardial	  perfusion	  spect:	  Risk	  stratification	  by	  
the	  amount	  of	  stress-­‐induced	  ischemia	  and	  the	  poststress	  ejection	  fraction.	  
Journal	  of	  Nuclear	  Medicine.	  2001;42:831-­‐837	  
25.	   Bax	  JJ,	  van	  der	  Wall	  EE,	  Harbinson	  M.	  Radionuclide	  techniques	  for	  the	  
assessment	  of	  myocardial	  viability	  and	  hibernation.	  Heart.	  2004;90	  Suppl	  
5:v26-­‐33	  
26.	   Allman	  KC,	  Shaw	  LJ,	  Hachamovitch	  R,	  Udelson	  JE.	  Myocardial	  viability	  
testing	  and	  impact	  of	  revascularization	  on	  prognosis	  in	  patients	  with	  
coronary	  artery	  disease	  and	  left	  ventricular	  dysfunction:	  A	  meta-­‐analysis.	  
Journal	  of	  the	  American	  College	  of	  Cardiology.	  2002;39:1151-­‐1158	  
27.	   Bonow	  RO,	  Maurer	  G,	  Lee	  KL,	  Holly	  TA,	  Binkley	  PF,	  Desvigne-­‐Nickens	  P,	  
Drozdz	  J,	  Farsky	  PS,	  Feldman	  AM,	  Doenst	  T,	  Michler	  RE,	  Berman	  DS,	  
  263 
Nicolau	  JC,	  Pellikka	  PA,	  Wrobel	  K,	  Alotti	  N,	  Asch	  FM,	  Favaloro	  LE,	  She	  L,	  
Velazquez	  EJ,	  Jones	  RH,	  Panza	  JA,	  Investigators	  ST.	  Myocardial	  viability	  
and	  survival	  in	  ischemic	  left	  ventricular	  dysfunction.	  N	  Engl	  J	  Med.	  
2011;364:1617-­‐1625	  
28.	   Nesto	  RW,	  Kowalchuk	  GJ.	  The	  ischemic	  cascade:	  Temporal	  sequence	  of	  
hemodynamic,	  electrocardiographic	  and	  symptomatic	  expressions	  of	  
ischemia.	  The	  American	  Journal	  of	  Cardiology.	  1987;59:23C-­‐30C	  
29.	   Leong-­‐Poi	  H,	  Rim	  S,	  Le	  DE,	  Fisher	  NG,	  Wei	  K,	  Kaul	  S.Perfusion	  versus	  
function:	  The	  ischemic	  cascade	  in	  demand	  ischemia:	  Implications	  of	  single-­‐
vessel	  versus	  multivessel	  stenosis.	  Circulation.	  2002;105:987-­‐992	  
30.	   Nagel	  E,	  Lehmkuhl	  HB,	  Bocksch	  W,	  Klein	  C,	  Vogel	  U,	  Frantz	  E,	  Ellmer	  A,	  
Dreysse	  S,	  Fleck	  E.	  Noninvasive	  diagnosis	  of	  ischemia-­‐induced	  wall	  motion	  
abnormalities	  with	  the	  use	  of	  high-­‐dose	  dobutamine	  stress	  mri:	  
Comparison	  with	  dobutamine	  stress	  echocardiography.	  Circulation.	  
1999;99:763-­‐770	  
31.	   Nandalur	  KR,	  Dwamena	  BA,	  Choudhri	  AF,	  Nandalur	  MR,	  Carlos	  RC.	  
Diagnostic	  performance	  of	  stress	  cardiac	  magnetic	  resonance	  imaging	  in	  
the	  detection	  of	  coronary	  artery	  disease:	  A	  meta-­‐analysis.	  Journal	  of	  the	  
American	  College	  of	  Cardiology.	  2007;50:1343-­‐1353	  
32.	   Wahl	  A,	  Paetsch	  I,	  Gollesch	  A,	  Roethemeyer	  S,	  Foell	  D,	  Gebker	  R,	  Langreck	  H,	  
Klein	  C,	  Fleck	  E,	  Nagel	  E.	  Safety	  and	  feasibility	  of	  high-­‐dose	  dobutamine-­‐
atropine	  stress	  cardiovascular	  magnetic	  resonance	  for	  diagnosis	  of	  
myocardial	  ischaemia:	  Experience	  in	  1000	  consecutive	  cases.	  Eur	  Heart	  J.	  
2004;25:1230-­‐1236	  
  264 
33.	   Lurz	  P,	  Muthurangu	  V,	  Schievano	  S,	  Nordmeyer	  J,	  Bonhoeffer	  P,	  Taylor	  AM,	  
Hansen	  MS.	  Feasibility	  and	  reproducibility	  of	  biventricular	  volumetric	  
assessment	  of	  cardiac	  function	  during	  exercise	  using	  real-­‐time	  radial	  k-­‐t	  
sense	  magnetic	  resonance	  imaging.	  J.	  Magn.	  Reson.	  Imaging.2009;29:1062-­‐
1070	  
34.	   Schalla	  S,	  Nagel	  E,	  Lehmkuhl	  H,	  Klein	  C,	  Bornstedt	  A,	  Schnackenburg	  B,	  
Schneider	  U,	  Fleck	  E.	  Comparison	  of	  magnetic	  resonance	  real-­‐time	  imaging	  
of	  left	  ventricular	  function	  with	  conventional	  magnetic	  resonance	  imaging	  
and	  echocardiography.	  The	  American	  Journal	  of	  Cardiology.	  2001;87:95-­‐
99	  
35.	   Camici	  PG,	  Rimoldi	  OE.	  The	  clinical	  value	  of	  myocardial	  blood	  flow	  
measurement.	  Journal	  of	  Nuclear	  Medicine.	  2009;50:1076-­‐1087	  
36.	   Camici	  PG,	  Crea	  F.	  Coronary	  microvascular	  dysfunction.	  N	  Engl	  J	  Med.	  
2007;356:830-­‐840	  
37.	   Algranati	  D,	  Kassab	  GS,	  Lanir	  Y.	  Why	  is	  the	  subendocardium	  more	  
vulnerable	  to	  ischemia?	  A	  new	  paradigm.	  Am	  J	  Physiol	  Heart	  Circ	  Physiol.	  
2011;300:H1090-­‐1100	  
38.	   Toyota	  E,	  Ogasawara	  Y,	  Hiramatsu	  O,	  Tachibana	  H,	  Kajiya	  F,	  Yamamori	  S	  
Chilian	  WM.	  Dynamics	  of	  flow	  velocities	  in	  endocardial	  and	  epicardial	  
coronary	  arterioles.	  AJP:	  Heart	  and	  Circulatory	  Physiology.	  
2004;288:H1598-­‐H1603	  
39.	   Cerqueira	  MD,	  Nguyen	  P,	  Staehr	  P,	  Underwood	  SR,	  Iskandrian	  AE,	  
Investigators	  A-­‐MT.	  Effects	  of	  age,	  gender,	  obesity,	  and	  diabetes	  on	  the	  
efficacy	  and	  safety	  of	  the	  selective	  A2A	  agonist	  regadenoson	  versus	  
  265 
adenosine	  in	  myocardial	  perfusion	  imaging	  integrated	  advance-­‐MPI	  trial	  
results.	  JACC	  Cardiovasc	  Imaging.	  2008;1:307-­‐316	  
40.	   Robinson	  PJ.	  Radiology's	  achilles'	  heel:	  Error	  and	  variation	  in	  the	  
interpretation	  of	  the	  röntgen	  image.	  Br	  J	  Radiol.	  1997;70:1085-­‐1098	  
41.	   Ghosh	  N,	  Rimoldi	  OE,	  Beanlands	  RSB,	  Camici	  PG.	  Assessment	  of	  myocardial	  
ischaemia	  and	  viability:	  Role	  of	  positron	  emission	  tomography.	  Eur	  Heart	  J.	  
2010;31:2984-­‐2995	  
42.	   Uren	  NG,	  Melin	  JA,	  De	  Bruyne	  B,	  Wijns	  W,	  Baudhuin	  T,	  Camici	  PG.	  Relation	  
between	  myocardial	  blood	  flow	  and	  the	  severity	  of	  coronary-­‐artery	  
stenosis.	  N	  Engl	  J	  Med.	  1994;330:1782-­‐1788	  
43.	   Di	  Carli	  M,	  Czernin	  J,	  Hoh	  CK,	  Gerbaudo	  VH,	  Brunken	  RC,	  Huang	  SC,	  Phelps	  
ME,	  Schelbert	  HR.	  Relation	  among	  stenosis	  severity,	  myocardial	  blood	  flow,	  
and	  flow	  reserve	  in	  patients	  with	  coronary	  artery	  disease.	  Circulation.	  
1995;91:1944-­‐1951	  
44.	   Herzog	  BA,	  Husmann	  L,	  Valenta	  I,	  Gaemperli	  O,	  Siegrist	  PT,	  Tay	  FM,	  
Burkhard	  N,	  Wyss	  CA,	  Kaufmann	  PA.	  Long-­‐term	  prognostic	  value	  of	  13N-­‐
ammonia	  myocardial	  perfusion	  positron	  emission	  tomography	  added	  
value	  of	  coronary	  flow	  reserve.	  Journal	  of	  the	  American	  College	  of	  
Cardiology.	  2009;54:150-­‐156	  
45.	   Tio	  RA,	  Dabeshlim	  A,	  Siebelink	  H-­‐MJ,	  de	  Sutter	  J,	  Hillege	  HL,	  Zeebregts	  CJ,	  
Dierckx	  RAJO,	  van	  Veldhuisen	  DJ,	  Zijlstra	  F,	  Slart	  RHJA.	  Comparison	  
between	  the	  prognostic	  value	  of	  left	  ventricular	  function	  and	  myocardial	  
perfusion	  reserve	  in	  patients	  with	  ischemic	  heart	  disease.	  J	  Nucl	  Med.	  
2009;50:214-­‐219	  
  266 
46.	   Vogel	  R,	  Indermuhle	  A,	  Seiler	  C.	  Determination	  of	  the	  absolute	  perfusion	  
threshold	  preventing	  myocardial	  ischaemia	  in	  humans.	  Heart.	  
2007;93:115-­‐116	  
47.	   Fox	  K,	  Garcia	  MAA,	  Ardissino	  D,	  Buszman	  P,	  Camici	  PG,	  Crea	  F,	  Daly	  C,	  De	  
Backer	  G,	  Hjemdahl	  P,	  Lopez-­‐Sendon	  J,	  Marco	  J,	  Morais	  J,	  Pepper	  J,	  Sechtem	  
U,	  Simoons	  M,	  Thygesen	  K,	  Priori	  SG,	  Blanc	  J-­‐J,	  Budaj	  A,	  Camm	  J,	  Dean	  V,	  
Deckers	  J,	  Dickstein	  K,	  Lekakis	  J,	  McGregor	  K,	  Metra	  M,	  Morais	  J,	  Osterspey	  
A,	  Tamargo	  J,	  Zamorano	  JL.	  Guidelines	  on	  the	  management	  of	  stable	  
angina	  pectoris:	  Executive	  summary:	  The	  task	  force	  on	  the	  management	  of	  
stable	  angina	  pectoris	  of	  the	  european	  society	  of	  cardiology.	  Eur	  Heart	  J.	  
2006;27:1341-­‐1381	  
48.	   Wagner	  A,	  Mahrholdt	  H,	  Holly	  TA,	  Elliott	  MD,	  Regenfus	  M,	  Parker	  M,	  
Klocke	  FJ,	  Bonow	  RO,	  Kim	  RJ,	  Judd	  RM.	  Contrast-­‐enhanced	  MRI	  and	  routine	  
single	  photon	  emission	  computed	  tomography	  (SPECT)	  perfusion	  imaging	  
for	  detection	  of	  subendocardial	  myocardial	  infarcts:	  An	  imaging	  study.	  
Lancet.	  2003;361:374-­‐379	  
49.	   Lee	  DC,	  Simonetti	  OP,	  Harris	  KR,	  Holly	  TA,	  Judd	  RM,	  Wu	  E,	  Klocke	  FJ.	  
Magnetic	  resonance	  versus	  radionuclide	  pharmacological	  stress	  perfusion	  
imaging	  for	  flow-­‐limiting	  stenoses	  of	  varying	  severity.	  Circulation.	  
2004;110:58-­‐65	  
50.	   Nandalur	  KR,	  Dwamena	  BA,	  Choudhri	  AF,	  Nandalur	  SR,	  Reddy	  P,	  Carlos	  RC.	  
Diagnostic	  performance	  of	  positron	  emission	  tomography	  in	  the	  detection	  
of	  coronary	  artery	  disease:	  A	  meta-­‐analysis.	  Acad	  Radiol.	  2008;15:444-­‐451	  
  267 
51.	   Manabe	  O,	  Yoshinaga	  K,	  Katoh	  C,	  Naya	  M,	  deKemp	  RA,	  Tamaki	  N.	  
Repeatability	  of	  rest	  and	  hyperemic	  myocardial	  blood	  flow	  measurements	  
with	  82Rb	  dynamic	  pet.	  Journal	  of	  Nuclear	  Medicine.	  2009;50:68-­‐71	  
52.	   Marwick	  TH,	  Shan	  K,	  Patel	  S,	  Go	  RT,	  Lauer	  MS.	  Incremental	  value	  of	  
rubidium-­‐82	  positron	  emission	  tomography	  for	  prognostic	  assessment	  of	  
known	  or	  suspected	  coronary	  artery	  disease.	  The	  American	  Journal	  of	  
Cardiology.	  1997;80:865-­‐870	  
53.	   Dorbala	  S,	  Hachamovitch	  R,	  Curillova	  Z,	  Thomas	  D,	  Vangala	  D,	  Kwong	  RY,	  
Di	  Carli	  MF.	  Incremental	  prognostic	  value	  of	  gated	  Rb-­‐82	  positron	  
emission	  tomography	  myocardial	  perfusion	  imaging	  over	  clinical	  variables	  
and	  rest	  LVEF.	  JACC	  Cardiovascular	  Imaging.	  2009;2:846-­‐854	  
54.	   Bhatia	  VK,	  Senior	  R.	  Contrast	  echocardiography:	  Evidence	  for	  clinical	  use.	  J	  
Am	  Soc	  Echocardiogr.	  2008;21:409-­‐416	  
55.	   Tsutsui	  JM,	  Elhendy	  A,	  Anderson	  J,	  Xie	  F,	  McGrain	  AC,	  TR	  Porter.	  
Prognostic	  value	  of	  dobutamine	  stress	  myocardial	  contrast	  perfusion	  
echocardiography.	  Circulation.	  2005;112:1444-­‐1450	  
56.	   Raman	  SV,	  Shah	  M,	  McCarthy	  B,	  Garcia	  A,	  Ferketich	  AK.	  Multi-­‐detector	  row	  
cardiac	  computed	  tomography	  accurately	  quantifies	  right	  and	  left	  
ventricular	  size	  and	  function	  compared	  with	  cardiac	  magnetic	  resonance.	  
American	  Heart	  Journal.	  2006;151:736-­‐744	  
57.	   Blankstein	  R,	  Shturman	  LD,	  Rogers	  IS,	  Rocha-­‐Filho	  JA,	  Okada	  DR,	  Sarwar	  A,	  
Soni	  AV,	  Bezerra	  H,	  Ghoshhajra	  BB,	  Petranovic	  M,	  Loureiro	  R,	  Feuchtner	  G,	  
Gewirtz	  H,	  Hoffmann	  U,	  Mamuya	  WS,	  Brady	  TJ,	  Cury	  RC.	  Adenosine-­‐
induced	  stress	  myocardial	  perfusion	  imaging	  using	  dual-­‐source	  cardiac	  
  268 
computed	  tomography.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2009;54:1072-­‐1084	  
58.	   Kido	  T,	  Kurata	  A,	  Higashino	  H,	  Inoue	  Y,	  Kanza	  RE,	  Okayama	  H,	  Higaki	  J,	  
Murase	  K,	  Mochizuki	  T.	  Quantification	  of	  regional	  myocardial	  blood	  flow	  
using	  first-­‐pass	  multidetector-­‐row	  computed	  tomography	  and	  adenosine	  
triphosphate	  in	  coronary	  artery	  disease.	  Circ	  J.	  2008;72:1086-­‐1091	  
59.	   George	  RT,	  Silva	  C,	  Cordeiro	  MAS,	  Dipaula	  A,	  Thompson	  DR,	  Mccarthy	  WF,	  
Ichihara	  T,	  Lima	  JAC,	  Lardo	  AC.	  Multidetector	  computed	  tomography	  
myocardial	  perfusion	  imaging	  during	  adenosine	  stress.	  Journal	  of	  the	  
American	  College	  of	  Cardiology.	  2006;48:153-­‐160	  
60.	   Cury	  RC,	  Magalhães	  TA,	  Borges	  AC,	  Shiozaki	  AA,	  Lemos	  PA,	  Júnior	  JS,	  
Meneghetti	  JC,	  Cury	  RC,	  Rochitte	  CE.	  Dipyridamole	  stress	  and	  rest	  
myocardial	  perfusion	  by	  64-­‐detector	  row	  computed	  tomography	  in	  
patients	  with	  suspected	  coronary	  artery	  disease.	  The	  American	  Journal	  of	  
Cardiology.	  2010;106:310-­‐315	  
61.	   Ko	  SM,	  Choi	  JW,	  Song	  MG,	  Shin	  JK,	  Chee	  HK,	  Chung	  HW,	  Kim	  DH.	  
Myocardial	  perfusion	  imaging	  using	  adenosine-­‐induced	  stress	  dual-­‐energy	  
computed	  tomography	  of	  the	  heart:	  Comparison	  with	  cardiac	  magnetic	  
resonance	  imaging	  and	  conventional	  coronary	  angiography.	  Eur	  Radiol.	  
2011;21:26-­‐35	  
62.	   Einstein	  AJ,	  Moser	  KW,	  Thompson	  RC,	  Cerqueira	  MD,	  Henzlova	  MJ.	  
Radiation	  dose	  to	  patients	  from	  cardiac	  diagnostic	  imaging.	  Circulation.	  
2007;116:1290-­‐1305	  
63.	   Salerno	  M,	  Beller	  GA.	  Noninvasive	  assessment	  of	  myocardial	  perfusion.	  
Circulation:	  Cardiovascular	  Imaging.	  2009;2:412-­‐424	  
  269 
64.	   Wyrick	  JJ,	  Kalvaitis	  S,	  Mcconnell	  KJ,	  Rinkevich	  D,	  Kaul	  S,	  Wei	  K.	  Cost-­‐
efficiency	  of	  myocardial	  contrast	  echocardiography	  in	  patients	  presenting	  
to	  the	  emergency	  department	  with	  chest	  pain	  of	  suspected	  cardiac	  origin	  
and	  a	  nondiagnostic	  electrocardiogram.	  The	  American	  Journal	  of	  
Cardiology.	  2008;102:649-­‐652	  
65.	   Schwitter	  J,	  Wacker	  CM,	  van	  Rossum	  AC,	  Lombardi	  M,	  Al-­‐Saadi	  N,	  Ahlstrom	  
H,	  Dill	  T,	  Larsson	  HB,	  Flamm	  SD,	  Marquardt	  M,	  Johansson	  L.	  MR-­‐IMPACT:	  
Comparison	  of	  perfusion-­‐cardiac	  magnetic	  resonance	  with	  single-­‐photon	  
emission	  computed	  tomography	  for	  the	  detection	  of	  coronary	  artery	  
disease	  in	  a	  multicentre,	  multivendor,	  randomized	  trial.	  Eur	  Heart	  J.	  
2008;29:480-­‐489	  
66.	   Greenwood	  JP,	  Maredia	  N,	  Younger	  JF,	  Brown	  JM,	  Nixon	  J,	  Everett	  CC,	  
Bijsterveld	  P,	  Ridgway	  JP,	  Radjenovic	  A,	  Dickinson	  CJ,	  Ball	  SG,	  Plein	  S.	  
Cardiovascular	  magnetic	  resonance	  and	  single-­‐photon	  emission	  computed	  
tomography	  for	  diagnosis	  of	  coronary	  heart	  disease	  (CE-­‐MARC):	  A	  
prospective	  trial.	  Lancet.	  2012;379:453-­‐460	  
67.	   Rieber	  J,	  Huber	  A,	  Erhard	  I,	  Mueller	  S,	  Schweyer	  M,	  Koenig	  A,	  Schiele	  TM,	  
Theisen	  K,	  Siebert	  U,	  Schoenberg	  SO,	  Reiser	  M,	  Klauss	  V.	  Cardiac	  magnetic	  
resonance	  perfusion	  imaging	  for	  the	  functional	  assessment	  of	  coronary	  
artery	  disease:	  A	  comparison	  with	  coronary	  angiography	  and	  fractional	  
flow	  reserve.	  Eur	  Heart	  J.	  2006;27:1465-­‐1471	  
68.	   Costa	  MA,	  Shoemaker	  S,	  Futamatsu	  H,	  Klassen	  C,	  Angiolillo	  DJ,	  Nguyen	  M,	  
Siuciak	  A,	  Gilmore	  P,	  Zenni	  MM,	  Guzman	  L,	  Bass	  TA,	  Wilke	  N.	  Quantitative	  
magnetic	  resonance	  perfusion	  imaging	  detects	  anatomic	  and	  physiologic	  
coronary	  artery	  disease	  as	  measured	  by	  coronary	  angiography	  and	  
  270 
fractional	  flow	  reserve.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2007;50:514-­‐522	  
69.	   Watkins	  S,	  Mcgeoch	  R,	  Lyne	  J,	  Steedman	  T,	  Good	  R,	  Mclaughlin	  M-­‐J,	  
Cunningham	  T,	  Bezlyak	  V,	  Ford	  I,	  Dargie	  HJ,	  Oldroyd	  KG.	  Validation	  of	  
magnetic	  resonance	  myocardial	  perfusion	  imaging	  with	  fractional	  flow	  
reserve	  for	  the	  detection	  of	  significant	  coronary	  heart	  disease.	  Circulation.	  
2009;120:2207-­‐2213	  
70.	   Kraitchman	  DL,	  Wilke	  N,	  Hexeberg	  E,	  Jerosch-­‐Herold	  M,	  Wang	  Y,	  Parrish	  
TB,	  Chang	  CN,	  Zhang	  Y,	  Bache	  RJ,	  Axel	  L.	  Myocardial	  perfusion	  and	  
function	  in	  dogs	  with	  moderate	  coronary	  stenosis.	  Magn	  Reson	  Med.	  
1996;35:771-­‐780	  
71.	   Klocke	  FJ,	  Simonetti	  OP,	  Judd	  RM,	  Kim	  RJ,	  Harris	  KR,	  Hedjbeli	  S,	  Fieno	  DS,	  
Miller	  S,	  Chen	  V,	  Parker	  MA.	  Limits	  of	  detection	  of	  regional	  differences	  in	  
vasodilated	  flow	  in	  viable	  myocardium	  by	  first-­‐pass	  magnetic	  resonance	  
perfusion	  imaging.	  Circulation.	  2001;104:2412-­‐2416	  
72.	   Nagel	  E,	  Klein	  C,	  Paetsch	  I,	  Hettwer	  S,	  Schnackenburg	  B,	  Wegscheider	  K,	  
Fleck	  E.	  Magnetic	  resonance	  perfusion	  measurements	  for	  the	  noninvasive	  
detection	  of	  coronary	  artery	  disease.	  Circulation.	  2003;108:432-­‐437	  
73.	   Ishida	  M,	  Sakuma	  H,	  Murashima	  S,	  Nishida	  J,	  Senga	  M,	  Kobayasi	  S,	  Takeda	  
K,	  Kato	  N.	  Absolute	  blood	  contrast	  concentration	  and	  blood	  signal	  
saturation	  on	  myocardial	  perfusion	  MRI:	  Estimation	  from	  CT	  data.	  J.	  Magn.	  
Reson.	  Imaging.	  2009;29:205-­‐210	  
74.	   Jerosch-­‐Herold	  M,	  Wilke	  N,	  Stillman	  AE.	  Magnetic	  resonance	  quantification	  
of	  the	  myocardial	  perfusion	  reserve	  with	  a	  fermi	  function	  model	  for	  
constrained	  deconvolution.	  Med	  Phys.	  1998;25:73-­‐84	  
  271 
75.	   Christian	  TF,	  Rettmann	  DW,	  Aletras	  AH,	  Liao	  SL,	  Taylor	  JL,	  Balaban	  RS,	  
Arai	  AE.	  Absolute	  myocardial	  perfusion	  in	  canines	  measured	  by	  using	  dual-­‐
bolus	  first-­‐pass	  mr	  imaging.	  Radiology.	  2004;232:677-­‐684	  
76.	   Christian	  TF,	  Aletras	  AH,	  Arai	  AE.	  Estimation	  of	  absolute	  myocardial	  blood	  
flow	  during	  first-­‐pass	  mr	  perfusion	  imaging	  using	  a	  dual-­‐bolus	  injection	  
technique:	  Comparison	  to	  single-­‐bolus	  injection	  method.	  J.	  Magn.	  Reson.	  
Imaging.	  2008;27:1271-­‐1277	  
77.	   Utz	  W,	  Greiser	  A,	  Niendorf	  T,	  Dietz	  R,	  Schulz-­‐Menger	  J.	  Single-­‐	  or	  dual-­‐
bolus	  approach	  for	  the	  assessment	  of	  myocardial	  perfusion	  reserve	  in	  
quantitative	  mr	  perfusion	  imaging.	  Magn	  Reson	  Med.	  2008;59:1373-­‐1377	  
78.	   Gatehouse	  PD,	  Elkington	  AG,	  Ablitt	  NA,	  Yang	  G-­‐Z,	  Pennell	  DJ,	  Firmin	  DN.	  
Accurate	  assessment	  of	  the	  arterial	  input	  function	  during	  high-­‐dose	  
myocardial	  perfusion	  cardiovascular	  magnetic	  resonance.	  J.	  Magn.	  Reson.	  
Imaging.	  2004;20:39-­‐45	  
79.	   Kurita	  T,	  Sakuma	  H,	  Onishi	  K,	  Ishida	  M,	  Kitagawa	  K,	  Yamanaka	  T,	  
Tanigawa	  T,	  Kitamura	  T,	  Takeda	  K,	  Ito	  M.	  Regional	  myocardial	  perfusion	  
reserve	  determined	  using	  myocardial	  perfusion	  magnetic	  resonance	  
imaging	  showed	  a	  direct	  correlation	  with	  coronary	  flow	  velocity	  reserve	  by	  
doppler	  flow	  wire.	  Eur	  Heart	  J.	  2009;30:444-­‐452	  
80.	   Kaufmann	  PA,	  Gnecchi-­‐Ruscone	  T,	  Yap	  JT,	  Rimoldi	  O,	  Camici	  PG.	  
Assessment	  of	  the	  reproducibility	  of	  baseline	  and	  hyperemic	  myocardial	  
blood	  flow	  measurements	  with	  15O-­‐labeled	  water	  and	  PET.	  J	  Nucl	  Med.	  
1999;40:1848-­‐1856	  
81.	   Kramer	  CM,	  Barkhausen	  J,	  Flamm	  SD,	  Kim	  RJ,	  Nagel	  E.	  Standardized	  
cardiovascular	  magnetic	  resonance	  imaging	  (CMR)	  protocols,	  society	  for	  
  272 
cardiovascular	  magnetic	  resonance:	  Board	  of	  trustees	  task	  force	  on	  
standardized	  protocols.	  J.	  Cardiovasc	  Magnetic	  Resonance	  2008;10:35	  
82.	   Baer	  FM,	  Voth	  E,	  Schneider	  CA,	  Theissen	  P,	  Schicha	  H,	  Sechtem	  U.	  
Comparison	  of	  low-­‐dose	  dobutamine-­‐gradient-­‐echo	  magnetic	  resonance	  
imaging	  and	  positron	  emission	  tomography	  with	  [18f]fluorodeoxyglucose	  
in	  patients	  with	  chronic	  coronary	  artery	  disease.	  A	  functional	  and	  
morphological	  approach	  to	  the	  detection	  of	  residual	  myocardial	  viability.	  
Circulation.	  1995;91:1006-­‐1015	  
83.	   Gunning	  MG,	  Anagnostopoulos	  C,	  Knight	  CJ,	  Pepper	  J,	  Burman	  ED,	  Davies	  G,	  
Fox	  KM,	  Pennell	  DJ,	  Ell	  PJ,	  Underwood	  SR.	  Comparison	  of	  201tl,	  99mtc-­‐
tetrofosmin,	  and	  dobutamine	  magnetic	  resonance	  imaging	  for	  identifying	  
hibernating	  myocardium.	  Circulation.	  1998;98:1869-­‐1874	  
84.	   Kim	  RJ,	  Fieno	  DS,	  Parrish	  TB,	  Harris	  K,	  Chen	  EL,	  Simonetti	  O,	  Bundy	  J,	  Finn	  
JP,	  Klocke	  FJ,	  Judd	  RM.	  Relationship	  of	  mri	  delayed	  contrast	  enhancement	  
to	  irreversible	  injury,	  infarct	  age,	  and	  contractile	  function.	  Circulation.	  
1999;100:1992-­‐2002	  
85.	   Klein	  C,	  Nekolla	  SG,	  Bengel	  FM,	  Momose	  M,	  Sammer	  A,	  Haas	  F,	  
Schnackenburg	  B,	  Delius	  W,	  Mudra	  H,	  Wolfram	  D,	  Schwaiger	  M.	  
Assessment	  of	  myocardial	  viability	  with	  contrast-­‐enhanced	  magnetic	  
resonance	  imaging:	  Comparison	  with	  positron	  emission	  tomography.	  
Circulation.	  2002;105:162-­‐167	  
86.	   Kim	  RJ,	  Wu	  E,	  Rafael	  A,	  Chen	  EL,	  Parker	  MA,	  Simonetti	  O,	  Klocke	  FJ,	  Bonow	  
RO,	  Judd	  RM.	  The	  use	  of	  contrast-­‐enhanced	  magnetic	  resonance	  imaging	  to	  
identify	  reversible	  myocardial	  dysfunction.	  N	  Engl	  J	  Med.	  2000;343:1445-­‐
1453	  
  273 
87.	   Wellnhofer	  E,	  Olariu	  A,	  Klein	  C,	  Gräfe	  M,	  Wahl	  A,	  Fleck	  E,	  Nagel	  E.	  Magnetic	  
resonance	  low-­‐dose	  dobutamine	  test	  is	  superior	  to	  scar	  quantification	  for	  
the	  prediction	  of	  functional	  recovery.	  Circulation.	  2004;109:2172-­‐2174	  
88.	   Kaandorp	  T.	  Cardiovascular	  mr	  to	  access	  myocardial	  viability	  in	  chronic	  
ischaemic	  LV	  dysfunction.	  Heart.	  2005;91:1359-­‐1365	  
89.	   McCrohon	  JA,	  Moon	  JCC,	  Prasad	  SK,	  McKenna	  WJ,	  Lorenz	  CH,	  Coats	  AJS,	  
Pennell	  DJ.	  Differentiation	  of	  heart	  failure	  related	  to	  dilated	  
cardiomyopathy	  and	  coronary	  artery	  disease	  using	  gadolinium-­‐enhanced	  
cardiovascular	  magnetic	  resonance.	  Circulation.	  2003;108:54-­‐59	  
90.	   Bruder	  O,	  Schneider	  S,	  Nothnagel	  D,	  Dill	  T,	  Hombach	  V,	  Schulz-­‐Menger	  J,	  
Nagel	  E,	  Lombardi	  M,	  van	  Rossum	  AC,	  Wagner	  A,	  Schwitter	  J,	  Senges	  J,	  
Sabin	  GV,	  Sechtem	  U,	  Mahrholdt	  H.	  Eurocmr	  (European	  cardiovascular	  
magnetic	  resonance)	  registry:	  Results	  of	  the	  german	  pilot	  phase.	  Journal	  of	  
the	  American	  College	  of	  Cardiology.	  2009;54:1457-­‐1466	  
91.	   Kwong	  RY,	  Chan	  AK,	  Brown	  KA,	  Chan	  CW,	  Reynolds	  HG,	  Tsang	  S,	  Davis	  RB.	  
Impact	  of	  unrecognized	  myocardial	  scar	  detected	  by	  cardiac	  magnetic	  
resonance	  imaging	  on	  event-­‐free	  survival	  in	  patients	  presenting	  with	  signs	  
or	  symptoms	  of	  coronary	  artery	  disease.	  Circulation.	  2006;113:2733-­‐2743	  
92.	   Roes	  SD,	  Kelle	  S,	  Kaandorp	  TAM,	  Kokocinski	  T,	  Poldermans	  D,	  Lamb	  HJ,	  
Boersma	  E,	  van	  der	  Wall	  EE,	  Fleck	  E,	  de	  Roos	  A,	  Nagel	  E,	  Bax	  JJ.	  
Comparison	  of	  myocardial	  infarct	  size	  assessed	  with	  contrast-­‐enhanced	  
magnetic	  resonance	  imaging	  and	  left	  ventricular	  function	  and	  volumes	  to	  
predict	  mortality	  in	  patients	  with	  healed	  myocardial	  infarction.	  The	  
American	  Journal	  of	  Cardiology.	  2007;100:930-­‐936	  
  274 
93.	   Kim	  WY,	  Danias	  PG,	  Stuber	  M,	  Flamm	  SD,	  Plein	  S,	  Nagel	  E,	  Langerak	  SE,	  
Weber	  OM,	  Pedersen	  EM,	  Schmidt	  M,	  Botnar	  RM,	  Manning	  WJ.	  Coronary	  
magnetic	  resonance	  angiography	  for	  the	  detection	  of	  coronary	  stenoses.	  N	  
Engl	  J	  Med.	  2001;345:1863-­‐1869	  
94.	   Sakuma	  H,	  Ichikawa	  Y,	  Chino	  S,	  Hirano	  T,	  Makino	  K,	  Takeda	  K.	  Detection	  of	  
coronary	  artery	  stenosis	  with	  whole-­‐heart	  coronary	  magnetic	  resonance	  
angiography.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2006;48:1946-­‐1950	  
95.	   Messroghli	  DR,	  Bainbridge	  GJ,	  Alfakih	  K,	  Jones	  TR,	  Plein	  S,	  Ridgway	  JP,	  
Sivananthan	  MU.	  Assessment	  of	  regional	  left	  ventricular	  function:	  
Accuracy	  and	  reproducibility	  of	  positioning	  standard	  short-­‐axis	  sections	  in	  
cardiac	  mr	  imaging.	  Radiology.	  2005;235:229-­‐236	  
96.	   Cerqueira	  MD,	  Weissman	  NJ,	  Dilsizian	  V,	  Jacobs	  AK,	  Kaul	  S,	  Laskey	  WK,	  
Pennell	  DJ,	  Rumberger	  JA,	  Ryan	  T,	  Verani	  MS.	  Standardized	  myocardial	  
segmentation	  and	  nomenclature	  for	  tomographic	  imaging	  of	  the	  heart:	  A	  
statement	  for	  healthcare	  professionals	  from	  the	  cardiac	  imaging	  
committee	  of	  the	  council	  on	  clinical	  cardiology	  of	  the	  american	  heart	  
association.	  Circulation.	  2002;105:539-­‐542	  
97.	   Ishida	  M,	  Schuster	  A,	  Morton	  G,	  Chiribiri	  A,	  Hussain	  S,	  Paul	  M,	  Merkle	  N,	  
Steen	  H,	  Lossnitzer	  D,	  Schnackenburg	  B,	  Alfakih	  K,	  Plein	  S,	  Nagel	  E.	  
Development	  of	  a	  universal	  dual-­‐bolus	  injection	  scheme	  for	  the	  
quantitative	  assessment	  of	  myocardial	  perfusion	  cardiovascular	  magnetic	  
resonance.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2011;13:28	  
  275 
98.	   Hsu	  LY,	  Rhoads	  KL,	  Holly	  JE,	  Kellman	  P,	  Aletras	  AH,	  Arai	  AE.	  Quantitative	  
myocardial	  perfusion	  analysis	  with	  a	  dual-­‐bolus	  contrast-­‐enhanced	  first-­‐
pass	  mri	  technique	  in	  humans.	  J.	  Magn.	  Reson.	  Imaging.	  2006;23:315-­‐322	  
99.	   Greenwood	  JP,	  Maredia	  N,	  Radjenovic	  A,	  Brown	  JM,	  Nixon	  J,	  Farrin	  AJ,	  
Dickinson	  C,	  Younger	  JF,	  Ridgway	  JP,	  Sculpher	  M,	  Ball	  SG,	  Plein	  S.	  Clinical	  
evaluation	  of	  magnetic	  resonance	  imaging	  in	  coronary	  heart	  disease:	  The	  
CE-­‐MARC	  study.	  Trials.	  2009;10:62	  
100.	   Schwitter	  J,	  Nanz	  D,	  Kneifel	  S,	  Bertschinger	  K,	  Buchi	  M,	  Knusel	  PR,	  
Marincek	  B,	  Luscher	  TF,	  von	  Schulthess	  GK.	  Assessment	  of	  myocardial	  
perfusion	  in	  coronary	  artery	  disease	  by	  magnetic	  resonance:	  A	  comparison	  
with	  positron	  emission	  tomography	  and	  coronary	  angiography.	  
Circulation.	  2001;103:2230-­‐2235	  
101.	   Elkington	  AG,	  Gatehouse	  PD,	  Cannell	  TM,	  Moon	  JC,	  Prasad	  SK,	  Firmin	  DN,	  
Pennell	  DJ.	  Comparison	  of	  hybrid	  echo-­‐planar	  imaging	  and	  flash	  
myocardial	  perfusion	  cardiovascular	  MR	  imaging.	  Radiology.	  
2005;235:237-­‐243	  
102.	   Lyne	  JC,	  Gatehouse	  PD,	  Assomull	  RG,	  Smith	  GC,	  Kellman	  P,	  Firmin	  DN,	  
Pennell	  DJ.	  Direct	  comparison	  of	  myocardial	  perfusion	  cardiovascular	  
magnetic	  resonance	  sequences	  with	  parallel	  acquisition.	  J.	  Magn.	  Reson.	  
Imaging.	  2007;26:1444-­‐1451	  
103.	   Weber	  S,	  Kronfeld	  A,	  Kunz	  RP,	  Fiebich	  M,	  Horstick	  G,	  Kreitner	  K-­‐F,	  
Schreiber	  WG.	  Comparison	  of	  three	  accelerated	  pulse	  sequences	  for	  
semiquantitative	  myocardial	  perfusion	  imaging	  using	  sensitivity	  encoding	  
incorporating	  temporal	  filtering	  (tsense).	  J.	  Magn.	  Reson.	  Imaging.	  
2007;26:569-­‐579	  
  276 
104.	   Fenchel	  M,	  Helber	  U,	  Simonetti	  OP,	  Stauder	  NI,	  Kramer	  U,	  Nguyen	  C-­‐N,	  Finn	  
JP,	  Claussen	  CD,	  Miller	  S.	  Multislice	  first-­‐pass	  myocardial	  perfusion	  
imaging:	  Comparison	  of	  saturation	  recovery	  (sr)-­‐truefisp-­‐two-­‐dimensional	  
(2d)	  and	  sr-­‐turboflash-­‐2d	  pulse	  sequences.	  J.	  Magn.	  Reson.	  Imaging.	  
2004;19:555-­‐563	  
105.	   Wang	  Y,	  Moin	  K,	  Akinboboye	  O,	  Reichek	  N.	  Myocardial	  first	  pass	  perfusion:	  
Steady-­‐state	  free	  precession	  versus	  spoiled	  gradient	  echo	  and	  segmented	  
echo	  planar	  imaging.	  Magn.	  Reson.	  Med.	  2005;54:1123-­‐1129	  
106.	   Pruessmann	  KP,	  Weiger	  M,	  Scheidegger	  MB,	  Boesiger	  P.	  Sense:	  Sensitivity	  
encoding	  for	  fast	  MRI.	  Magn	  Reson	  Med.	  1999;42:952-­‐962	  
107.	   Kozerke	  S,	  Plein	  S.	  Accelerated	  CMR	  using	  zonal,	  parallel	  and	  prior	  
knowledge	  driven	  imaging	  methods.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  
2008;10:29	  
108.	   Chiribiri	  A,	  Schuster	  A,	  Ishida	  M,	  Hautvast	  G,	  Nooralipour	  N,	  Paul	  M,	  
Hussain	  S,	  Batchelor	  P,	  Breeuwer	  M,	  Schaeffter	  T,	  Nagel	  E.	  Dynamic	  
simulation	  of	  first	  pass	  myocardial	  perfusion	  MR	  with	  a	  novel	  perfusion	  
phantom.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2011;13(Suppl	  1):O43	  
109.	   Plein	  S,	  Ryf	  S,	  Schwitter	  J,	  Radjenovic	  A,	  Boesiger	  P,	  Kozerke	  S.	  Dynamic	  
contrast-­‐enhanced	  myocardial	  perfusion	  MRI	  accelerated	  with	  k-­‐t	  sense.	  
Magn	  Reson	  Med.	  2007;58:777-­‐785	  
110.	   Maredia	  N,	  Radjenovic	  A,	  Kozerke	  S,	  Larghat	  A,	  Greenwood	  JP,	  Plein	  S.	  
Effect	  of	  improving	  spatial	  or	  temporal	  resolution	  on	  image	  quality	  and	  
quantitative	  perfusion	  assessment	  with	  k-­‐t	  sense	  acceleration	  in	  first-­‐pass	  
cmr	  myocardial	  perfusion	  imaging.	  Magn	  Reson	  Med.	  2010;64:1616-­‐1624	  
  277 
111.	   Plein	  S,	  Schwitter	  J,	  Suerder	  D,	  Greenwood	  JP,	  Boesiger	  P,	  Kozerke	  S.	  K-­‐
space	  and	  time	  sensitivity	  encoding-­‐accelerated	  myocardial	  perfusion	  MR	  
imaging	  at	  3.0T:	  Comparison	  with	  1.5T.	  Radiology.	  2008;249:493-­‐500	  
112.	   Manka	  R,	  Vitanis	  V,	  Boesiger	  P,	  Flammer	  AJ,	  Plein	  S,	  Kozerke	  S.	  Clinical	  
feasibility	  of	  accelerated,	  high	  spatial	  resolution	  myocardial	  perfusion	  
imaging.	  JACC	  Cardiovasc	  Imaging.	  2010;3:710-­‐717	  
113.	   Thiele	  H,	  Plein	  S,	  Ridgway	  JP,	  Breeuwer	  M,	  Higgins	  D,	  Schuler	  G,	  
Sivananthan	  M.	  Effects	  of	  missing	  dynamic	  images	  on	  myocardial	  
perfusion	  reserve	  index	  calculation:	  Comparison	  between	  an	  every	  
heartbeat	  and	  an	  alternate	  heartbeat	  acquisition.	  J.	  Cardiovasc	  Magnetic	  
Resonance.	  2003;5:343-­‐352	  
114.	   Muhling	  OM,	  Dickson	  ME,	  Zenovich	  A,	  Huang	  Y,	  Wilson	  BV,	  Wilson	  RF,	  
Anand	  IS,	  Seethamraju	  RT,	  Jerosch-­‐Herold	  M,	  Wilke	  NM.	  Quantitative	  
magnetic	  resonance	  first-­‐pass	  perfusion	  analysis:	  Inter-­‐	  and	  intraobserver	  
agreement.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2001;3:247-­‐256	  
115.	   Schreiber	  WGN,	  Schmitt	  M,	  Kalden	  P,	  Mohrs	  OK,	  Kreitner	  K-­‐F,	  Thelen	  M.	  
Dynamic	  contrast-­‐enhanced	  myocardial	  perfusion	  imaging	  using	  
saturation-­‐prepared	  truefisp.	  J.	  Magn.	  Reson.	  Imaging.	  2002;16:641-­‐652	  
116.	   Kellman	  P,	  Mcveigh	  ER.	  Image	  reconstruction	  in	  SNR	  units:	  A	  general	  
method	  for	  SNR	  measurement.	  Magn	  Reson	  Med.	  2005;54:1439-­‐1447	  
117.	   Di	  Bella	  EVR,	  Parker	  DL,	  Sinusas	  AJ.	  On	  the	  dark	  rim	  artifact	  in	  dynamic	  
contrast-­‐enhanced	  mri	  myocardial	  perfusion	  studies.	  Magn	  Reson	  Med.	  
2005;54:1295-­‐1299	  
118.	   Idée	  J-­‐M,	  Port	  M,	  Raynal	  I,	  Schaefer	  M,	  Le	  Greneur	  S,	  Corot	  C.	  Clinical	  and	  
biological	  consequences	  of	  transmetallation	  induced	  by	  contrast	  agents	  for	  
  278 
magnetic	  resonance	  imaging:	  A	  review.	  Fundam	  Clin	  Pharmacol.	  
2006;20:563-­‐576	  
119.	   Giang	  TH,	  Nanz	  D,	  Coulden	  R,	  Friedrich	  M,	  Graves	  M,	  Al-­‐Saadi	  N,	  Lüscher	  
TF,	  von	  Schulthess	  GK,	  Schwitter	  J.	  Detection	  of	  coronary	  artery	  disease	  by	  
magnetic	  resonance	  myocardial	  perfusion	  imaging	  with	  various	  contrast	  
medium	  doses:	  First	  european	  multi-­‐centre	  experience.	  Eur	  Heart	  J.	  
2004;25:1657-­‐1665	  
120.	   Wolff	  SD,	  Schwitter	  J,	  Coulden	  R,	  Friedrich	  MG,	  Bluemke	  DA,	  Biederman	  
RW,	  Martin	  ET,	  Lansky	  AJ,	  Kashanian	  F,	  Foo	  TKF,	  Licato	  PE,	  Comeau	  CR.	  
Myocardial	  first-­‐pass	  perfusion	  magnetic	  resonance	  imaging:	  A	  
multicenter	  dose-­‐ranging	  study.	  Circulation.	  2004;110:732-­‐737	  
121.	   Klem	  I,	  Heitner	  J,	  Shah	  D,	  Jr	  S,	  Michael	  H	  ,	  Behar	  V,	  Weinsaft	  J,	  Cawley	  P,	  
Parker	  M,	  Elliott	  M,	  Judd	  R,	  Kim	  R.	  Improved	  detection	  of	  coronary	  artery	  
disease	  by	  stress	  perfusion	  cardiovascular	  magnetic	  resonance	  with	  the	  
use	  of	  delayed	  enhancement	  infarction	  imaging.	  Journal	  of	  the	  American	  
College	  of	  Cardiology.	  2006;47:1630	  
122.	   Knuuti	  J,	  Kajander	  S,	  Mäki	  M,	  Ukkonen	  H.	  Quantification	  of	  myocardial	  
blood	  flow	  will	  reform	  the	  detection	  of	  cad.	  J	  Nucl	  Cardiol.	  2009;16:497-­‐
506	  
123.	   Kajander	  SA,	  Joutsiniemi	  E,	  Saraste	  M,	  Pietila	  M,	  Ukkonen	  H,	  Saraste	  A,	  
Sipila	  HT,	  Teras	  M,	  Maki	  M,	  Airaksinen	  J,	  Hartiala	  J,	  Knuuti	  J.	  Clinical	  value	  
of	  absolute	  quantification	  of	  myocardial	  perfusion	  with	  15O-­‐water	  in	  
coronary	  artery	  disease.	  Circulation:	  Cardiovascular	  Imaging.	  2011:1-­‐31	  
124.	   Patel	  AR,	  Antkowiak	  PF,	  Nandalur	  KR,	  West	  AM,	  Salerno	  M,	  Arora	  V,	  
Christopher	  J,	  Epstein	  FH,	  Kramer	  CM.	  Assessment	  of	  advanced	  coronary	  
  279 
artery	  disease:	  Advantages	  of	  quantitative	  cardiac	  magnetic	  resonance	  
perfusion	  analysis.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2010;56:561-­‐569	  
125.	   Ichihara	  T,	  Ishida	  M,	  Kitagawa	  K,	  Ichikawa	  Y,	  Natsume	  T,	  Yamaki	  N,	  
Maeda	  H,	  Takeda	  K,	  Sakuma	  H.	  Quantitative	  analysis	  of	  first-­‐pass	  contrast-­‐
enhanced	  myocardial	  perfusion	  MRI	  using	  a	  patlak	  plot	  method	  and	  blood	  
saturation	  correction.	  Magn.	  Reson.	  Med.	  2009;62:373-­‐383	  
126.	   Fritz-­‐Hansen	  T,	  Hove	  JD,	  Kofoed	  KF,	  Kelbaek	  H,	  Larsson	  HBW.	  
Quantification	  of	  mri	  measured	  myocardial	  perfusion	  reserve	  in	  healthy	  
humans:	  A	  comparison	  with	  positron	  emission	  tomography.	  J	  Magn	  Reson	  
Imaging.	  2008;27:818-­‐824	  
127.	   Pärkkä	  JP,	  Niemi	  P,	  Saraste	  A,	  Koskenvuo	  JW,	  Komu	  M,	  Oikonen	  V,	  Toikka	  
JO,	  Kiviniemi	  TO,	  Knuuti	  J,	  Sakuma	  H,	  Hartiala	  JJ.	  Comparison	  of	  MRI	  and	  
positron	  emission	  tomography	  for	  measuring	  myocardial	  perfusion	  reserve	  
in	  healthy	  humans.	  Magn	  Reson	  Med.	  2006;55:772-­‐779	  
128.	   Pack	  NA,	  DiBella	  EVR,	  Rust	  TC,	  Kadrmas	  DJ,	  McGann	  CJ,	  Butterfield	  R,	  
Christian	  PE,	  Hoffman	  JM.	  Estimating	  myocardial	  perfusion	  from	  dynamic	  
contrast-­‐enhanced	  CMR	  with	  a	  model-­‐independent	  deconvolution	  method.	  
J.	  Cardiovasc	  Magnetic	  Resonance.	  2008;10:52	  
129.	   Choi	  Y,	  Huang	  SC,	  Hawkins	  RA,	  Kuhle	  WG,	  Dahlbom	  M,	  Hoh	  CK,	  Czernin	  J,	  
Phelps	  ME,	  Schelbert	  HR.	  A	  simplified	  method	  for	  quantification	  of	  
myocardial	  blood	  flow	  using	  nitrogen-­‐13-­‐ammonia	  and	  dynamic	  pet.	  
Journal	  of	  Nuclear	  Medicine.	  1993;34:488-­‐497	  
130.	   Lockie	  T,	  Ishida	  M,	  Perera	  D,	  Chiribiri	  A,	  De	  Silva	  K,	  Kozerke	  S,	  Marber	  M,	  
Nagel	  E,	  Rezavi	  R,	  Redwood	  S,	  Plein	  S.	  High-­‐resolution	  magnetic	  resonance	  
  280 
myocardial	  perfusion	  imaging	  at	  3.0-­‐tesla	  to	  detect	  hemodynamically	  
significant	  coronary	  stenoses	  as	  determined	  by	  fractional	  flow	  reserve.	  
Journal	  of	  the	  American	  College	  of	  Cardiology.	  2010;57:70-­‐75	  
131.	   Ibrahim	  T,	  Nekolla	  SG,	  Schreiber	  K,	  Odaka	  K,	  Volz	  S,	  Mehilli	  J,	  Güthlin	  M,	  
Delius	  W,	  Schwaiger	  M.	  Assessment	  of	  coronary	  flow	  reserve:	  Comparison	  
between	  contrast-­‐enhanced	  magnetic	  resonance	  imaging	  and	  positron	  
emission	  tomography.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2002;39:864-­‐870	  
132.	   Hajjiri	  MM,	  Leavitt	  MB,	  Zheng	  H,	  Spooner	  AE,	  Fischman	  AJ,	  Gewirtz	  H.	  
Comparison	  of	  positron	  emission	  tomography	  measurement	  of	  adenosine-­‐
stimulated	  absolute	  myocardial	  blood	  flow	  versus	  relative	  myocardial	  
tracer	  content	  for	  physiological	  assessment	  of	  coronary	  artery	  stenosis	  
severity	  and	  location.	  JACC	  Cardiovasc	  Imaging.	  2009;2:751-­‐758	  
133.	   Iida	  H,	  Kanno	  I,	  Takahashi	  A,	  Miura	  S,	  Murakami	  M,	  Takahashi	  K,	  Ono	  Y,	  
Shishido	  F,	  Inugami	  A,	  Tomura	  N.	  Measurement	  of	  absolute	  myocardial	  
blood	  flow	  with	  h215o	  and	  dynamic	  positron-­‐emission	  tomography.	  
Strategy	  for	  quantification	  in	  relation	  to	  the	  partial-­‐volume	  effect.	  
Circulation.	  1988;78:104-­‐115	  
134.	   Karamitsos	  T,	  Leccisotti	  L,	  Arnold	  J,	  Recio-­‐Mayoral	  A,	  Bhamra-­‐Ariza	  P,	  
Howells	  R,	  Searle	  N,	  Robson	  M,	  Rimoldi	  O,	  Camici	  P,	  Neubauer	  S,	  
Selvanayagam	  J.	  Relationship	  between	  regional	  myocardial	  oxygenation	  
and	  perfusion	  in	  patients	  with	  coronary	  artery	  disease:	  Insights	  from	  
cardiovascular	  magnetic	  resonance	  and	  positron	  emission	  tomography.	  
Circulation:	  Cardiovascular	  Imaging.	  2009	  
  281 
135.	   Czernin	  J,	  Müller	  P,	  Chan	  S,	  Brunken	  RC,	  Porenta	  G,	  Krivokapich	  J,	  Chen	  K,	  
Chan	  A,	  Phelps	  ME,	  Schelbert	  HR.	  Influence	  of	  age	  and	  hemodynamics	  on	  
myocardial	  blood	  flow	  and	  flow	  reserve.	  Circulation.	  1993;88:62-­‐69	  
136.	   Selvanayagam	  J,	  Cheng	  A,	  Jerosch-­‐Herold	  M,	  Rahimi	  K,	  Porto	  I,	  Van	  Gaal	  W,	  
Channon	  K,	  Neubauer	  S,	  Banning	  A.	  Effect	  of	  distal	  embolization	  on	  
myocardial	  perfusion	  reserve	  after	  percutaneous	  coronary	  intervention:	  A	  
quantitative	  magnetic	  resonance	  perfusion	  study.	  Circulation.	  
2007;116:1458-­‐1464	  
137.	   Nesterov	  SV,	  Han	  C,	  Mäki	  M,	  Kajander	  S,	  Naum	  AG,	  Helenius	  H,	  Lisinen	  I,	  
Ukkonen	  H,	  Pietilä	  M,	  Joutsiniemi	  E,	  Knuuti	  J.	  Myocardial	  perfusion	  
quantitation	  with	  15O-­‐labelled	  water	  pet:	  High	  reproducibility	  of	  the	  new	  
cardiac	  analysis	  software	  (CARISMAS).	  Eur	  J	  Nucl	  Med	  Mol	  Imaging.	  
2009;36:1594-­‐1602	  
138.	   Mullani	  NA.	  Is	  the	  patlak	  graphical	  analysis	  method	  applicable	  to	  
measurement	  of	  myocardial	  blood	  flow	  with	  nitrogen-­‐13-­‐ammonia?	  J	  Nucl	  
Med.	  1993;34:1831-­‐1834	  
139.	   Jerosch-­‐Herold	  M,	  Seethamraju	  RT,	  Swingen	  CM,	  Wilke	  NM,	  Stillman	  AE.	  
Analysis	  of	  myocardial	  perfusion	  MRI.	  J.	  Magn.	  Reson.	  Imaging.	  
2004;19:758-­‐770	  
140.	   Nagamachi	  S,	  Czernin	  J,	  Kim	  AS,	  Sun	  KT,	  Böttcher	  M,	  Phelps	  ME,	  Schelbert	  
HR.	  Reproducibility	  of	  measurements	  of	  regional	  resting	  and	  hyperemic	  
myocardial	  blood	  flow	  assessed	  with	  PET.	  Journal	  of	  Nuclear	  Medicine.	  
1996;37:1626-­‐1631	  
141.	   Jerosch-­‐Herold	  M,	  Vazquez	  G,	  Wang	  L,	  Jacobs	  DR,	  Folsom	  AR.	  Variability	  of	  
myocardial	  blood	  flow	  measurements	  by	  magnetic	  resonance	  imaging	  in	  
  282 
the	  multi-­‐ethnic	  study	  of	  atherosclerosis.	  Investigative	  radiology.	  
2008;43:155-­‐161	  
142.	   Ortiz-­‐Perez	  JT,	  Meyers	  SN,	  Lee	  DC,	  Kansal	  P,	  Klocke	  FJ,	  Holly	  TA,	  Davidson	  
CJ,	  Bonow	  RO,	  Wu	  E.	  Angiographic	  estimates	  of	  myocardium	  at	  risk	  during	  
acute	  myocardial	  infarction:	  Validation	  study	  using	  cardiac	  magnetic	  
resonance	  imaging.	  Eur	  Heart	  J.	  2007;28:1750-­‐1758	  
143.	   Moise	  A,	  Clement	  B,	  Saltiel	  J.	  Clinical	  and	  angiographic	  correlates	  and	  
prognostic	  significance	  of	  the	  coronary	  extent	  score.	  The	  American	  Journal	  
of	  Cardiology.	  1988;61:1255-­‐1259	  
144.	   Kimmel	  SE,	  Berlin	  JA,	  Strom	  BL,	  Laskey	  WK.	  Development	  and	  validation	  of	  
simplified	  predictive	  index	  for	  major	  complications	  in	  contemporary	  
percutaneous	  transluminal	  coronary	  angioplasty	  practice.	  The	  registry	  
committee	  of	  the	  society	  for	  cardiac	  angiography	  and	  interventions.	  
Journal	  of	  the	  American	  College	  of	  Cardiology.	  1995;26:931-­‐938	  
145.	   Perera	  D,	  Stables	  R,	  Booth	  J,	  Thomas	  M,	  Redwood	  S.	  The	  balloon	  pump-­‐
assisted	  coronary	  intervention	  study	  (bcis-­‐1):	  Rationale	  and	  design.	  
American	  Heart	  Journal.	  2009;158:910-­‐916.e912	  
146.	   Perera	  D,	  Stables	  R,	  Thomas	  M,	  Booth	  J,	  Pitt	  M,	  Blackman	  D,	  de	  Belder	  A,	  
Redwood	  S,	  Investigators	  B-­‐.	  Elective	  intra-­‐aortic	  balloon	  counterpulsation	  
during	  high-­‐risk	  percutaneous	  coronary	  intervention:	  A	  randomized	  
controlled	  trial.	  The	  Journal	  of	  the	  American	  Medical	  Association.	  
2010;304:867-­‐874	  
147.	   Califf	  RM,	  Phillips	  HR,	  Hindman	  MC,	  Mark	  DB,	  Lee	  KL,	  Behar	  VS,	  Johnson	  
RA,	  Pryor	  DB,	  Rosati	  RA,	  Wagner	  GS.	  Prognostic	  value	  of	  a	  coronary	  artery	  
  283 
jeopardy	  score.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
1985;5:1055-­‐1063	  
148.	   Kappetein	  AP,	  Dawkins	  KD,	  Mohr	  FW,	  Morice	  MC,	  Mack	  MJ,	  Russell	  ME,	  
Pomar	  J,	  Serruys	  PWJC.	  Current	  percutaneous	  coronary	  intervention	  and	  
coronary	  artery	  bypass	  grafting	  practices	  for	  three-­‐vessel	  and	  left	  main	  
coronary	  artery	  disease.	  Insights	  from	  the	  syntax	  run-­‐in	  phase.	  Eur	  J	  
Cardiothorac	  Surg.	  2006;29:486-­‐491	  
149.	   Sianos	  G,	  Morel	  M-­‐A,	  Kappetein	  AP,	  Morice	  M-­‐C,	  Colombo	  A,	  Dawkins	  K,	  van	  
den	  Brand	  M,	  Van	  Dyck	  N,	  Russell	  ME,	  Mohr	  FW,	  Serruys	  PW.	  The	  syntax	  
score:	  An	  angiographic	  tool	  grading	  the	  complexity	  of	  coronary	  artery	  
disease.	  EuroIntervention.	  2005;1:219-­‐227	  
150.	   Liao	  L,	  Kong	  DF,	  Shaw	  LK,	  Sketch	  MH,	  Milano	  CA,	  Lee	  KL,	  Mark	  DB.	  A	  new	  
anatomic	  score	  for	  prognosis	  after	  cardiac	  catheterization	  in	  patients	  with	  
previous	  bypass	  surgery.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2005;46:1684-­‐1692	  
151.	   Graham	  MM,	  Faris	  PD,	  Ghali	  WA,	  Galbraith	  PD,	  Norris	  CM,	  Badry	  JT,	  
Mitchell	  LB,	  Curtis	  MJ,	  Knudtson	  ML.	  Validation	  of	  three	  myocardial	  
jeopardy	  scores	  in	  a	  population-­‐based	  cardiac	  catheterization	  cohort.	  
American	  Heart	  Journal.	  2001;142:254-­‐261	  
152.	   Alderman	  E,	  Stadius	  M.	  The	  angiographic	  definitions	  of	  the	  bypass	  
angioplasty	  revascularization	  investigation.	  Coronary	  Artery	  Disease.	  
1992;3:1189-­‐1207	  
153.	   Berry	  C,	  Kellman	  P,	  Mancini	  C,	  Chen	  MY,	  Bandettini	  WP,	  Lowrey	  T,	  Hsu	  L-­‐Y,	  
Aletras	  AH,	  Arai	  AE.	  Magnetic	  resonance	  imaging	  delineates	  the	  ischemic	  
  284 
area	  at	  risk	  and	  myocardial	  salvage	  in	  patients	  with	  acute	  myocardial	  
infarction.	  Circulation:	  Cardiovascular	  Imaging.	  2010;3:527-­‐535	  
154.	   Fuernau	  G,	  Eitel	  I,	  Franke	  V,	  Hildebrandt	  L,	  Meissner	  J,	  de	  Waha	  S,	  Lurz	  P,	  
Gutberlet	  M,	  Desch	  S,	  Schuler	  G,	  Thiele	  H.	  Myocardium	  at	  risk	  in	  st-­‐segment	  
elevation	  myocardial	  infarction	  comparison	  of	  t2-­‐weighted	  edema	  
imaging	  with	  the	  MR-­‐assessed	  endocardial	  surface	  area	  and	  validation	  
against	  angiographic	  scoring.	  JACC.	  Cardiovascular	  imaging.	  2011;4:967-­‐
976	  
155.	   Morton	  G,	  De	  Silva	  K,	  Sicard	  P,	  Chong	  E,	  Rashid	  R,	  Indermuhle	  A,	  Clapp	  B,	  
Redwood	  S,	  Perera	  D.	  The	  BCIS-­‐1	  myocardial	  jeopardy	  score	  predicts	  
mortality	  after	  percutaneous	  coronary	  intervention.	  Journal	  of	  the	  
American	  College	  of	  Cardiology.	  2010;56:B40	  
156.	   Lanza	  GA,	  Buffon	  A,	  Sestito	  A,	  Natale	  L,	  Sgueglia	  GA,	  Galiuto	  L,	  Infusino	  F,	  
Mariani	  L,	  Centola	  A,	  Crea	  F.	  Relation	  between	  stress-­‐induced	  myocardial	  
perfusion	  defects	  on	  cardiovascular	  magnetic	  resonance	  and	  coronary	  
microvascular	  dysfunction	  in	  patients	  with	  cardiac	  syndrome	  X.	  Journal	  of	  
the	  American	  College	  of	  Cardiology.	  2008;51:466-­‐472	  
157.	   Morton	  G,	  Schuster	  A,	  Perera	  D,	  Nagel	  E.	  Cardiac	  magnetic	  resonance	  
imaging	  to	  guide	  complex	  revascularization	  in	  stable	  coronary	  artery	  
disease.	  Eur	  Heart	  J.	  2010:2209-­‐2216	  
158.	   Sdringola	  S,	  Johnson	  NP,	  Kirkeeide	  RL,	  Cid	  E,	  Gould	  KL.	  Impact	  of	  
unexpected	  factors	  on	  quantitative	  myocardial	  perfusion	  and	  coronary	  
flow	  reserve	  in	  young,	  asymptomatic	  volunteers.	  JACC	  Cardiovasc	  Imaging.	  
2011;4:402-­‐412	  
  285 
159.	   Elkington	  A,	  Gatehouse	  P,	  Ablitt	  N,	  Yang	  G-­‐Z,	  Firmin	  D,	  Pennell	  D.	  
Interstudy	  reproducibility	  of	  quantitative	  perfusion	  cardiovascular	  
magnetic	  resonance.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2005;7:815-­‐822	  
160.	   Fox	  KM,	  Mulcahy	  DA.	  Circadian	  rhythms	  in	  cardiovascular	  function.	  
Postgrad	  Med	  J.	  1991;67	  Suppl	  3:S33-­‐36	  
161.	   Grothues	  F,	  Smith	  GC,	  Moon	  JCC,	  Bellenger	  NG,	  Collins	  P,	  Klein	  HU,	  Pennell	  
DJ.	  Comparison	  of	  interstudy	  reproducibility	  of	  cardiovascular	  magnetic	  
resonance	  with	  two-­‐dimensional	  echocardiography	  in	  normal	  subjects	  and	  
in	  patients	  with	  heart	  failure	  or	  left	  ventricular	  hypertrophy.	  The	  
American	  Journal	  of	  Cardiology.	  2002;90:29-­‐34	  
162.	   Chih	  S,	  Macdonald	  PS,	  Feneley	  MP,	  Law	  M,	  Graham	  RM,	  McCrohon	  JA.	  
Reproducibility	  of	  adenosine	  stress	  cardiovascular	  magnetic	  resonance	  in	  
multi-­‐vessel	  symptomatic	  coronary	  artery	  disease.	  J.	  Cardiovasc	  Magnetic	  
Resonance.	  2010;12:42	  
163.	   Wyss	  CA,	  Koepfli	  P,	  Mikolajczyk	  K,	  Burger	  C,	  von	  Schulthess	  GK,	  Kaufmann	  
PA.	  Bicycle	  exercise	  stress	  in	  pet	  for	  assessment	  of	  coronary	  flow	  reserve:	  
Repeatability	  and	  comparison	  with	  adenosine	  stress.	  Journal	  of	  Nuclear	  
Medicine.	  2003;44:146-­‐154	  
164.	   El	  Fakhri	  G,	  Kardan	  A,	  Sitek	  A,	  Dorbala	  S,	  Abi-­‐Hatem	  N,	  Lahoud	  Y,	  
Fischman	  A,	  Coughlan	  M,	  Yasuda	  T,	  Di	  Carli	  MF.	  Reproducibility	  and	  
accuracy	  of	  quantitative	  myocardial	  blood	  flow	  assessment	  with	  82Rb	  pet:	  
Comparison	  with	  13n-­‐ammonia	  PET.	  Journal	  of	  Nuclear	  Medicine.	  
2009;50:1062-­‐1071	  
  286 
165.	   Wilson	  RF,	  Wyche	  K,	  Christensen	  BV,	  Zimmer	  S,	  Laxson	  DD.	  Effects	  of	  
adenosine	  on	  human	  coronary	  arterial	  circulation.	  Circulation.	  
1990;82:1595-­‐1606	  
166.	   Reyes	  E,	  Loong	  CY,	  Harbinson	  M,	  Donovan	  J,	  Anagnostopoulos	  C,	  
Underwood	  SR.	  High-­‐dose	  adenosine	  overcomes	  the	  attenuation	  of	  
myocardial	  perfusion	  reserve	  caused	  by	  caffeine.	  Journal	  of	  the	  American	  
College	  of	  Cardiology.	  2008;52:2008-­‐2016	  
167.	   Muehling	  O,	  Jerosch?Herold	  M,	  Panse	  P,	  Zenovich	  A,	  Wilson	  B,	  Wilson	  R,	  
Wilke	  N.	  Regional	  heterogeneity	  of	  myocardial	  perfusion	  in	  healthy	  human	  
myocardium:	  Assessment	  with	  magnetic	  resonance	  perfusion	  imaging.	  J.	  
Cardiovasc	  Magnetic	  Resonance.	  2004;6:499-­‐507	  
168.	   Muzik	  O,	  Duvernoy	  C,	  Beanlands	  RS,	  Sawada	  S,	  Dayanikli	  F,	  Wolfe	  ER,	  
Schwaiger	  M.	  Assessment	  of	  diagnostic	  performance	  of	  quantitative	  flow	  
measurements	  in	  normal	  subjects	  and	  patients	  with	  angiographically	  
documented	  coronary	  artery	  disease	  by	  means	  of	  nitrogen-­‐13	  ammonia	  
and	  positron	  emission	  tomography.	  Journal	  of	  the	  American	  College	  of	  
Cardiology.	  1998;31:534-­‐540	  
169.	   Ishida	  M,	  Morton	  G,	  Schuster	  A,	  Nagel	  E,	  Chiribiri	  A.	  Quantitative	  
assessment	  of	  myocardial	  perfusion	  MRI.	  Curr	  Cardiovasc	  Imaging	  Rep.	  
2010;3:65-­‐73	  
170.	   Schwaiger	  M,	  Muzik	  O.	  Assessment	  of	  myocardial	  perfusion	  by	  positron	  
emission	  tomography.	  The	  American	  Journal	  of	  Cardiology.	  1991;67:35D-­‐
43D	  
171.	   Pickering	  TG,	  Harshfield	  GA,	  Kleinert	  HD,	  Blank	  S,	  Laragh	  JH.	  Blood	  
pressure	  during	  normal	  daily	  activities,	  sleep,	  and	  exercise.	  Comparison	  of	  
  287 
values	  in	  normal	  and	  hypertensive	  subjects.	  The	  Journal	  of	  the	  American	  
Medical	  Association.	  1982;247:992-­‐996	  
172.	   Karabag	  T,	  Aydin	  M,	  Dogan	  SM,	  Sayin	  MR,	  Cetiner	  MA.	  The	  influence	  of	  
circadian	  variations	  on	  echocardiographic	  parameters	  in	  healthy	  people.	  
Echocardiography.	  2011;28:612-­‐618	  
173.	   Bull	  SC,	  Main	  ML,	  Stevens	  GR,	  Goldman	  JH,	  Constable	  SA,	  Becher	  H.	  Cardiac	  
toxicity	  screening	  by	  echocardiography	  in	  healthy	  volunteers:	  A	  study	  of	  
the	  effects	  of	  diurnal	  variation	  and	  use	  of	  a	  core	  laboratory	  on	  the	  
reproducibility	  of	  left	  ventricular	  function	  measurement.	  
Echocardiography.	  2011;28:502-­‐507	  
174.	   Voutilainen	  S,	  Kupari	  M,	  Hippelainen	  M,	  Karppinen	  K,	  Ventila	  M.	  Circadian	  
variation	  of	  left	  ventricular	  diastolic	  function	  in	  healthy	  people.	  Heart.	  
1996;75:35-­‐39	  
175.	   Bellenger	  N,	  Davies	  L,	  Francis	  J,	  Coats	  A,	  Pennell	  D.	  Reduction	  in	  sample	  
size	  for	  studies	  of	  remodeling	  in	  heart	  failure	  by	  the	  use	  of	  cardiovascular	  
magnetic	  resonance.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2000;2:271-­‐278	  
176.	   Schuster	  A,	  Morton	  G,	  Chiribiri	  A,	  Perera	  D,	  Vanoverschelde	  J,	  Nagel	  E.	  
Imaging	  in	  the	  management	  of	  ischemic	  cardiomyopathy:	  Special	  focus	  on	  
magnetic	  resonance.	  Journal	  of	  the	  American	  College	  of	  Cardiology.	  
2012;59(4):	  359-­‐70.	  
177.	   Karamitsos	  TD,	  Francis	  JM,	  Myerson	  S,	  Selvanayagam	  JB,	  Neubauer	  S.	  The	  
role	  of	  cardiovascular	  magnetic	  resonance	  imaging	  in	  heart	  failure.	  
Journal	  of	  the	  American	  College	  of	  Cardiology.	  2009;54:1407-­‐1424	  
178.	   Paetsch	  I,	  Jahnke	  C,	  Ferrari	  VA,	  Rademakers	  FE,	  Pellikka	  PA,	  Hundley	  WG,	  
Poldermans	  D,	  Bax	  JJ,	  Wegscheider	  K,	  Fleck	  E,	  Nagel	  E.	  Determination	  of	  
  288 
interobserver	  variability	  for	  identifying	  inducible	  left	  ventricular	  wall	  
motion	  abnormalities	  during	  dobutamine	  stress	  magnetic	  resonance	  
imaging.	  Eur	  Heart	  J.	  2006;27:1459-­‐1464	  
179.	   Ibrahim	  E-­‐SH.	  Myocardial	  tagging	  by	  cardiovascular	  magnetic	  resonance:	  
Evolution	  of	  techniques-­‐-­‐pulse	  sequences,	  analysis	  algorithms,	  and	  
applications.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2032;13:36	  
180.	   Schuster	  A,	  Nagel	  E.	  Toward	  full	  quantification	  of	  wall	  motion	  with	  mri.	  
Curr	  Cardiovasc	  Imaging	  Reports.	  2011:85-­‐86	  
181.	   Maret	  E,	  Todt	  T,	  Brudin	  L,	  Nylander	  E,	  Swahn	  E,	  Ohlsson	  JL,	  Engvall	  JE.	  
Functional	  measurements	  based	  on	  feature	  tracking	  of	  cine	  magnetic	  
resonance	  images	  identify	  left	  ventricular	  segments	  with	  myocardial	  scar.	  
Cardiovasc	  Ultrasound.	  2009;7:53	  
182.	   Hor	  KN,	  Baumann	  R,	  Pedrizzetti	  G,	  Tonti	  G,	  Gottliebson	  WM,	  Taylor	  M,	  
Benson	  W,	  Mazur	  W.	  Magnetic	  resonance	  derived	  myocardial	  strain	  
assessment	  using	  feature	  tracking.	  Journal	  of	  Visaulized	  Experiments.	  2011	  
183.	   Schuster	  A,	  Kutty	  S,	  Padiyath	  A,	  Parish	  V,	  Gribben	  P,	  Danford	  DA,	  Makowski	  
MR,	  Bigalke	  B,	  Beerbaum	  P,	  Nagel	  E.	  Cardiovascular	  magnetic	  resonance	  
myocardial	  feature	  tracking	  detects	  quantitative	  wall	  motion	  during	  
dobutamine	  stress.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  2011;13:58	  
184.	   Schuster	  A,	  Paul	  M,	  Bettencourt	  N,	  Morton	  G,	  Chiribiri	  A,	  Ishida	  M,	  Hussain	  
S,	  Jogiya	  R,	  Kutty	  S,	  Bigalke	  B,	  Perera	  D,	  Nagel	  E.	  Cardiovascular	  magnetic	  
resonance	  myocardial	  feature	  tracking	  for	  quantitative	  viability	  
assessment	  in	  ischemic	  cardiomyopathy.	  International	  Journal	  of	  
Cardiology.	  2011;[E-­‐pub	  ahead	  of	  print],	  doi:10.1016/j.ijcard.2011.10.137	  
  289 
185.	   Hopp	  E,	  Lunde	  K,	  Solheim	  S,	  Aakhus	  S,	  Arnesen	  H,	  Forfang	  K,	  Edvardsen	  T,	  
Smith	  H-­‐J.	  Regional	  myocardial	  function	  after	  intracoronary	  bone	  marrow	  
cell	  injection	  in	  reperfused	  anterior	  wall	  infarction	  -­‐	  a	  cardiovascular	  
magnetic	  resonance	  tagging	  study.	  J.	  Cardiovasc	  Magnetic	  Resonance.	  
2011;13:22	  
186.	   Herbots	  L,	  D'hooge	  J,	  Eroglu	  E,	  Thijs	  D,	  Ganame	  J,	  Claus	  P,	  Dubois	  C,	  
Theunissen	  K,	  Bogaert	  J,	  Dens	  J,	  Kalantzi	  M,	  Dymarkowski	  S,	  Bijnens	  B,	  
Belmans	  A,	  Boogaerts	  M,	  Sutherland	  G,	  Van	  De	  Werf	  F,	  Rademakers	  F,	  
Janssens	  S.	  Improved	  regional	  function	  after	  autologous	  bone	  marrow-­‐
derived	  stem	  cell	  transfer	  in	  patients	  with	  acute	  myocardial	  infarction:	  A	  
randomized,	  double-­‐blind	  strain	  rate	  imaging	  study.	  Eur	  Heart	  J.	  
2008;30:662-­‐670	  
187.	   Hor	  KN,	  Gottliebson	  WM,	  Carson	  C,	  Wash	  E,	  Cnota	  J,	  Fleck	  R,	  Wansapura	  J,	  
Klimeczek	  P,	  Al-­‐Khalidi	  HR,	  Chung	  ES,	  Benson	  DW,	  Mazur	  W.	  Comparison	  
of	  magnetic	  resonance	  feature	  tracking	  for	  strain	  calculation	  with	  
harmonic	  phase	  imaging	  analysis.	  JACC	  Cardiovasc	  Imaging.	  2010;3:144-­‐
151	  
188.	   Harrild	  DM,	  Han	  Y,	  Geva	  T,	  Zhou	  J,	  Marcus	  E,	  Powell	  AJ.	  Comparison	  of	  
cardiac	  MRI	  tissue	  tracking	  and	  myocardial	  tagging	  for	  assessment	  of	  
regional	  ventricular	  strain.	  The	  international	  journal	  of	  cardiovascular	  
imaging.	  2012;	  doi:	  10.1007/s10554-­‐012-­‐0035-­‐3	  
189.	   Pavlopoulos	  H,	  Nihoyannopoulos	  P.	  Strain	  and	  strain	  rate	  deformation	  
parameters:	  From	  tissue	  doppler	  to	  2d	  speckle	  tracking.	  The	  international	  
journal	  of	  cardiovascular	  imaging.	  2008;24:479-­‐491	  
  290 
190.	   Bansal	  M,	  Jeffriess	  L,	  Leano	  R,	  Mundy	  J,	  Marwick	  TH.	  Assessment	  of	  
myocardial	  viability	  at	  dobutamine	  echocardiography	  by	  deformation	  
analysis	  using	  tissue	  velocity	  and	  speckle-­‐tracking.	  JACC	  Cardiovasc	  
Imaging.	  2010;3:121-­‐131	  
191.	   Roes	  SD,	  Mollema	  SA,	  Lamb	  HJ,	  van	  der	  Wall	  EE,	  de	  Roos	  A,	  Bax	  JJ.	  
Validation	  of	  echocardiographic	  two-­‐dimensional	  speckle	  tracking	  
longitudinal	  strain	  imaging	  for	  viability	  assessment	  in	  patients	  with	  
chronic	  ischemic	  left	  ventricular	  dysfunction	  and	  comparison	  with	  
contrast-­‐enhanced	  magnetic	  resonance	  imaging.	  The	  American	  Journal	  of	  
Cardiology.	  2009;104:312-­‐317	  
192.	   Phan	  TT,	  Shivu	  GN,	  Abozguia	  K,	  Gnanadevan	  M,	  Ahmed	  I,	  Frenneaux	  M.	  
Left	  ventricular	  torsion	  and	  strain	  patterns	  in	  heart	  failure	  with	  normal	  
ejection	  fraction	  are	  similar	  to	  age-­‐related	  changes.	  Eur	  J	  Echocardiogr.	  
2009;10:793-­‐800	  
193.	   Sjoli	  B,	  Orn	  S,	  Grenne	  B,	  Ihlen	  H,	  Edvardsen	  T,	  Brunvand	  H.	  Diagnostic	  
capability	  and	  reproducibility	  of	  strain	  by	  doppler	  and	  by	  speckle	  tracking	  
in	  patients	  with	  acute	  myocardial	  infarction.	  JACC.	  Cardiovascular	  imaging.	  
2009;2:24-­‐33	  
194.	   Kempny	  A,	  Diller	  GP,	  Orwat	  S,	  Kaleschke	  G,	  Kerckhoff	  G,	  Bunck	  AC,	  Maintz	  
D,	  Baumgartner	  H.	  Right	  ventricular-­‐left	  ventricular	  interaction	  in	  adults	  
with	  tetralogy	  of	  fallot:	  A	  combined	  cardiac	  magnetic	  resonance	  and	  
echocardiographic	  speckle	  tracking	  study.	  International	  Journal	  of	  
Cardiology.	  2010	  
195.	   Van	  Dalen	  BM,	  Soliman	  OII,	  Vletter	  WB,	  Kauer	  F,	  Van	  Der	  Zwaan	  HB,	  Ten	  
Cate	  FJ,	  Geleijnse	  ML.	  Feasibility	  and	  reproducibility	  of	  left	  ventricular	  
  291 
rotation	  parameters	  measured	  by	  speckle	  tracking	  echocardiography.	  
European	  Journal	  of	  Echocardiography.	  2009;10:669-­‐676	  
196.	   Stanton	  T,	  Leano	  R,	  Marwick	  TH.	  Prediction	  of	  all-­‐cause	  mortality	  from	  
global	  longitudinal	  speckle	  strain:	  Comparison	  with	  ejection	  fraction	  and	  
wall	  motion	  scoring.	  Circulation:	  Cardiovascular	  Imaging.	  2009;2:356-­‐364	  
197.	   Assomull	  R,	  Pennell	  D,	  Prasad	  S.	  Cardiovascular	  magnetic	  resonance	  in	  the	  
evaluation	  of	  heart	  failure.	  Heart.	  2007;93:985-­‐992	  
198.	   Kim	  RJ,	  Shah	  DJ,	  Judd	  RM.	  How	  we	  perform	  delayed	  enhancement	  imaging.	  
J.	  Cardiovasc	  Magnetic	  Resonance.	  2003;5:505-­‐514	  
199.	   Simonetti	  OP,	  Kim	  RJ,	  Fieno	  DS,	  Hillenbrand	  HB,	  Wu	  E,	  Bundy	  JM,	  Finn	  JP,	  
Judd	  RM.	  An	  improved	  MR	  imaging	  technique	  for	  the	  visualization	  of	  
myocardial	  infarction.	  Radiology.	  2001;218:215-­‐223	  
200.	   Kellman	  P,	  Chung	  Y-­‐C,	  Simonetti	  OP,	  McVeigh	  ER,	  Arai	  AE.	  Multi-­‐contrast	  
delayed	  enhancement	  provides	  improved	  contrast	  between	  myocardial	  
infarction	  and	  blood	  pool.	  J	  Magn	  Reson	  Imaging.	  2005;22:605-­‐613	  
201.	   Farrelly	  C,	  Rehwald	  W,	  Salerno	  M,	  Davarpanah	  A,	  Keeling	  AN,	  Jacobson	  JT,	  
Carr	  JC.	  Improved	  detection	  of	  subendocardial	  hyperenhancement	  in	  
myocardial	  infarction	  using	  dark	  blood-­‐pool	  delayed	  enhancement	  mri.	  
AJR	  Am	  J	  Roentgenol.	  2011;196:339-­‐348	  
202.	   Yarnykh	  VL,	  Yuan	  C.	  T1-­‐insensitive	  flow	  suppression	  using	  quadruple	  
inversion-­‐recovery.	  Magn	  Reson	  Med.	  2002;48:899-­‐905	  
203.	   Tonino	  PAL,	  Fearon	  WF,	  de	  Bruyne	  B,	  Oldroyd	  KG,	  Leesar	  MA,	  Ver	  Lee	  PN,	  
MacCarthy	  PA,	  Van't	  Veer	  M,	  Pijls	  NHJ.	  Angiographic	  versus	  functional	  
severity	  of	  coronary	  artery	  stenoses	  in	  the	  fame	  study	  fractional	  flow	  
  292 
reserve	  versus	  angiography	  in	  multivessel	  evaluation.	  Journal	  of	  the	  
American	  College	  of	  Cardiology.	  2010;55:2816-­‐2821	  
204.	   Falk	  E,	  Shah	  PK,	  Fuster	  V.	  Coronary	  plaque	  disruption.	  Circulation.	  
1995;92:657-­‐671	  
205.	   Razavi	  R,	  Hill	  DLG,	  Keevil	  SF,	  Miquel	  ME,	  Muthurangu	  V,	  Hegde	  S,	  Rhode	  K,	  
Barnett	  M,	  van	  Vaals	  J,	  Hawkes	  DJ,	  Baker	  E.	  Cardiac	  catheterisation	  guided	  
by	  mri	  in	  children	  and	  adults	  with	  congenital	  heart	  disease.	  Lancet.	  
2003;362:1877-­‐1882	  
206.	   Schenck	  JF,	  Jolesz	  FA,	  Roemer	  PB,	  Cline	  HE,	  Lorensen	  WE,	  Kikinis	  R,	  
Silverman	  SG,	  Hardy	  CJ,	  Barber	  WD,	  Laskaris	  ET,	  et	  al.	  Superconducting	  
open-­‐configuration	  MR	  imaging	  system	  for	  image-­‐guided	  therapy.	  
Radiology.	  1995;195:805-­‐814	  
207.	   Tzifa	  A,	  Krombach	  GA,	  Kramer	  N,	  Kruger	  S,	  Schutte	  A,	  Von	  Walter	  M,	  
Schaeffter	  T,	  Qureshi	  S,	  Krasemann	  T,	  Rosenthal	  E,	  Schwartz	  CA,	  Varma	  G,	  
Buhl	  A,	  Kohlmeier	  A,	  Bucker	  A,	  Gunther	  RW,	  Razavi	  R.	  Magnetic	  resonance-­‐
guided	  cardiac	  interventions	  using	  magnetic	  resonance-­‐compatible	  
devices:	  A	  preclinical	  study	  and	  first-­‐in-­‐man	  congenital	  interventions.	  
Circulation:	  Cardiovascular	  Interventions.	  2010;3:585-­‐592	  
208.	   Dick	  AJ,	  Raman	  VK,	  Raval	  AN,	  Guttman	  MA,	  Thompson	  RB,	  Ozturk	  C,	  Peters	  
DC,	  Stine	  AM,	  Wright	  VJ,	  Schenke	  WH,	  Lederman	  RJ.	  Invasive	  human	  
magnetic	  resonance	  imaging:	  Feasibility	  during	  revascularization	  in	  a	  
combined	  XMR	  suite.	  Catheterization	  and	  cardiovascular	  interventions.	  
2005;64:265-­‐274	  
  293 
209.	   Spuentrup	  E,	  Ruebben	  A,	  Schaeffter	  T,	  Manning	  WJ,	  Günther	  RW,	  Buecker	  A.	  
Magnetic	  resonance-­‐-­‐guided	  coronary	  artery	  stent	  placement	  in	  a	  swine	  
model.	  Circulation.	  2002;105:874-­‐879	  
210.	   Rhode	  KS,	  Hill	  DLG,	  Edwards	  PJ,	  Hipwell	  J,	  Rueckert	  D,	  Sanchez-­‐Ortiz	  G,	  
Hegde	  S,	  Rahunathan	  V,	  Razavi	  R.	  Registration	  and	  tracking	  to	  integrate	  x-­‐
ray	  and	  mr	  images	  in	  an	  xmr	  facility.	  IEEE	  Trans	  Med	  Imaging.	  
2003;22:1369-­‐1378	  
211.	   Duckett	  SG,	  Ginks	  MR,	  Knowles	  BR,	  Ma	  Y,	  Shetty	  A,	  Bostock	  J,	  Cooklin	  M,	  Gill	  
JS,	  Carr-­‐White	  GS,	  Razavi	  R,	  Schaeffter	  T,	  Rhode	  KS,	  Rinaldi	  CA.	  Advanced	  
image	  fusion	  to	  overlay	  coronary	  sinus	  anatomy	  with	  real-­‐time	  
fluoroscopy	  to	  facilitate	  left	  ventricular	  lead	  implantation	  in	  CRT.	  Pacing	  
and	  Clinical	  Electrophysiology.	  2010;34:226-­‐234	  
212.	   Ishida	  M,	  Ichihara	  T,	  Nagata	  M,	  Ishida	  N,	  Takase	  S,	  Kurita	  T,	  Ito	  M,	  Takeda	  
K,	  Sakuma	  H.	  Quantification	  of	  myocardial	  blood	  flow	  using	  model	  based	  
analysis	  of	  first-­‐pass	  perfusion	  mri:	  Extraction	  fraction	  of	  gd-­‐dtpa	  varies	  
with	  myocardial	  blood	  flow	  in	  human	  myocardium.	  Magn	  Reson	  Med.	  
2011;66:1391-­‐1399	  
213.	   Ferreira	  P,	  Gatehouse	  P,	  Bucciarelli-­‐Ducci	  C,	  Wage	  R,	  Firmin	  D.	  
Measurement	  of	  myocardial	  frequency	  offsets	  during	  first	  pass	  of	  a	  
gadolinium-­‐based	  contrast	  agent	  in	  perfusion	  studies.	  Mag	  Reson	  Med.	  
2008;60:860-­‐870	  
214.	   Schmitt	  M,	  Viallon	  M,	  Thelen	  M,	  Schreiber	  WG.	  Quantification	  of	  
myocardial	  blood	  flow	  and	  blood	  flow	  reserve	  in	  the	  presence	  of	  arterial	  
dispersion:	  A	  simulation	  study.	  Magn	  Reson	  Med.	  2002;47:787-­‐793	  
  294 
215.	   Schuster	  A,	  Grünwald	  I,	  Chiribiri	  A,	  Southworth	  R,	  Ishida	  M,	  Hay	  G,	  
Neumann	  N,	  Morton	  G,	  Perera	  D,	  Schaeffter	  T,	  Nagel	  E.	  An	  isolated	  
perfused	  pig	  heart	  model	  for	  the	  development,	  validation	  and	  translation	  
of	  novel	  cardiovascular	  magnetic	  resonance	  techniques.	  J.	  Cardiovasc	  
Magnetic	  Resonance.	  2010:12:53	  
216.	   Jahnke	  C,	  Gebker	  R,	  Manka	  R,	  Schnackenburg	  B,	  Fleck	  E,	  Paetsch	  I.	  
Navigator-­‐gated	  3d	  blood	  oxygen	  level–dependent	  cmr	  at	  3.0-­‐t	  for	  
detection	  of	  stress-­‐induced	  myocardial	  ischemic	  reactions.	  JACC.	  
Cardiovascular	  imaging.	  2010;3:375-­‐384	  
217.	   Blankstein	  R,	  Carli	  MFD.	  Integration	  of	  coronary	  anatomy	  and	  myocardial	  
perfusion	  imaging.	  Nat	  Rev	  Cardiol.	  2010;7:226-­‐236	  
218.	   Kajander	  S,	  Joutsiniemi	  E,	  Saraste	  M,	  Pietila	  M,	  Ukkonen	  H,	  Saraste	  A,	  
Sipila	  HT,	  Teras	  M,	  Maki	  M,	  Airaksinen	  J,	  Hartiala	  J,	  Knuuti	  J.	  Cardiac	  
positron	  emission	  tomography/computed	  tomography	  imaging	  accurately	  
detects	  anatomically	  and	  functionally	  significant	  coronary	  artery	  disease.	  
Circulation.	  2010;122:603-­‐613	  
	  	  	   	  
  295 
Appendix	  A	   Study	  Protocols,	  Patient	  Information	  Sheets	  
and	  Consent	  Forms	  
	  
	  
Validation	   of	   new	   quantitative	   MR	   perfusion	   algorithms	   in	  
comparison	  to	  SPECT,	  PET-­‐CT	  and	  fractional	  flow	  reserve	  in	  a	  
prospective	   group	   of	   patients	   with	   suspected	   or	   known	  
coronary	  artery	  disease	  
 
 
 
 
 
 
Study protocol Version 4 
28 October 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  296 
Introduction 
 
Background: Myocardial perfusion and functional assessment of the 
haemodynamic significance of coronary stenoses, as well as the extent and 
distribution of ischaemia are determining factors in the management of 
coronary artery disease (CAD) in clinical practice.  
 
Non-invasive assessment of perfusion is usually performed with single 
photon emission computed tomography (SPECT) or positron emission 
tomography (PET-CT). Both PET and SPECT involve exposure of patients to 
ionising radiation. In addition PET-CT has limited availability and higher 
expense when compared to SPECT, whereas the latter has a higher rate of 
attenuation artefacts. A recent multicenter study showed that perfusion 
Cardiac Magnetic Resonance (CMR) can be used as an alternative method 
of detecting and assessing CAD (1). Normal perfusion CMR predicts 
approximately a 0.7% 2 -year cumulative event rate whereas the detection of 
ischaemia 12.2% (2).  
 
CMR combines the advantage of higher spatial resolution (3x3mm versus 
10x10mm for SPECT) with no exposure to ionising radiation and shorter 
acquisition times in comparison to nuclear imaging. MR perfusion imaging 
can be further improved using higher field strengths and advanced 
acceleration methods such as k-t sensitivity encoding (k-t SENSE) (3, 4, 5). 
k-t SENSE allows acceleration of data acquisition in dynamic MR studies 
through sparse data sampling along the spatial (k) and temporal (t) encoding 
axes and spatio- temporal data correlation.  Data undersampling leads to 
faster acquisition times and has been validated in previous studies mainly at 
1.5 Tesla.  Preliminary data have demonstrated the superiority of 3 Tesla 
accelerated with k-t SENSE in perfusion imaging.	  	  
 
 
Aim: In this prospective study we aim to evaluate the diagnostic accuracy of 
perfusion CMR at 1.5 and 3 Tesla with SPECT and PET-CT in a population 
with suspected or known CAD planned to have diagnostic coronary 
angiography. We will also compare CMR perfusion findings with invasive 
measurements such as Fractional Flow Reserve (FFR), Coronary Flow 
Reserve (CFR) and Hyperaemia Stenosis Resistance (HSR).  
 Primary end points 
1. To validate new CMR methods of assessing myocardial perfusion and 
ischaemia burden in patients with suspected or known CAD against 
other non-invasive methods such as SPECT and PET-CT and 
invasive coronary angiography with FFR, CFR and HSR 
measurement. 
2. Identify the optimal cut off point for the detection of significant 
coronary artery stenoses requiring further intervention. 
Secondary end points 
1. To evaluate image quality by using the new methods of assessing 
perfusion and ischaemia burden at a 1.5 Tesla and a 3 Tesla 
(stronger magnet) MR scanner.  
2. To assess the type, frequency, and severity of the artefacts.  
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3. To assess the reproducibility of perfusion CMR at 1.5 and 3 Tesla 
4. To quantify the CMR examination time  
5. To assess the feasibility of full quantification of CMR perfusion 
6. To validate perfusion CMR algorithms at 1.5 and 3 Tesla 
7. To assess the prognostic value of perfusion CMR at 1.5 and 3 Tesla 
8. To assess image quality of CMR, PET and SPECT with ECG and 
respiratory monitoring 
 
 
 
Study Design 
 
Methods: In a randomly selected population (77 patients) with suspected or 
known CAD prior to their planned diagnostic coronary angiography we will 
perform perfusion CMR and either SPECT (17 patients) or PET-CT (60 
patients). Patients will be identified from the chest pain clinic, the diagnostic 
coronary angiography list or the waiting lists for clinical SPECT or PET-CT 
studies. This is a validation study, which will provide data for future larger 
trials. The following study steps are planned:  
 
Step 1: Patient identification from the chest pain clinic, the diagnostic 
coronary angiography list or the waiting lists for SPECT or PET-CT. Inform 
patients about the study and obtain informed consent. 
Step 2: Perform perfusion CMR at 1.5 or 3 Tesla. 
Step 3: Perform either PET-CT or SPECT. Quantitative and qualitative CMR 
measurements will be compared with PET-CT and SPECT measurements to 
explore agreement among different methods of non–invasive assessment of 
CAD.  
Step 4: Coronary Angiography providing with a qualitative assessment of 
CAD initially for all patients. A number of patients with 40-90-% luminal 
reduction will undergo a second coronary angiography with invasive 
measurements including FFR, HSR, CFR. These measurements will be 
compared with MRI findings.  
Step 5: A small number of patients will be asked to have a second CMR to 
assess reproducibility. 
Step 6: Patients from the PET arm who are subsequently revascularised will 
be invited back for one final CMR during the first 6 months post operatively. 
Step 7: Follow up at 2, 5 and 10 years for adverse cardiac events to assess 
the prognostic value of CMR at 1.5 and 3 Tesla. 
 
The flow chart of the study is as shown in Figure 1. 	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Figure 1. Study Flow chart 
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Eligibility 
 
Inclusion Criteria 
1. Patients with suspected or known CAD undergoing invasive coronary 
angiography 
2. Patients with a history of angina Canadian Cardiovascular Society Class I, 
II and III 
3. Patients who have given informed written consent 
 
 
 
Exclusion Criteria 
1. Contraindications to MR (implanted electronic devices, metallic foreign 
bodies, and others according to manufacturer’s recommendations and 
generally accepted guidelines)(6, 7) 
2. Pregnancy/breastfeeding/females of child-bearing age 
3. Claustrophobia 
4. Mental disability/ Inability to consent  
5. Allergy to contrast media  
6. Poor renal function eGFR<30ml/min  
7. Heart Failure New York Heart Association Class III/IV  
8. Inability to lie flat (i.e MSK disease/ COPD with cor pulmonale) 
9. Body weight > 140kg and waist perimeter > 95cm 
10. Unstable medically  
11. Atrio-ventricular block II/III, sick sinus syndrome, symptomatic 
bradycardia, asthma or Chronic Obstructive Pulmonary Disease as 
contraindications to adenosine 
12. Previous ST Elevation Myocardial Infarction or Coronary Artery 
Bypass Graft. 
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Investigation protocols 
 
CMR study 
1. Consent 
Written informed consent will be obtained for participation to the study.  
 
2. Patient preparation 
Prior to the examination, the patient will be provided with detailed information 
about the course of the examination, the breathhold procedure, the use of 
contrast agents and the use of medication. Generally breathholding should 
be performed during end-expiration to ensure reproducible slice geometry. A 
venous line will be inserted into the cubital vein of one arm and connected to 
the contrast pump. A second venous line will be inserted into the other arm 
and connected to the adenosine infusion. An MR compatible blood pressure 
monitor will be connected. Patients will be instructed not to take caffeine, tea 
or smoke if smokers for 24 hours prior to the scan. They will be also told not 
to take medications such as b-blockers, nitrates and calcium channel 
blockers for 24 hours prior to the scan. 
 
3. CMR protocol 
The CMR studies will be carried out on a 1.5 or 3Tesla cardiac research 
scanner (Philips) at Guy’s and St Thomas’ NHS Foundation Trust or at Bart’s 
and The London NHS Trust. The study will include localisers, cine images 
and rest and Adenosine-stress perfusion imaging. Rest and adenosine stress 
myocardial perfusion flow studies will be performed. Adenosine will be 
administered as a continuous peripheral intravenous infusion at 140 
mcg/kg/min for 3-6 minutes. First-pass contrast-enhanced perfusion imaging 
will use a bolus intravenous injection of non-ionic gadolinium (up to 
0.2mmol/kg bodyweight). Late enhancement will take place 15mins after the 
gadolinium injection. 	  
4. Stress agent adenosine 
Adenosine, an endogenous nucleotide, is a potent vasodilator of most 
vascular beds, except for hepatic and renal arterioles. With adenosine a 
maximal coronary vasodilatation can be achieved safely with an intravenous 
infusion at a rate of 140 µg/kg/min.  
The short biological half-life (approximately 20 seconds) of this agent allows 
for repeated administration of this agent. 
 
Side Effects 
The vasodilatory effect of adenosine may result in a mild-to-moderate reduction in 
systolic, diastolic and mean arterial blood pressure (< 10 mmHg) with a reflex 
increase in heart rate. Most patients complain about chest discomfort. These effects, 
however, are transient and usually do not require medical intervention. 
Since adenosine exerts a direct depressant effect on the SA and AV nodes 
transient first-, second- and third-degree AV block and sinus bradycardia have been 
reported in 2.9%, 2.6% and 0.8% of patients. Also, adenosine can cause 
hypotension. Patients with intact baroreceptor reflex are able to maintain blood 
pressure in response to adenosine by increasing cardiac output and heart rate. 
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Adenosine can also cause a paradoxical increase in systolic and diastolic blood 
pressure, which mostly develops in individuals with significant left ventricular 
hypertrophy. These increases are transient and resolve spontaneously. Because 
adenosine is a respiratory stimulant primarily through activation of carotid body 
chemoreceptors, intravenous administration showed increases in minute ventilation, 
reduction in arterial PCO2 and respiratory alkalosis. Approximately 14% of patients 
complain of dyspnea and an urge to breathe deeply during adenosine infusion. 
 
Contraindications 
Adenosine should be used with caution in patients with pre-existing AV block or 
bundle branch block and should be avoided in patients with high-grade AV block or 
sinus node dysfunction. Adenosine should be used with caution if a patient is 
receiving any medications that already depress the sinus node and/or AV node (e.g. 
beta-blockers, calcium channel blockers, cardiac glycosides). Adenosine should be 
discontinued in patients who develop persistent or symptomatic high-grade block or 
significant drop in systolic blood pressure (>20 mmHg). The drug should be 
discontinued in case of persistent or symptomatic hypotension.  
Also, adenosine should be used with caution in patients with autonomic dysfunction, 
stenotic valvular heart disease, pericarditis and pericardial effusion, stenotic carotid 
artery disease, cerebrovascular insufficiency and uncorrected hypovolemia. 
Adenosine infusion should be exercised with caution in patients with obstructive 
lung disease not associated with broncho-constriction (emphysema, bronchitis, etc), 
and should be avoided in patients with bronchoconstriction or bronchospasm (e.g. 
asthma). If a patient develops severe respiratory difficulties, adenosine should be 
immediately discontinued. 
 
5. Monitoring and Safety 
During the entire CMR examination, volunteers and patients are being 
monitored closely. In general, monitoring during a MR examination requires 
the same precautions and emergency equipment as any other stress 
examination.  
 
Monitoring requirements for adenosine stress MR imaging: 	  	  	  	  
	  
6. Termination criteria 
• Clinical symptoms (significant chest pain, severe respiratory difficulty) 
• Blood pressure increase > 240/120 mmHg 
• Persistent or symptomatic hypotension 
• Complex cardiac arrhythmias 
 
 
 
 
 
Heart rate and rhythm Continuously 
Blood pressure During Adenosine infusion every 2 min 
Vector-ECG Continuously 
Symptoms Continuously 
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SPECT protocol 
This study will be conducted as in routine clinical practice. Patient 
preparation and instructions regarding medications and caffeinated drinks 
prior to the scan are very similar to the CMR study. SPECT rest and stress 
studies though are conducted in two separate sessions.  
A) Rest study: An intravenous line will be inserted and the radioactive 
tracer Technecium 99m Tetrafosmin (maximum dose 10mSv) will be 
injected.  45 minutes later imaging will be initiated. 
B) Stress study: This study involves in comparison to the rest study the 
additional injection of adenosine, the pharmacological stressor used in 
CMR. Similar patient monitoring and safety regulations to the CMR 
study will apply. 
 
PET-CT protocol 
This study is conducted as in routine clinical practice.  13N Ammonia will be 
used as a radioactive tracer and stress will be induced with adenosine both 
of which will be injected intravenously. Patient instructions prior to the scan, 
monitoring and safety are as per the MR study.  
 
Coronary angiography 
Angiography will be performed by clinical indication using a standard 
technique. Multiple projections will be acquired of the left and right coronary 
artery systems. Invasive measurements of FFR, CFR and HSR will be 
obtained only if patients have a 40-90% luminal reduction and require a 
second procedure. FFR will be measured in all first order coronary arteries 
using an intracoronary flow wire and intracoronary or peripheral 
administration of Adenosine.  
 
Data analysis 
Perfusion CMR, SPECT and PET-CT results will be read by 2 readers with 
over two years of experience blinded to patients’ clinical information or 
results of any other studies. In case of a significant inter-reader variation a 
third reader will review the scan in question. 
Myocardial perfusion with CMR will be analysed in a quantitative manner 
using model-independent deconvolution analysis and various “semi”-
quantitative methods (such as upslopes derived from signal-time intensity 
profiles). Data will be therefore transferred to a Philips “Viewforum” 
workstation. 
SPECT and PET-CT data will be also analysed in a quantitative manner. 
Data from the three non- invasive tests will be compared to explore 
agreement. 
CMR perfusion data will be also compared to angiography qualitative data 
from all patients. In patients undergoing invasive measurements during 
angiography CMR perfusion analysis methods will be compared against 
invasive pressure-wire derived FFR using a cut-off for normal FFR of 0.75. 
The correlation of CMR and X-ray measurements will be determined.  
The diagnostic accuracy of CMR to detect the presence of flow-limiting 
coronary stenosis on x-ray angiography defined as >70% luminal stenosis of 
a first order coronary artery segment will be determined. 
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Statistical Analysis 
All analyses will be conducted using appropriate quantitative methods for 
each test. 1) ROC curves will be used to determine a cut off value for MR 
measurements predicting ischaemia. Sensitivity and specificity will be equally 
weighted and thus the Youden index will be used to determine the best 
possible cut off value. 2)To compare the prediction of ischaemia by different 
parameters MRI, SPECT and PET ROC curves will be used. 
Additionally the measurements of MRI and SPECT or MRI and PET will be 
compared using correlation analysis and weighted K values.  
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You	   are	   being	   invited	   to	   take	   part	   in	   a	   research	   study.	   	   Before	   you	   decide	   it	   is	  
important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  will	  
involve.	   	   Please	   take	   time	   to	   read	   the	   following	   information	   carefully.	   Talk	   to	  
others	  about	  the	  study	  if	  you	  wish.	  	  
• Part	  1	   tells	   you	   the	  purpose	  of	   this	   study	  and	  what	  will	  happen	   to	  you	   if	   you	  
take	  part.	  	  	  
• Part	  2	  gives	  you	  more	  detailed	  information	  about	  the	  conduct	  of	  the	  study.	  	  
Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  	  
Take	  time	  to	  decide	  whether	  or	  not	  you	  wish	  to	  take	  part.	  
PART	  1	  
What	  is	  the	  purpose	  of	  the	  study?	  Magnetic	  Resonance	   Imaging	  (MRI)	   is	  an	  effective	  method	  of	   taking	   images	  of	  the	   internal	   organs	   of	   the	   body.	   It	   can	   also	   provide	   information	   of	   the	   blood	  supply	   to	   the	   heart	   muscle.	   This	   information	   is	   particularly	   important	   in	  patients	  who	   have	   chest	   pain	   because	   of	   blocked	   or	   narrowed	   heart	   arteries.	  This	  is	  usually	  the	  disease	  called	  coronary	  artery	  disease	  (CAD).	  	  MRI	   has	   several	   advantages	   over	   other	   tests	   as	   it	   is	   simple,	   does	   not	   involve	  radiation	   and	   can	   lead	   to	   images	   of	   very	   high	   detail.	   We	   have	   recently	  developed	   a	   new	  method	   that	   allows	   us	   to	   further	   improve	   the	   clarity	   of	   the	  MRI	  images	  of	  the	  heart’s	  blood	  supply.	  	  In	  this	  study,	  we	  want	  to	  test	  this	  new	  method	  and	  find	  out	  how	  it	  compares	  to	  other	   tests	   called	   Positron	   Emission	   Tomography	   (PET-­‐CT),	   single	   photon	  emission	  tomography	  (SPECT)	  and	  coronary	  angiography.	  This	  may	  allow	  us	  in	  future	  to	  assess	  patients	  with	  suspected	  without	  needing	  invasive	  tests	  or	  scans	  using	  radiation.	  	  Our	  study	  has	  different	  parts	  and	  each	  participant	  will	  be	  involved	  only	  in	  some,	  therefore	  we	  will	   provide	   you	   only	  with	   the	   relevant	   information.	   Participant	  selection	  to	  the	  different	  parts	  is	  done	  in	  randomised	  fashion.	  	  
Why	  have	  I	  been	  chosen?	  	  We	  are	   interested	   in	   patients	   that	   have	   or	  may	  have	  CAD	  and	   you	  have	  been	  referred	  for	  a	  coronary	  angiography	  to	  investigate	  your	  heart’s	  blood	  supply.	  	  
Do	  I	  have	  to	  take	  part?	  No.	  It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  do,	  you	  will	  be	  given	  this	   information	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  a	  consent	  form.	  You	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are	  still	  free	  to	  withdraw	  at	  any	  time	  and	  without	  giving	  a	  reason.	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  decision	  not	  to	  take	  part,	  will	  not	  affect	  your	  medical	  management.	  	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  	  1)	   We	   will	   contact	   you	   by	   phone	   to	   discuss	   the	   study	   and	   if	   you	   wish	   to	  participate	  we	  will	  arrange	  an	  appointment	  to	  sign	  a	  consent	  form	  and	  perform	  an	  MRI	  scan.	  	  	  2)	  MRI	  scan	  (research	  scan)	  	  This	  involves	  placing	  you	  in	  a	  tunnel	  shaped	  scanner,	  so	  it	  is	  important	  you	  feel	  comfortable	  in	  closed	  spaces.	  While	  the	  images	  are	  taken,	  you	  will	  be	  asked	  to	  lie	  quietly	  on	  your	  back	  and	   follow	  breathing	   instructions.	   Inside	   the	  scanner,	  you	  will	  hear	  loud	  machine-­‐like	  noises,	  as	  part	  of	  the	  imaging	  process	  –	  this	  is	  normal.	  	  The	   purpose	   of	   this	   exam	   is	   to	   identify	   the	   areas	   of	   your	   heart	   where	   blood	  supply	   is	   reduced.	  During	   the	   test	  we	  will	  make	   the	  heart	   stress	   that	   aims	   to	  maximise	  blood	  flow	  to	  the	  heart.	  For	  this	  reason	  two	  intravenous	  lines	  will	  be	  inserted	  in	  arm	  veins	  and	  will	  be	  used	  to	  inject	  the	  contrast	  agent	  (a	  substance	  allowing	  to	  take	  images	  of	  the	  heart)	  for	  the	  blood	  flow	  measurements	  and	  the	  medicine	   causing	   the	   heart	   to	   stress.	   Throughout	   the	   scan	   we	   will	   be	  monitoring	  your	  heart	  tracing,	  pulse	  and	  breathing.	  If	  you	  feel	  uncomfortable	  at	  any	  point	  you	  can	   let	  us	  know	  by	  squeezing	  a	  small	  ball	   that	  will	  be	  placed	   in	  your	  hand.	  	  The	  scan	  will	  take	  approximately	  60mins.	  	  3)	  PET-­‐CT	  (research	  scan)	  The	  procedure	   is	  very	   similar	   to	  MRI	  and	   takes	  approximately	  1	  hour	  and	  20	  minutes.	   It	   requires	   the	   injection	   of	   a	   radioactive	   dye	   that	   is	   taken	   up	   by	   the	  heart	  and	  is	  imaged	  by	  the	  PET	  scanner.	  	  4)	  We	  would	  like	  with	  your	  permission	  to	  compare	  the	  results	  of	  your	  coronary	  angiography	  with	  our	  scans.	  	  5)	  You	  may	  be	  asked	  to	  perform	  another	  MRI	  scan	  on	  another	  day	  if	  you	  agree.	  	  This	   is	   to	   help	   us	   demonstrate	   that	   this	   technique	   can	   provide	   us	   with	  reproducible	  results.	  	  	  6)	  If	  you	  go	  on	  to	  have	  an	  operation	  to	  improve	  the	  blood	  supply	  to	  the	  heart	  we	  may	  invite	  you	  back	  for	  one	  final	  MRI	  scan	  in	  the	  6	  months	  after	  the	  operation.	  	  7)	  We	  would	  like	  to	  follow	  you	  up	  at	  2,	  5	  and	  10	  years.	  Follow	  up	  will	   involve	  initially	  contacting	  your	  GP	  and	  then	  you	  and	  obtaining	  information	  about	  your	  health.	  In	  the	  case	  you	  are	  unable	  to	  provide	  us	  with	  information	  for	  the	  follow	  up	  we	  would	  like	  to	  obtain	  it	  with	  your	  permission	  from	  your	  next	  of	  kin	  or	  GP.	  	  
What	  do	  I	  have	  to	  do?	  	  1) Sign	  a	  consent	  form	  2) Attend	   the	   MRI	   and	   PET	   scans,	   scheduled	   according	   to	   yours	   and	   the	  hospital’s	  convenience,	  that	  involves	  two	  visits.	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What	  is	  the	  procedure	  that	  is	  being	  tested?	  The	  procedure	  tested	  is	  perfusion	  MRI	  at	  3	  Tesla.	  Perfusion	  MRI	  at	  1.5	  Tesla	  has	  been	  so	   far	  used	   in	  clinical	  practice	  however	   in	   this	   study	  we	  aim	   to	   improve	  standard	  MRI	  using	  a	  stronger	  magnet	  (3	  Tesla).	  	  
	  
What	  are	  the	  alternatives	  for	  diagnosis?	  PET,	  SPECT,	  MRI	  at	  1.5	  Tesla	  and	  coronary	  angiography	  are	  also	  used	  in	  clinical	  practice	  as	  methods	  of	  evaluating	  CAD.	  
	  
What	  are	  the	  side	  effects	  of	  taking	  part?	  	  The	  MRI	  scan	  cannot	  be	  done	  under	  certain	  circumstances	  such	  as	  if	  you	  suffer	  from	  claustrophobia	  or	  have	  previously	  had	  any	  metal	  implants	  inserted	  in	  your	  body.	  	  It	  is	  noisy,	  so	  ear	  protection	  is	  provided.	  Overall,	  it	  is	  very	  low	  risk.	  The	  medication	  which	  increases	  the	  blood	  flow	  to	  the	  heart	  and	  will	  be	  used	  in	  both	   MRI	   and	   PET-­‐CT	   can	   cause	   shortness	   of	   breath,	   chest	   pain,	   dizziness,	  flushing	  and	  changes	  to	  the	  heart	  rhythm.	  All	  these	  effects,	  if	  they	  occur,	  last	  for	  a	  few	  minutes	  only	  and	  settle	  completely	  thereafter.	  All	  scans	  are	  painless	  and	  you	  should	  be	  able	  to	  return	  home	  on	  the	  same	  day	  without	  any	  side	  effects	  or	  restriction	  to	  your	  normal	  daily	  activities.	  
	  
What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  	  	  A)	   The	   PET-­‐CT	   scan	   and	   the	   radioactive	   dye	   gives	   you	   a	   radiation	   dose.	   The	  radiation	  in	  this	  study	  is	  the	  same	  amount	  that	   is	  used	  for	  this	  type	  of	  scan	  in	  routine	  clinical	  practice.	  The	  risk	  from	  the	  radiation	  is	  equivalent	  to	  4	  years	  of	  background	   radiation	   in	   the	  UK	   i.e.	   the	   radiation	   anyone	   receives	  by	   living	   in	  the	  UK	  4	  years.	  	  	  B)	   A	   small	   number	   of	   participants	   undergoing	   MRI	   develop	   feelings	   of	  claustrophobia.	  If	  you	  feel	  claustrophobic	  then	  you	  can	  ask	  for	  the	  study	  to	  be	  terminated.	  C)	  During	  MRI	  and	  PET-­‐CT	  there	  is	  the	  potential	  for	  an	  allergic	  reaction	  to	  the	  contrast	  agent.	   If	  you	  have	  had	  an	  allergic	  reaction	  to	  a	  contrast	  agent	  we	  will	  not	   perform	   the	   tests.	   Should	   an	   allergic	   reaction	   develop	   you	   are	   in	   the	  hospital	  environment	  and	  will	  be	  treated	  immediately	  D)	   The	   medication	   which	   increases	   the	   blood	   flow	   to	   the	   heart	   can	   cause	  changes	  to	  the	  heart	  rhythm	  that	  usually	  settles	  completely	  thereafter.	  
	  
What	  happens	  when	  the	  research	  study	  stops?	  Your	  further	  management	  depends	  on	  the	  findings	  in	  angiography.	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What	  if	  there	  is	  a	  problem?	  	  Any	  complaint	  about	  the	  way	  you	  have	  been	  dealt	  with	  during	  the	  study	  or	  any	  possible	  harm	  you	  might	  suffer	  will	  be	  addressed.	  The	  detailed	  information	  on	  this	  is	  given	  in	  Part	  2	  	  
Will	  my	  taking	  part	  in	  the	  study	  be	  kept	  confidential?	  Yes.	   All	   the	   information	   about	   your	   participation	   in	   this	   study	   will	   be	   kept	  confidential.	  The	  details	  are	  included	  in	  Part	  2.	  
	  
This	  completes	  Part	  1	  of	  the	  Information	  Sheet.	  
If	   the	   information	   in	   Part	   1	   has	   interested	   you	   and	   you	   are	   considering	  
participation,	  please	  continue	  to	  read	  the	  additional	  information	  in	  Part	  2	  
before	  making	  any	  decision.	  
	  
PART	  2	  
What	  if	  relevant	  new	  information	  becomes	  available?	  Sometimes	  during	   the	   course	  of	   a	   research	  project,	  new	   information	  becomes	  available	   about	   the	   procedure	   that	   is	   being	   studied.	   	   If	   this	   happens,	   your	  research	  doctor	  will	  tell	  you	  about	  it	  and	  discuss	  whether	  you	  want	  to	  or	  should	  continue	  in	  the	  study.	   	   If	  you	  decide	  not	  to	  carry	  on,	  your	  research	  doctor	  will	  make	  arrangements	  for	  your	  care	  to	  continue.	  	  If	  you	  decide	  to	  continue	  in	  the	  study	  you	  will	  be	  asked	  to	  sign	  an	  updated	  consent	  form.	  Also,	  on	  receiving	  new	  information	  your	  research	  doctor	  might	  consider	  it	  to	  be	  in	  your	  best	  interests	  to	  withdraw	  you	  from	  the	  study.	   	  He/she	  will	  explain	  the	  reasons	  and	  arrange	  for	  your	  care	  to	  continue.	  If	  the	  study	  is	  stopped	  for	  any	  other	  reason,	  you	  will	  be	  told	  why	  and	  your	  continuing	  care	  will	  be	  arranged.	  
What	  will	  happen	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  You	  can	  withdraw	  at	  any	  point	  and	  this	  will	  not	  affect	  your	  medical	  treatment.	  If	  you	  withdraw	  from	  the	  study,	  we	  will	  need	  to	  use	  the	  data	  collected	  up	  to	  your	  withdrawal.	  	  
What	  if	  there	  is	  a	  problem?	  
Complaints:	   If	  you	  have	  a	  concern	  about	  any	  aspect	  of	   this	  study,	  you	  should	  ask	   to	   speak	   with	   the	   researchers	   who	   will	   do	   their	   best	   to	   answer	   your	  questions	   (Prof.	   Eike	  Nagel;	  Office	  number	  +44	  20	  7188	  8363.	   	   If	   you	   remain	  unhappy	   and	   wish	   to	   complain	   formally,	   you	   can	   do	   this	   through	   the	   NHS	  Complaints	  Procedure.	  	  Details	  can	  be	  obtained	  from	  the	  hospital.	  
Harm:	  	  In	  the	  event	  that	  something	  does	  go	  wrong	  and	  you	  are	  harmed	  during	  the	  research	  study	  there	  are	  no	  special	  compensation	  arrangements.	  	  If	  you	  are	  harmed	  and	  this	  is	  due	  to	  someone’s	  negligence	  then	  you	  may	  have	  grounds	  for	  a	   legal	  action	   for	  compensation	  against	  Guy’	  &	  St.	  Thomas’	  NHS	  Trust	  but	  you	  may	   have	   to	   pay	   your	   legal	   costs.	   The	   normal	   National	   Health	   Service	  complaints	  mechanisms	  will	  still	  be	  available	  to	  you.	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Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  Procedures	   for	  handling,	  processing,	   storage	  and	  destruction	  of	   your	  data	  are	  compliant	  with	  the	  Data	  Protection	  Act	  1998.	  All	   information	  which	  is	  collected	  about	  you	  during	  the	  course	  of	  the	  research	  will	  be	  kept	  strictly	  confidential.	   	  Any	   information	  about	  you	  which	   leaves	  the	  hospital	   will	   have	   your	   name	   and	   address	   removed	   so	   that	   you	   cannot	   be	  recognised	  from	  it.	  Your	  data	  will	  be	  collected	   from	  the	   referral	   letter	  and	  hospital	  notes,	   as	  well	  from	  discussing	  with	  you	  during	  the	  interview;	  Data	  will	  be	  stored	  securely,	  in	  an	   encrypted	   format;	   Authorised	   persons	   such	   as	   researchers,	   regulatory	  authorities	  and	  Research	  and	  Development	  (for	  monitoring	  of	  the	  quality	  of	  the	  research)	  will	  have	  assess	  to	  these	  data;	  Data	  will	  be	  retained	  for	  15	  years.	  Your	   own	   GP	   may	   be	   notified	   of	   your	   participation	   in	   the	   trial,	   after	   your	  consent.	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  These	   will	   be	   published	   in	   a	   research	   paper	   with	   the	   aim	   of	   advancing	   the	  knowledge	  of	  MRI	  and	  ischemic	  heart	  disease.	  All	  patient	  identities	  are	  treated	  as	  strictly	  confidential	  and	  anonymous	  in	  any	  publication.	  
Who	  is	  organising	  and	  funding	  the	  research?	  The	  research	  is	  organised	  by	  Professor	  Eike	  Nagel	  and	  will	  be	  partially	  funded	  by	  Kings	   College	   London	   and	  Guy’s	   and	   St	   Thomas’	  Hospital	  NHS	   Foundation	  Trust.	  
Who	  has	  reviewed	  the	  study?	  The	  study	  has	  been	  independently	  reviewed	  by	  the	  St	  Thomas’	  Hospital	  Ethics	  Committee.	  	  
Contact	  Details:	  Professor	  Eike	  Nagel.	  St	  Thomas’	  Hospital,	  4th	  Floor	  Lambeth	  Wing.	  Telephone:	  02071887242.	  Mobile	  phone:	  07949680239.	  	  Dr	  Geraint	  Morton,	  St	  Thomas’	  Hospital,	  4th	  Floor	  Lambeth	  Wing.	  Telephone:	  020	  7188	  7188	  ext	  52022.	  Mobile	  phone:	  07859	  857357.	  Email:	  geraint.morton@kcl.ac.uk	  	  	  	  
A	  copy	  of	  the	  information	  sheet	  and	  a	  signed	  consent	  form	  to	  keep	  will	  be	  
given	  to	  you.	  
	  
Thank	  you	  for	  considering	  taking	  part	  or	  taking	  time	  to	  read	  this	  sheet.	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PATIENT	  INFORMATION	  SHEET	  	   	  
Study	  title:	  MRI	  sequence	  development	  in	  a	  clinical	  setting.	  REC	  Study	  No:	  09-­‐H0802-­‐78.	  Chief	  Investigator:	  Prof	  Eike	  Nagel.	  	   	   	   	  You	   are	   being	   invited	   to	   take	   part	   in	   some	   research	   during	   your	   Magnetic	  Resonance	   Imaging	   (MRI)	   scan.	   Before	   you	   decide	   whether	   to	   take	   part	   it	   is	  important	  that	  you	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  will	  involve.	  Please	  take	  your	  time	  to	  read	  the	  following	  information	  carefully.	  	  
	  Your	  doctor	  has	  requested	  that	  you	  undergo	  an	  MRI	  scan	  as	  part	  of	  your	  clinical	  care.	  Unlike	  most	  medical	  imaging	  methods,	  MRI	  does	  not	  use	  ionising	  	  
radiation	  but	  instead	  uses	  magnetic	  fields	  and	  radio−frequency	  (RF)	  waves	  to	  produce	   images	   of	   the	   internal	   structure	   of	   the	   human	   body.	   A	   clinical	  examination	  will	   consist	  of	  a	  number	  of	   sequences	  of	  magnetic	  and	  RF	  pulses	  with	   each	   sequence	   producing	   an	   image	   or	   set	   of	   images.	   Whilst	   MRI	   is	   an	  established	   and	   safe	   technique	   we	   are	   continually	   looking	   for	   ways	   of	  improving	   the	   information	   that	   we	   get	   from	   the	   scan.	   Improved	   information	  from	   the	   scan	  means	   better	   quality	   images	   and	   better	   care	   for	   patients.	  With	  MRI	  small	  adjustments	  in	  the	  way	  we	  take	  the	  images	  (sequences)	  can	  lead	  to	  very	  different	  results.	  In	  order	  to	  work	  out	  whether	  an	  adjustment	  we	  make	  is	  useful	  we	  need	  to	  try	  it	  out	  in	  patients.	  	  In	  addition	   to	   the	   imaging	  you	  need	   for	  clinical	   reasons	  we	  would	  also	   like	   to	  test	   new	   imaging	   sequences	   during	   your	   scan.	   	   From	   your	   point	   of	   view	   this	  simply	  involves	  spending	  a	  few	  extra	  minutes	  in	  the	  MRI	  scanner.	  Your	  normal	  MRI	  scan	  will	   last	  approximately	  60	  minutes.	  The	  extra	   time	  required	   for	   this	  research	  would	  add	  a	  maximum	  further	  15	  minutes.	  We	  will	  not	  administer	  any	  extra	   dye	   or	   medication	   to	   you	   over	   and	   above	   what	   is	   required	   for	   clinical	  purposes.	  The	  extra	  scanning	  is	  not	  painful	  or	  dangerous.	  There	  are	  no	  known	  extra	  risks	  to	  you	  should	  you	  agree	  to	  this	  extra	  scanning.	  	  It	  is	  entirely	  voluntary	  whether	  you	  allow	  us	  to	  perform	  this	  extra	  scanning	  for	  research	  purposes.	  If	  you	  refuse	  your	  clinical	  care	  will	  not	  be	  affected	  and	  you	  do	  not	  have	  to	  give	  a	  reason	  for	  your	  refusal.	  You	  are	  free	  to	  change	  your	  mind	  at	   any	   point	   during	   the	   scan.	   Should	   you	   do	   so	   we	  will	   not	   take	   any	   further	  research	  images.	  	  Information	  collected	  during	  this	  research	  will	  be	  kept	  strictly	  confidential.	  The	  procedures	   for	  handling,	  processing,	   storage	  and	  destruction	  of	   your	  data	   are	  compliant	  with	  the	  Data	  Protection	  Act	  1998.	  Any	  information	  about	  you,	  which	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leaves	  the	  NHS,	  will	  be	  entirely	  anonymous,	  as	  your	  name	  and	  address	  will	  be	  removed.	  	  	  If	  you	  have	  any	  questions	  please	  ask	  a	  member	  of	  the	  MRI	  department	  staff.	  If	  you	  are	  happy	  to	  take	  part	  we	  will	  ask	  you	  to	  sign	  a	  consent	  form.	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CONSENT	  FORM	  	   	   	   	  	  
Study	  title:	  MRI	  Sequence	  Development	  in	  a	  Clinical	  Setting	  REC	  Study	  No:	  09-­‐H0802-­‐78	  Chief	  Investigator:	  Prof	  Eike	  Nagel	  
	   	   	   	  
	  
May	  we	  take	  some	  extra	  images	  for	  research?	  	  This	  will	  require	  no	  extra	  injections	  and	  will	  take	  a	  maximum	  of	  an	  extra	  15	  minutes	  in	  the	  scanner.	  Participation	  is	  entirely	  voluntary	  and	  choosing	  not	  to	  participate	  will	  not	  affect	  your	  medical	  care.	  	  	  
Please	  initial	  box	  
	   	   	   	   	   	   	   	   	   	  1.	   I	   confirm	   that	   I	   have	   read	   and	   understand	   the	   information	   sheet	   dated	  17/07/2009	   (version	   2)	   for	   the	   above	   study.	   I	   have	   had	   the	   opportunity	   to	  consider	   the	   information,	   ask	   questions	   and	   have	   had	   these	   answered	  satisfactorily.	  	  2.	   I	   understand	   I	  may	   choose	   at	   any	   point	   not	   to	   have	   any	   further	   research	  scans	  without	  giving	  any	  reason,	  without	  my	  medical	  care	  or	  legal	  rights	  being	  affected.	  	  	  	  3.	   I	  give	  my	  consent	  to	  have	  some	  additional	  scans	  for	  research.	  	  	  	  _________________________	   __________________	   ________________	  Name	  of	  Patient	   Signature	   Date	   	   	  	  	  	  _________________________	   ________________	   ________________	  Name	  of	  Person	  taking	  consent	   Signature	   Date	   	   	  (if	  different	  from	  researcher)	  	  	  _________________________	   ________________	   ________________	  Researcher	   Signature	   Date	   	   	  	  	  When	  completed,	  1	  for	  patient;	  1	  for	  researcher	  site	  file;	  1	  (original)	  to	  be	  kept	  in	  medical	  notes	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Appendix	  B:	  	  BCIS-­‐1	  Jeopardy	  Score	  
	  The	  Duke	  Jeopardy	  Score	  145	  ascribes	  2	  points	  each	  for	  6	  myocardial	  territories,	  those	  subtended	  by	  the	  Left	  Anterior	  Descending	  (LAD),	  Diagonal	  Branch	  (DG),	  Circumflex	  (Cx),	  Obtuse	  Marginal	  branch	  (OM),	  Right	  Coronary	  (RCA)	  and	  Posterior	  Descending	  Branch	  (PDA)	  arteries.	  2	  points	  are	  allocated	  to	  each	  coronary	  lesion	  plus	  2	  further	  points	  if	  the	  lesion	  affects	  2	  of	  the	  6	  downstream	  myocardial	  territories.	  The	  BCIS-­‐1	  Jeopardy	  Score	  is	  a	  modification	  of	  this	  scoring	  system	  which	  allows	  classification	  of	  left	  main	  coronary	  artery	  disease	  as	  well	  as	  coronary	  bypass	  graft	  disease.	  
• Coronary	  or	  graft	  lesions	  ≥	  70%	  diameter	  stenosis	  on	  visual	  estimation	  should	  be	  considered	  significant.	  Left	  main	  coronary	  lesions	  ≥	  50%	  should	  be	  considered	  significant.	  
	  
• Where	  a	  main	  vessel	  gives	  rise	  to	  multiple	  branches	  (DG,	  OM	  or	  PDA),	  only	  lesions	  in	  the	  branch	  supplying	  the	  largest	  territory	  (called	  the	  Major	  Branch	  below)	  should	  be	  scored.	  	  	  
• For	  anatomical	  variations,	  equivalent	  myocardial	  territories	  should	  be	  assessed	  (Example	  1:	  the	  Ramus	  Intermedius	  Branch	  could	  be	  scored	  as	  Major	  DG	  or	  Major	  OM,	  if	  considered	  to	  supply	  a	  similar	  territory;	  Example	  2:	  when	  RCA	  dominant,	  the	  Proximal	  Cx	  should	  be	  scored	  as	  Major	  OM)	  	  
• For	  true	  anatomic	  co-­‐dominance	  assign	  the	  right	  coronary	  artery	  as	  dominant	  	  
• When	  using	  the	  scoring	  table	  below,	  it	  is	  important	  to	  complete	  each	  numbered	  row	  sequentially.	   	  
  313 
	  	  	  
	  
	  
	  
Coronary	  Artery/Graft	   Instructions	   Score	  
1	   LMS	   if	  ≥50%	  lesion,	  score	  8	  and	  go	  to	  row	  11	  if	  <50%	  lesion,	  score	  0	  and	  go	  to	  row	  2	   	  2	   Proximal	  LAD	  	  (Before	  DG)	   if	  	  ≥70%	  lesion,	  score	  6	  and	  go	  to	  row	  5	  if	  <70%	  lesion,	  score	  0	  and	  go	  to	  row	  3	   	  3	   Mid	  LAD	  (After	  DG)	   if	  	  ≥70%	  lesion,	  score	  2	  and	  go	  to	  row	  4	  if	  <70%	  lesion,	  score	  0	  and	  go	  to	  row	  4	   	  4	   Major	  DG	   if	  	  ≥70%	  lesion,	  score	  2	  and	  go	  to	  row	  5	  if	  <70%	  lesion,	  score	  0	  and	  go	  to	  row	  5	   	  5	   	   If	  Cx	  dominant,	  go	  to	  row	  8	  If	  RCA	  dominant,	  go	  to	  row	  6	   	  6	   Proximal	  RCA	  (Before	  PDA)	   if	  	  ≥70%	  lesion,	  score	  4	  and	  go	  to	  row	  10	  if	  <70%	  lesion,	  score	  0,	  go	  to	  row	  7	   	  7	   PDA	   if	  	  ≥70%	  lesion,	  score	  2	  and	  go	  to	  row	  10	  if	  <70%	  lesion,	  score	  0,	  go	  to	  row	  10	   	  8	   Proximal	  Cx	  	  (Before	  OM)	   if	  	  ≥70%	  lesion,	  score	  6	  and	  go	  to	  row	  14	  if	  <70%	  lesion,	  score	  0,	  go	  to	  row	  9	   	  9	   Mid	  Cx	  (After	  OM)	   if	  	  ≥70%	  lesion,	  score	  2	  and	  go	  to	  row	  10	  if	  <70%	  lesion,	  score	  0,	  go	  to	  row	  10	   	  10	   Major	  OM	   if	  	  ≥70%	  lesion,	  score	  2	  and	  go	  to	  row	  14	  if	  <70%	  lesion	  –score	  0	  and	  go	  to	  row	  14	   	  11	   	   If	  Cx	  dominant,	  score	  4	  and	  go	  to	  row	  14	  If	  RCA	  dominant,	  score	  0	  and	  go	  to	  row	  12	   	  12	   Proximal	  RCA	  (Before	  PDA)	   if	  	  ≥70%	  lesion,	  score	  4	  and	  go	  to	  row	  14	  if	  <70%	  lesion,	  score	  0	  and	  go	  to	  row	  13	   	  13	   PDA	   if	  	  ≥70%	  lesion,	  score	  2	  and	  go	  to	  row	  14	  if	  <70%	  lesion,	  score	  0,	  go	  to	  row	  14	   	  14	   	   Previous	  CABG?	  If	  yes,	  go	  to	  row	  15	  If	  no,	  go	  to	  row	  21	   	  15	   LAD	  graft	  beyond	  DG	   if	  <70%	  graft	  lesion,	  score	  -­‐4,	  go	  to	  row	  16	  if	  >70%,	  poor	  run-­‐off	  or	  n/a,	  score	  0,	  go	  to	  row	  16	   	  16	   Major	  DG	  graft	   if	  <70%	  graft	  lesion,	  score	  -­‐2,	  go	  to	  row	  17	  if	  	  ≥70%,	  poor	  run-­‐off	  or	  n/a,	  score	  0,	  go	  to	  row	  17	   	  17	   Major	  OM	  graft	   if	  <70%	  graft	  lesion,	  score	  -­‐2,	  go	  to	  row	  18	  if	  	  ≥70%,	  poor	  run-­‐off	  or	  n/a,	  score	  0,	  go	  to	  row	  18	   	  18	   Cx	  graft	  beyond	  OM	  (Cx	  dominant	  system)	   if	  <70%	  graft	  lesion,	  score	  -­‐4,	  go	  to	  row	  19	  if	  	  ≥70%,	  poor	  run-­‐off	  or	  n/a,	  score	  0,	  go	  to	  row	  19	   	  19	   RCA	  graft	  (before	  PDA)	   if	  <70%	  graft	  lesion,	  score	  -­‐4,	  go	  to	  row	  21	  if	  	  ≥70%	  poor	  run-­‐off	  or	  n/a,	  score	  0,	  go	  to	  row	  20	   	  20	   PDA	  graft	   if	  <70%	  graft	  lesion,	  score	  -­‐2,	  go	  to	  row	  21	  if	  	  ≥70%	  poor	  run-­‐off	  or	  n/a,	  score	  0,	  go	  to	  row	  21	   	  
21	   TOTAL	  SCORE	   add	  filled	  in	  scores	  and	  enter	  	  
(range:	  0	  to	  12)	  
	  
